U.S. patent number 11,059,894 [Application Number 16/696,411] was granted by the patent office on 2021-07-13 for alk7 binding proteins and uses thereof.
This patent grant is currently assigned to Acceleron Pharma Inc.. The grantee listed for this patent is Acceleron Pharma Inc., Adimab, LLC. Invention is credited to Jonathan Belk, Roselyne Castonguay, Yossi Dagon, Asya Grinberg, John Knopf, Ravindra Kumar, Dianne Sako, Nathan J. Sharkey.
United States Patent |
11,059,894 |
Knopf , et al. |
July 13, 2021 |
ALK7 binding proteins and uses thereof
Abstract
This disclosure provides ALK7-binding proteins such as anti-ALK7
antibodies, and compositions and methods for making the
ALK7-binding proteins. In certain embodiments the ALK7-binding
proteins inhibit, or antagonize ALK7 activity. In addition, the
disclosure provides compositions and methods for diagnosing and
treating overweight, obesity, diabetes, overweight, obesity, type 2
diabetes, and their associated conditions; metabolic disorders, and
other diseases or conditions that can be treated, prevented or
ameliorated by targeting ALK7.
Inventors: |
Knopf; John (Cambridge, MA),
Belk; Jonathan (Lebanon, NH), Sharkey; Nathan J.
(Lebanon, NH), Kumar; Ravindra (Acton, MA), Grinberg;
Asya (Lexington, MA), Sako; Dianne (Medford, MA),
Castonguay; Roselyne (Watertown, MA), Dagon; Yossi
(Cambridge, MA) |
Applicant: |
Name |
City |
State |
Country |
Type |
Acceleron Pharma Inc.
Adimab, LLC |
Cambridge
Lebanon |
MA
NH |
US
US |
|
|
Assignee: |
Acceleron Pharma Inc.
(Cambridge, MA)
|
Family
ID: |
1000005671568 |
Appl.
No.: |
16/696,411 |
Filed: |
November 26, 2019 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20200087406 A1 |
Mar 19, 2020 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
15494081 |
Apr 21, 2017 |
10501547 |
|
|
|
62326313 |
Apr 22, 2016 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P
3/04 (20180101); C07K 16/2863 (20130101); C07K
2317/565 (20130101); C07K 2317/76 (20130101); C07K
2317/56 (20130101); A61K 2039/505 (20130101); C07K
2317/92 (20130101) |
Current International
Class: |
A61P
3/04 (20060101); C07K 16/28 (20060101); A61K
39/00 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
WO-9612805 |
|
May 1996 |
|
WO |
|
WO-2015/091935 |
|
Jun 2015 |
|
WO |
|
WO-2017/177013 |
|
Oct 2017 |
|
WO |
|
WO-2017/185037 |
|
Oct 2017 |
|
WO |
|
Other References
Extended European Search Report for EP Application No. EP 17786759
dated Jan. 21, 2020. cited by applicant .
Zhang et al., "Activin receptor-like kinase 7 induces apoptosis
pancreatic beta cells and beta cells lines," Diabetolog
49(3):506-518 (2006). cited by applicant .
Zhao et al., "Nodal induces apoptosis through activation of the
ALK7 signaling pathway in pancreatic INS-1 [beta]-cells," Amer J
Physio Endocrin Metab 303(1):E132-E143 (2012). cited by applicant
.
Guo et al., "Adipocyte ALK7 links nutrient overload to
catecholamine resistance in obesity," ELife, 3:e03245 (2014). cited
by applicant .
International Preliminary Report on Patentability for International
Application No. PCT/US2017/028952 dated Oct. 23, 2018. cited by
applicant .
International Search Report and Written Opinion for International
Application No. PCT/US17/28952 dated Sep. 22, 2017. cited by
applicant .
International Search Report and Written Opinion for International
Application No. PCT/US2018/057482 dated Jan. 8, 2019. cited by
applicant .
Kogame et al., "ALK7 is a novel marker for adipocyte
differentiation," The Journal of Medical Investigation, 4:238-245
(2006). cited by applicant .
Supplementary Partial European Search Report for EP application No.
EP 17786759 dated Sep. 18, 2019. cited by applicant .
UniProtKB--I7ZP16 (I7ZP16_ASPO3), Oct. 3, 2012
[http://www.uniprot.org/uniprot/I7ZP16]. cited by applicant .
Yogosawa et al., "Activin Receptor-Like Kinase 7 Suppresses
Lipolysis to Accumulate Fat in Obesity Through Downregulation of
Peroxisome Proliferator-Activated Receptor y and C/EBP.alpha.,"
Diabetes, 62(1): 115-123 (2013). cited by applicant.
|
Primary Examiner: Li; Ruixiang
Attorney, Agent or Firm: Foley Hoag LLP
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATION
This application is a divisional of U.S. application Ser. No.
15/494,081, filed Apr. 21, 2017, which claims the benefit of U.S.
Provisional Appl. No. 62/326,313, filed Apr. 22, 2016, each of
which is incorporated herein by reference.
Claims
What is claimed is:
1. An activin receptor-Like Kinase 7 (ALK7)-binding protein
comprising a heavy chain variable region (VH) comprising the amino
acid sequence of SEQ ID NO: 117 and a light chain variable region
(VL) comprising the amino acid sequence of SEQ ID NO: 124, wherein
the protein binds to ALK7.
2. The ALK7-binding protein of claim 1, wherein the ALK7-binding
protein is an antibody, wherein the antibody is a monoclonal
antibody, a recombinant antibody, a humanized antibody, a chimeric
antibody, a bi-specific antibody, a multi-specific antibody, or an
ALK7-binding antibody fragment.
3. The ALK7-binding protein of claim 2, wherein the ALK7-binding
antibody fragment is selected from the group consisting of a Fab
fragment, a Fab' fragment, a F(ab').sub.2 fragment, a Fv fragment,
a diabody, or a single chain antibody molecule.
4. The ALK7-binding protein of claim 2, wherein the antibody
further comprises a heavy chain immunoglobulin constant domain
selected from the group consisting of: (a) a human IgA constant
domain; (b) a human IgD constant domain; (c) a human IgE constant
domain; (d) a human IgG1 constant domain; (e) a human IgG2 constant
domain; (f) a human IgG3 constant domain; (g) a human IgG4 constant
domain; and (h) a human IgM constant domain.
5. The ALK7-binding protein of claim 2, wherein the antibody
further comprises a light chain immunoglobulin constant domain
selected from the group consisting of: (a) a human Ig kappa
constant domain; and (b) a human Ig lambda constant domain.
6. The ALK7-binding protein of claim 2, wherein the antibody
further comprises a human IgG1 heavy chain constant domain and a
human lambda light chain constant domain.
7. An ALK7-binding protein comprising a set of CDRs in which: (i)
VH-CDR1 comprises the amino acid sequence of SEQ ID NO:114; (ii)
VH-CDR2 comprises the amino acid sequence of SEQ ID NO:115; (iii)
VH-CDR3 comprises the amino acid sequence of SEQ ID NO:116; (iv)
VL-CDR1 comprises the amino acid sequence of SEQ ID NO:121; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:122; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:123;
wherein the protein binds ALK7.
Description
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
The content of the electronically submitted sequence listing in
ASCII text file 3174.004PC01_SeqList.ST25txt (Size: 72,898 bytes;
and Date of Creation: Apr. 21, 2017) filed with the application is
herein incorporated by reference in its entirety.
BACKGROUND
Overweight and obesity have reached epidemic proportion in the
United States and a number of countries throughout the world,
increasing among all age, race and ethnic groups and in both men
and women. Overweight and obesity are also associated with other
diseases or conditions that disrupt life activities and lifestyles.
Obesity is recognized as a serious risk factor for other diseases
and conditions such as type 2 diabetes, inflammation, and
cardiovascular, pulmonary, fatty liver disease, neurologic, and
hepatic, and renal disease.
Type 2 diabetes is a chronic, progressive disease that has likewise
reached epidemic proportion. There is no established cure for type
II diabetes, but there are numerous recognized treatments that
attempt to delay or mitigate the inevitable consequences of the
disease. Type 2 diabetes is initially treated by adjustments in
diet and exercise, and by weight loss, most especially in obese
subjects. The amount of weight loss which improves the clinical
picture is sometimes modest (e.g., 4.4 to 11 lbs.); this is likely
due to poorly understood aspects of fat tissue activity, for
instance chemical signaling (especially in visceral fat tissue in
and around abdominal organs).
In view of the foregoing, there is a need for new treatments for
controlling and treating the overweight, obesity and type 2
diabetes epidemics. It is an object of this disclosure to provide
ALK7-binding proteins and uses of the same in the diagnosis and
treatment, prevention and/or amelioration of overweight, obesity,
type 2 diabetes, and their associated conditions; metabolic
disorders, and other diseases or conditions that can be treated,
prevented or ameliorated by targeting ALK7.
BRIEF SUMMARY
The disclosure provides ALK7-binding proteins and methods of using
the ALK7-binding proteins. In particular embodiments, the
ALK7-binding proteins are capable of inhibiting or blocking the
binding of ALK7 to one or more cognate ALK7 ligands and/or one or
more cognate ActRI receptors. In some embodiments, the ALK7-binding
proteins are capable of inhibiting or blocking the multimerization
of ALK7, and ActRII receptor (ActRIIA or ActRIIB) and GDF1, GDF3,
GDF8, activin B, activin A/B, or Nodal. The disclosure also
provides methods of using ALK7-binding proteins for the diagnosis,
or treatment, prevention and/or amelioration of a disease or
condition associated with ALK7 expression and/or elevated
ALK7-mediated signaling. Such diseases or conditions include but
are not limited to, overweight, obesity (e.g., abdominal obesity);
insulin resistance; metabolic syndrome and other metabolic diseases
or conditions; a lipid disorder such as, low HDL levels, high LDL
levels, hyperlipidemia, hypertriglyceridemia or dyslipidemia;
lipoprotein aberrations; decreased triglycerides; inflammation
(e.g., liver inflammation and/or inflammation of adipose tissue),
fatty liver disease; non-alcoholic fatty liver disease;
hyperglycemia; impaired glucose tolerance (IGT); hyperinsulinemia;
high cholesterol (e.g., high LDL levels and hypercholesterolemia);
cardiovascular disease such as, heart disease including coronary
heart disease, congestive heart failure, stroke, peripheral
vascular disease, disordered fibrinolysis, atherosclerosis;
arteriosclerosis, and hypertension; Syndrome X; vascular
restenosis; neuropathy; retinopathy; neurodegenerative disease;
endothelial dysfunction, respiratory dysfunction, renal disease
(e.g., nephropathy); pancreatitis; polycystic ovarian syndrome;
elevated uric acid levels; haemochromatosis (iron overload);
acanthosis nigricans (dark patches on the skin); and cancer (e.g.,
myeloma (e.g., multiple myeloma, plasmacytoma, localized myeloma,
or extramedullary myeloma), or an ovarian, breast, colon,
endometrial, liver, kidney, pancreatic, gastric, uterine or colon
cancer); and other disorders/conditions associated with one or more
of the above diseases or conditions, or with excessive body weight
(e.g., body mass index (BMI).gtoreq.25 kg/m.sup.2), or too much
body fat. The disclosure also provides without limitation, methods
for reducing body weight (e.g., promoting weight loss), and methods
for reducing weight gain (e.g., preventing weight gain), using
antagonist ALK7-binding proteins, such as antibodies.
In some embodiments, the ALK7-binding protein specifically binds
ALK7. In further embodiments, the provided ALK7-binding protein
specifically binds ALK7 and has at least one characteristic
selected from the group consisting of: (a) decreases the formation
of a complex containing ALK7, a type II receptor (e.g., ActRIIA or
ActRIIB), and one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) on the
surface of cells expressing ALK7 and the ActRII receptor in the
presence of the one or more TGF-beta superfamily ligands; (b)
competes with ActRIIA or ActRIIB) for binding to ALK7; (c) competes
with one or more TGF-beta superfamily ligands (e.g., activin B,
activin AB, Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d)
decreases the phosphorylation of ALK7 in cells expressing ALK7 and
a type II receptor (e.g., ActRIIA or ActRIIB) in the presence of
one or more TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8,
activin B, activin AB, and/or Nodal); (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics. In further embodiments, the ALK7-binding
protein cross-blocks or competes for binding to ALK7 with an
antibody having an ALK7-binding VH and VL pair disclosed herein. In
further embodiments, the ALK7-binding protein is an anti-ALK7
antibody or an ALK7-binding antibody fragment.
In some embodiments, the ALK7-binding protein comprises a set of
complementary determining regions (CDRs): heavy chain variable
region (VH)-CDR1, VH-CDR2, VH-CDR3, light chain variable region
(VL)-CDR1, VL-CDR2 and VL-CDR3, wherein the CDRs are present in a
heavy chain variable region (VH) and a light chain variable region
(VL) pair disclosed in Table 1A. In some embodiments, the
ALK7-binding protein comprises a set of CDRs present in a VH and a
VL pair selected from the group consisting of: (a) a VH sequence of
SEQ ID NO:4, and a VL sequence of SEQ ID NO:13; (b) a VII sequence
of SEQ ID NO:22, and a VL sequence of SEQ ID NO:31; (c) a VH
sequence of SEQ ID NO:40, and a VL sequence of SEQ ID NO:49; and
(d) a VH sequence of SEQ ID NO:58 and a VL sequence of SEQ ID
NO:67.
In some embodiments, the ALK7-binding protein comprises a set of
complementary determining regions (CDRs): heavy chain variable
region (VH)-CDR1, VH-CDR2, VH-CDR3, light chain variable region
(VL)-CDR1, VL-CDR2 and VL-CDR3, wherein the CDRs are present in a
heavy chain variable region (VH) and a light chain variable region
(VL) pair disclosed in Table 1B or Table 3. In some embodiments,
the ALK7-binding protein comprises a set of CDRs present in a VH
and a VL pair selected from the group consisting of: (a) a VII
sequence of SEQ ID NO: 152, and a VL sequence of SEQ ID NO:98; (b)
a VII sequence of SEQ ID NO:159, and a VL sequence of SEQ ID
NO:110; and (c) a VII sequence of SEQ ID NO:165, and a VL sequence
of SEQ ID NO:171. In some embodiments, the ALK7-binding protein
comprises a set of CDRs present in a VH and a VL pair selected from
the group consisting of: (a) a VH sequence of SEQ ID NO:91, and a
VL sequence of SEQ ID NO:98; (b) a VH sequence of SEQ ID NO: 105,
and a VL sequence of SEQ ID NO:110; (c) a VH sequence of SEQ ID
NO:117, and a VL sequence of SEQ ID NO:124; (d) a VH sequence of
SEQ ID NO:128 and a VL sequence of SEQ ID NO:135; and (e) a VH
sequence of SEQ ID NO:140 and a VL sequence of SEQ ID NO:148.
In additional embodiments, the ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3,
VL-CDR1, VL-CDR2, and VL-CDR3, wherein the set of CDRs is identical
to, or has a total of one, two, three, four, five, six, seven,
eight, nine, ten, or fewer than ten, amino acid substitutions,
deletions, and/or insertions from a reference set of CDRs in which:
(a)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:2;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:3;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 10;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 11; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 12;
(b)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:19;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:20;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:21;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:28; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:29; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:30; (c)(i)
VH-CDR1 comprises the amino acid sequence of SEQ ID NO:37; (ii)
VH-CDR2 comprises the amino acid sequence of SEQ ID NO:38; (iii)
VH-CDR3 comprises the amino acid sequence of SEQ ID NO:39; (iv)
VL-CDR1 comprises the amino acid sequence of SEQ ID NO:46; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:47: and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:48; or
(d)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:55;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:56;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:57;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:64; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:65; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:66; and
wherein the protein binds ALK7.
In additional embodiments, the ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3,
VL-CDR1, VL-CDR2, and VL-CDR3, wherein the set of CDRs is identical
to, or has a total of one, two, three, four, five, six, seven,
eight, nine, ten, or fewer than ten, amino acid substitutions,
deletions, and/or insertions from a reference set of CDRs in which:
(a)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:88;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:89;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:90;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:95; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:96; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:97; (b)(i)
VH-CDR1 comprises the amino acid sequence of SEQ ID NO:102; (ii)
VH-CDR2 comprises the amino acid sequence of SEQ ID NO:103; (iii)
VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 104; (iv)
VL-CDR1 comprises the amino acid sequence of SEQ ID NO:107; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:108; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:109;
(c)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:114;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:115;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:116;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:121;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:122; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:123;
(d)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:125;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:126;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:127;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:132;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 133;
and (vi) VL-CDR3 comprises the amino acid sequence of SEQ ID
NO:134; or (e)(i) VH-CDR1 comprises the amino acid sequence of SEQ
ID NO:137; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:138; (iii) VH-CDR3 comprises the amino acid sequence of SEQ ID
NO:139; (iv) VL-CDR1 comprises the amino acid sequence of SEQ ID
NO:145; (v) VL-CDR2 comprises the amino acid sequence of SEQ ID
NO:146; and (vi) VL-CDR3 comprises the amino acid sequence of SEQ
ID NO:147; and wherein the protein binds ALK7.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs in which: (a)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO: 1; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:2; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:3; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:10; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO: 11; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:12; (b)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:19; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:20; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:21; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:28; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:29; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:30; (c)(i) VH-CDR1 comprises the
amino acid sequence of SEQ ID NO:37; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:38; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:39; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:46; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:47; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:48; or (d)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:55; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:56; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:57; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:64; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:65; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:66; and wherein the protein binds
ALK7.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs in which: (a)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:88; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:89; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:90; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:95; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:96; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:97; (b)(i) VH-CDR1 comprises the
amino acid sequence of SEQ ID NO:102; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:103; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:104; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:107; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:108; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:109; (c)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:114; (ii) VH-CDR2 comprises
the amino acid sequence of SEQ ID NO:115; (iii) VH-CDR3 comprises
the amino acid sequence of SEQ ID NO:116; (iv) VL-CDR1 comprises
the amino acid sequence of SEQ ID NO:121; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:122; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:123; (d)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO: 125; (ii) VH-CDR2 comprises
the amino acid sequence of SEQ ID NO: 126; (iii) VH-CDR3 comprises
the amino acid sequence of SEQ ID NO:127; (iv) VL-CDR1 comprises
the amino acid sequence of SEQ ID NO:132; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:133; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:134; or (e)(i) VH-CDR
comprises the amino acid sequence of SEQ ID NO:137; (ii) VH-CDR2
comprises the amino acid sequence of SEQ ID NO:138; (iii) VH-CDR3
comprises the amino acid sequence of SEQ ID NO:139; (iv) VL-CDR1
comprises the amino acid sequence of SEQ ID NO:145; (v) VL-CDR2
comprises the amino acid sequence of SEQ ID NO:146; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:147; and
wherein the protein binds ALK7.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VH and a VL pair selected from the group
consisting of: (a)(i) a VH having at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO:4, and (ii) a VL having
at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
SEQ ID NO:13; (b)(i) a VH having at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO:22, or 132, and (ii) a
VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:31; (c)(i) a VH having at least 90%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:40, and
(ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to SEQ ID NO:49; and (d)(i) a VH having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:58, and (ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%,
or 100% sequence identity to SEQ ID NO:67; and wherein the protein
binds ALK7.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VH and a VL pair selected from the group
consisting of: (a)(i) a VH having at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO:91, and (ii) a VL
having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:98; (b)(i) a VH having at least 90%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:105, or
132, and (ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID NO:110; (c)(i) a VH having at
least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
SEQ ID NO: 117, and (ii) a VL having at least 90%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to SEQ ID NO:124; (d)(i) a VH
having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:128, and (ii) a VL having at least 90%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:135; and
(e)(i) a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to SEQ ID NO:140, and (ii) a VL having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO: 148; and wherein the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
containing a VH sequence of SEQ ID NO:40 or 58, and a VL sequence
of SEQ ID NO:49 or 67; and the protein binds ALK7. In a further
embodiment, the ALK7-binding protein comprises a VH sequence of SEQ
ID NO:40 and a VL sequence of SEQ ID NO:49, and the protein binds
ALK7. In a further embodiment, the ALK7-binding protein comprises a
VH sequence of SEQ ID NO:58 and a VL sequence of SEQ ID NO:67, and
the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO:4 and a VL sequence of
SEQ ID NO: 13, and the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO:22 and a VL sequence of
SEQ ID NO:31, and the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO:40 and a VL sequence of
SEQ ID NO:49, and the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO:58 and a VL sequence of
SEQ ID NO:67, and the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO:91 and a VL sequence of
SEQ ID NO:98, and the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO: 105 and a VL sequence
of SEQ ID NO:110, and the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO:117 and a VL sequence of
SEQ ID NO:124, and the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO: 128 and a VL sequence
of SEQ ID NO: 135, and the protein binds ALK7.
In one embodiment, the ALK7-binding protein comprises a VH and a VL
pair comprising a VH sequence of SEQ ID NO:140 and a VL sequence of
SEQ ID NO:148, and the protein binds ALK7.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL pair selected from the group consisting of: (a)(i) a VH sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VH sequence selected
from the group consisting of SEQ ID NO:4, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO: 13; (b)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:22, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:31; (c)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:40, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:49; and (d)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:58, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:67; and wherein the protein binds ALK7.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL pair selected from the group consisting of: (a)(i) a VH sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VH sequence selected
from the group consisting of SEQ ID NO:91, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:98; (b)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO: 105, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:110; (c)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:117, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO: 124; (d)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:128, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:135; and (e)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:140, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO: 148; and wherein the protein binds ALK7.
In some embodiments, the ALK7-binding protein is an antibody that
specifically binds ALK7. In additional embodiments, the antibody is
a monoclonal antibody, a recombinant antibody, a human antibody, a
humanized antibody, a chimeric antibody, a bi-specific antibody, or
a multi-specific antibody. In some embodiments, the ALK7-binding
protein is an ALK7-binding antibody fragment. In some embodiments
the antibody is an antibody fragment selected from the group
consisting of a Fab, Fab', F(ab').sub.2, Fv, diabody, DART, and a
single chain antibody molecule (e.g., a BiTE).
In some embodiments, the ALK7-binding protein specifically binds to
ALK7 between amino acids 20-113 of SEQ ID NO:85. In some
embodiments, the ALK7-binding protein specifically binds to ALK7
between amino acids 20-113 of SEQ ID NO:85 and inhibits one or more
ALK ligands (e.g., GDF1, GDF3, GDF8, activin B, activin A/B, and/or
Nodal) from binding to ALK7. In some embodiments, the ALK7-binding
protein specifically binds to ALK7 between amino acids 20-113 of
SEQ ID NO: 85 and contacts one or more amino acids selected from
the group consisting of: (a) a Glu at position 21 of SEQ ID NO:85;
(b) a Leu at position 22 of SEQ ID NO:85; (c) a Ser at position 23
of SEQ ID NO:85; (d) a Pro at position 24 of SEQ ID NO:85; (e) a
Gly at position 25 of SEQ ID NO:85; (f) a Leu at position 26 of SEQ
ID NO:85; (g) a Lys at position 27 of SEQ ID NO:85; (h) a Cys at
position 28 of SEQ ID NO:85; (i) a Val at position 29 of SEQ ID
NO:85; (j) a Cys at position 30 of SEQ ID NO:85; (k) a Leu at
position 31 of SEQ ID NO:85; (l) a Leu at position 32 of SEQ ID
NO:85; (m) a Cys at position 33 of SEQ ID NO:85; (n) a Asp at
position 34 of SEQ ID NO:85; (o) a Ser at position 35 of SEQ ID
NO:85; (p) a Ser at position 36 of SEQ ID NO:85; (q) a Asn at
position 37 of SEQ ID NO:85; (r) a Phe at position 38 of SEQ ID
NO:85; (s) a Thr at position 39 of SEQ ID NO:85; (t) a Cys at
position 40 of SEQ ID NO:85; (u) a Gln at position 41 of SEQ ID
NO:85; (v) a Thr at position 42 of SEQ ID NO:85; (w) a Glu at
position 43 of SEQ ID NO:85; (x) a Gly at position 44 of SEQ ID
NO:85; (y) a Ala at position 45 of SEQ ID NO:85; (z) a Cys at
position 46 of SEQ ID NO:85; (aa) a Trp at position 47 of SEQ ID
NO:85; (ab) a Ala at position 48 of SEQ ID NO:85; (ac) a Ser at
position 49 of SEQ ID NO:85; (ad) a Val at position 50 of SEQ ID
NO:85; (ae) a Met at position 51 of SEQ ID NO:85; (af) a Leu at
position 52 of SEQ ID NO:85; (ag) a Thr at position 53 of SEQ ID
NO:85; (ah) a Asn at position 54 of SEQ ID NO:85; (ai) a Gly at
position 55 of SEQ ID NO:85; (aj) a Lys at position 56 of SEQ ID
NO:85; (ak) a Glu at position 57 of SEQ ID NO:85; (al) a Gln at
position 58 of SEQ ID NO:85; (am) a Val at position 59 of SEQ ID
NO:85; (an) a lie at position 60 of SEQ ID NO:85; (ao) a Lys at
position 61 of SEQ ID NO:85; (ap) a Ser at position 62 of SEQ ID
NO:85; (aq) a Cys at position 63 of SEQ ID NO:85; (ar) a Val at
position 64 of SEQ ID NO:85; (as) a Ser at position 65 of SEQ ID
NO:85; (at) a Leu at position 66 of SEQ ID NO:85; (au) a Pro at
position 67 of SEQ ID NO:85; (av) a Glu at position 68 of SEQ ID
NO:85; (aw) a Leu at position 69 of SEQ ID NO:85; (ax) a Asn at
position 70 of SEQ ID NO:85; (ay) a Ala at position 71 of SEQ ID
NO:85; (az) a Gln at position 72 of SEQ ID NO:85; (ba) a Val at
position 73 of SEQ ID NO:85; (bb) a Phe at position 74 of SEQ ID
NO:85; (be) a Cys at position 75 of SEQ ID NO:85; (bd) a His at
position 76 of SEQ ID NO:85; (be) a Ser at position 77 of SEQ ID
NO:85; (bf) a Ser at position 78 of SEQ ID NO:85; (bg) a Asn at
position 79 of SEQ ID NO:85; (bh) a Asn at position 80 of SEQ ID
NO:85; (bi) a Val at position 81 of SEQ ID NO:85; (bj) a Thr at
position 82 of SEQ ID NO:85; (bk) a Lys at position 83 of SEQ ID
NO:85; (bl) a Thr at position 84 of SEQ ID NO:85; (bm) a Glu at
position 85 of SEQ ID NO:85; (bn) a Cys at position 86 of SEQ ID
NO:85; (bo) a Cys at position 87 of SEQ ID NO:85; (bp) a Phe at
position 88 of SEQ ID NO:85; (bq) a Thr at position 89 of SEQ ID
NO:85; (br) a Asp at position 90 of SEQ ID NO:85; (bs) a Phe at
position 91 of SEQ ID NO:85; (bt) a Cys at position 92 of SEQ ID
NO:85; (bu) a Asn at position 93 of SEQ ID NO:85; (bv) a Asn at
position 94 of SEQ ID NO:85; (bw) a Ile at position 95 of SEQ ID
NO:85; (bx) a Thr at position 96 of SEQ ID NO:85; (by) a Leu at
position 97 of SEQ ID NO:85; (bz) a His at position 98 of SEQ ID
NO:85; (ca) a Leu at position 99 of SEQ ID NO:85; (cb) a Pro at
position 100 of SEQ ID NO:85; (cc) a Thr at position 101 of SEQ ID
NO:85; (cd) a Ala at position 102 of SEQ ID NO:85; (ce) a Ser at
position 103 of SEQ ID NO:85; (cf) a Pro at position 104 of SEQ ID
NO:85; (cg) a Asn at position 105 of SEQ ID NO:85; (ch) a Ala at
position 106 of SEQ ID NO:85; (ci) a Pro at position 107 of SEQ ID
NO:85; (cj) a Lys at position 108 of SEQ ID NO:85; (ck) a Leu at
position 109 of SEQ ID NO:85; (cl) a Gly at position 110 of SEQ ID
NO:85; (cm) a Pro at position 111 of SEQ ID NO:85: (cn) a Met at
position 112 of SEQ ID NO:85; and (co) a Glu at position 113 of SEQ
ID NO:85. In some embodiments, the ALK7-binding protein
specifically binds to ALK7 between amino acids 20-113 of SEQ ID NO:
85 and contacts one or more amino acids selected from the group
consisting of: (a) a Glu at position 21 of SEQ ID NO:85; (b) a Leu
at position 22 of SEQ ID NO:85; (c) a Ser at position 23 of SEQ ID
NO:85; (d) a Pro at position 24 of SEQ ID NO:85; (e) a Gly at
position 25 of SEQ ID NO:85; (f) a Leu at position 26 of SEQ ID
NO:85; (g) a Lys at position 27 of SEQ ID NO:85; (h) a Cys at
position 28 of SEQ ID NO:85; (i) a Val at position 29 of SEQ ID
NO:85; (j) a Cys at position 30 of SEQ ID NO:85; (k) a Leu at
position 31 of SEQ ID NO:85; (l) a Leu at position 32 of SEQ ID
NO:85; (m) a Cys at position 33 of SEQ ID NO:85; (n) a Asp at
position 34 of SEQ ID NO:85; (o) a Ser at position 35 of SEQ ID
NO:85; (p) a Ser at position 36 of SEQ ID NO:85; (q) a Asn at
position 37 of SEQ ID NO:85; (r) a Phe at position 38 of SEQ ID
NO:85; (s) a Thr at position 39 of SEQ ID NO:85; (t) a Cys at
position 40 of SEQ ID NO:85; (u) a Gln at position 41 of SEQ ID
NO:85; (v) a Thr at position 42 of SEQ ID NO:85; (w) a Glu at
position 43 of SEQ ID NO:85; (x) a Gly at position 44 of SEQ ID
NO:85; (y) a Ala at position 45 of SEQ ID NO:85; (z) a Cys at
position 46 of SEQ ID NO:85; (aa) a Trp at position 47 of SEQ ID
NO:85; (ab) a Ala at position 48 of SEQ ID NO:85; (ac) a Ser at
position 49 of SEQ ID NO:85; (ad) a Val at position 50 of SEQ ID
NO:85; (ae) a Met at position 51 of SEQ ID NO:85; (af) a Leu at
position 52 of SEQ ID NO:85; (ag) a Thr at position 53 of SEQ ID
NO:85; (ah) a Asn at position 54 of SEQ ID NO:85; (ai) a Gly at
position 55 of SEQ ID NO:85; (aj) a Lys at position 56 of SEQ ID
NO:85; (ak) a Glu at position 57 of SEQ ID NO:85; (al) a Gln at
position 58 of SEQ ID NO:85; (am) a Val at position 59 of SEQ ID
NO:85; (an) a Ile at position 60 of SEQ ID NO:85; (ao) a Lys at
position 61 of SEQ ID NO:85; (ap) a Ser at position 62 of SEQ ID
NO:85; (aq) a Cys at position 63 of SEQ ID NO:85; (ar) a Val at
position 64 of SEQ ID NO:85; (as) a Ser at position 65 of SEQ ID
NO:85; (at) a Leu at position 66 of SEQ ID NO:85; (au) a Pro at
position 67 of SEQ ID NO:85; (av) a Glu at position 68 of SEQ ID
NO:85; (aw) a Leu at position 69 of SEQ ID NO:85; (ax) a Asn at
position 70 of SEQ ID NO:85; (ay) a Ala at position 71 of SEQ ID
NO:85; (az) a Gln at position 72 of SEQ ID NO:85; (ba) a Val at
position 73 of SEQ ID NO:85; (bb) a Phe at position 74 of SEQ ID
NO:85; (bc) a Cys at position 75 of SEQ ID NO:85; (bd) a His at
position 76 of SEQ ID NO:85; (be) a Ser at position 77 of SEQ ID
NO:85; (bf) a Ser at position 78 of SEQ ID NO:85; (bg) a Asn at
position 79 of SEQ ID NO:85; (bh) a Asn at position 80 of SEQ TD
NO:85; (bi) a Val at position 81 of SEQ ID NO:85; (bj) a Thr at
position 82 of SEQ ID NO:85; (bk) a Lys at position 83 of SEQ ID
NO:85; (bl) a Thr at position 84 of SEQ ID NO:85; (bm) a Glu at
position 85 of SEQ ID NO:85; (bn) a Cys at position 86 of SEQ ID
NO:85; (bo) a Cys at position 87 of SEQ ID NO:85; (bp) a Phe at
position 88 of SEQ ID NO:85; (bq) a Thr at position 89 of SEQ ID
NO:85; (br) a Asp at position 90 of SEQ ID NO:85; (bs) a Phe at
position 91 of SEQ ID NO:85; (bt) a Cys at position 92 of SEQ ID
NO:85; (bu) a Asn at position 93 of SEQ ID NO:85; (bv) a Asn at
position 94 of SEQ ID NO:85; (bw) a Ile at position 95 of SEQ ID
NO:85; (bx) a Thr at position 96 of SEQ ID NO:85; (by) a Leu at
position 97 of SEQ ID NO:85; (bz) a His at position 98 of SEQ ID
NO:85; (ca) a Leu at position 99 of SEQ ID NO:85; (cb) a Pro at
position 100 of SEQ ID NO:85; (cc) a Thr at position 101 of SEQ ID
NO:85; (cd) a Ala at position 102 of SEQ ID NO:85; (ce) a Ser at
position 103 of SEQ ID NO:85; (cf) a Pro at position 104 of SEQ ID
NO:85; (cg) a Asn at position 105 of SEQ ID NO:85; (ch) a Ala at
position 106 of SEQ ID NO:85; (ci) a Pro at position 107 of SEQ ID
NO:85; (cj) a Lys at position 108 of SEQ ID NO:85; (ck) a Leu at
position 109 of SEQ ID NO:85; (cl) a Gly at position 110 of SEQ ID
NO:85; (cm) a Pro at position 111 of SEQ ID NO:85; (cn) a Met at
position 112 of SEQ ID NO:85; and (co) a Glu at position 113 of SEQ
ID NO:85; and inhibits one or more ALK7 ligands (e.g., GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal) from binding to ALK7.
In some embodiments, the ALK7-binding protein specifically binds to
ALK7 between amino acids 20-113 of SEQ ID NO:85 and increases
lipolysis (e.g., lipolysis of white adipocytes and/or brown
adipocytes). In some embodiments, the ALK7-binding protein
specifically binds to ALK7 between amino acids 20-113 of SEQ ID NO:
85 and contacts one or more amino acids selected from the group
consisting of: (a) a Glu at position 21 of SEQ ID NO:85; (b) a Leu
at position 22 of SEQ ID NO:85; (c) a Ser at position 23 of SEQ ID
NO:85; (d) a Pro at position 24 of SEQ ID NO:85; (e) a Gly at
position 25 of SEQ ID NO:85; (f) a Leu at position 26 of SEQ ID
NO:85; (g) a Lys at position 27 of SEQ ID NO:85; (h) a Cys at
position 28 of SEQ ID NO:85; (i) a Val at position 29 of SEQ ID
NO:85; (j) a Cys at position 30 of SEQ ID NO:85; (k) a Leu at
position 31 of SEQ ID NO:85; (l) a Leu at position 32 of SEQ ID
NO:85; (m) a Cys at position 33 of SEQ ID NO:85; (n) a Asp at
position 34 of SEQ ID NO:85; (o) a Ser at position 35 of SEQ ID
NO:85; (p) a Ser at position 36 of SEQ ID NO:85; (q) a Asn at
position 37 of SEQ ID NO:85; (r) a Phe at position 38 of SEQ ID
NO:85; (s) a Thr at position 39 of SEQ ID NO:85; (t) a Cys at
position 40 of SEQ ID NO:85; (u) a Gln at position 41 of SEQ ID
NO:85; (v) a Thr at position 42 of SEQ ID NO:85; (w) a Glu at
position 43 of SEQ ID NO:85; (x) a Gly at position 44 of SEQ ID
NO:85; (y) a Ala at position 45 of SEQ ID NO:85; (z) a Cys at
position 46 of SEQ ID NO:85; (aa) a Trp at position 47 of SEQ ID
NO:85: (ab) a Ala at position 48 of SEQ ID NO:85; (ac) a Ser at
position 49 of SEQ ID NO:85; (ad) a Val at position 50 of SEQ ID
NO:85; (ae) a Met at position 51 of SEQ ID NO:85; (af) a Leu at
position 52 of SEQ ID NO:85; (ag) a Thr at position 53 of SEQ ID
NO:85; (ah) a Asn at position 54 of SEQ ID NO:85; (ai) a Gly at
position 55 of SEQ ID NO:85; (aj) a Lys at position 56 of SEQ ID
NO:85; (ak) a Glu at position 57 of SEQ ID NO:85; (al) a Gln at
position 58 of SEQ ID NO:85; (am) a Val at position 59 of SEQ ID
NO:85; (an) a lie at position 60 of SEQ ID NO:85; (ao) a Lys at
position 61 of SEQ ID NO:85; (ap) a Ser at position 62 of SEQ ID
NO:85; (aq) a Cys at position 63 of SEQ ID NO:85; (ar) a Val at
position 64 of SEQ ID NO:85; (as) a Ser at position 65 of SEQ ID
NO:85; (at) a Leu at position 66 of SEQ ID NO:85; (au) a Pro at
position 67 of SEQ ID NO:85; (av) a Glu at position 68 of SEQ ID
NO:85; (aw) a Leu at position 69 of SEQ ID NO:85; (ax) a Asn at
position 70 of SEQ ID NO:85; (ay) a Ala at position 71 of SEQ ID
NO:85; (az) a Gln at position 72 of SEQ ID NO:85; (ba) a Val at
position 73 of SEQ ID NO:85; (bb) a Phe at position 74 of SEQ ID
NO:85; (be) a Cys at position 75 of SEQ ID NO:85; (bd) a His at
position 76 of SEQ ID NO:85; (be) a Ser at position 77 of SEQ ID
NO:85; (bf) a Ser at position 78 of SEQ ID NO:85; (bg) a Asn at
position 79 of SEQ ID NO:85; (bh) a Asn at position 80 of SEQ ID
NO:85; (bi) a Val at position 81 of SEQ ID NO:85; (bj) a Thr at
position 82 of SEQ ID NO:85; (bk) a Lys at position 83 of SEQ ID
NO:85; (bl) a Thr at position 84 of SEQ ID NO:85; (bm) a Glu at
position 85 of SEQ ID NO:85; (bn) a Cys at position 86 of SEQ ID
NO:85; (bo) a Cys at position 87 of SEQ ID NO:85; (bp) a Phe at
position 88 of SEQ ID NO:85; (bq) a Thr at position 89 of SEQ ID
NO:85; (br) a Asp at position 90 of SEQ ID NO:85; (bs) a Phe at
position 91 of SEQ ID NO:85; (bt) a Cys at position 92 of SEQ ID
NO:85; (bu) a Asn at position 93 of SEQ ID NO:85; (bv) a Asn at
position 94 of SEQ ID NO:85; (bw) a Ile at position 95 of SEQ ID
NO:85; (bx) a Thr at position 96 of SEQ ID NO:85; (by) a Leu at
position 97 of SEQ ID NO:85; (bz) a His at position 98 of SEQ ID
NO:85; (ca) a Leu at position 99 of SEQ ID NO:85; (cb) a Pro at
position 100 of SEQ ID NO:85; (cc) a Thr at position 101 of SEQ ID
NO:85; (cd) a Ala at position 102 of SEQ ID NO:85; (ce) a Ser at
position 103 of SEQ ID NO:85; (cf) a Pro at position 104 of SEQ ID
NO:85; (cg) a Asn at position 105 of SEQ ID NO:85; (ch) a Ala at
position 106 of SEQ ID NO:85; (ci) a Pro at position 107 of SEQ ID
NO:85; (cj) a Lys at position 108 of SEQ ID NO:85; (ck) a Leu at
position 109 of SEQ ID NO:85; (cl) a Gly at position 110 of SEQ ID
NO:85; (cm) a Pro at position 111 of SEQ ID NO:85; (cn) a Met at
position 112 of SEQ ID NO:85; and (co) a Glu at position 113 of SEQ
ID NO:85; and increases lipolysis (e.g., lipolysis of white
adipocytes and/or brown adipocytes).
In some embodiments, the ALK7-binding protein specifically binds to
ALK7 between amino acids 28-92 of SEQ ID NO:85. In some
embodiments, the ALK7-binding protein specifically binds to ALK7
between amino acids 28-92 of SEQ ID NO:85 and inhibits one or more
ALK7 ligands (e.g., GDF1, GDF3, GDF8, activin B, activin A/B,
and/or Nodal) from binding to ALK7. In some embodiments, the
ALK7-binding protein specifically binds to ALK7 between amino acids
28-92 of SEQ ID NO:85 and contacts one or more amino acids selected
from the group consisting of: (a) a Cys at position 28 of SEQ ID
NO:85; (b) a Val at position 29 of SEQ ID NO:85; (c) a Cys at
position 30 of SEQ ID NO:85; (d) a Leu at position 31 of SEQ ID
NO:85; (e) a Leu at position 32 of SEQ ID NO:85; (f) a Cys at
position 33 of SEQ ID NO:85; (g) a Asp at position 34 of SEQ ID
NO:85; (h) a Ser at position 35 of SEQ ID NO:85; (i) a Ser at
position 36 of SEQ ID NO:85; (j) a Asn at position 37 of SEQ ID
NO:85; (k) a Phe at position 38 of SEQ ID NO:85; (l) a Thr at
position 39 of SEQ ID NO:85; (m) a Cys at position 40 of SEQ ID
NO:85; (n) a Gln at position 41 of SEQ ID NO:85; (o) a Thr at
position 42 of SEQ ID NO:85; (p) a Glu at position 43 of SEQ ID
NO:85; (q) a Gly at position 44 of SEQ ID NO:85; (r) a Ala at
position 45 of SEQ ID NO:85; (s) a Cys at position 46 of SEQ ID
NO:85; (t) a Trp at position 47 of SEQ ID NO:85; (u) a Ala at
position 48 of SEQ ID NO:85; (v) a Ser at position 49 of SEQ ID
NO:85; (w) a Val at position 50 of SEQ ID NO:85; (x) a Met at
position 51 of SEQ ID NO:85; (y) a Leu at position 52 of SEQ ID
NO:85; (z) a Thr at position 53 of SEQ ID NO:85; (aa) a Asn at
position 54 of SEQ ID NO:85; (ab) a Gly at position 55 of SEQ ID
NO:85; (ac) a Lys at position 56 of SEQ ID NO:85; (ad) a Glu at
position 57 of SEQ ID NO:85; (ae) a Gln at position 58 of SEQ ID
NO:85; (af) a Val at position 59 of SEQ ID NO:85; (ag) a Ile at
position 60 of SEQ ID NO:85; (ah) a Lys at position 61 of SEQ ID
NO:85; (ai) a Ser at position 62 of SEQ ID NO:85; (aj) a Cys at
position 63 of SEQ ID NO:85; (ak) a Val at position 64 of SEQ ID
NO:85; (al) a Ser at position 65 of SEQ ID NO:85; (am) a Leu at
position 66 of SEQ ID NO:85; (an) a Pro at position 67 of SEQ ID
NO:85; (ao) a Glu at position 68 of SEQ ID NO:85; (ap) a Leu at
position 69 of SEQ ID NO:85; (aq) a Asn at position 70 of SEQ ID
NO:85; (ar) a Ala at position 71 of SEQ ID NO:85; (as) a Gln at
position 72 of SEQ ID NO:85; (at) a Val at position 73 of SEQ ID
NO:85; (au) a Phe at position 74 of SEQ ID NO:85; (av) a Cys at
position 75 of SEQ ID NO:85; (aw) a His at position 76 of SEQ ID
NO:85; (ax) a Ser at position 77 of SEQ ID NO:85; (ay) a Ser at
position 78 of SEQ ID NO:85; (az) a Asn at position 79 of SEQ ID
NO:85; (ba) a Asn at position 80 of SEQ ID NO:85; (bb) a Val at
position 81 of SEQ ID NO:85; (bc) a Thr at position 82 of SEQ ID
NO:85; (bd) a Lys at position 83 of SEQ ID NO:85; (be) a Thr at
position 84 of SEQ ID NO:85; (bf) a Glu at position 85 of SEQ ID
NO:85; (bg) a Cys at position 86 of SEQ ID NO:85; (bh) a Cys at
position 87 of SEQ ID NO:85; (bi) a Phe at position 88 of SEQ ID
NO:85; (bj) a Thr at position 89 of SEQ ID NO:85; (bk) a Asp at
position 90 of SEQ ID NO:85: (bl) a Phe at position 91 of SEQ ID
NO:85; and (bm) a Cys at position 92 of SEQ ID NO:85. In some
embodiments, the ALK7-binding protein specifically binds to ALK7
between amino acids 28-92 of SEQ ID NO: 85 and contacts one or more
amino acids selected from the group consisting of: (a) a Cys at
position 28 of SEQ ID NO:85; (b) a Val at position 29 of SEQ ID
NO:85; (c) a Cys at position 30 of SEQ ID NO:85; (d) a Leu at
position 31 of SEQ ID NO:85; (e) a Leu at position 32 of SEQ ID
NO:85; (f) a Cys at position 33 of SEQ ID NO:85; (g) a Asp at
position 34 of SEQ ID NO:85; (h) a Ser at position 35 of SEQ ID
NO:85; (i) a Ser at position 36 of SEQ ID NO:85; (j) a Asn at
position 37 of SEQ ID NO:85; (k) a Phe at position 38 of SEQ ID
NO:85; (l) a Thr at position 39 of SEQ ID NO:85; (m) a Cys at
position 40 of SEQ II) NO:85; (n) a Gln at position 41 of SEQ ID
NO:85; (o) a Thr at position 42 of SEQ ID NO:85; (p) a Glu at
position 43 of SEQ ID NO:85; (q) a Gly at position 44 of SEQ ID
NO:85; (r) a Ala at position 45 of SEQ ID NO:85; (s) a Cys at
position 46 of SEQ ID NO:85; (t) a Trp at position 47 of SEQ ID
NO:85; (u) a Ala at position 48 of SEQ ID NO:85; (v) a Ser at
position 49 of SEQ ID NO:85; (w) a Val at position 50 of SEQ ID
NO:85; (x) a Met at position 51 of SEQ ID NO:85; (y) a Leu at
position 52 of SEQ ID NO:85; (z) a Thr at position 53 of SEQ ID
NO:85; (aa) a Asn at position 54 of SEQ ID NO:85; (ab) a Gly at
position 55 of SEQ ID NO:85; (ac) a Lys at position 56 of SEQ ID
NO:85; (ad) a Glu at position 57 of SEQ ID NO:85; (ae) a Gln at
position 58 of SEQ ID NO:85; (af) a Val at position 59 of SEQ ID
NO:85; (ag) a lie at position 60 of SEQ ID NO:85; (ah) a Lys at
position 61 of SEQ ID NO:85; (ai) a Ser at position 62 of SEQ ID
NO:85; (aj) a Cys at position 63 of SEQ ID NO:85; (ak) a Val at
position 64 of SEQ ID NO:85; (al) a Ser at position 65 of SEQ ID
NO:85; (am) a Leu at position 66 of SEQ ID NO:85; (an) a Pro at
position 67 of SEQ ID NO:85; (ao) a Glu at position 68 of SEQ ID
NO:85; (ap) a Leu at position 69 of SEQ ID NO:85; (aq) a Asn at
position 70 of SEQ ID NO:85; (ar) a Ala at position 71 of SEQ ID
NO:85; (as) a Gln at position 72 of SEQ ID NO:85; (at) a Val at
position 73 of SEQ ID NO:85; (au) a Phe at position 74 of SEQ ID
NO:85; (av) a Cys at position 75 of SEQ ID NO:85; (aw) a His at
position 76 of SEQ ID NO:85; (ax) a Ser at position 77 of SEQ ID
NO:85; (ay) a Ser at position 78 of SEQ ID NO:85; (az) a Asn at
position 79 of SEQ ID NO:85; (ba) a Asn at position 80 of SEQ ID
NO:85; (bb) a Val at position 81 of SEQ ID NO:85; (bc) a Thr at
position 82 of SEQ ID NO:85; (bd) a Lys at position 83 of SEQ ID
NO:85; (be) a Thr at position 84 of SEQ ID NO:85; (bf) a Glu at
position 85 of SEQ ID NO:85; (bg) a Cys at position 86 of SEQ ID
NO:85; (bh) a Cys at position 87 of SEQ ID NO:85; (bi) a Phe at
position 88 of SEQ ID NO:85; (bj) a Thr at position 89 of SEQ ID
NO:85; (bk) a Asp at position 90 of SEQ ID NO:85; (bl) a Phe at
position 91 of SEQ ID NO:85; and (bm) a Cys at position 92 of SEQ
ID NO:85; and inhibits one or more ALK7 ligands (e.g., GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal) from binding to ALK7.
In some embodiments, the ALK7-binding protein specifically binds to
ALK7 between amino acids 28-92 of SEQ ID NO:85 and increases
lipolysis (e.g., lipolysis of white adipocytes and/or brown
adipocytes). In some embodiments, the ALK7-binding protein
specifically binds to ALK7 between amino acids 28-92 of SEQ ID
NO:85 and contacts one or more amino acids selected from the group
consisting of: (a) a Cys at position 28 of SEQ ID NO:85; (b) a Val
at position 29 of SEQ ID NO:85; (c) a Cys at position 30 of SEQ ID
NO:85; (d) a Leu at position 31 of SEQ ID NO:85; (e) a Leu at
position 32 of SEQ ID NO:85; (f) a Cys at position 33 of SEQ ID
NO:85; (g) a Asp at position 34 of SEQ ID NO:85; (h) a Ser at
position 35 of SEQ ID NO:85; (i) a Ser at position 36 of SEQ ID
NO:85; (j) a Asn at position 37 of SEQ ID NO:85; (k) a Phe at
position 38 of SEQ ID NO:85; (l) a Thr at position 39 of SEQ ID
NO:85; (m) a Cys at position 40 of SEQ ID NO:85; (n) a Gln at
position 41 of SEQ ID NO:85; (o) a Thr at position 42 of SEQ ID
NO:85; (p) a Glu at position 43 of SEQ ID NO:85; (q) a Gly at
position 44 of SEQ ID NO:85; (r) a Ala at position 45 of SEQ ID
NO:85; (s) a Cys at position 46 of SEQ ID NO:85; (t) a Trp at
position 47 of SEQ ID NO:85; (u) a Ala at position 48 of SEQ ID
NO:85; (v) a Ser at position 49 of SEQ ID NO:85; (w) a Val at
position 50 of SEQ ID NO:85; (x) a Met at position 51 of SEQ ID
NO:85; (y) a Leu at position 52 of SEQ ID NO:85; (z) a Thr at
position 53 of SEQ ID NO:85; (aa) a Asn at position 54 of SEQ ID
NO:85; (ab) a Gly at position 55 of SEQ ID NO:85; (ac) a Lys at
position 56 of SEQ ID NO:85; (ad) a Glu at position 57 of SEQ ID
NO:85; (ae) a Gln at position 58 of SEQ ID NO:85; (af) a Val at
position 59 of SEQ ID NO:85; (ag) a lie at position 60 of SEQ ID
NO:85; (ah) a Lys at position 61 of SEQ ID NO:85; (ai) a Ser at
position 62 of SEQ ID NO:85; (aj) a Cys at position 63 of SEQ ID
NO:85; (ak) a Val at position 64 of SEQ ID NO:85; (al) a Ser at
position 65 of SEQ ID NO:85; (am) a Leu at position 66 of SEQ ID
NO:85; (an) a Pro at position 67 of SEQ ID NO:85; (ao) a Glu at
position 68 of SEQ ID NO:85; (ap) a Leu at position 69 of SEQ ID
NO:85; (aq) a Asn at position 70 of SEQ ID NO:85; (ar) a Ala at
position 71 of SEQ ID NO:85; (as) a Gln at position 72 of SEQ ID
NO:85; (at) a Val at position 73 of SEQ ID NO:85; (au) a Phe at
position 74 of SEQ ID NO:85; (av) a Cys at position 75 of SEQ ID
NO:85; (aw) a His at position 76 of SEQ ID NO:85; (ax) a Ser at
position 77 of SEQ ID NO:85; (ay) a Ser at position 78 of SEQ ID
NO:85; (az) a Asn at position 79 of SEQ ID NO:85; (ba) a Asn at
position 80 of SEQ ID NO:85; (bb) a Val at position 81 of SEQ ID
NO:85; (bc) a Thr at position 82 of SEQ ID NO:85; (bd) a Lys at
position 83 of SEQ ID NO:85; (be) a Thr at position 84 of SEQ ID
NO:85; (bf) a Glu at position 85 of SEQ ID NO:85; (bg) a Cys at
position 86 of SEQ ID NO:85; (bh) a Cys at position 87 of SEQ ID
NO:85; (bi) a Phe at position 88 of SEQ ID NO:85; (bj) a Thr at
position 89 of SEQ ID NO:85; (bk) a Asp at position 90 of SEQ ID
NO:85; (bl) a Phe at position 91 of SEQ ID NO:85; and (bm) a Cys at
position 92 of SEQ ID NO:85; and increases lipolysis (e.g.,
lipolysis of white adipocytes and/or brown adipocytes).
Nucleic acids and sets of nucleic acids encoding ALK7-binding
proteins are also provided. Vectors and sets of vectors containing
the nucleic acids and sets of nucleic acids, and host cells
transformed with the nucleic acids and vectors are further
provided. In some embodiments, the host cell is a hybridoma or
mammalian host cell such as, a NS0 murine myeloma cell, a
PER.C6.RTM. human cell, or a Chinese hamster ovary (CHO) cell. Host
cells including mammalian host cells and hybridomas that produce
ALK7-binding proteins are also provided.
Methods for making an ALK7-binding protein are also provided. In
some embodiments, the method comprises culturing a host cell
capable of expressing the ALK7-binding protein under suitable
conditions for expressing the protein and optionally isolating the
expressed ALK7-binding protein. ALK7-binding proteins prepared
and/or isolated using methods disclosed herein or otherwise known
in the art are also provided.
Pharmaceutical compositions comprising an ALK7-binding protein and
a pharmaceutically acceptable carrier are further provided. In some
embodiments, the disclosure provides methods for treating and/or
ameliorating a condition in a subject associated with elevated ALK7
expression or ALK7-mediated signaling, or that can be treated
and/or ameliorated by decreased ALK7 signaling. In some
embodiments, the methods decrease ALK7-mediated signaling in the
subject.
Conditions that may be treated and/or ameliorated in a subject
using the provided methods include, but are not limited to: obesity
(e.g., abdominal obesity); overweight; insulin resistance;
metabolic syndrome and other metabolic diseases or conditions; a
lipid disorder such as, low HDL levels, high LDL levels,
hyperlipidemia, hypertriglyceridemia or dyslipidemia; lipoprotein
aberrations; decreased triglycerides; inflammation (e.g., liver
inflammation and/or inflammation of adipose tissue), fatty liver
disease; non-alcoholic fatty liver disease; hyperglycemia; impaired
glucose tolerance (IGT); hyperinsulinemia; high cholesterol (e.g.,
high LDL levels and hypercholesterolemia); cardiovascular disease
such as, heart disease including coronary heart disease, congestive
heart failure, stroke, peripheral vascular disease, disordered
fibrinolysis, atherosclerosis; arteriosclerosis, and hypertension;
Syndrome X; vascular restenosis; neuropathy; retinopathy;
neurodegenerative disease; endothelial dysfunction, respiratory
dysfunction, renal disease (e.g., nephropathy); pancreatitis;
polycystic ovarian syndrome; elevated uric acid levels;
haemochromatosis (iron overload); acanthosis nigricans (dark
patches on the skin); and cancer (e.g., myeloma (multiple myeloma,
plasmacytoma, localized myeloma, or extramedullary myeloma), or an
ovarian, breast, colon, endometrial, liver, kidney, pancreatic,
gastric, uterine and/or colon cancer); and other
disorders/conditions associated with one or more of the above
diseases or conditions, or with overweight (e.g., BMI.gtoreq.25
kg/m.sup.2), or too much body fat.
In some embodiments, the disclosed methods include administering a
pharmaceutical composition comprising an effective amount of an
ALK7-binding protein (e.g., an antagonist ALK7 binding protein such
as an antagonist anti-ALK7 antibody) to a subject in need thereof.
In some embodiments, the ALK7-binding protein is administered
alone. In other embodiments, the ALK7-binding protein is
administered as a combination therapy. In further embodiments, the
ALK7-binding protein is administered as a combination therapy to
the standard of care treatment/therapy.
Methods of blocking or reducing ALK7 activity (e.g., ligand binding
and/or signaling) are also provided. In some embodiments the method
comprises contacting an ALK7-binding protein and a cell that
expresses ALK7, (e.g., a differentiated white or brown adipocyte).
In some instances the method comprises contacting an ALK7-binding
protein and a cell that expresses ALK7, in the presence of GDF1,
GDF3, GDF8, activin B, activin A/B, and/or Nodal. In some
embodiments, the method is performed in vivo. In other embodiments,
the method is performed in vitro. In some embodiments the blocked
or reduced ALK7 activity is the phosphorylation of ALK7. In
additional embodiments the blocked or reduced ALK7 activity is the
phosphorylation of Smads (e.g., Smad2 and/or Smad3). In some
embodiments, the disclosure provides a method of blocking or
reducing ALK7 activity in a subject that comprises administering an
effective amount of an ALK7-binding protein to a subject in need
thereof.
Also provided is a method of blocking or reducing ALK7 activity in
a pathological condition associated with ALK7 expression and/or
ALK7 signaling, or in a pathological condition that can be treated
and/or ameliorated by reducing or inhibiting the activity of an
ALK7-ligand. In some instances, the method comprises administering
an ALK7-binding protein to a subject having increased expression of
ALK7 or an ALK7-ligand. In some embodiments, the pathological
condition is obesity, diabetes, metabolic disease, dyslipidemia;
cardiovascular disease, type 2 diabetes, inflammation, or a
pulmonary, fatty liver disease, neurologic, and hepatic, or renal
disease.
In one embodiment, the disclosure provides a method of treating or
ameliorating overweight or a condition associated with being
overweight, comprising administering to an overweight subject an
effective amount of an ALK7-binding protein (e.g., an antagonist
ALK7 binding protein such as an antagonist anti-ALK7 antibody). In
one embodiment, the he treated or ameliorated condition is obesity.
In another embodiment, the treated or ameliorated condition is a
member selected from the group consisting of dyslipidemia,
hyperlipidemia, hypercholesterolemia, low HDL serum level, high LDL
serum level (e.g., LDL-C.gtoreq.100 mg/dL, .gtoreq.130 mg/dL,
.gtoreq.160 mg/dL), and hypertriglyceridemia (e.g., TG.gtoreq.150
mg/dL, .gtoreq.160 mg/dL, .gtoreq.170 mg/dL). In another
embodiment, the treated or ameliorated condition is hypertension.
In another embodiment, the treated or ameliorated condition is
diabetes. In one embodiment, the administered ALK7-binding protein
is an ALK7 antagonist. In one embodiment, the administered
antagonist ALK7-binding protein is an anti-ALK7 antibody or an
ALK7-binding antibody fragment. In another embodiment the
administered antagonist ALK7-binding protein is an anti-ALK7
antibody or an ALK7-binding antibody fragment disclosed herein. In
one embodiment, the administered ALK7-binding protein comprises a
VH and VL pair disclosed in Table 1A. In another embodiment, the
administered ALK7-binding protein cross-blocks or competes for
binding to ALK7 with an antibody comprising a VH and a VL sequence
pair disclosed in Table 1A. In one embodiment, the administered
ALK7-binding protein comprises a VH and VL pair disclosed in Table
1B or Table 3. In another embodiment, the administered ALK7-binding
protein cross-blocks or competes for binding to ALK7 with an
antibody comprising a VH and a VL sequence pair disclosed in Table
1B or Table 3. In one embodiment, the administered ALK7-binding
protein comprises a VH and VL pair disclosed in Table 1A, Table 1B,
or Table 3. In another embodiment, the administered ALK7-binding
protein cross-blocks or competes for binding to ALK7 with an
antibody comprising a VH and a VL sequence pair disclosed in Table
1A, Table 1B, or Table 3.
In one embodiment, the disclosure provides a method of treating or
ameliorating obesity or a condition associated with obesity,
comprising administering to an obese subject an effective amount of
an ALK7-binding protein (e.g., an antagonist ALK7 binding protein
such as an antagonist anti-ALK7 antibody). In one embodiment the
treated or ameliorated condition is hypertension, dyslipidemia (for
example, high total cholesterol or high levels of triglycerides),
type 2 diabetes, coronary heart disease, stroke, gallbladder
disease, osteoarthritis, sleep disorders, respiratory problems,
cancer (e.g., myeloma (multiple myeloma, plasmacytoma, localized
myeloma, or extramedullary myeloma), or an ovarian, breast, colon,
endometrial, liver, kidney, pancreatic, gastric, uterine and/or
colon cancer), obesity linked gallbladder disease, obesity linked
inflammation, obesity induced sleep apnea, steatosis (fatty liver),
glucagonomas, arteriosclerosis or heart failure. In some
embodiments the subject to which the ALK7 binding protein is
administered is at risk of developing hypertension, dyslipidemia
(for example, high total cholesterol or high levels of
triglycerides), type 2 diabetes, coronary heart disease, stroke,
gallbladder disease, osteoarthritis, sleep disorders, respiratory
problems, cancer (e.g., a myeloma (multiple myeloma, plasmacytoma,
localized myeloma, or extramedullary myeloma), or an ovarian,
breast, colon, endometrial, liver, kidney, pancreatic, gastric,
uterine or colon cancer), obesity linked gallbladder disease,
obesity linked inflammation, obesity induced sleep apnea,
steatosis, glucagonomas, arteriosclerosis or heart failure. In one
embodiment, the administered ALK7-binding protein is an ALK7
antagonist. In one embodiment, the administered antagonist
ALK7-binding protein is an anti-ALK7 antibody or an ALK7-binding
antibody fragment. In another embodiment the administered
antagonist ALK7-binding protein is an anti-ALK7 antibody or an
ALK7-binding antibody fragment disclosed herein. In one embodiment,
the administered ALK7-binding protein comprises a VH and VL pair
disclosed in Table 1A. In another embodiment, the administered
ALK7-binding protein cross-blocks or competes for binding to ALK7
with an antibody comprising a VH and a VL sequence pair disclosed
in Table 1A. In one embodiment, the administered ALK7-binding
protein comprises a VH and VL pair disclosed in Table 3. In another
embodiment, the administered ALK7-binding protein cross-blocks or
competes for binding to ALK7 with an antibody comprising a VH and a
VL sequence pair disclosed in Table 3. In one embodiment, the
administered ALK7-binding protein comprises a VH and VL pair
disclosed in Table 1A, Table 1B, or Table 3. In another embodiment,
the administered ALK7-binding protein cross-blocks or competes for
binding to ALK7 with an antibody comprising a VH and a VL sequence
pair disclosed in Table 1A, Table 1B, or Table 3.
In one embodiment, the disclosure provides a method of treating or
ameliorating type II diabetes or a condition associated with type
II diabetes, comprising administering to a diabetic subject an
effective amount of an ALK7-binding protein (e.g., an antagonist
ALK7 binding protein such as an antagonist anti-ALK7 antibody). In
one embodiment, the disclosure provides a method of treating or
ameliorating a condition associated with type II diabetes. In a
further embodiment, the condition is a member selected from: an eye
condition (e.g., glaucoma, cataracts, and retinopathy),
cardiovascular disease (e.g., hypertension, atherosclerosis,
myocardial infarction, and stroke), hyperglycemia, peripheral
neuropathy, and kidney disease (e.g., nephropathy). In an
additional embodiment, the subject is at risk of developing type II
diabetes or a condition associated with type II diabetes. In
another embodiment, the subject is at risk of developing an eye
condition (e.g., glaucoma, cataracts, and retinopathy),
cardiovascular disease (e.g., hypertension, atherosclerosis,
myocardial infarction, disordered fibrinolysis, and stroke),
hyperglycemia, peripheral neuropathy, or kidney disease (e.g.,
nephropathy). In one embodiment, the administered ALK7-binding
protein is an ALK7 antagonist. In one embodiment, the administered
antagonist ALK7-binding protein is an anti-ALK7 antibody or an
ALK7-binding antibody fragment. In another embodiment the
administered antagonist ALK7-binding protein is an anti-ALK7
antibody or an ALK7-binding antibody fragment disclosed herein. In
one embodiment, the administered ALK7-binding protein comprises a
VH and VL pair disclosed in Table 1A. In one embodiment, the
administered ALK7-binding protein comprises a VH and VL pair
disclosed in Table 3. In another embodiment, the administered
ALK7-binding protein cross-blocks or competes for binding to ALK7
with an antibody comprising a VH and a VL sequence pair disclosed
in Table 1B or Table 3.
In one embodiment, the disclosure provides a method of treating or
ameliorating a metabolic disease or disorder or a condition
associated with a metabolic disease or disorder, comprising
administering to an effective amount of an ALK7-binding protein
(e.g., an antagonist ALK7 binding protein such as an antagonist
anti-ALK7 antibody) to a subject in need thereof. In one embodiment
the treated or ameliorated condition is an alteration of lipid,
lipoprotein or apolipoprotein metabolism. In another embodiment the
embodiment, the metabolic condition is high plasma triglyceride
levels, hypertension, dyslipidemia high fasting blood sugar, low
HDL cholesterol levels. In another embodiment, the treated or
ameliorated condition is atherosclerosis, arteriosclerosis, or
endothelial dysfunction. In one embodiment the treated or
ameliorated condition is chronic inflammation. In another
embodiment the treated or ameliorated condition is non-alcoholic
fatty liver disease (e.g., fatty liver and/or NASH). In one
embodiment, the administered ALK7-binding protein is an ALK7
antagonist. In one embodiment, the administered antagonist
ALK7-binding protein is an anti-ALK7 antibody or an ALK7-binding
antibody fragment. In another embodiment the administered
antagonist ALK7-binding protein is an anti-ALK7 antibody or an
ALK7-binding antibody fragment disclosed herein. In one embodiment,
the administered ALK7-binding protein comprises a VH and VL pair
disclosed in Table 1A. In another embodiment, the administered
ALK7-binding protein cross-blocks or competes for binding to ALK7
with an antibody comprising a VH and a VL sequence pair disclosed
in Table 1A. In one embodiment, the administered ALK7-binding
protein comprises a VH and VL pair disclosed in Table 1B or Table
3. In another embodiment, the administered ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH and a VL sequence pair disclosed in Table 1B or
Table 3.
In one embodiment, the disclosure provides a method of treating or
ameliorating insulin resistance or a condition associated with
insulin resistance, comprising administering an effective amount of
an ALK7-binding protein (e.g., an antagonist ALK7 binding protein
such as an antagonist anti-ALK7 antibody) to a subject in need
thereof. In a further embodiment, the he treated or ameliorated
condition is associated with impaired glucose tolerance or
hyperglycemia. In another embodiment, the treated or ameliorated
condition is associated with hypertension or atherosclerosis. In
another embodiment, the treated or ameliorated condition is a
member selected from the group consisting of: dyslipidemia,
hyperlipidemia, hypercholesterolemia, low HDL serum level, high LDL
serum level (e.g., LDL-C.gtoreq.100 mg/dL, .gtoreq.130 mg/dL,
.gtoreq.160 mg/dL), and hypertriglyceridemia (e.g., TG.gtoreq.150
mg/dL, .gtoreq.160 mg/dL, .gtoreq.170 mg/dL). In one embodiment,
the administered ALK7-binding protein is an ALK7 antagonist. In one
embodiment, the administered antagonist ALK7-binding protein is an
anti-ALK7 antibody or an ALK7-binding antibody fragment. In another
embodiment the administered antagonist ALK7-binding protein is an
anti-ALK7 antibody or an ALK7-binding antibody fragment disclosed
herein. In one embodiment, the administered ALK7-binding protein
comprises a VH and VL pair disclosed in Table 1A. In another
embodiment, the administered ALK7-binding protein cross-blocks or
competes for binding to ALK7 with an antibody comprising a VH and a
VL sequence pair disclosed in Table 1A. In one embodiment, the
administered ALK7-binding protein comprises a VH and VL pair
disclosed in Table 1B or Table 3. In another embodiment, the
administered ALK7-binding protein crossblocks or competes for
binding to ALK7 with an antibody comprising a VH and a VL sequence
pair disclosed in Table 1B or Table 3.
In one embodiment, the disclosure provides a method of treating or
ameliorating a disease or disorder of the eyes, nervous system,
kidney, lungs, and/or liver, or associated condition, comprising
administering to an effective amount of an ALK7-binding protein
(e.g., an antagonist ALK7 binding protein such as an antagonist
anti-ALK7 antibody) to a subject in need thereof. In one
embodiment, the treated or ameliorated condition is inflammation.
In one embodiment, the treated or ameliorated condition is
nephropathy (e.g., diabetic nephropathy), arteriosclerosis of the
renal artery), or kidney failure. In a further embodiment, the
treated or ameliorated condition is chronic inflammation. In a
further embodiment the treated or ameliorated condition
inflammation of adipose tissue. In another embodiment, the treated
or ameliorated condition is inflammation of the liver. In another
embodiment the treated or ameliorated condition is NAFLD (e.g.,
fatty liver and/or NASH). In some embodiments, the subject to which
the ALK7 binding protein is administered is at risk of developing a
disease or disorder of the kidney, lungs, or liver. In some
embodiments, the subject to which the ALK7 binding protein is
administered is at risk of developing nephropathy. In some
embodiments, the subject to which the ALK7 binding protein is
administered is at risk of developing nephropathy. In one
embodiment, the subject is at risk of developing chronic
inflammation. In one embodiment, the subject is at risk of
developing inflammation of adipose tissue. In an additional
embodiment, the subject is at risk of developing inflammation of
the liver. In one embodiment, the administered ALK7-binding protein
is an ALK7 antagonist. In one embodiment, the administered
antagonist ALK7-binding protein is an anti-ALK7 antibody or an
ALK7-binding antibody fragment. In another embodiment the
administered antagonist ALK7-binding protein is an anti-ALK7
antibody or an ALK7-binding antibody fragment disclosed herein. In
one embodiment, the administered ALK7-binding protein comprises a
VH and VL pair disclosed in Table 1A. In another embodiment, the
administered ALK7-binding protein cross-blocks or competes for
binding to ALK7 with an antibody comprising a VH and a VL sequence
pair disclosed in Table 1A. In one embodiment, the administered
ALK7-binding protein comprises a VH and VL pair disclosed in Table
1B or Table 3. In another embodiment, the administered ALK7-binding
protein cross-blocks or competes for binding to ALK7 with an
antibody comprising a VH and a VL sequence pair disclosed in Table
1B or Table 3.
In one embodiment, the disclosure provides a method of treating or
ameliorating a cardiovascular disease or disorder or a condition
associated with a cardiovascular disease or disorder, comprising
administering to an effective amount of an ALK7-binding protein
(e.g., an antagonist ALK7 binding protein such as an antagonist
anti-ALK7 antibody) to a subject in need thereof. In one
embodiment, the treated or ameliorated condition is coronary heart
disease, congestive heart failure, vascular restenosis, stroke,
peripheral vascular disease, microvascular disease, disordered
fibrinolysis, or arteriosclerosis. In one embodiment, the subject
to which the ALK7 binding protein is administered is at risk of
developing coronary heart disease, congestive heart failure,
vascular restenosis, stroke, peripheral vascular disease,
microvascular disease, or arteriosclerosis. In one embodiment, the
treated or ameliorated condition is hypertension (e.g., blood
pressure>130/80 mmHg in a resting state). In one embodiment, the
subject to which the ALK7 binding protein is administered is at
risk of developing hypertension. In one embodiment, the treated or
ameliorated condition is atherosclerosis. In one embodiment, the
subject to which the ALK7 binding protein is administered is at
risk of developing atherosclerosis. In one embodiment, the
administered ALK7-binding protein is an ALK7 antagonist. In one
embodiment, the administered antagonist ALK7-binding protein is an
anti-ALK7 antibody or an ALK7-binding antibody fragment. In another
embodiment the administered antagonist ALK7-binding protein is an
anti-ALK7 antibody or an ALK7-binding antibody fragment disclosed
herein. In one embodiment, the administered ALK7-binding protein
comprises a VH and VL pair disclosed in Table 1A. In another
embodiment, the administered ALK7-binding protein cross-blocks or
competes for binding to ALK7 with an antibody comprising a VH and a
VL sequence pair disclosed in Table 1A. In one embodiment, the
administered ALK7-binding protein comprises a VH and VL pair
disclosed in Table 1B. In another embodiment, the administered
ALK7-binding protein cross-blocks or competes for binding to ALK7
with an antibody comprising a VH and a VL sequence pair disclosed
in Table 1B. In one embodiment, the administered ALK7-binding
protein comprises a VH and VL pair disclosed in Table 3. In another
embodiment, the administered ALK7-binding protein cross-blocks or
competes for binding to ALK7 with an antibody comprising a VH and a
VL sequence pair disclosed in Table 3.
BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES
FIG. 1 shows the amount of adipose change in TBS and ALK7 mAb
treated high-fat diet (HFD) mice. Changes in the amount of adipose
are relative to baseline prior to ALK7 Ab or TBS treatment.
Treatment with ALK7 mAbs (i.e., J02, K02, G05, C03, and L02)
significantly reduced fat mass in HFD mice. * designates p>0.001
vs. HFD+TBS.
FIG. 2 shows the amount of lean body mass change in TBS and ALK7
mAb treated high-fat diet (HFD) mice. Changes in the amount of lean
mass are relative to baseline prior to ALK7 Ab or TBS treatment.
Treatment with ALK7 mAbs (i.e., J02, K02, G05, C03, and L02) did
not change lean body mass in HFD mice.
DETAILED DESCRIPTION
The disclosure provides isolated and/or recombinant ALK7-binding
proteins. In certain embodiments the ALK7-binding proteins
specifically bind ALK7. In further embodiments, the ALK7-binding
proteins are anti-ALK7 antibodies. Nucleic acids encoding the
ALK7-binding proteins, vectors and host cells containing the
nucleic acids, and methods of making and using the ALK7-binding
proteins are also provided. The provided ALK7-binding proteins have
uses in diagnosing, treating, and/or ameliorating diseases and
conditions associated with increased ALK7 expression and/or
signaling. Such uses include but are not limited to, preventing,
and/or ameliorating obesity (e.g., abdominal obesity); overweight;
insulin resistance; metabolic syndrome and other metabolic diseases
or conditions; a lipid disorder such as, low HDL levels, high LDL
levels, hyperlipidemia, hypertriglyceridemia or dyslipidemia;
lipoprotein aberrations; decreased triglycerides; inflammation
(e.g., liver inflammation and/or inflammation of adipose tissue),
fatty liver disease; non-alcoholic fatty liver disease;
hyperglycemia; impaired glucose tolerance (IGT); hyperinsulinemia;
high cholesterol (e.g., high LDL levels and hypercholesterolemia);
cardiovascular disease such as, heart disease including coronary
heart disease, congestive heart failure, stroke, peripheral
vascular disease, atherosclerosis; arteriosclerosis, and
hypertension; Syndrome X; vascular restenosis; neuropathy;
retinopathy; neurodegenerative disease; endothelial dysfunction,
respiratory dysfunction, renal disease (e.g., nephropathy);
pancreatitis; polycystic ovarian syndrome; elevated uric acid
levels; haemochromatosis (iron overload); acanthosis nigricans
(dark patches on the skin); and cancer (e.g., a myeloma (multiple
myeloma, plasmacytoma, localized myeloma, or extramedullary
myeloma), or an ovarian, breast, colon, endometrial, liver, kidney,
pancreatic, gastric, uterine and/or colon cancer); and other
disorders/conditions associated with one or more of the above
diseases or conditions, or with overweight (e.g., BMI of 25
kg/m.sup.2), or too much body fat.
Definitions
Unless defined otherwise, all technical and scientific terms used
herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this disclosure is related. For
example, the Concise Dictionary of Biomedicine and Molecular
Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of
Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the
Oxford Dictionary Of Biochemistry And Molecular Biology, Revised,
2000, Oxford University Press, provide one of skill with a general
dictionary of many of the terms used in this disclosure. The
headings provided herein are not limitations of the various
embodiments which can be had by reference to the specification as a
whole. Moreover, the terms defined immediately below are more fully
defined by reference to the specification in its entirety.
The terms "a," "an" and "the" include plural referents unless the
context in which the term is used clearly dictates otherwise. The
terms "a" (or "an"), as well as the terms "one or more," and "at
least one" can be used interchangeably herein. Furthermore,
"and/or" where used herein is to be taken as specific disclosure of
each of the two or more specified features or components with or
without the other. Thus, the term "and/or" as used in a phrase such
as "A and/or B" herein is intended to include "A and B," "A or B,"
"A" (alone), and "B" (alone). Likewise, the term "and/or" as used
in a phrase such as "A, B, and/or C" is intended to encompass each
of the following embodiments: A, B, and C; A, B, or C; A or C; A or
B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C
(alone).
The term "comprise" is generally used in the sense of include, that
is to say permitting the presence of one or more features or
components. Wherever embodiments are described herein with the
language "comprising," otherwise analogous embodiments described in
terms of "consisting of," and/or "consisting essentially of" are
also provided.
The terms "about" and "approximately" as used in connection with a
numerical value throughout the specification and the claims denotes
an interval of accuracy, familiar and acceptable to a person
skilled in the art. In general, such interval of accuracy is
.+-.10%. Alternatively, and particularly in biological systems, the
terms "about" and "approximately" may mean values that are within
an order of magnitude, preferably .ltoreq.5-fold and more
preferably .ltoreq.2-fold of a given value.
Numeric ranges are inclusive of the numbers defining the range.
An ALK7-binding protein refers to a protein that specifically binds
to ALK7, preferably binding to the extracellular domain of
ALK7.
The terms "ALK7" and "ALK7 receptor" are used interchangeably and
refer to ALK7 (also referred to as ACVRLK7, Activin A Receptor,
Type IC, ACVR-1C, Activin Receptor-Like kinase 7, and EC 2.7.11 in
the literature). Reference sequence for human ALK7 is provided in
NCBI Reference Sequences NP_001104501.1. The provided ALK7-binding
proteins bind the extracellular domain of human ALK7 corresponding
to the amino acid sequence of SEQ ID NO:86. Reference sequence for
rat ALK7 is provided in NCBI Reference Sequences P70539. In some
embodiments, the provided ALK7-binding proteins bind the
extracellular domain of rat ALK7 corresponding to the amino acid
sequence of SEQ ID NO:87.
The term "compete" or "competes" when used in the context of
ALK7-binding proteins (e.g., neutralizing antibodies) means
competition between antigen binding proteins as determined by an
assay in which the antigen binding protein (e.g., an anti-ALK7
antibody or an ALK7-binding fragment thereof) under test prevents
or inhibits specific binding of a reference antigen binding protein
(e.g., a ligand, or a reference antibody) to a common antigen
(e.g., an ALK7 extracellular domain or a fragment thereof).
Numerous types of competitive binding assays can be used, for
example: solid phase direct or indirect radioimmunoassay (RIA)
(see, e.g., Moldenhauer et al., Scand. J. Immunol. 32:77-82 (1990)
and Morel et al., Molec. Immunol. 25:7-15 (1988)), solid phase
direct or indirect enzyme immunoassay (EIA), solid phase direct
biotin-avidin EIA (see, e.g., Cheung, et al., Virology 176:546-552
(1990) and Kirkland et al., J. Immunol. 137:3614-3619 (1986)) and a
sandwich competition assay (see, e.g., Stahli et al., Methods in
Enzymology 92:242-253 (1983)). Typically, such an assay involves
the use of purified antigen bound to a solid surface or cells
bearing either of these, an unlabeled test antigen binding protein
and a labeled reference antigen binding protein.
Competitive inhibition can be measured by determining the amount of
label bound to the solid surface or cells in the presence of the
test antigen binding protein. Usually the test antigen binding
protein is present in excess. Antigen binding proteins identified
by competition assay (competing antigen binding proteins) include
ALK7-binding proteins that bind to the same epitope as the
reference ALK7-binding protein as well as ALK7-binding proteins
that bind to an adjacent epitope sufficiently proximal to the
epitope bound by the reference ALK7-binding protein for steric
hindrance to occur. Usually, when a competing ALK7 binding protein
is present in excess, it will inhibit specific binding of a
reference ALK7-binding protein to ALK7 by at least 40%, 45%, 50%,
55%, 60%, 65%, 70% or 75%. In some instance, a competing antigen
binding protein inhibits specific binding of a reference
ALK7-binding protein by at least 80%, 85%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97% 98%, or 99%.
The term "epitope" when used in context of an ALK7 protein refers
to an ALK7 (e.g., human ALK7 or murine ALK7) protein determinant
capable of binding to an ALK7-binding protein (e.g., an antibody)
of the disclosure. Epitopes usually consist of chemically active
surface groupings of molecules such as amino acids or sugar side
chains and usually have specific three-dimensional structural
characteristics, as well as specific charge characteristics.
Conformational and non-conformational epitopes are distinguished in
that the binding to the former but not the latter is lost in the
presence of denaturing solvents. The ALK7 epitope bound by an
ALK7-binding protein can readily be determined using techniques
known in the art.
Antigen binding proteins such as the anti-ALK7-binding antibodies
and ALK7-binding fragments, variants, or derivatives thereof
disclosed herein, can be described or specified in terms of the
epitope(s) or portion(s) of an antigen, e.g., a target polypeptide
that they recognize or specifically bind. For example, the portion
of ALK7 that specifically interacts with the antigen binding domain
of an ALK7-binding protein disclosed herein is an "epitope."
Epitopes can be formed both from contiguous amino acids or
noncontiguous amino acids juxtaposed by tertiary folding of a
protein. Epitopes formed from contiguous amino acids are typically
retained on exposure to denaturing solvents, whereas epitopes
formed by tertiary folding are typically lost on treatment with
denaturing solvents. Epitope determinants may include chemically
active surface groupings of molecules such as amino acids, sugar
side chains, phosphoryl or sulfonyl groups, and may have specific
three dimensional structural characteristics, and/or specific
charge characteristics. An epitope typically includes at least 3,
4, 5, 6, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 25, 30, 35 amino acids in a unique spatial conformation.
Epitopes can routinely be determined using methods known in the
art.
The terms "inhibit," "block," "reduce," "decrease," "suppress,"
"antagonize," and "neutralize" are used interchangeably and refer
to any statistically significant decrease in activity (e.g., ALK7
ligand binding and/or ALK7 signaling), including full blocking of
the activity. For example, "inhibition," "suppression," or
"antagonize" can refer to a decrease of about 10%, 20%, 30%, 40%,
50%, 60%, 70%, 80%, 90% or 100% in activity compared to a
control.
In some embodiments, the term "decrease," "inhibit," or
"antagonize" may refer to the ability of an ALK7-binding protein
such as an antibody or ALK7-binding fragment thereof, to
statistically significantly (e.g., with a p value less than or
equal to 0.05) decrease the phosphorylation of one or more Smads
(e.g., Smad2 and/or Smad3) induced by contacting a cell expressing
ALK7 and ActrIIA/B with an ALK7 ligand such as, GDF1, GDF3, GDF8,
activin B, activin A/B, and/or Nodal, relative to the extent of
Smad phosphorylation in the cell when not contacted with the
ALK7-binding protein. The cell which expresses ALK7 can be a
naturally occurring cell or a cell line, or can be recombinantly
produced by introducing a nucleic acid encoding ALK7 into a host
cell. In one embodiment, the ALK7-binding protein, e.g., an ALK7
antibody or ALK7-binding fragment thereof, antagonizes (decreases)
ALK7 ligand mediated phosphorylation of one or more Smads (e.g.,
Smad2 and/or Smad3) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, or 95%, or by about 100%, as determined, for example, by
Western blotting followed by probing with an anti-phosphotyrosine
antibody or by ELISA (e.g., P-Smad ELISA) or a Smad dependent
reporter gene assay using techniques described herein or otherwise
known in the art. In one embodiment, the ALK7-binding protein,
antagonizes (decreases) ALK7-mediated inhibition of lipolysis in
adipose cells. In one embodiment, an ALK7-binding protein is an
ALK7 antagonist and antagonizes ALK7-mediated inhibition of
lipolysis in white adipose cell by 5% to 100%, 10% to 95%, 10 to
90%, 10 to 85%, 10 to 80%, 10 to 75%, 10 to 70%, 10 to 75%, 10 to
70%, 10 to 60%, 10 to 55%, 10 to 50%, or 10 to 45%, as determined
in a lipolysis assay. In another embodiment, an ALK7-binding
protein reduces or decreases ALK7-mediated inhibition of lipolysis
in white adipose cells by at least 5%, 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, or 95%, or by about 100%, as determined in a
lipolysis assay. In some embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands. In further
embodiments, the lipolysis assay is performed in the presence of
one or more ALK7 ligands selected from the group consisting of
GDF1, GDF3, GDF8, activin B, activin A/B, and Nodal).
In one embodiment, an ALK7-binding protein is an ALK7 antagonist
and antagonizes ALK7-mediated inhibition of lipolysis in white
and/or brown adipose cells by 5% to 100%, 10% to 95%, 10 to 90%, 10
to 85%, 10 to 80%, 10 to 75%, 10 to 70%, 10 to 75%, 10 to 70%, 10
to 60%, 10 to 55%, 10 to 50%, or 10 to 45%, as determined in a
lipolysis assay. In another embodiment, an ALK7-binding protein
reduces or decreases ALK7-mediated inhibition of lipolysis in white
and/or brown adipose cells by at least 5%, 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, or 950, or by about 100%, as determined in a
lipolysis assay. In some embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands. In further
embodiments, the lipolysis assay is performed in the presence of
one or more ALK7 ligands selected from the group consisting of
GDF1, GDF3, GDF8, activin B, activin A/B, and Nodal).
The terms "increase," "promote" and "agonist" are used
interchangeably and refer to any statistically significant increase
in activity (e.g., ALK7 ligand binding and/or ALK7 signaling). For
example, "increase" or "promote" can refer to an increase of about
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% in activity
compared to a control.
In some embodiments, the ALK7-binding protein increases lipolysis
in cells. In some embodiments, the ALK7-binding protein increases
lipolysis in cells by at least 5% to 100%, 10% to 95%, 10 to 90%,
10 to 85%, 10 to 80%, 10 to 75%, 10 to 70%, 10 to 75%, 10 to 70%,
10 to 60%, 10 to 55%, 10 to 50%, or 10 to 45%, as determined in a
lipolysis assay. In some embodiments, the ALK7-binding protein
increases lipolysis in adipose cells. In some embodiments, the
ALK7-binding protein increases lipolysis in adipose cells by at
least 5% to 100%, 10% to 95%, 10 to 90%, 10 to 85%, 10 to 80%, 10
to 75%, 10 to 70%, 10 to 75%, 10 to 70%, 10 to 60%, 10 to 55%, 10
to 50%, or 10 to 45%, as determined in a lipolysis assay. In some
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands. In further embodiments, the lipolysis assay
is performed in the presence of one or more ALK7 ligands selected
from the group consisting of GDF1, GDF3, GDF8, activin B, activin
A/B, and Nodal. In some embodiments, the ALK7-binding protein
increases lipolysis in white adipose cells or brown adipose
cells.
In some embodiments, the ALK7-binding protein increases lipolysis
in white adipose cells. In some embodiments, the ALK7-binding
protein increases lipolysis in white adipose cells by at least 5%
to 100%, 10% to 95%, 10 to 90%, 10 to 85%, 10 to 80%, 10 to 75%, 10
to 70%, 10 to 75%, 10 to 70%, 10 to 60%, 10 to 55%, 10 to 50%, or
10 to 45%, as determined in a lipolysis assay. In some embodiments
the lipolysis assay is performed in the presence of one or more
ALK7 ligands. In further embodiments, the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal.
In some embodiments, the ALK7-binding protein increases lipolysis
in brown adipose cells. In some embodiments, the ALK7-binding
protein increases lipolysis in brown adipose cells by at least 5%
to 100%, 10% to 95%, 10 to 90%, 10 to 85%, 10 to 80%, 10 to 75%, 10
to 70%, 10 to 75%, 10 to 70%, 10 to 60%, 10 to 55%, 10 to 50%, or
10 to 45%, as determined in a lipolysis assay. In some embodiments
the lipolysis assay is performed in the presence of one or more
ALK7 ligands. In further embodiments, the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal.
In some embodiments, the ALK7-binding protein increases lipolysis
in white and brown adipose cells. In some embodiments, the
ALK7-binding protein increases lipolysis in white and brown adipose
cells by at least 5% to 100%, 10% to 95%, 10 to 90%, 10 to 85%, 10
to 80%, 10 to 75%, 10 to 70%, 10 to 75%, 10 to 70%, 10 to 60%, 10
to 55%, 10 to 50%, or 10 to 45%, as determined in a lipolysis
assay. In some embodiments the lipolysis assay is performed in the
presence of one or more ALK7 ligands. In further embodiments, the
lipolysis assay is performed in the presence of one or more ALK7
ligands selected from the group consisting of GDF1, GDF3, GDF8,
activin B, activin A/B, and Nodal.
In an additional embodiment, an ALK7-binding protein increases
lipolysis in white adipose cells by at least 5% to 100%, 10% to
95%, 10 to 90%, 10 to 85%, 10 to 80%, 10 to 75%, 10 to 70%, 10 to
75%, 10 to 70%, 10 to 60%, 10 to 55%, 10 to 50%, or 10 to 45%, as
determined using standard techniques and conditions in a lipolysis
assay performed in the presence of activin B (50 ng/ml) (e.g., as
described in the examples herein). In another embodiment, an
ALK7-binding protein reduces or decreases ALK7-mediated inhibition
of lipolysis in white adipose cells by at least 5%, 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, or 95%, or by about 1000, as
determined, using standard techniques and conditions in a lipolysis
inhibition assay. the lipolysis assay is performed in the presence
of activin B (50 ng/ml) (e.g., as described in the examples
herein).
In an additional embodiment, an ALK7-binding protein increases
lipolysis in white and/or brown adipose cells by at least 5% to
100%, 10% to 95%, 10 to 90%, 10 to 85%, 10 to 80%, 10 to 75%, 10 to
70%, 10 to 75%, 10 to 70%, 10 to 60%, 10 to 55%, 10 to 50%, or 10
to 45%, as determined using standard techniques and conditions in a
lipolysis assay performed in the presence of activin B (50 ng/ml)
(e.g., as described in the examples herein). In another embodiment,
an ALK7-binding protein reduces or decreases ALK7-mediated
inhibition of lipolysis in white adipose cells by at least 5%, 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or by about 100%,
as determined, using standard techniques and conditions in a
lipolysis inhibition assay. the lipolysis assay is performed in the
presence of activin B (50 ng/ml) (e.g., as described in the
examples herein).
In some embodiments, the ALK7-binding protein increases glycerol
production in adipose cells. In some embodiments, the ALK7-binding
protein increases glycerol production in adipose cells by at least
5% to 100%, 10% to 95%, 10 to 90%, 10 to 85%, 10 to 80%, 10 to 75%,
10 to 70%, 10 to 75%, 10 to 70%, 10 to 60%, 10 to 55%, 10 to 50%,
or 10 to 45%, as determined in a lipolysis assay. In some
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands. In some embodiments, the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein increases
glycerol production in white adipose cells or brown adipose
cells.
The terms "antibody" and "immunoglobulin," are used interchangeably
herein, and include whole (full-length) antibodies and antigen
binding fragment or single chains thereof. A typical antibody
comprises at least two heavy (H) chains and two light (L) chains
interconnected by disulfide bonds. Each heavy chain is comprised of
a heavy chain variable region (abbreviated herein as VH) and a
heavy chain constant region. The heavy chain constant region is
comprised of three domains, CH1, CH2, and CH3. Each light chain is
comprised of a light chain variable region (abbreviated herein as
VL) and a light chain constant region. The light chain constant
region is comprised of one domain, CL. The VH and VL regions can be
further subdivided into regions of hypervariability, termed
Complementarity Determining Regions (CDR), interspersed with
regions that are more conserved, termed framework regions (FW).
Each VH and VL is composed of three CDRs and four FWs, arranged
from amino-terminus to carboxy-terminus in the following order:
FW1, CDR1, FW2, CDR2, FW3, CDR3, FW4. The variable regions of the
heavy and light chains contain a binding domain that interacts with
an antigen. The constant regions of the antibodies can mediate the
binding of the immunoglobulin to host tissues or factors, including
various cells of the immune system (e.g., effector cells) and the
first component (Clq) of the classical complement system. Exemplary
antibodies include typical antibodies, scFvs, and combinations
thereof where, for example, an scFv is covalently linked (for
example, via peptidic bonds or via a chemical linker) to the N or
C-terminus of either the heavy chain and/or the light chain of a
typical antibody, or intercalated in the heavy chain and/or the
light chain of a typical antibody.
The terms "antibody" and "immunoglobulin," encompass intact
polyclonal antibodies, intact monoclonal antibodies, antibody
fragments (such as Fab, Fab', F(ab')2, and Fv fragments), single
chain Fv (scFv) derivatives and mutants, multispecific antibodies
such as bispecific antibodies, chimeric antibodies, humanized
antibodies, human antibodies, fusion proteins comprising an antigen
determination portion of an antibody, and any other modified
immunoglobulin molecule comprising an antigen recognition site so
long as the antibodies exhibit the desired binding activity. An
antibody can be of any the five major classes of immunoglobulins:
IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof
(e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), based on the
identity of their heavy-chain constant domains referred to as
alpha, delta, epsilon, gamma, and mu, respectively. The different
classes of immunoglobulins have different and well known subunit
structures and three-dimensional configurations. Antibodies can be
naked or conjugated to other molecules such as toxins,
radioisotopes, etc. The term "IgG" refers to a polypeptide
belonging to the class of antibodies that are substantially encoded
by a recognized immunoglobulin gamma gene. In humans this class
comprises IgG1, IgG2, IgG3, and IgG4. In mice this class comprises
IgG1, IgG2a, IgG2b, and IgG3.
The terms "ALK7 antibody," "an antibody that binds to ALK7," or
"anti-ALK7 antibody" refer to an antibody that is capable of
binding ALK7 with sufficient affinity such that the antibody is
useful as a therapeutic agent or diagnostic reagent in targeting
ALK7, respectively.
By "specifically binds" when used in the context of ALK7 proteins,
it is generally meant the ability of a binding protein such as an
antibody, to bind to ALK7 (e.g., human ALK7, preferably an
extracellular domain of ALK7), with greater affinity than the
binding protein binds to an unrelated control protein. In some
embodiments, the control protein is hen egg white lysozyme.
Preferably the binding protein binds ALK7 with an affinity that is
at least, 100, 500, or 1000 times greater than the affinity for a
control protein. Preferably, the binding protein has a binding
affinity for human ALK7 of .ltoreq.1.times.10.sup.-7 M or
.ltoreq.1.times.10.sup.-8 as measured using a binding assay known
in the art. In some embodiments, the binding affinity is measured
using a radioimmunoassay (RIA) or BIACORE.RTM. (e.g., using ALK7 as
the analyte and ALK7-binding protein as the ligand, or vice
versa).
In some embodiments, the extent of binding of an ALK7-binding
protein (e.g., an anti-ALK7 antibody) to an unrelated, non-ALK7
protein is less than about 10% of the binding of the ALK7-binding
protein to ALK7 as measured, for example, by a radioimmunoassay
(RIA), BIACORE.RTM. (using recombinant ALK7 as the analyte and
ALK7-binding protein as the ligand, or vice versa), kinetic
exclusion assay (KINEXA.RTM.), or other binding assays known in the
art. In certain embodiments, the ALK7-binding protein is a
full-length antibody or an ALK7-binding antibody fragment that has
a dissociation constant (K.sub.D) of .ltoreq.1 .mu.M, .ltoreq.100
nM, .ltoreq.10 nM, .ltoreq.1 nM, .ltoreq.0.1 nM, .ltoreq.10 pM,
.ltoreq.1 pM, or .ltoreq.0.1 pM.
The term "antigen binding antibody fragment" (e.g., "ALK7-binding
antibody fragment") refers to a fragment containing all or a
portion of an antigen binding variable region (e.g., CDR3) of an
intact antibody. It is known that the antigen binding function of
an antibody can be performed by fragments of a full-length
antibody. Examples of antibody fragments include, but are not
limited to Fab, Fab', F(ab')2, and Fv fragments, linear antibodies,
single chain antibodies, and multispecific antibodies formed from
one or more antibody fragments. In some embodiments the disclosure
provides ALK7-binding antibody fragments wherein the antibody
fragment is a Fab fragment, a Fab' fragment, a F(ab').sub.2
fragment, a Fv fragment, a diabody, or a single chain antibody
molecule.
The Fc region includes polypeptides comprising the constant region
of an antibody excluding the first constant region immunoglobulin
domain. Thus, Fc refers to the last two constant region
immunoglobulin domains of IgA, IgD, and IgG, and the last three
constant region immunoglobulin domains of IgE and IgM, and the
flexible hinge N-terminal to these domains. For IgA and 1 .mu.M Fc
may include the J chain. For IgG, Fe comprises immunoglobulin
domains C.gamma.2 and C.gamma.3 and the hinge between C.gamma.1 and
C.gamma.2. Although the boundaries of the Fe region may vary, the
human IgG heavy chain Fc region is usually defined to comprise
residues C226 or P230 to its carboxyl-terminus, wherein the
numbering is according to the EU index as set forth in Kabat (Kabat
et al., Sequences of Proteins of Immunological Interest, 5th Ed.
Public Health Service, NIH, Bethesda, Md. (1991)). Fc may refer to
this region in isolation, or this region in the context of a whole
antibody, antibody fragment, or Fc fusion protein. Polymorphisms
have been observed at a number of different Fc positions, including
but not limited to positions 270, 272, 312, 315, 356, and 358 as
numbered by the EU index, and thus slight differences between the
presented sequence and sequences in the prior art may exist.
A "monoclonal antibody" refers to a homogeneous antibody population
involved in the highly specific recognition and binding of a single
antigenic determinant or epitope. This is in contrast to polyclonal
antibodies that typically include different antibodies directed
against different antigenic determinants. The term "monoclonal
antibody" encompasses both intact and full-length monoclonal
antibodies as well as antibody fragments (such as Fab, Fab',
F(ab')2, and Fv), single chain (scFv) mutants, and fusion proteins)
comprising an antibody portion, and any other modified
immunoglobulin molecule comprising an antigen recognition site. A
monoclonal antibody may be made in any number of ways including,
but not limited to, by hybridoma, phage selection, recombinant
expression, and transgenic animals.
The term "chimeric antibody" refers to an antibody wherein the
amino acid sequence of the immunoglobulin molecule is derived from
two or more species. Typically, the variable region of both light
and heavy chains corresponds to the variable region of antibodies
derived from one species of mammal (e.g., mouse, rat, rabbit, etc.)
with the desired antigen-binding specificity, affinity, and/or
capability while the constant regions are homologous to the
sequences in antibodies derived from another species (usually
human) to avoid eliciting an immune response in that species.
The term "humanized antibody" refers to an antibody derived from a
non-human (e.g., murine) immunoglobulin, which has been engineered
to contain fewer preferably minimal non-human (e.g., murine)
sequences. Typically, humanized antibodies are human
immunoglobulins in which residues from the CDR are replaced by
residues from the CDR of a non-human species (e.g., mouse, rat,
rabbit, or hamster) that have the desired antigen-binding
specificity, affinity, and/or capability (Jones, Nature 321:522-525
(1986); Riechmann, Nature 332:323-327 (1988); Verhoeyen, Science
239:1534-1536 (1988)). In some instances, the Fv framework region
(FW) residues of a human immunoglobulin are replaced with the
corresponding residues in an antibody from a non-human species that
has the desired antigen-binding specificity, affinity, and/or
capability. The humanized antibody can be further modified by the
substitution of additional residues either in the Fv framework
region and/or within the replaced non-human residues to refine and
optimize antibody specificity, affinity, and/or capability. In
general, the humanized antibody will comprise substantially all of
at least one, and typically two or three, variable domains
containing all or substantially all of the CDR regions that
correspond to the non-human immunoglobulin whereas all or
substantially all of the FR regions are those of a human
immunoglobulin consensus sequence. The humanized antibody can also
comprise at least a portion of an immunoglobulin constant region or
domain (Fc), typically that of a human immunoglobulin. Examples of
methods used to generate humanized antibodies are described in U.S.
Pat. Nos. 5,225,539 and 5,639,641.
The term "human antibody" refers to an antibody produced by a human
or an antibody having an amino acid sequence corresponding to an
antibody produced by a human made using any technique known in the
art. The term "human antibody" includes intact (full-length)
antibodies, fragments thereof, and/or antibodies comprising at
least one human heavy and/or light chain polypeptide such as, an
antibody comprising murine light chain and human heavy chain
polypeptides.
An "antagonist," "blocking," or "neutralizing" binding protein is
one that inhibits or reduces activity of the antigen it binds, such
as ALK7. In some embodiments, the antagonist ALK7-binding protein
reduces or inhibits the multimerization of ALK7, and ActRII
receptor (e.g., ActRIIA or ActRIIB) an GDF1, GDF3, GDF8, activin B,
activin A/B, and/or Nodal. In certain embodiments the antagonist
ALK7-binding protein substantially or completely inhibits the
activity of the ALK7. In some embodiments, the ALK7 activity is
reduced by 10%, 20%, 30%, 50%, 70%, 80%, 90%, 95%, or 100%. In
certain embodiments the antagonist ALK7-binding protein is an
anti-ALK7 antibody, such as a full-length antibody or an
ALK7-binding antibody fragment. In further embodiments, the
antagonist anti-ALK7 antibody inhibits or reduces the activity of
ALK7 by at least 10%, 20%, 30%, 50%, 70%, 80%, 90%, 95%, or even
100%.
"Binding affinity" generally refers to the strength of the sum
total of non-covalent interactions between a single binding site of
a molecule (e.g., an antibody) and its binding partner (e.g., an
antigen). Unless indicated otherwise, "binding affinity" refers to
intrinsic binding affinity which reflects a 1:1 interaction between
members of a binding pair (e.g., antibody and antigen). The
affinity of a molecule X for its partner Y can generally be
represented by the dissociation constant (K.sub.D). Affinity can be
measured by common methods known in the art, including those
described herein and can be used for the purposes of the present
disclosure.
"Potency" is a measure of pharmacological activity of a compound
expressed in terms of the amount of the compound required to
produce an effect of given intensity. It refers to the amount of
the compound required to achieve a defined biological effect; the
smaller the dose required, the more potent the drug. Potency is
normally expressed as an IC.sub.50 value, in nM unless otherwise
stated. IC.sub.50 is the median inhibitory concentration of an
ALK7-binding protein (e.g., an anti-ALK7 antibody). In functional
assays, IC.sub.50 is the concentration that reduces a biological
response by 50% of its maximum. In ligand-receptor binding studies,
IC.sub.50 is the concentration that reduces ligand-receptor binding
by 50% of maximal specific binding level. IC.sub.50 can be
calculated by any number of means known in the art. The fold
improvement in potency for the antibodies or other binding protein
provided herein as compared to a reference anti-ALK7 antibody or
other ALK7-binding protein can be at least 2-fold, 4-fold, 6-fold,
8-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold,
70-fold, 80-fold, 90-fold, 100-fold, 110-fold, 120-fold, 130-fold,
140-fold, 150-fold, 160-fold, 170-fold, or at least 180-fold.
"Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to
a form of cytotoxicity in which secreted Ig bound onto Fc receptors
(FcRs) present on certain cytotoxic cells (e.g., Natural Killer
(NK) cells, neutrophils, and macrophages) enables these cytotoxic
effector cells to bind specifically to an antigen-bearing target
cell and subsequently kill the target cell with cytotoxins.
Specific high-affinity IgG antibodies directed to the surface of
target cells "arm" the cytotoxic cells and are absolutely required
for such killing. Lysis of the target cell is extracellular,
requires direct cell-to-cell contact, and does not involve
complement. It is contemplated that, in addition to antibodies,
other proteins comprising Fc regions, specifically Fc fusion
proteins, having the capacity to specifically bind to an
ALK7-bearing target cell will be able to effect cell-mediated
cytotoxicity. For simplicity, the cell-mediated cytotoxicity
resulting from the activity of an Fc fusion protein is also
referred to herein as ADCC activity.
An ALK7-binding protein (e.g., an ALK7 antibody, including an
ALK7-binding fragment, variant, and derivative thereof),
polynucleotide, vector, cell, or composition which is "isolated" is
a protein (e.g., antibody), polynucleotide, vector, cell, or
composition which is in a form not found in nature. Isolated
proteins, polynucleotides, vectors, cells or compositions include
those which have been purified to a degree that they are no longer
in a form in which they are found in nature. In some embodiments, a
protein, polynucleotide, vector, cell, or composition which is
isolated is substantially pure. Isolated proteins and isolated
nucleic acid will be free or substantially free of material with
which they are naturally associated such as other polypeptides or
nucleic acids with which they are found in their natural
environment, or the environment in which they are prepared (e.g.,
cell culture) when such preparation is by recombinant DNA
technology practiced in vitro or in vivo. Proteins and nucleic acid
may be formulated with diluents or adjuvants and still for
practical purposes be isolated--for example the proteins will
normally be mixed with gelatin or other carriers if used to coat
microtitre plates for use in immunoassays, or will be mixed with
pharmaceutically acceptable carriers or diluents when used in
diagnosis or therapy.
The terms "subject," "individual," "animal," "patient," and
"mammal," refer to any subject, particularly a mammalian subject,
for whom diagnosis, prognosis, or therapy is desired. Mammalian
subjects include but are not limited to humans, non-human primates,
domestic animals, farm animals, rodents, and the like, which is to
be the recipient of a particular treatment.
The term "pharmaceutical composition" refers to a preparation which
is in such form as to permit the biological activity of the active
ingredient to be effective, and which contains no additional
components at concentrations that are unacceptably toxic to a
subject to which the composition would be administered. Such
composition can be sterile.
An "effective amount" of a polypeptide, e.g., an antigen binding
protein including an antibody, as disclosed herein is an amount
sufficient to carry out a specifically stated purpose. An
"effective amount" can be determined empirically and in a routine
manner, in relation to the stated purpose. The term
"therapeutically effective amount" refers to an amount of a
polypeptide, e.g., an antigen binding protein including an
antibody, or other drug effective to "treat" a disease or condition
in a subject (e.g., a mammal such as a human) and provides some
improvement or benefit to a subject having the disease or
condition. Thus, a "therapeutically effective" amount is an amount
that provides some alleviation, mitigation, and/or decrease in at
least one clinical symptom of an ALK7-mediated disease or
condition. Clinical symptoms associated with the diseases or
conditions that can be treated by the methods of the disclosure are
well known. Further, therapeutic effects need not be complete or
curative, as long as some benefit is provided to the subject. In
some embodiments, the term "therapeutically effective" refers to an
amount of a therapeutic agent that is capable of reducing ALK7
activity in a subject in need thereof. The actual amount
administered and rate and time-course of administration, will
depend on the nature and severity of what is being treated.
Prescription of treatment, e.g., decisions on dosage etc., is
within the responsibility of general practitioners and other
medical doctors. Appropriate doses of antibodies and antigen
binding fragments thereof are generally known; see, Ledermann et
al., Int. J. Cancer 47:659-664 (1991); Bagshawe et al., Ant. Immun.
and Radiopharm. 4:915-922 (1991).
A "sufficient amount" or "an amount sufficient to" achieve a
particular result in a subject having an ALK7-mediated disease or
condition refers to an amount of a therapeutic agent (e.g., an
antigen binding protein including an antibody, as disclosed herein)
that is effective to produce a desired effect, which is optionally
a therapeutic effect (i.e., by administration of a therapeutically
effective amount). In some embodiments, such particular result is a
reduction in ALK7 activity in a subject in need thereof.
The term "label" refers to a detectable compound or composition
which is conjugated directly or indirectly to a moiety such as an
anti-ALK7 antibody so as to generate a "labeled" moiety. The label
can be detectable by itself (e.g., radioisotope labels or
fluorescent labels) or, in the case of an enzymatic label, can
catalyze chemical alteration of a substrate compound or composition
which is detectable.
Terms such as "treating," or "treatment," "to treat" or
"ameliorating" and "to ameliorate" refer to both (a) therapeutic
measures that cure, slow down, lessen symptoms of, and/or halt
progression of a diagnosed pathologic condition or disorder and (b)
prophylactic or preventative measures that prevent and/or slow the
development of a targeted disease or condition. Thus, subjects in
need of treatment include those already with the disease or
condition; those at risk of developing the disease or condition;
and those in whom the disease or condition is to be prevented. In
certain embodiments, a subject is successfully "treated" according
to the methods provided herein if the subject shows, e.g., total,
partial, or transient amelioration or elimination of a symptom
associated with the disease or condition. In some embodiments, the
disclosure provides a method for treating a disease, disorder or
condition selected from, obesity (e.g., abdominal obesity); insulin
resistance; metabolic syndrome and other metabolic diseases or
conditions; a lipid disorder such as, low HDL levels, high LDL
levels, hyperlipidemia, hypertriglyceridemia or dyslipidemia;
lipoprotein aberrations; decreased triglycerides; inflammation
(e.g., liver inflammation and/or inflammation of adipose tissue),
fatty liver disease; non-alcoholic fatty liver disease;
hyperglycemia; impaired glucose tolerance (IGT); hyperinsulinemia;
high cholesterol (e.g., high LDL levels and hypercholesterolemia);
cardiovascular disease such as, heart disease including coronary
heart disease, congestive heart failure, stroke, peripheral
vascular disease, atherosclerosis; arteriosclerosis, and
hypertension; Syndrome X; vascular restenosis; neuropathy;
retinopathy; neurodegenerative disease; endothelial dysfunction,
respiratory dysfunction, renal disease (e.g., nephropathy);
pancreatitis; polycystic ovarian syndrome; elevated uric acid
levels; haemochromatosis (iron overload); acanthosis nigricans
(dark patches on the skin); and cancer (e.g., myeloma (multiple
myeloma, plasmacytoma, localized myeloma, or extramedullary
myeloma), or an ovarian (e.g., epithelial ovarian), breast, colon,
endometrial, liver, kidney, pancreatic, gastric, uterine, or colon
cancer); and other disorders/conditions associated with one or more
of the above diseases or conditions, or with overweight (e.g., BMI
of 25 kg/m.sup.2), or with too much body fat.
As used herein, "in combination with" or "combination therapies"
refers to any form of administration such that additional therapies
(e.g., second, third, fourth, etc.) are still effective in the body
(e.g., multiple compounds are simultaneously effective in the
subject, which may include synergistic effects of those compounds).
Effectiveness may not correlate to measurable concentration of the
agent in blood, serum, or plasma. For example, the different
therapeutic compounds can be administered either in the same
formulation or in separate formulations, either concomitantly or
sequentially, and on different schedules. Thus, a subject that
receives such treatment can benefit from a combined effect of
different therapies. One or more ALK7-binding proteins provided
herein can be administered concurrently with, prior to, or
subsequent to, one or more other additional agents and/or
supportive therapies. In general, each therapeutic agent will be
administered at a dose and/or on a time schedule determined for
that particular agent. The particular combination to employ in a
regimen will take into account compatibility of the antagonist of
the present disclosure with therapy and/or the desired outcome.
The methods and techniques of the present disclosure are generally
performed according to known conventional methods and as described
in various general and more specific references that are cited and
discussed throughout the present disclosure unless otherwise
indicated. See, e.g., Sambrook et al., Molecular Cloning: A
Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y. (2001) and Ausubel et al., Current
Protocols in Molecular Biology, Greene Publishing Associates
(1992), and Harlow and Lane Antibodies: A Laboratory Manual Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990),
all of which are herein incorporated by reference.
The terms "cancer," "tumor," "cancerous," and "malignant" refer to
or describe the physiological condition in mammals that is
typically characterized by unregulated cell growth. Examples of
cancers include but are not limited to, carcinoma including
adenocarcinomas, lymphomas, blastomas, melanomas, sarcomas, and
leukemias. More particular examples of such cancers include
squamous cell cancer, small-cell lung cancer, non-small cell lung
cancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin's
lymphoma, pancreatic cancer, glioblastoma, glioma, cervical cancer,
ovarian cancer, liver cancer such as hepatic carcinoma and
hepatoma, bladder cancer, breast cancer (including hormonally
mediated breast cancer, see, e.g., Innes et al., Br. J. Cancer
94:1057-1065 (2006)), colon cancer, colorectal cancer, endometrial
carcinoma, myeloma (such as multiple myeloma), salivary gland
carcinoma, kidney cancer such as renal cell carcinoma and Wilms'
tumors, basal cell carcinoma, melanoma, prostate cancer, vulval
cancer, thyroid cancer, testicular cancer, esophageal cancer,
various types of head and neck cancer and cancers of mucinous
origins, such as, mucinous ovarian cancer, cholangiocarcinoma
(liver) and renal papillary carcinoma. In a particular embodiment,
the cancer is breast, endometrial, or uterine cancer. In another
embodiment, the cancer is a myeloma (e.g., multiple myeloma,
plasmacytoma, localized myeloma, and extramedullary myeloma), or
endometrial, gastric, liver, colon, renal or pancreatic cancer.
The terms "polynucleotide" and "nucleic acid" are used
interchangeably and are intended to encompass a singular nucleic
acid as well as plural nucleic acids, and refers to an isolated
nucleic acid molecule or construct, e.g., messenger RNA (mRNA),
complementary DNA (cDNA), or plasmid DNA (pDNA). In certain
embodiments, a polynucleotide comprises a conventional
phosphodiester bond or a non-conventional bond (e.g., an amide
bond, such as found in peptide nucleic acids (PNA)). The term
"nucleic acid" refers to any one or more nucleic acid segments,
e.g., DNA, cDNA, or RNA fragments, present in a polynucleotide.
When applied to a nucleic acid or polynucleotide, the term
"isolated" refers to a nucleic acid molecule, DNA or RNA, which has
been removed from its native environment, for example, a
recombinant polynucleotide encoding an antigen binding protein
contained in a vector is considered isolated for the purposes of
the present disclosure. Further examples of an isolated
polynucleotide include recombinant polynucleotides maintained in
heterologous host cells or purified (partially or substantially)
from other polynucleotides in a solution. Isolated RNA molecules
include in vivo or in vitro RNA transcripts of polynucleotides of
the present disclosure. Isolated polynucleotides or nucleic acids
according to the present disclosure further include such molecules
produced synthetically. In addition, polynucleotides or nucleic
acids can include regulatory elements such as promoters, enhancers,
ribosome binding sites, or transcription termination signals.
The term "vector" means a construct, which is capable of
delivering, and in some embodiments expressing, one or more gene(s)
or sequence(s) of interest in a host cell. Examples of vectors
include, but are not limited to, viral vectors, naked DNA or RNA
expression vectors, plasmid, cosmid or phage vectors, DNA or RNA
expression vectors associated with cationic condensing agents, DNA
or RNA expression vectors encapsulated in liposomes, and certain
eukaryotic cells, such as producer cells.
The term "host cell" refers to a cell or a population of cells
harboring or capable of harboring a recombinant nucleic acid. Host
cells can be prokaryotic (e.g., E. coli), or eukaryotic. The host
cells can be fungal cells including yeast such as Saccharomyces
cerevisiae, Pichia pastoris, or Schizosaccharomyces pombe. The host
cells also be any of various animal cells, such as insect cells
(e.g., Sf-9) or mammalian cells (e.g., HEK293F, CHO, COS-7,
NIH-3T3, NS0, PER.C6.RTM., and hybridoma). In further embodiments,
the host cells is a CHO cell selected from the group consisting of
CHO-K, CHO-0 CHO-Lec10, CHO-Lec13, CHO-Lec1, CHO Pro.sup.-5, and
CHO dhfr.sup.-. In particular embodiments, the host cell is a
hybridoma.
The terms "polypeptide," "peptide," and "protein" are used
interchangeably herein to refer to polymers of amino acids of any
length. The polymer can be linear or branched, it can comprise
modified amino acids, and it can be interrupted by non-amino acids.
The terms also encompass an amino acid polymer that has been
modified naturally or by intervention; for example, disulfide bond
formation, glycosylation, lipidation, acetylation, phosphorylation,
or any other manipulation or modification, such as conjugation with
a labeling component. Also included within the definition are, for
example, polypeptides containing one or more analogs of an amino
acid (including, for example, unnatural amino acids, etc.), as well
as other modifications known in the art. It is understood that,
because in some embodiments the provided ALK7-binding proteins are
based upon antibodies, the ALK7-binding proteins can occur as
single chains or associated chains.
A "recombinant" polypeptide, protein or antibody refers to
polypeptide, protein or antibody produced via recombinant DNA
technology. Recombinantly produced polypeptides, proteins and
antibodies expressed in host cells are considered isolated for the
purpose of the present disclosure, as are native or recombinant
polypeptides which have been separated, fractionated, or partially
or substantially purified by any suitable technique.
Also included in the present disclosure are fragments, variants, or
derivatives of polypeptides, and any combination thereof. The term
"fragment" when referring to polypeptides and proteins include any
polypeptides or proteins which retain at least some of the
properties of the reference polypeptide or protein. Fragments of
polypeptides include proteolytic fragments, as well as deletion
fragments.
The term "variant" refers to an antibody or polypeptide sequence
that differs from that of a parent antibody or polypeptide sequence
by virtue of at least one amino acid modification. Variants of
antibodies or polypeptides include fragments, and also antibodies
or polypeptides with altered amino acid sequences due to amino acid
substitutions, deletions, or insertions. Variants can be naturally
or non-naturally occurring. Non-naturally occurring variants can be
produced using art-known mutagenesis techniques. Variant
polypeptides can comprise conservative or non-conservative amino
acid substitutions, deletions or additions.
The term "derivatives" as applied to antibodies or polypeptides
refers to antibodies or polypeptides which have been altered so as
to exhibit additional features not found on the native antibody or
polypeptide. An example of a "derivative" antibody is a fusion or a
conjugate with a second polypeptide or another molecule (e.g., a
polymer such as PEG, a chromophore, or a fluorophore) or atom
(e.g., a radioisotope).
The term "amino acid substitution" refers to replacing an amino
acid residue present in a parent sequence with another amino acid
residue. An amino acid can be substituted in a parent sequence, for
example, via chemical peptide synthesis or through known
recombinant methods. Accordingly, references to a "substitution at
position X" or "substitution at position X" refer to the
substitution of an amino acid residue present at position X with an
alternative amino acid residue. In some embodiments, substitution
patterns can described according to the schema AXY, wherein A is
the single letter code corresponding to the amino acid residue
naturally present at position X, and Y is the substituting amino
acid residue. In other embodiments, substitution patterns can
described according to the schema XY, wherein Y is the single
letter code corresponding to the amino acid residue substituting
the amino acid residue naturally present at position X.
A "conservative amino acid substitution" is one in which the amino
acid residue is replaced with an amino acid residue having a
similar side chain. Families of amino acid residues having similar
side chains have been previously defined, including basic side
chains (e.g., Lys, Arg, His), acidic side chains (e.g., Asp, Glu),
uncharged polar side chains (e.g., Gly, Asp, Gln, Ser, Thr, Tyr,
Cys), nonpolar side chains (e.g., Ala, Val, Leu, lie, Pro, Phe,
Met, Trp), beta-branched side chains (e.g., Thr, Val, Ile) and
aromatic side chains (e.g., Tyr, Phe, Trp, His). Thus, if an amino
acid residue in a polypeptide is replaced with another amino acid
residue from the same side chain family, the substitution is
considered to be conservative. In another embodiment, a string of
amino acid residues can be conservatively replaced with a
structurally similar string that differs in order and/or
composition of side chain family members.
Non-conservative substitutions include those in which (a) a residue
having an electropositive side chain (e.g., Arg, His, or Lys) is
substituted for, or by, an electronegative residue (e.g., Glu or
Asp), (b) a hydrophilic residue (e.g., Ser or Thr) is substituted
for, or by, a hydrophobic residue (e.g., Ala, Leu, lie, Phe, or
Val), (c) a Cys or Pro is substituted for, or by, any other
residue, or (d) a residue having a bulky hydrophobic or aromatic
side chain (e.g., Val, His, lie, or Trp) is substituted for, or by,
one having a smaller side chain (e.g., Ala or Ser) or no side chain
(e.g., Gly).
Other substitutions can be readily identified. For example, for the
amino acid alanine, a substitution can be taken from any one of
D-Ala, Gly, beta-Ala, L-Cys and D-Cys. For lysine, a replacement
can be any one of D-Lys, Arg, D-Arg, homo-Arg, Met, D-Met,
ornithine, or D-omithine. Generally, substitutions in functionally
important regions that can be expected to induce changes in the
properties of isolated polypeptides are those in which (a) a polar
residue (e.g., Ser or Thr) is substituted for (or by) a hydrophobic
residue (e.g., Leu, Ile, Phe, or Ala); (b) a Cys residue is
substituted for (or by) any other residue; (c) a residue having an
electropositive side chain (e.g., Lys, Arg, or His), is substituted
for (or by) a residue having an electronegative side chain (e.g.,
Glu or Asp); or (d) a residue having a bulky side chain (e.g., Phe)
is substituted for (or by) one not having such a side chain (e.g.,
Gly). The likelihood that one of the foregoing non-conservative
substitutions can alter functional properties of the protein is
also correlated to the position of the substitution with respect to
functionally important regions of the protein: some
non-conservative substitutions can accordingly have little or no
effect on biological properties.
The term "amino acid insertion" refers to introducing a new amino
acid residue between two amino acid residues present in the parent
sequence. An amino acid residue can be inserted in a parent
sequence, for example, via chemical peptide synthesis or through
recombinant methods known in the art. Accordingly, the phrases
"insertion between positions X and Y" or "insertion between Kabat
positions X and Y," wherein X and Y correspond to amino acid
residue positions (e.g., a cysteine amino acid residue insertion
between positions 239 and 240), refers to the insertion of an amino
acid residue between the X and Y positions, and also to the
insertion in a nucleic acid sequence of a codon encoding an amino
acid residue between the codons encoding the amino acid residues at
positions X and Y.
The term "percent sequence identity" or "percent identity" between
two polynucleotide or polypeptide sequences refers to the number of
identical matched positions shared by the sequences over a
comparison window, taking into account additions or deletions
(i.e., gaps) that must be introduced for optimal alignment of the
two sequences. A matched position is any position where an
identical nucleotide or amino acid is presented in both the target
and reference sequence. Gaps presented in the target sequence are
not counted since gaps are not nucleotides or amino acids.
Likewise, gaps presented in the reference sequence are not counted
since target sequence nucleotides or amino acids are counted, not
nucleotides or amino acids from the reference sequence. The
percentage of sequence identity is calculated by determining the
number of positions at which the identical amino-acid residue or
nucleic acid base occurs in both sequences to yield the number of
matched positions, dividing the number of matched positions by the
total number of positions in the window of comparison and
multiplying the result by 100 to yield the percentage of sequence
identity. The comparison of sequences and determination of percent
sequence identity between two sequences can be accomplished using
readily available software programs. Suitable software programs are
available from various sources, and for alignment of both protein
and nucleotide sequences. One suitable program to determine percent
sequence identity is bl2seq, part of the BLAST suite of program
available from the U.S. government's National Center for
Biotechnology Information BLAST web site (blast.ncbi.nlm.nih.gov).
Bl2seq performs a comparison between two sequences using either the
BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid
sequences, while BLASTP is used to compare amino acid sequences.
Other suitable programs are, e.g., Needle, Stretcher, Water, or
Matcher, part of the EMBOSS suite of bioinformatics programs and
also available from the European Bioinformatics Institute (EBI) at
www.ebi.ac.uk/Tools/psa.
The structure for carrying a CDR or a set of CDRs will generally be
of an antibody heavy or light chain sequence or substantial portion
thereof in which the CDR or set of CDRs is located at a location
corresponding to the CDR or set of CDRs of naturally occurring VH
and VL antibody variable domains encoded by rearranged
immunoglobulin genes. The structures and locations of
immunoglobulin variable domains and their CDRs can readily be
determined by one skilled in the art using programs and known
variable domain residue numbering systems such as Chothia,
Chothia+, and Kabat can routinely be determined by reference to
Kabat (Kabat et al., Sequences of Proteins of Immunological
Interest. 4th Edition. U.S. DHHS. 1987, and tools available on the
Internet (e.g., at
bioinf.org.uk/abysis/sequence_input/key_annotation/key_annotation.
html; and immuno.bme.nwu.edu)), herein incorporated by reference in
its entirety.
CDRs can also be carried by other scaffolds such as fibronectin,
cytochrome B, albumin (e.g., ALBUdAb (Domantis/GSK) and ALB-Kunitz
(Dyax)), unstructured repeat sequences of 3 or 6 amino acids (e.g.,
PASylation.RTM. technology and XTEN.RTM. technology), and sequences
containing elastin-like repeat domains (see, e.g., U.S. Pat. Appl.
No. 61/442,106, which is herein incorporated by reference in its
entirety).
A CDR amino acid sequence substantially as set out herein can be
carried as a CDR in a human variable domain or a substantial
portion thereof. The HCDR3 sequences substantially as set out
herein represent embodiments of the present disclosure and each of
these may be carried as a HCDR3 in a human heavy chain variable
domain or a substantial portion thereof.
Variable domains employed in the present disclosure can be obtained
from any germ-line or rearranged human variable domain, or can be a
synthetic variable domain based on consensus sequences of known
human variable domains. A CDR sequence (e.g., CDR3) can be
introduced into a repertoire of variable domains lacking a CDR
(e.g., CDR3), using recombinant DNA technology.
For example, Marks et al., (Bio/Technology 10:779-783 (1992); which
is herein incorporated by reference in its entirety) provide
methods of producing repertoires of antibody variable domains in
which consensus primers directed at or adjacent to the 5' end of
the variable domain area are used in conjunction with consensus
primers to the third framework region of human VH genes to provide
a repertoire of VH variable domains lacking a CDR3. Marks et al.,
further describe how this repertoire can be combined with a CDR3 of
a particular antibody. Using analogous techniques, the CDR3-derived
sequences of the present disclosure can be shuffled with
repertoires of VH or VL domains lacking a CDR3, and the shuffled
complete VH or VL domains combined with a cognate VL or VH domain
to provide antigen binding proteins. The repertoire can then be
displayed in a suitable host system such as the phage display
system of Intl. Appl. Publ. No. WO92/01047 or any of a subsequent
large body of literature, including Kay et al., (1996) Phage
Display of Peptides and Proteins: A Laboratory Manual, San Diego:
Academic Press, so that suitable antigen binding proteins may be
selected. A repertoire can consist of from anything from 104
individual members upwards, for example from 10.sup.6 to 10.sup.8,
or 10.sup.10, members. Other suitable host systems include yeast
display, bacterial display, T7 display, and ribosome display. For a
review of ribosome display for see Lowe et al., Curr. Pharm.
Biotech. 517-527 (2004) and Intl. Appl. Publ. No. WO92/01047, each
of which is herein incorporated by reference herein in its
entirety. Analogous shuffling or combinatorial techniques are also
disclosed by Stemmer (Nature 370:389-391 (1994), which is herein
incorporated by reference in its entirety), which describes the
technique in relation to a .beta.-lactamase gene but observes that
the approach may be used for the generation of antibodies.
An ALK7-binding protein (e.g., an anti-ALK7 antibody) is said to
"compete" with a reference molecule for binding to ALK7 if it binds
to ALK7 to the extent that it blocks, to some degree, binding of
the reference molecule to ALK7. The ability of proteins to compete
for binding to ALK7 and thus to interfere with, block or
"cross-block" one another's binding to ALK7 can be determined by
any standard competitive binding assay known in the art including,
for example, a competition ELISA assay, surface plasmon resonance
(SPR; BIACORE.RTM., Biosensor, Piscataway, N.J.) or according to
methods described by Scatchard et al. (Ann. N.Y Acad. Sci.
51:660-672 (1949)). An ALK7-binding protein may be said to
competitively inhibit binding of the reference molecule to ALK7,
for example, by at least 90%, at least 80%, at least 70%, at least
60%, or at least 50%. According to some embodiments, the
ALK7-binding protein competitively inhibits binding of the
reference molecule to ALK7, by at least 90%, at least 80%, at least
70%, at least 60%, or at least 50%/c. According to other
embodiments, the ALK7-binding protein competitively inhibits
binding of a reference molecule to ALK7, by at least 90%, at least
80%, at least 70%, at least 60%, or at least 50%.
ALK7-Binding Proteins
Proteins that specifically bind ALK7 are provided. In some
embodiments, antagonist ALK-7 binding proteins are provided. In
some embodiments, the ALK7 binding proteins are antibodies. In
further embodiments, the antibodies are antagonist anti-ALK7
antibodies.
As used herein, the term "ALK7" refers to a family of activin
receptor-like kinase-7 proteins from any species and variants
derived from such ALK7 proteins by mutagenesis or other
modification. Reference to ALK7 herein is understood to be a
reference to any one of the currently identified forms. Members of
the ALK7 family are generally transmembrane proteins, composed of a
ligand-binding extracellular domain with a cysteine-rich region, a
transmembrane domain, and a cytoplasmic domain with predicted
serine/threonine kinase activity. There are various naturally
occurring isoforms of human ALK7. The sequence of canonical human
ALK7 isoform 1 precursor protein (NCBI Ref Seq NP_660302.2) is as
follows:
TABLE-US-00001 (SEQ ID NO: 85) 1 MTRALCSALR QALLLLAAAA ELSPGLKCVC
LLCDSSNFTC QTEGACWASV MLTNGKEQVI 61 KSCVSLPELN AQVFCHSSNN
VTKTECCFTD FCNNITLHLP TASPNAPKLG PMELAIIITV 121 PVCLLSIAAM
LTVWACQGRQ CSYRKKKRPN VEEPLSECNL VNAGKTLKDL IYDVTASGSG 181
SGLPLLVQRT IARTIVLQEI VGKGRFGEVW HGRWCGEDVA VKIFSSRDER SWFREAEIYQ
241 TVMLRHENIL GFIAADNKDN GTWTQLWLVS EYHEQGSLYD YLNRNIVTVA
GMIKLALSIA 301 SGLAHLHMEI VGTQGKPAIA HRDIKSKNIL VKKCETCAIA
DLGLAVKHDS ILNTIDIPQN 361 PKVGTKRYMA PEMLDDTMNV NIFESFKRAD
IYSVGLVYWE IARRCSVGGI VEEYQLPYYD 421 MVPSDPSIEE MRKVVCDQKF
RPSIPNQWQS CEALRVMGRI MRECWYANGA ARLTALRIKK 481 TISQLCVKED CKA
The signal peptide is indicated by a single underline and the
extracellular domain is indicated in bold font.
In some embodiments, the ALK7-binding protein binds ALK7 with an
affinity that is at least, 100, 500, or 1000 times greater than the
affinity of the ALK7-binding protein for a control protein that is
not a TGF-beta receptor family member. In certain embodiments, the
ALK7-binding protein binds ALK7 and has a dissociation constant
(K.sub.D) of <1 .mu.M, <100 nM, <10 nM, <1 nM, <0.1
nM, <10 pM, <1 pM, or <0.1 pM. In some embodiments, the
ALK7-binding protein has a K.sub.D for human ALK7 within the range
of .ltoreq.1 .mu.M and .gtoreq.0.1 pM, .ltoreq.100 .mu.M and
.ltoreq.0.1 pM, or .ltoreq.100 .mu.M and .ltoreq.1 pM.
In some embodiments, BIACORE.RTM. analysis is used to determine the
ability of an ALK7-binding protein (e.g., an anti-ALK7 antibody) to
compete with/block the binding to ALK7 protein by a reference
ALK7-binding protein (e.g., an anti-ALK7 antibody). In a further
embodiment in which a BIACORE.RTM. instrument (for example the
BIACORE.RTM. 3000) is operated according to the manufacturer's
recommendations, ALK7-Fc fusion protein is captured on a CM5
BIACORE.RTM. chip by previously attached anti-niFc IgG to generate
an ALK7-coated surface. Typically 200-800 resonance units of
ALK7-Fc (dimeric) would be coupled to the chip (an amount that
gives easily measurable levels of binding but that is readily
saturable by the concentrations of test reagent being used).
The two ALK7-binding proteins (termed A* and B*) to be assessed for
their ability to compete with/block each other are mixed at a one
to one molar ratio of binding sites in a suitable buffer to create
a test mixture. When calculating the concentrations on a binding
site basis the molecular weight of an ALK7-binding protein is
assumed to be the total molecular weight of the ALK7-binding
protein divided by the number of ALK7-binding sites on that
ALK7-binding protein. The concentration of each ALK7-binding
protein (i.e., A* and B*) in the test mixture should be high enough
to readily saturate the binding sites for that ALK7-binding protein
on the ALK7-Fc molecules captured on the BIACORE.RTM. chip. The A*
and B* ALK7-binding proteins in the mixture are at the same molar
concentration (on a binding basis) and that concentration would
typically be between 1.00 and 1.5 micromolar (on a binding site
basis). Separate solutions containing ALK7-binding protein A* alone
and ALK7-binding protein B* alone are also prepared. ALK7-binding
protein A* and ALK7-binding protein B* in these solutions should be
in the same buffer and at the same concentration as in the test
mixture. The test mixture is passed over the ALK7-Fc-coated
BIACORE.RTM. chip and the total amount of binding recorded. The
chip is then treated in such a way as to remove the bound
ALK7-binding proteins without damaging the chip-bound ALK7-Fc.
Typically, this is done by treating the chip with 30 mM HCl for 60
seconds. The solution of ALK7-binding protein A* alone is then
passed over the ALK7-Fc-coated surface and the amount of binding
recorded. The chip is again treated to remove the bound antibody
without damaging the chip-bound ALK7-Fc. The solution of
ALK7-binding protein B* alone is then passed over the
ALK7-Fc-coated surface and the amount of binding recorded. The
maximum theoretical binding of the mixture of ALK7-binding protein
A* and ALK7-binding protein B* is next calculated, and is the sum
of the binding of each ALK7-binding protein when passed over the
ALK7 surface alone. If the actual recorded binding of the mixture
is less than this theoretical maximum then the two ALK7-binding
proteins are competing with/blocking each other. Thus, in general,
a blocking ALK7-binding protein is one which will bind to ALK7 in
the above BIACORE.RTM. blocking assay such that during the assay
and in the presence of a second ALK7-binding protein the recorded
binding is between 80% and 0.1% (e.g., 80%>to 4%) of the maximum
theoretical binding, specifically between 75% and 0.1% (e.g., 75%
to 4%) of the maximum theoretical binding, and more specifically
between 70% and 0.1% (e.g., 70% to 4%) of maximum theoretical
binding (as defined above) of the two ALK7-binding proteins in
combination.
The BIACORE.RTM. assay described above is an exemplary assay used
to determine if two ALK7-binding proteins such as anti-ALK7
antibodies compete with/block each other for binding ALK7. On rare
occasions, particular ALK7-binding proteins may not bind to ALK7-Fc
coupled via anti-Fc IgG to a CM5 BIACORE.RTM. chip (this might
occur when the relevant binding site on ALK7 is masked or destroyed
by ALK7 linkage to Fc). In such cases, blocking can be determined
using a tagged version of ALK7, for example C-terminal His-tagged
ALK7. In this particular format, an anti-His antibody would be
coupled to the BIACORE.RTM. chip and then the His-tagged ALK7 would
be passed over the surface of the chip and captured by the anti-His
antibody. The cross-blocking analysis would be carried out
essentially as described above, except that after each chip
regeneration cycle, new His-tagged ALK7 would be loaded back onto
the surface coated with anti-His antibody. Moreover, various other
known tags and tag binding protein combinations can be used for
such a blocking analysis (e.g., HA tag with anti-HA antibodies;
FLAG tag with anti-FLAG antibodies; biotin tag with streptavidin).
The following generally describes an ELISA assay for determining
whether an ALK7-binding protein blocks or is capable of blocking
the binding of a reference ALK7-binding protein to ALK7.
In some embodiments, an ELISA is used to determine the ability of
an ALK7-binding protein (e.g., an anti-ALK7 antibody) to compete
for binding to ALK7 with a reference ALK7-binding protein (e.g., an
anti-ALK7 antibody or ALK7 ligand). The general principle of such
an assay is to have a reference ALK7-binding protein (e.g., an
anti-ALK7 antibody) coated onto the wells of an ELISA plate. An
excess amount of a second potentially blocking, test ALK7-binding
protein is added in solution (i.e., not bound to the ELISA plate).
A limited amount of ALK7 (or alternatively ALK7-Fc) is then added
to the wells. The coated reference ALK7-binding protein and the
test ALK7-binding protein in solution compete for binding of the
limited number of ALK7 (or ALK7-Fc) molecules. The plate is washed
to remove ALK7 that has not been bound by the coated reference
ALK7-binding protein and to also remove the test, solution-phase
ALK7-binding protein as well as any complexes formed between the
test, solution-phase ALK7-binding protein and ALK7. The amount of
bound ALK7 is then measured using an appropriate ALK7 detection
reagent. A test ALK7-binding protein in solution that is able to
block binding of the coated reference ALK7-binding protein to ALK7
will be able to cause a decrease in the number of ALK7 molecules
that the coated reference ALK7-binding protein can bind relative to
the number of ALK7 molecules that the coated reference ALK7-binding
protein can bind in the absence of the second, solution-phase test
ALK7-binding protein. The background signal for the assay is
defined as the signal obtained in wells with the coated reference
ALK7-binding protein, solution-phase test ALK7-binding protein,
ALK7 buffer only (i.e., no ALK7) and ALK7 detection reagents. The
positive control signal for the assay is defined as the signal
obtained in wells with the coated reference ALK7-binding protein,
solution-phase test ALK7-binding protein buffer only (i.e., no
solution-phase test ALK7-binding protein), ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB) detection reagents. The ELISA
assay is be run in such a manner so as to have the positive control
signal at least 3 times the background signal. As a control for
methodologic artifacts, the cross-blocking assay may be run in the
format just described and also reversed, with the test ALK7-binding
protein as the coated antibody and the reference ALK7-binding
protein as the solution-phase antibody.
In some embodiments, the ALK7-binding protein binds ALK7 with an
affinity that is at least, 100, 500, or 1000 times greater than the
affinity of the ALK7-binding protein for a control protein that is
not a TGF-beta receptor family member. In additional embodiments,
the ALK7-binding protein binds ALK7 with an affinity that is at
least, 100, 500, or 1000 times greater than the affinity of the
ALK7-binding protein for a control protein that is not a TGF-beta
receptor family member. In certain embodiments, the ALK7-binding
protein binds ALK7 and has a dissociation constant (K.sub.D) of
<1 .mu.M, <100 nM, <10 nM, <1 nM, <0.1 nM, <10
pM, <1 pM, or <0.1 pM. In some embodiments, the ALK7-binding
protein has a K.sub.D for human ALK7 within the range of .ltoreq.1
.mu.M and .gtoreq.0.1 pM, .ltoreq.100 .mu.M and .gtoreq.0.1 pM, or
.ltoreq.100 .mu.M and .gtoreq.1 pM.
In some embodiments, a cell-based lipolysis inhibition assay is
used to determine the ability of an ALK7-binding protein (e.g., an
antagonist anti-ALK7 antibody) to reduce (inhibit) ALK7-mediated
inhibition of lipolysis in mammalian white adipocytes. In some
embodiments, the lipolysis inhibition assay is performed using
mature whit adipocytes (e.g., human, mouse, or rat) to determine
the ability of an ALK7-binding protein (e.g., an anti-ALK7
antibody) to reduce ALK7 activity. Kits, reagents and methods for
conducting a lipolysis assay are commercially available and known
in the art. In particular embodiments, the lipolysis inhibition
assay is performed as provided in the Examples herein. In other
embodiments, the assay is performed according to the instructions
and reagents as provided in a commercially available lipolysis
assay kit (e.g., BioAssay Systems, EnzyChrom.TM. Adipolysis Assay
Kit, Cat. No. EAPL-200; Abeam Cat. No. ab185433; Zen-Bio, Cat. No.
LIP-1-NCL; BioVision, Cat. No. K577-100; Sigma-Aldrich, Cat. No.
MAK211; and AdipoLyze.TM. Lipolysis Detection Assay, Lonza, Cat.
No. 193339).
In some embodiments, the ALK7-binding protein, an ALK7-binding
protein is an ALK7 antagonist and increases lipolysis by 5% to
100%, 10% to 80%, or 10%0/to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a mature white adipose
cell by 5% to 100%, 10% 95%, 10 to 90%, 10 to 85%, 10 to 80%, 10 to
75%, 10 to 70%, 10 to 65%, 10 to 60%, 10 to 55%, 10 to 50%, or 10
to 45%, as determined using standard techniques and conditions in a
lipolysis inhibition assay performed in the presence of activin B
(50 ng/ml) (e.g., as described in the examples herein). In another
embodiment, an ALK7-binding protein increases lipolysis by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a mature white adipose
cell by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
or 95%, or by about 100%, as determined, using standard techniques
and conditions in a lipolysis inhibition assay performed in the
presence of activin B (50 ng/ml) (e.g., as described in the
examples herein).
Pharmacodynamic parameters dependent on ALK7 signaling can be
measured as endpoints for in vivo testing of ALK7-binding proteins
in order to identify those binding proteins that are able to
neutralize ALK7 and provide a therapeutic benefit. An ALK7
neutralizing binding agent is defined as one capable of causing a
statistically significant change, as compared to vehicle-treated
animals, in such a pharmacodynamic parameter. Such in vivo testing
can be performed in any suitable mammal (e.g., mouse, rat, or
monkey).
In some embodiments, an ALK7-binding protein is an antibody that
specifically binds ALK7. In additional embodiments, the
ALK7-binding protein is a full-length anti-ALK7 antibody. In
additional embodiments, the antibody is a monoclonal antibody, a
recombinant antibody, a human antibody, a humanized antibody, a
chimeric antibody, a bi-specific antibody, a multi-specific
antibody, or an ALK7-binding antibody fragment thereof.
In some embodiments, the anti-ALK7 antibody is an ALK7-binding
antibody fragment. In some embodiments, the ALK7-binding antibody
fragment is a: Fab, Fab', F(ab').sub.2, Fv fragment, diabody, or
single chain antibody molecule. In additional embodiments, the
ALK7-antibody is a Fd, single chain Fv(scFv), disulfide linked Fv,
V-NAR domain, IgNar, intrabody, IgG.DELTA.CH2, minibody,
F(ab').sub.3, tetrabody, triabody, diabody, single-domain antibody,
DVD-Ig, Fcab, mAb.sup.2, (scFv).sub.2, scFv-Fc or bis-scFv.
In additional embodiments the ALK7-binding protein is an antibody
that includes a VH and a VL. In some embodiments the anti-ALK7
antibody further includes a heavy chain constant region or fragment
thereof. In some embodiments, the antibody comprises a heavy chain
immunoglobulin constant region selected from the group consisting
of: (a) a human IgA constant region, or fragment thereof; (b) a
human IgD constant region, or fragment thereof; (c) a human IgE
constant domain, or fragment thereof; (d) a human IgG1 constant
region, or fragment thereof; (e) a human IgG2 constant region, or
fragment thereof; (f) a human IgG3 constant region, or fragment
thereof; (g) a human IgG4 constant region, or fragment thereof; and
(h) a human IgM constant region, or fragment thereof. In certain
embodiments an ALK7-binding protein comprises a heavy chain
constant region or fragment thereof, e.g., a human IgG constant
region or fragment thereof. In further embodiments, the
ALK7-binding protein comprises a heavy chain immunoglobulin
constant domain that has, or has been mutated to have altered
effector function and/or half-life.
In particular embodiments, the ALK7-binding protein is an antibody
that comprises an IgG1 heavy chain constant region containing a
mutation that decreases effector function (see, e.g., Idusogie et
al., J. Immunol. 166:2571-2575 (2001); Sazinsky et al., PNAS USA
105:20167-20172 (2008); Davis et al., J. Rheumatol. 34:2204-2210
(2007); Bolt et al., Eur. J. Immunol. 23:403-411 (1993); Alegre et
al., Transplantation 57:1537-1543 (1994); Xu et al., Cell Immunol.
200:16-26 (2000); Cole et al., Transplantation 68:563-571 (1999);
Hutchins et al., PNAS USA 92:11980-11984 (1995); Reddy et al., J.
Immunol. 164:1925-1933 (2000); WO97/11971, and WO07/106585; U.S.
Appl. Publ. 2007/0148167A1; McEarchern et al., Blood 109:1185-1192
(2007); Strohl, Curr. Op. Biotechnol. 20:685-691 (2009); and
Kumagai et al., J. Clin. Pharmacol. 47:1489-1497 (2007), each of
which is herein incorporated by reference in its entirety).
In some embodiments, the heavy chain constant region or fragment
thereof includes one or more amino acid substitutions relative to a
wild-type IgG constant domain wherein the modified IgG has
decreased ADCC compared to the half-life of an IgG having the
wild-type IgG constant domain. Examples of Fc sequence engineering
modifications contained in the provided antibodies that decrease
ADCC include one or more modifications corresponding to:
IgG1-K326W, E333S; IgG2-E333S; IgG1-N297A; IgG1-L234A, L235A;
IgG2-V234A, G237A; IgG4-L235A, G237A, E318A; IgG4-S228P, L236E;
IgG2-EU sequence 118-260; IgG4-EU sequence 261-447; IgG2-H268Q,
V309L, A330S, A331S; IgG1-C220S, C226S, C229S, P238S; IgG1-C226S,
C229S, E233P, L234V, L235A; and IgG1-L234F, L235E, P331S, wherein
the position numbering is according to the EU index as in
Kabat.
In certain embodiments an ALK7-binding protein comprises a heavy
chain immunoglobulin constant domain that has, or has been mutated
to have, reduced CDC activity. In particular embodiments, the
ALK7-binding protein is an antibody that comprises an IgG1 heavy
chain constant region containing a mutation that decreases CDC
activity (see, e.g., WO97/11971 and WO07/106585; U.S. Appl. Publ.
2007/0148167A1; McEarchern et al., Blood 109:1185-1192 (2007);
Hayden-Ledbetter et al., Clin. Cancer 15:2739-2746 (2009); Lazar et
al., PNAS USA 103:4005-4010 (2006); Bruckheimer et al., Neoplasia
11:509-517 (2009); Strohl, Curr. Op. Biotechnol. 20:685-691 (2009);
and Sazinsky et al., PNAS USA 105:20167-20172 (2008); each of which
is herein incorporated by reference in its entirety). Examples of
Fc sequence engineering modifications contained in an anti-ALK7
antibody that decrease CDC include one or more modifications
corresponding to: IgG1-S239D. A330L, 1332E; IgG2 EU sequence
118-260; IgG4-EU sequence 261-447; IgG2-H268Q, V309L, A330S, A331S;
IgG1-C226S, C229S, E233P, L234V, L235A; IgG1-L234F, L235E, P331S;
and IgG1-C226S, P230S.
In further embodiments, the heavy chain constant region or fragment
thereof includes one or more amino acid substitutions relative to a
wild-type IgG constant domain wherein the modified IgG has an
increased half-life compared to the half-life of an IgG having the
wild-type IgG constant domain. For example, the IgG constant domain
can contain one or more amino acid substitutions of amino acid
residues at positions 251-257, 285-290, 308-314, 385-389, and
428-436, wherein the amino acid position numbering is according to
the EU index as set forth in Kabat. In certain embodiments the IgG
constant domain can contain one or more of a substitution of the
amino acid at Kabat position 252 with Tyr, Phe, Trp, or Thr; a
substitution of the amino acid at Kabat position 254 with Thr; a
substitution of the amino acid at Kabat position 256 with Ser, Arg,
Gln, Glu, Asp, or Thr; a substitution of the amino acid at Kabat
position 257 with Leu; a substitution of the amino acid at Kabat
position 309 with Pro; a substitution of the amino acid at Kabat
position 311 with Ser; a substitution of the amino acid at Kabat
position 428 with Thr, Leu, Phe, or Ser; a substitution of the
amino acid at Kabat position 433 with Arg, Ser, Iso, Pro, or Gln;
or a substitution of the amino acid at Kabat position 434 with Trp,
Met, Ser, His, Phe, or Tyr. More specifically, the IgG constant
domain can contain amino acid substitutions relative to a wild-type
human IgG constant domain including a substitution of the amino
acid at Kabat position 252 with Tyr, a substitution of the amino
acid at Kabat position 254 with Thr, and a substitution of the
amino acid at Kabat position 256 with Glu.
In additional embodiments, the ALK7-binding protein is an antibody
that comprises a light chain immunoglobulin constant region. In a
further embodiment, the antibody comprises a human Ig kappa
constant region or a human Ig lambda constant region.
In some embodiments, the ALK7-binding protein comprises a set of
CDRs: VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3,
wherein the CDRs are present in a VH and a VL pair disclosed in
Table 1A. In further embodiments, the ALK7-binding protein
comprises a set of CDRs wherein the CDRs are present in a VH and a
VL pair selected from the group consisting of: (a) a VH sequence of
SEQ ID NO:4, and a VL sequence of SEQ ID NO:13; (b) a VH sequence
of SEQ ID NO:22, and a VL sequence of SEQ ID NO:31; (c) a VH
sequence of SEQ ID NO:40, and a VL sequence of SEQ ID NO:49; and
(d) a VH sequence of SEQ ID NO:58 and a VL sequence of SEQ ID
NO:67; and wherein the protein binds ALK7.
In some embodiments, the ALK7-binding protein comprises a set of
CDRs: VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3,
wherein the CDRs are present in a VH and a VL pair disclosed in
Table 1B. In further embodiments, the ALK7-binding protein
comprises a set of CDRs wherein the CDRs are present in a VH and a
VL pair selected from the group consisting of: (a) a VH sequence of
SEQ ID NO:152, and a VL sequence of SEQ ID NO:98; (b) a VH sequence
of SEQ ID NO:159, and a VL sequence of SEQ ID NO:110; and (c) a VH
sequence of SEQ ID NO:165, and a VL sequence of SEQ ID NO:171; and
wherein the protein binds ALK7.
In some embodiments, the ALK7-binding protein comprises a set of
CDRs: VII-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3,
wherein the CDRs are present in a VH and a VL pair disclosed in
Table 3. In further embodiments, the ALK7-binding protein comprises
a set of CDRs wherein the CDRs are present in a VH and a VL pair
selected from the group consisting of: (a) a VH sequence of SEQ ID
NO:91, and a VL sequence of SEQ ID NO:98; (b) a VH sequence of SEQ
ID NO:105, and a VL sequence of SEQ ID NO:110; (c) a VH sequence of
SEQ ID NO:117, and a VL sequence of SEQ ID NO:124; (d) a VH
sequence of SEQ ID NO:128 and a VL sequence of SEQ ID NO:135; and
(d) a VH sequence of SEQ ID NO:140 and a VL sequence of SEQ ID
NO:148; and wherein the protein binds ALK7.
In some embodiments an ALK7-binding protein comprises a set of
CDRs: (a) VH-CDR1, VH-CDR2, and VH-CDR3, or (b) VL-CDR1, VL-CDR2,
and VL-CDR3, wherein the set of CDRs is identical to, or has a
total of one, two, three, four, five, six, seven, eight, nine, ten,
or fewer than ten, amino acid substitutions, deletions, and/or
insertions from a reference set of CDRs disclosed herein. In
further embodiments, the ALK7-binding protein comprises a set of
CDRs, wherein the set of CDRs is identical to, or has a total of
one, two, three, four, five, six, seven, eight, nine, ten, or fewer
than ten, amino acid substitutions, deletions, and/or insertions
from a reference set of CDRs in a VH or VL sequence disclosed in
Table 1A.
In some embodiments an ALK7-binding protein comprises a set of
CDRs: (a) VH-CDR1, VH-CDR2, and VH-CDR3, or (b) VL-CDR1, VL-CDR2,
and VL-CDR3, wherein the set of CDRs is identical to, or has a
total of one, two, three, four, five, six, seven, eight, nine, ten,
or fewer than ten, amino acid substitutions, deletions, and/or
insertions from a reference set of CDRs disclosed herein. In
further embodiments, the ALK7-binding protein comprises a set of
CDRs, wherein the set of CDRs is identical to, or has a total of
one, two, three, four, five, six, seven, eight, nine, ten, or fewer
than ten, amino acid substitutions, deletions, and/or insertions
from a reference set of CDRs in a VH or VL sequence disclosed in
Table 1B.
In some embodiments an ALK7-binding protein comprises a set of
CDRs: VII-CDR1, VH-CDR2, VII-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs disclosed herein. In further embodiments, the
ALK7-binding protein comprises a set of CDRs, wherein the set of
CDRs is identical to, or has a total of one, two, three, four,
five, six, seven, eight, nine, ten, or fewer than ten, amino acid
substitutions, deletions, and/or insertions from a reference set of
CDRs in a VH and VL sequence pair disclosed in Table 3.
In additional embodiments, the ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3,
VL-CDR1, VL-CDR2, and VL-CDR3, wherein the set of CDRs is identical
to, or has a total of one, two, three, four, five, six, seven,
eight, nine, ten, or fewer than ten, amino acid substitutions,
deletions, and/or insertions from a reference set of CDRs in which:
(a)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 1;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:2;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:3;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:10; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:11; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:12; (b)(i)
VH-CDR1 comprises the amino acid sequence of SEQ ID NO:19; (ii)
VH-CDR2 comprises the amino acid sequence of SEQ ID NO:20; (iii)
VH-CDR3 comprises the amino acid sequence of SEQ ID NO:21; (iv)
VL-CDR1 comprises the amino acid sequence of SEQ ID NO:28; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:29; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:30; (c)(i)
VH-CDR1 comprises the amino acid sequence of SEQ ID NO:37; (ii)
VH-CDR2 comprises the amino acid sequence of SEQ ID NO:38; (iii)
VH-CDR3 comprises the amino acid sequence of SEQ ID NO:39; (iv)
VL-CDR1 comprises the amino acid sequence of SEQ ID NO:46; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:47; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:48; or
(d)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:55;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:56;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:57;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:64; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:65; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:66; and
wherein the protein binds to ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the type II receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis) and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the
ALK7-binding protein increases lipolysis by 5% to 100%, 10% to 80%,
or 10% to 60%. In some embodiments, the ALK7-binding protein
increase lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In additional embodiments, the ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3,
VL-CDR1, VL-CDR2, and VL-CDR3, wherein the set of CDRs is identical
to, or has a total of one, two, three, four, five, six, seven,
eight, nine, ten, or fewer than ten, amino acid substitutions,
deletions, and/or insertions from a reference set of CDRs in which:
(a)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:37;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:56;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:90;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:95; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:96; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:97; (b)(i)
VH-CDR1 comprises the amino acid sequence of SEQ ID NO:156; (ii)
VH-CDR2 comprises the amino acid sequence of SEQ ID NO:157; (iii)
VH-CDR3 comprises the amino acid sequence of SEQ ID NO:184; (iv)
VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 107; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 108; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:109;
and (c)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:1; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:163; (iii) VH-CDR3 comprises the amino acid sequence of SEQ ID
NO:164; (iv) VL-CDR1 comprises the amino acid sequence of SEQ ID
NO:167; (v) VL-CDR2 comprises the amino acid sequence of SEQ ID
NO:168; and (vi) VL-CDR3 comprises the amino acid sequence of SEQ
ID NO:169; and wherein the protein binds to ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the type II
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis) and (g)
decreases the formation of a complex containing ALK7, a co-receptor
(e.g., cripto and/or cryptic), and one or more TGF-beta superfamily
ligands (e.g., Nodal). In some embodiments, the ALK7-binding
protein is an ALK7 antagonist (e.g., a neutralizing anti-ALK7
antibody). In further embodiments, the ALK7-binding protein
increases lipolysis by 5% to 100%, 10% to 80%, or 10% to 60%. In
some embodiments, the ALK7-binding protein increase lipolysis in
adipocyte cells by 5% to 100%, 10% to 80%, or 10% to 60%. In some
embodiments, the ALK7-binding protein increase lipolysis in a
lipolysis assay using adipocyte cells (e.g., white adipocytes) by
5% to 100%, 10% to 80%, or 10% to 60%. In further embodiments the
lipolysis assay is performed in the presence of one or more ALK7
ligands selected from the group consisting of: GDF1, GDF3, GDF8,
activin B, activin A/B, and Nodal. In some embodiments, the
ALK7-binding protein has 2, 3, or 4 of the above characteristics.
In some embodiments, the ALK7-binding protein has at least 2, at
least 3, or at least 4, of the above characteristics.
In additional embodiments, the ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3,
VL-CDR1, VL-CDR2, and VL-CDR3, wherein the set of CDRs is identical
to, or has a total of one, two, three, four, five, six, seven,
eight, nine, ten, or fewer than ten, amino acid substitutions,
deletions, and/or insertions from a reference set of CDRs in which:
(a)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:88;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:89;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:90;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:95; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:96; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:97; (b)(i)
VH-CDR1 comprises the amino acid sequence of SEQ ID NO:102; (ii)
VH-CDR2 comprises the amino acid sequence of SEQ ID NO:103; (iii)
VH-CDR3 comprises the amino acid sequence of SEQ ID NO:104; (iv)
VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 107; (v)
VL-CDR2 comprises the amino acid sequence of SEQ ID NO:108; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 109;
(c)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:114;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:115;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 116;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:121;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:122; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:123;
(d)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:125;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:126;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:127;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:132;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:133; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:134; or
(e)(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:137;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:138;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 139;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 145;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:146; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:147;
and wherein the protein binds to ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the type II receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis) and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the
ALK7-binding protein increases lipolysis by 5% to 100%, 10% to 80%,
or 10% to 60%. In some embodiments, the ALK7-binding protein
increase lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1.
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In additional embodiments, the ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3,
VL-CDR1, VH-CDR2, and VL-CDR3, wherein: (a)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:1; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:2; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:3; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:10; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO: 11; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:12; (b)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:19; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ TD NO:20; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:21; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:28; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:29; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:30; (c)(i) VH-CDR1 comprises the
amino acid sequence of SEQ ID NO:37; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:38; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:39; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:46; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:47; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:48; or (d)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:55; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:56; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:57; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:64; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:65; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:66; and wherein the protein binds
ALK7.
In additional embodiments, the ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3,
VL-CDR1, VL-CDR2, and VL-CDR3, wherein: (a)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:37; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:56; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:90; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:95; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:96; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:97; (b)(i) VH-CDR1 comprises the
amino acid sequence of SEQ ID NO:156; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:157; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:104; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:107; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:108; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:109; and (c)(i) VH-CDR1
comprises the amino acid sequence of SEQ ID NO:1; (ii) VH-CDR2
comprises the amino acid sequence of SEQ ID NO:163; (iii) VH-CDR3
comprises the amino acid sequence of SEQ ID NO:1164; (iv) VL-CDR1
comprises the amino acid sequence of SEQ ID NO:107; (v) VL-CDR2
comprises the amino acid sequence of SEQ ID NO: 168; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO:169; and
wherein the protein binds ALK7.
In additional embodiments, the ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3,
VL-CDR1, VL-CDR2, and VL-CDR3, wherein: (a)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:88; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:89; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:90; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:95; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:96: and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:97; (b)(i) VH-CDR1 comprises the
amino acid sequence of SEQ ID NO: 102; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:103; (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:104; (iv) VL-CDR1 comprises the
amino acid sequence of SEQ ID NO:107; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:108; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:109; (c)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO: 114; (ii) VH-CDR2 comprises
the amino acid sequence of SEQ ID NO:115; (iii) VH-CDR3 comprises
the amino acid sequence of SEQ ID NO:116; (iv) VL-CDR1 comprises
the amino acid sequence of SEQ ID NO:121; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:122; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:123; (d)(i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:125; (ii) VH-CDR2 comprises
the amino acid sequence of SEQ ID NO:126; (iii) VH-CDR3 comprises
the amino acid sequence of SEQ ID NO:127; (iv) VL-CDR1 comprises
the amino acid sequence of SEQ ID NO:132; (v) VL-CDR2 comprises the
amino acid sequence of SEQ ID NO:133; and (vi) VL-CDR3 comprises
the amino acid sequence of SEQ ID NO:134; or (e)(i) VH-CDR1
comprises the amino acid sequence of SEQ ID NO:137; (ii) VH-CDR2
comprises the amino acid sequence of SEQ ID NO:138; (iii) VH-CDR3
comprises the amino acid sequence of SEQ ID NO: 139; (iv) VL-CDR1
comprises the amino acid sequence of SEQ ID NO:145; (v) VL-CDR2
comprises the amino acid sequence of SEQ ID NO: 146; and (vi)
VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 147; and
wherein the protein binds ALK7.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (a)(i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO: 1; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:2; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:3; (iv) VL-CDR1 comprises the amino acid
sequence of SEQ ID NO:10; (v) VL-CDR2 comprises the amino acid
sequence of SEQ ID NO: 11; and (vi) VL-CDR3 comprises the amino
acid sequence of SEQ ID NO:12; and wherein the protein binds ALK7.
In further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and activin B on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with ActRIIA or
ActRIIB) for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB) in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO: 19; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:20; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:21; (iv) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:28; (v) VL-CDR2 comprises the amino acid
sequence of SEQ ID NO:29; and (vi) VL-CDR3 comprises the amino acid
sequence of SEQ ID NO:30; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a A type II receptor
(e.g., ActRIIA or ActRIIB), and activin B on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB) in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:37; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:38; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:39; (iv) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:46; (v) VL-CDR2 comprises the amino acid
sequence of SEQ ID NO:47; and (vi) VL-CDR3 comprises the amino acid
sequence of SEQ ID NO:48; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and an ActRII receptor (e.g., ActRIIA
or ActRIIB) in the presence of GDF1, GDF3, GDF8, activin B, activin
A/B, and/or Nodal; (e) decreases the phosphorylation of Smads
(e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA and/or ActRIIB) in the presence of one or
more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin
AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM
and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis),
and (g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:55; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:56; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:57; (iv) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:64; (v) VL-CDR2 comprises the amino acid
sequence of SEQ ID NO:65; and (vi) VL-CDR3 comprises the amino acid
sequence of SEQ ID NO:66; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and an ActRII receptor (e.g., ActRIIA
or ActRIIB) in the presence of GDF1, GDF3, GDF8, activin B, activin
A/B, and/or Nodal; (e) decreases the phosphorylation of Smads
(e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA and/or ActRIIB) in the presence of one or
more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin
AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM
and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis),
and (g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (a)(i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:88; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID N089; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:90: (iv) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:95; (v) VL-CDR2 comprises the amino acid
sequence of SEQ ID NO:96; and (vi) VL-CDR3 comprises the amino acid
sequence of SEQ ID NO:97; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and activin B on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with ActRIIA or
ActRIIB) for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB) in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:102; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:103; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:104; (iv) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO: 107; (v) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:108; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:109; and wherein the protein binds
ALK7. In further embodiments, the ALK7-binding protein has at least
one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a A type II
receptor (e.g., ActRIIA or ActRIIB), and activin B on the surface
of cells expressing ALK7 and the ActRII receptor in the presence of
the one or more TGF-beta superfamily ligands; (b) competes with one
or more type II receptors for binding to ALK7; (c) competes with
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d)
decreases the phosphorylation of ALK7 in cells expressing ALK7 and
an ActRII receptor (e.g., ActRIIA or ActRIIB) in the presence of
GDF1, GDF3, GDF8, activin B, activin A/B, and/or Nodal; (e)
decreases the phosphorylation of Smads (e.g., Smad2 and/or Smad3)
in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
and/or ActRIIB) in the presence of one or more TGF-beta ligands
(e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f)
binds to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM
(e.g., as determined by BIACORE.RTM. analysis), and (g) decreases
the formation of a complex containing ALK7, a co-receptor (e.g.,
cripto and/or cryptic), and one or more TGF-beta superfamily
ligands (e.g., Nodal). In some embodiments, the ALK7-binding
protein is an ALK7 antagonist (e.g., a neutralizing anti-ALK7
antibody). In further embodiments, the ALK-7 binding protein
increases lipolysis by 5% to 100%, 10% to 80%, or 10% to 60%. In
some embodiments, the ALK7-binding protein increase lipolysis in
adipocyte cells by 5% to 100%, 10% to 80%, or 10% to 60%. In some
embodiments, the ALK7-binding protein increase lipolysis in a
lipolysis assay using adipocyte cells (e.g., white adipocytes) by
5% to 100%, 10% to 80%, or 10% to 60%. In further embodiments the
lipolysis assay is performed in the presence of one or more ALK7
ligands selected from the group consisting of: GDF1, GDF3, GDF8,
activin B, activin A/B, and Nodal. In some embodiments, the
ALK7-binding protein has 2, 3, or 4 of the above characteristics.
In some embodiments, the ALK7-binding protein has at least 2, at
least 3, or at least 4, of the above characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:114; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO: 115; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:116; (iv) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:121; (v) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:122; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:123; and wherein the protein binds
ALK7. In further embodiments, the ALK7-binding protein has at least
one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and an ActRII receptor (e.g., ActRIIA
or ActRIIB) in the presence of GDF1, GDF3, GDF8, activin B, activin
A/B, and/or Nodal; (e) decreases the phosphorylation of Smads
(e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA and/or ActRIIB) in the presence of one or
more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin
AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM
and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis),
and (g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:125; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:126; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:127; (iv) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:132; (v) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:133; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:134; and wherein the protein binds
ALK7. In further embodiments, the ALK7-binding protein has at least
one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and an ActRII receptor (e.g., ActRIIA
or ActRIIB) in the presence of GDF1, GDF3, GDF8, activin B, activin
A/B, and/or Nodal; (e) decreases the phosphorylation of Smads
(e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA and/or ActRIIB) in the presence of one or
more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin
AB, and/or Nodal); (t) binds to ALK7 with a K.sub.D of .ltoreq.1 nM
and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis),
and (g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs that has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than ten, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:137; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:138; (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:139; (iv) VL-CDR 1 comprises the amino
acid sequence of SEQ ID NO: 145; (v) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:146; and (vi) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:147; and wherein the protein binds
ALK7. In further embodiments, the ALK7-binding protein has at least
one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and an ActRII receptor (e.g., ActRIIA
or ActRIIB) in the presence of GDF1, GDF3, GDF8, activin B, activin
A/B, and/or Nodal; (e) decreases the phosphorylation of Smads
(e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA and/or ActRIIB) in the presence of one or
more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin
AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM
and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis),
and (g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:37; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:38; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:39 or 57; and the protein binds
ALK7. In a further embodiment, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and
VH-CDR3, wherein: (i) VH-CDR1 comprises the amino acid sequence of
SEQ ID NO:37; (ii) VH-CDR2 comprises the amino acid sequence of SEQ
ID NO:38; and (iii) VH-CDR3 comprises the amino acid sequence of
SEQ ID NO:39; and the protein binds ALK7. In a further embodiment,
an ALK7-binding protein specifically binds ALK7 and comprises a set
of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3, wherein the set of CDRs is
identical to, or has a total of one, two, three, four, five, six,
seven, eight, nine, ten, or fewer than ten, amino acid
substitutions, deletions, and/or insertions from a reference set of
CDRs in which: (i) VH-CDR1 comprises the amino acid sequence of SEQ
ID NO:37; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:38; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:39; and the protein binds ALK7. In a further embodiment, an
ALK7-binding protein specifically binds ALK7 and comprises a set of
CDRs: VH-CDR1, VH-CDR2, and VH-CDR3, wherein the set of CDRs is
identical to, or has a total of one, two, three, four, five, six,
seven, eight, nine, ten, or fewer than ten, amino acid
substitutions, deletions, and/or insertions from a reference set of
CDRs in which: (i) VH-CDR1 comprises the amino acid sequence of SEQ
ID NO:37; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:38; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:57; and the protein binds ALK7. In a further embodiment, an
ALK7-binding protein specifically binds ALK7 and comprises a set of
CDRs: VH-CDR1, VH-CDR2, and VH-CDR3, wherein: (i) VH-CDR1 comprises
the amino acid sequence of SEQ ID NO:37; (ii) VH-CDR2 comprises the
amino acid sequence of SEQ ID NO:38; and (iii) VH-CDR3 comprises
the amino acid sequence of SEQ ID NO:57; and the protein binds
ALK7. In further embodiments, the ALK7-binding protein has at least
one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and an ActRII receptor (e.g., ActRIIA
or ActRIIB in the presence of GDF1, GDF3, GDF8, activin B, activin
A/B, and/or Nodal; (e) decreases the phosphorylation of Smads
(e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA and/or ActRIIB) in the presence of one or
more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin
AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM
and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis),
and (g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO: 1; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:2; and (iii) VH-CDR3 comprises the amino
acid sequence of SEQ ID NO:3; and the protein binds ALK7. In some
embodiments, an ALK7-binding protein specifically binds ALK7 and
comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3, wherein:
(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:1; (ii)
VH-CDR2 comprises the amino acid sequence of SEQ ID NO:2; and (iii)
VH-CDR3 comprises the amino acid sequence of SEQ ID NO:3; and the
protein binds ALK7. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:19; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:20; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:21; and the protein binds ALK7. In
some embodiments, an ALK7-binding protein specifically binds ALK7
and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein: (i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:19; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:20; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:21; and the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRI receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:37; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:38; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:39; and the protein binds ALK7. In
a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein (i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:37; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:38; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:39; and the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:55; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:56; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:57; and the protein binds ALK7. In
a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein (i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:55; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:56; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:57; and the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:88; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:89; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:90; and the protein binds ALK7. In
some embodiments, an ALK7-binding protein specifically binds ALK7
and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein: (i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:88; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:89; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:90; and the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type IT receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO: 102; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO: 103; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:104; and the protein binds ALK7.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein: (i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:102; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:103; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:104; and the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO: 114; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:115; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:116; and the protein binds ALK7.
In a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein (i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:114; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:115; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:116; and the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type H receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:125; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:126; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:127; and the protein binds ALK7.
In a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein (i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:125; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:126; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:127; and the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VH-CDR1 comprises the amino
acid sequence of SEQ ID NO:137; (ii) VH-CDR2 comprises the amino
acid sequence of SEQ ID NO:138; and (iii) VH-CDR3 comprises the
amino acid sequence of SEQ ID NO:139; and the protein binds ALK7.
In a further embodiment, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VH-CDR1, VH-CDR2, and VH-CDR3,
wherein (i) VH-CDR1 comprises the amino acid sequence of SEQ ID
NO:137; (ii) VH-CDR2 comprises the amino acid sequence of SEQ ID
NO:138; and (iii) VH-CDR3 comprises the amino acid sequence of SEQ
ID NO:139; and the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and an ActRII
receptor (e.g., ActRIIA or ActRIIB in the presence of GDF1, GDF3,
GDF8, activin B, activin A/B, and/or Nodal; (e) decreases the
phosphorylation of Smads (e.g., Smad2 and/or Smad3) in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA and/or
ActRIIB) in the presence of one or more TGF-beta ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f) binds
to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:10; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO: 11; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:12; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO:10; (ii) VL-CDR2 comprises the amino acid sequence of SEQ
ID NO: 11; and (iii) VL-CDR3 comprises the amino acid sequence of
SEQ ID NO:12; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:28; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:29; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:30; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO:28; (ii) VL-CDR2 comprises the amino acid sequence of SEQ
ID NO:29; and (iii) VL-CDR3 comprises the amino acid sequence of
SEQ ID NO:30; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:46; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:47; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:48; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO:46; (ii) VL-CDR2 comprises the amino acid sequence of SEQ
ID NO:47; and (iii) VL-CDR3 comprises the amino acid sequence of
SEQ ID NO:48; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:64; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:65; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:66; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO:64; (ii) VL-CDR2 comprises the amino acid sequence of SEQ
ID NO:65; and (iii) VL-CDR3 comprises the amino acid sequence of
SEQ ID NO:66; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:95; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:96; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:97; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO:95; (ii) VL-CDR2 comprises the amino acid sequence of SEQ
ID NO:96; and (iii) VL-CDR3 comprises the amino acid sequence of
SEQ ID NO:97; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:107; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:108; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:109; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO: 107; (ii) VL-CDR2 comprises the amino acid sequence of
SEQ ID NO:108; and (iii) VL-CDR3 comprises the amino acid sequence
of SEQ ID NO:109; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%/c, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:121; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:122; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:123; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO: 121; (ii) VL-CDR2 comprises the amino acid sequence of
SEQ ID NO:122; and (iii) VL-CDR3 comprises the amino acid sequence
of SEQ ID NO:123; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActrIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO: 132; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:133; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:134; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO: 132; (ii) VL-CDR2 comprises the amino acid sequence of
SEQ ID NO:133; and (iii) VL-CDR3 comprises the amino acid sequence
of SEQ ID NO:134; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, an ALK7-binding protein specifically binds
ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and VL-CDR3,
wherein the set of CDRs is identical to, or has a total of one,
two, three, four, five, six, seven, eight, nine, ten, or fewer than
ten, amino acid substitutions, deletions, and/or insertions from a
reference set of CDRs in which: (i) VL-CDR1 comprises the amino
acid sequence of SEQ ID NO:145; (ii) VL-CDR2 comprises the amino
acid sequence of SEQ ID NO:146; and (iii) VL-CDR3 comprises the
amino acid sequence of SEQ ID NO:147; and wherein the protein binds
ALK7. In some embodiments, an ALK7-binding protein specifically
binds ALK7 and comprises a set of CDRs: VL-CDR1, VL-CDR2, and
VL-CDR3, wherein: (i) VL-CDR1 comprises the amino acid sequence of
SEQ ID NO:145; (ii) VL-CDR2 comprises the amino acid sequence of
SEQ ID NO:146; and (iii) VL-CDR3 comprises the amino acid sequence
of SEQ ID NO:147; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments an ALK7-binding protein comprises a VH-CDR3 or
a VL-CDR3 sequence disclosed herein. In further embodiments, the
ALK7-binding protein comprises a VH-CDR3 or a VL-CDR3 sequence
disclosed in Table 1A. In some embodiments an ALK7-binding protein
comprises a VH-CDR3 and a VL-CDR3 sequence disclosed herein. In
further embodiments, the ALK7-binding protein comprises a VH-CDR3
and a VL-CDR3 sequence disclosed in Table 1A. In some embodiments,
the ALK7-binding protein comprises a VH-CDR3 or a VL-CDR3 sequence
disclosed in Table 1B. In further embodiments, the ALK7-binding
protein comprises a VH-CDR3 and a VL-CDR3 sequence disclosed in
Table 1B. In some embodiments, the ALK7-binding protein comprises a
VH-CDR3 or a VL-CDR3 sequence disclosed in Table 3. In further
embodiments, the ALK7-binding protein comprises a VH-CDR3 and a
VL-CDR3 sequence disclosed in Table 3.
In some embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR3 having the amino acid sequence of SEQ
ID NO:3. In further embodiments the ALK7-binding protein comprises
a VH-CDR3 having the amino acid sequence of SEQ ID NO:3 and a
VH-CDR2 having the amino acid sequence of SEQ ID NO:2. In further
embodiments, the ALK7-binding protein comprises a VH-CDR3 having
the amino acid sequence of SEQ ID NO:3, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:2, and a VH-CDR1 having the amino acid
sequence of SEQ ID NO: 1. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR3 having the amino acid sequence of SEQ
ID NO:21. In further embodiments the ALK7-binding protein comprises
a VH-CDR3 having the amino acid sequence of SEQ ID NO:21 and a
VH-CDR2 having the amino acid sequence of SEQ ID NO:20. In further
embodiments, the ALK7-binding protein comprises a VH-CDR3 having
the amino acid sequence of SEQ ID NO:21, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:20, and a VH-CDR1 having the amino acid
sequence of SEQ ID NO: 19. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VH-CDR3
having the amino acid sequence of SEQ ID NO:39. In further
embodiments the ALK7-binding protein comprises a VH-CDR3 having the
amino acid sequence of SEQ ID NO:39 and a VH-CDR2 having the amino
acid sequence of SEQ ID NO:38. In further embodiments, the
ALK7-binding protein comprises a VH-CDR3 having the amino acid
sequence of SEQ ID NO:39, a VH-CDR2 having the amino acid sequence
of SEQ ID NO:38, and a VH-CDR1 having the amino acid sequence of
SEQ ID NO:37. In further embodiments, the ALK7-binding protein has
at least one characteristic selected from the group consisting of:
(a) decreases the formation of a complex containing ALK7, a type IT
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VH-CDR3
having the amino acid sequence of SEQ ID NO:57. In further
embodiments the ALK7-binding protein comprises a VH-CDR3 having the
amino acid sequence of SEQ ID NO:57 and a VH-CDR2 having the amino
acid sequence of SEQ ID NO:56. In further embodiments, the
ALK7-binding protein comprises a VH-CDR3 having the amino acid
sequence of SEQ ID NO:57, a VH-CDR2 having the amino acid sequence
of SEQ ID NO:56, and a VH-CDR1 having the amino acid sequence of
SEQ ID NO:55. In further embodiments, the ALK7-binding protein has
at least one characteristic selected from the group consisting of:
(a) decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR1 having the amino acid sequence of SEQ
ID NO:1. In further embodiments, the disclosure provides an
ALK7-binding protein comprising a VH-CDR1 having the amino acid
sequence of SEQ ID NO:1 and a VH-CDR2 having the amino acid
sequence of SEQ ID NO:2. In further embodiments, the disclosure
provides an ALK7-binding protein comprising a VH-CDR1 having the
amino acid sequence of SEQ ID NO:1, a VH-CDR2 having the amino acid
sequence of SEQ ID NO:2, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:3 or 21.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR2 having the amino acid sequence of SEQ
ID NO:2. In further embodiments the ALK7-binding protein comprises
a VH-CDR2 having the amino acid sequence of SEQ ID NO:2 and a
VH-CDR1 having the amino acid sequence of SEQ ID NO:1. In further
embodiments, the ALK7-binding protein comprises a VH-CDR2 having
the amino acid sequence of SEQ ID NO:2, a VH-CDR1 having the amino
acid sequence of SEQ ID NO:1, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:3 or 21.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR1 having the amino acid sequence of SEQ
ID NO:38. In further embodiments, the disclosure provides an
ALK7-binding protein comprising a VH-CDR1 having the amino acid
sequence of SEQ ID NO:37 and a VH-CDR2 having the amino acid
sequence of SEQ ID NO:38. In further embodiments, the disclosure
provides an ALK7-binding protein comprising a VH-CDR1 having the
amino acid sequence of SEQ ID NO:37, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:38, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:39 or 57.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR2 having the amino acid sequence of SEQ
ID NO:38. In further embodiments the ALK7-binding protein comprises
a VH-CDR2 having the amino acid sequence of SEQ ID NO:38 and a
VH-CDR1 having the amino acid sequence of SEQ ID NO:37. In further
embodiments, the ALK7-binding protein comprises a VH-CDR2 having
the amino acid sequence of SEQ ID NO:38, a VH-CDR1 having the amino
acid sequence of SEQ ID NO:37, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:39 or 57.
In some embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR3 having the amino acid sequence of SEQ
ID NO:90. In further embodiments the ALK7-binding protein comprises
a VH-CDR3 having the amino acid sequence of SEQ ID NO:90 and a
VH-CDR2 having the amino acid sequence of SEQ ID NO:89. In further
embodiments, the ALK7-binding protein comprises a VH-CDR3 having
the amino acid sequence of SEQ ID NO:90, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:89, and a VH-CDR1 having the amino acid
sequence of SEQ ID NO:88. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR3 having the amino acid sequence of SEQ
ID NO:104. In further embodiments the ALK7-binding protein
comprises a VH-CDR3 having the amino acid sequence of SEQ ID NO:
104 and a VH-CDR2 having the amino acid sequence of SEQ ID NO: 103.
In further embodiments, the ALK7-binding protein comprises a
VH-CDR3 having the amino acid sequence of SEQ ID NO:104, a VH-CDR2
having the amino acid sequence of SEQ ID NO:103, and a VH-CDR1
having the amino acid sequence of SEQ ID NO:102. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VH-CDR3
having the amino acid sequence of SEQ ID NO: 116. In further
embodiments the ALK7-binding protein comprises a VH-CDR3 having the
amino acid sequence of SEQ ID NO: 116 and a VH-CDR2 having the
amino acid sequence of SEQ ID NO:115. In further embodiments, the
ALK7-binding protein comprises a VH-CDR3 having the amino acid
sequence of SEQ ID NO: 116, a VH-CDR2 having the amino acid
sequence of SEQ ID NO: 115, and a VH-CDR1 having the amino acid
sequence of SEQ ID NO: 114. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (t) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VH-CDR3
having the amino acid sequence of SEQ ID NO:127. In further
embodiments the ALK7-binding protein comprises a VH-CDR3 having the
amino acid sequence of SEQ ID NO: 127 and a VH-CDR2 having the
amino acid sequence of SEQ ID NO:126. In further embodiments, the
ALK7-binding protein comprises a VH-CDR3 having the amino acid
sequence of SEQ ID NO: 127, a VH-CDR2 having the amino acid
sequence of SEQ ID NO: 126, and a VH-CDR1 having the amino acid
sequence of SEQ ID NO: 125. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR3 having the amino acid sequence of SEQ
ID NO:164. In further embodiments the ALK7-binding protein
comprises a VH-CDR3 having the amino acid sequence of SEQ ID NO:164
and a VH-CDR2 having the amino acid sequence of SEQ ID NO: 138 or
163. In further embodiments, the ALK7-binding protein comprises a
VH-CDR3 having the amino acid sequence of SEQ ID NO:164, a VH-CDR2
having the amino acid sequence of SEQ ID NO:103, and a VH-CDR1
having the amino acid sequence of SEQ ID NO:1 or 137. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VH-CDR3
having the amino acid sequence of SEQ ID NO: 139. In further
embodiments the ALK7-binding protein comprises a VH-CDR3 having the
amino acid sequence of SEQ ID NO: 139 and a VH-CDR2 having the
amino acid sequence of SEQ ID NO: 138. In further embodiments, the
ALK7-binding protein comprises a VH-CDR3 having the amino acid
sequence of SEQ ID NO:139, a VH-CDR2 having the amino acid sequence
of SEQ ID NO:138, and a VH-CDR1 having the amino acid sequence of
SEQ ID NO:137. In further embodiments, the ALK7-binding protein has
at least one characteristic selected from the group consisting of:
(a) decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type IT receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR1 having the amino acid sequence of SEQ
ID NO:88. In further embodiments, the disclosure provides an
ALK7-binding protein comprising a VH-CDR1 having the amino acid
sequence of SEQ ID NO:88 and a VH-CDR2 having the amino acid
sequence of SEQ ID NO:89. In further embodiments, the disclosure
provides an ALK7-binding protein comprising a VH-CDR1 having the
amino acid sequence of SEQ ID NO:88, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:89, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:90.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR2 having the amino acid sequence of SEQ
ID NO:89. In further embodiments the ALK7-binding protein comprises
a VH-CDR2 having the amino acid sequence of SEQ ID NO:89 and a
VH-CDR1 having the amino acid sequence of SEQ ID NO:88. In further
embodiments, the ALK7-binding protein comprises a VH-CDR2 having
the amino acid sequence of SEQ ID NO:89, a VH-CDR1 having the amino
acid sequence of SEQ ID NO:88, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:90.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR1 having the amino acid sequence of SEQ
ID NO: 102. In further embodiments, the disclosure provides an
ALK7-binding protein comprising a VH-CDR1 having the amino acid
sequence of SEQ ID NO:102 and a VH-CDR2 having the amino acid
sequence of SEQ ID NO:103. In further embodiments, the disclosure
provides an ALK7-binding protein comprising a VH-CDR1 having the
amino acid sequence of SEQ ID NO: 102, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:103, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:104.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR2 having the amino acid sequence of SEQ
ID NO:103. In further embodiments the ALK7-binding protein
comprises a VH-CDR2 having the amino acid sequence of SEQ ID NO:103
and a VH-CDR1 having the amino acid sequence of SEQ ID NO:102. In
further embodiments, the ALK7-binding protein comprises a VH-CDR2
having the amino acid sequence of SEQ ID NO:103, a VH-CDR1 having
the amino acid sequence of SEQ ID NO:102, and a VH-CDR3 having the
amino acid sequence of SEQ ID NO:104.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR1 having the amino acid sequence of SEQ
ID NO: 114. In further embodiments, the disclosure provides an
ALK7-binding protein comprising a VH-CDR1 having the amino acid
sequence of SEQ ID NO: 114 and a VH-CDR2 having the amino acid
sequence of SEQ ID NO:115. In further embodiments, the disclosure
provides an ALK7-binding protein comprising a VH-CDR1 having the
amino acid sequence of SEQ ID NO: 114, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:115, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:116.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR2 having the amino acid sequence of SEQ
ID NO: 115. In further embodiments the ALK7-binding protein
comprises a VH-CDR2 having the amino acid sequence of SEQ ID NO:115
and a VH-CDR1 having the amino acid sequence of SEQ ID NO:114. In
further embodiments, the ALK7-binding protein comprises a VH-CDR2
having the amino acid sequence of SEQ ID NO:115, a VH-CDR1 having
the amino acid sequence of SEQ ID NO: 114, and a VH-CDR3 having the
amino acid sequence of SEQ ID NO:116.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR1 having the amino acid sequence of SEQ
ID NO:125. In further embodiments, the disclosure provides an
ALK7-binding protein comprising a VH-CDR1 having the amino acid
sequence of SEQ ID NO:125 and a VH-CDR2 having the amino acid
sequence of SEQ ID NO:126. In further embodiments, the disclosure
provides an ALK7-binding protein comprising a VH-CDR1 having the
amino acid sequence of SEQ ID NO:125, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:126, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:127.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR2 having the amino acid sequence of SEQ
ID NO:126. In further embodiments the ALK7-binding protein
comprises a VH-CDR2 having the amino acid sequence of SEQ ID NO:126
and a VH-CDR1 having the amino acid sequence of SEQ ID NO:125. In
further embodiments, the ALK7-binding protein comprises a VH-CDR2
having the amino acid sequence of SEQ ID NO:126, a VH-CDR1 having
the amino acid sequence of SEQ ID NO: 125, and a VH-CDR3 having the
amino acid sequence of SEQ ID NO: 127.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR having the amino acid sequence of SEQ
ID NO:137. In further embodiments, the disclosure provides an
ALK7-binding protein comprising a VH-CDR1 having the amino acid
sequence of SEQ ID NO:137 and a VH-CDR2 having the amino acid
sequence of SEQ ID NO:138. In further embodiments, the disclosure
provides an ALK7-binding protein comprising a VII-CDR1 having the
amino acid sequence of SEQ ID NO:137, a VH-CDR2 having the amino
acid sequence of SEQ ID NO:138, and a VH-CDR3 having the amino acid
sequence of SEQ ID NO:139.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-CDR2 having the amino acid sequence of SEQ
ID NO:138. In further embodiments the ALK7-binding protein
comprises a VH-CDR2 having the amino acid sequence of SEQ ID NO:138
and a VH-CDR1 having the amino acid sequence of SEQ ID NO:137. In
further embodiments, the ALK7-binding protein comprises a VH-CDR2
having the amino acid sequence of SEQ ID NO:138, a VH-CDR1 having
the amino acid sequence of SEQ ID NO:137, and a VH-CDR3 having the
amino acid sequence of SEQ ID NO:139.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VL-CDR3 having the amino acid sequence of SEQ
ID NO:12. In further embodiments the ALK7-binding protein comprises
a VL-CDR3 having the amino acid sequence of SEQ ID NO:12 and a
VL-CDR2 having the amino acid sequence of SEQ ID NO:11. In further
embodiments, the ALK7-binding protein comprises a VL-CDR3 having
the amino acid sequence of SEQ ID NO:12, a VL-CDR2 having the amino
acid sequence of SEQ ID NO: 11, and a VL-CDR1 having the amino acid
sequence of SEQ ID NO: 10. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VL-CDR3 having the amino acid sequence of SEQ
ID NO:30. In further embodiments the ALK7-binding protein comprises
a VL-CDR3 having the amino acid sequence of SEQ ID NO:30 and a
VL-CDR2 having the amino acid sequence of SEQ ID NO:29. In further
embodiments, the ALK7-binding protein comprises a VL-CDR3 having
the amino acid sequence of SEQ ID NO:30, a VL-CDR2 having the amino
acid sequence of SEQ ID NO:29, and a VL-CDR1 having the amino acid
sequence of SEQ ID NO:28. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VL-CDR3 having the amino acid sequence of SEQ
ID NO:48. In further embodiments the ALK7-binding protein comprises
a VL-CDR3 having the amino acid sequence of SEQ ID NO:48 and a
VL-CDR2 having the amino acid sequence of SEQ ID NO:47. In further
embodiments, the ALK7-binding protein comprises a VL-CDR3 having
the amino acid sequence of SEQ ID NO:48, a VL-CDR2 having the amino
acid sequence of SEQ ID NO:47, and a VL-CDR1 having the amino acid
sequence of SEQ ID NO:46. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActrIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VL-CDR3
having the amino acid sequence of SEQ ID NO:66. In further
embodiments the ALK7-binding protein comprises a VL-CDR3 having the
amino acid sequence of SEQ ID NO:66 and a VL-CDR2 having the amino
acid sequence of SEQ ID NO:65. In further embodiments, the
ALK7-binding protein comprises a VL-CDR3 having the amino acid
sequence of SEQ ID NO:66, a VL-CDR2 having the amino acid sequence
of SEQ ID NO:65, and a VL-CDR1 having the amino acid sequence of
SEQ ID NO:64. In further embodiments, the ALK7-binding protein has
at least one characteristic selected from the group consisting of:
(a) decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VL-CDR3 having the amino acid sequence of SEQ
ID NO:97. In further embodiments the ALK7-binding protein comprises
a VL-CDR3 having the amino acid sequence of SEQ ID NO:97 and a
VL-CDR2 having the amino acid sequence of SEQ ID NO:96. In further
embodiments, the ALK7-binding protein comprises a VL-CDR3 having
the amino acid sequence of SEQ ID NO:97, a VL-CDR2 having the amino
acid sequence of SEQ ID NO:96, and a VL-CDR1 having the amino acid
sequence of SEQ ID NO:95. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VL-CDR3 having the amino acid sequence of SEQ
ID NO:109. In further embodiments the ALK7-binding protein
comprises a VL-CDR3 having the amino acid sequence of SEQ ID NO:109
and a VL-CDR2 having the amino acid sequence of SEQ ID NO:108. In
further embodiments, the ALK7-binding protein comprises a VL-CDR3
having the amino acid sequence of SEQ ID NO:109, a VL-CDR2 having
the amino acid sequence of SEQ ID NO:108, and a VL-CDR1 having the
amino acid sequence of SEQ ID NO:107. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (t) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VL-CDR3 having the amino acid sequence of SEQ
ID NO:123. In further embodiments the ALK7-binding protein
comprises a VL-CDR3 having the amino acid sequence of SEQ ID NO:123
and a VL-CDR2 having the amino acid sequence of SEQ ID NO:122. In
further embodiments, the ALK7-binding protein comprises a VL-CDR3
having the amino acid sequence of SEQ ID NO: 123, a VL-CDR2 having
the amino acid sequence of SEQ ID NO:122, and a VL-CDR1 having the
amino acid sequence of SEQ ID NO:121. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VL-CDR3
having the amino acid sequence of SEQ ID NO: 134. In further
embodiments the ALK7-binding protein comprises a VL-CDR3 having the
amino acid sequence of SEQ ID NO: 134 and a VL-CDR2 having the
amino acid sequence of SEQ ID NO:133. In further embodiments, the
ALK7-binding protein comprises a VH-CDR3 having the amino acid
sequence of SEQ ID NO: 134, a VL-CDR2 having the amino acid
sequence of SEQ ID NO:133, and a VL-CDR1 having the amino acid
sequence of SEQ ID NO:132. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VL-CDR3
having the amino acid sequence of SEQ ID NO: 147. In further
embodiments the ALK7-binding protein comprises a VL-CDR3 having the
amino acid sequence of SEQ ID NO: 147 and a VL-CDR2 having the
amino acid sequence of SEQ ID NO:146. In further embodiments, the
ALK7-binding protein comprises a VL-CDR3 having the amino acid
sequence of SEQ ID NO:147, a VL-CDR2 having the amino acid sequence
of SEQ ID NO:146, and a VL-CDR1 having the amino acid sequence of
SEQ ID NO:145. In further embodiments, the ALK7-binding protein has
at least one characteristic selected from the group consisting of:
(a) decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In further embodiments, the disclosure provides an ALK7-binding
protein comprising a VH-antigen binding domain 3 (ABD3) having the
amino acid sequence of SEQ ID NO:75, 78, 81, or 84. In one
embodiment, the ALK7-binding protein comprises a VH-ABD3 having the
amino acid sequence of SEQ ID NO:75. In one embodiment, the
ALK7-binding protein comprises a VH-ABD3 having the amino acid
sequence of SEQ ID NO:75 and a VH-antigen binding domain 2
(VH-ABD2) having the amino acid sequence of SEQ ID NO:74. In
further embodiments, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:75, a VH-ABD2 having
the amino acid sequence of SEQ ID NO:74, and a VH-antigen binding
domain 1 (VH-ABD1) having the amino acid sequence of SEQ ID NO:73.
In one embodiment, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:75. In one embodiment,
the ALK7-binding protein comprises a VH-ABD3 having the amino acid
sequence of SEQ ID NO:75 and a VH-antigen binding domain 2
(VH-ABD2) having the amino acid sequence of SEQ ID NO:74. In
further embodiments, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:75, a VH-ABD2 having
the amino acid sequence of SEQ ID NO:74, and a VH-antigen binding
domain 1 (VH-ABD1) having the amino acid sequence of SEQ ID NO:73.
In one embodiment, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:78. In one embodiment,
the ALK7-binding protein comprises a VH-ABD3 having the amino acid
sequence of SEQ ID NO:78 and a VH-antigen binding domain 2
(VH-ABD2) having the amino acid sequence of SEQ ID NO:77. In
further embodiments, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:78, a VH-ABD2 having
the amino acid sequence of SEQ ID NO:77, and a VH-antigen binding
domain 1 (VH-ABD1) having the amino acid sequence of SEQ ID NO:76.
In one embodiment, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:81. In one embodiment,
the ALK7-binding protein comprises a VH-ABD3 having the amino acid
sequence of SEQ ID NO:81 and a VH-antigen binding domain 2
(VH-ABD2) having the amino acid sequence of SEQ ID NO:80. In
further embodiments, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:81, a VH-ABD2 having
the amino acid sequence of SEQ ID NO:80, and a VH-antigen binding
domain 1 (VH-ABD1) having the amino acid sequence of SEQ ID NO:79.
In one embodiment, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:84. In one embodiment,
the ALK7-binding protein comprises a VH-ABD3 having the amino acid
sequence of SEQ ID NO:84 and a VH-antigen binding domain 2
(VH-ABD2) having the amino acid sequence of SEQ ID NO:83. In
further embodiments, the ALK7-binding protein comprises a VH-ABD3
having the amino acid sequence of SEQ ID NO:84, a VH-ABD2 having
the amino acid sequence of SEQ ID NO:83, and a VH-antigen binding
domain 1 (VH-ABD1) having the amino acid sequence of SEQ ID NO:82.
In further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments an ALK7-binding protein comprises a VH or a VL
which has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions compared to a reference
VH or VL disclosed herein. In further embodiments, the ALK7-binding
protein comprises a VH or a VL which has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions compared to a reference VH or VL disclosed in Table 1B.
In some embodiments an ALK7-binding protein comprises a VH and a VL
pair which has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions compared to a reference
VH and VL pair disclosed herein. In further embodiments, the
ALK7-binding protein comprises a VH and VL pair which has a total
of one, two, three, four, five, six, seven, eight, nine, ten, fewer
than fifteen, or zero, amino acid substitutions, deletions, and/or
insertions compared to a reference VH and VL pair disclosed in
Table 1B.
In further embodiments, the ALK7-binding protein comprises a VH or
a VL which has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions compared to a reference
VH or VL disclosed in Table 3. In further embodiments, the
ALK7-binding protein comprises a VH and VL pair which has a total
of one, two, three, four, five, six, seven, eight, nine, ten, fewer
than fifteen, or zero, amino acid substitutions, deletions, and/or
insertions compared to a reference VH and VL pair disclosed in
Table 1B or Table 3.
In some embodiments, the ALK7-binding protein a VH and a VL pair
selected from the group consisting of: (a)(i) a VH sequence having
a total of one, two, three, four, five, six, seven, eight, nine,
ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VH sequence selected
from the group consisting of SEQ ID NO:4, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:13; (b)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:22, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:31; (c)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:40, 170, or 171, and (ii) a VL
sequence having a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:49; and (d)(i) a VH sequence having a total
of one, two, three, four, five, six, seven, eight, nine, ten, fewer
than fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:58, and (ii) a
VL sequence having a total of one, two, three, four, five, six,
seven, eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:67; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein a VH and a VL pair
selected from the group consisting of: (a)(i) a VH sequence having
a total of one, two, three, four, five, six, seven, eight, nine,
ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VH sequence selected
from the group consisting of SEQ ID NO:91, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:98; (b)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:105, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:110; (c)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:117, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO: 124; (d)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:128, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:135; and (e)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:140, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:148; and wherein the protein binds ALK7. In further embodiments,
the ALK7-binding protein has at least one characteristic selected
from the group consisting of: (a) decreases the formation of a
complex containing ALK7, a type II receptor (e.g., ActRIIA or
ActRIIB), and one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) on the
surface of cells expressing ALK7 and the ActRII receptor in the
presence of the one or more TGF-beta superfamily ligands; (b)
competes with one or more type II receptors for binding to ALK7;
(c) competes with one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) for binding
to ALK7; (d) decreases the phosphorylation of ALK7 in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA or ActRIIB)
in the presence of one or more TGF-beta super family ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (e)
decreases the phosphorylation of Smads (e.g., Smad2 and/or Smad3)
in cells expressing ALK7 and a type II receptor (e.g., ActrIIA
and/or ActRIIB) in the presence of one or more TGF-beta ligands
(e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f)
binds to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM
(e.g., as determined by BIACORE.RTM. analysis), and (g) decreases
the formation of a complex containing ALK7, a co-receptor (e.g.,
cripto and/or cryptic), and one or more TGF-beta superfamily
ligands (e.g., Nodal). In some embodiments, the ALK7-binding
protein is an ALK7 antagonist (e.g., a neutralizing anti-ALK7
antibody). In further embodiments, the ALK-7 binding protein
increases lipolysis by 5% to 100%, 10% to 80%, or 10% to 60%. In
some embodiments, the ALK7-binding protein increase lipolysis in
adipocyte cells by 5% to 100%, 10% to 80%, or 10% to 60%. In some
embodiments, the ALK7-binding protein increase lipolysis in a
lipolysis assay using adipocyte cells (e.g., white adipocytes) by
5% to 100%, 10% to 80%, or 10% to 60%. In further embodiments the
lipolysis assay is performed in the presence of one or more ALK7
ligands selected from the group consisting of: GDF1, GDF3, GDF8,
activin B, activin A/B, and Nodal. In some embodiments, the
ALK7-binding protein has 2, 3, or 4 of the above characteristics.
In some embodiments, the ALK7-binding protein has at least 2, at
least 3, or at least 4, of the above characteristics.
In some embodiments, the ALK7-binding protein a VH and a VL pair
selected from the group consisting of: (a)(i) a VH sequence having
a total of one, two, three, four, five, six, seven, eight, nine,
ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VH sequence selected
from the group consisting of SEQ ID NO:152, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:98; (b)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO: 159, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:110; and (c)(i) a VH sequence having a total of one, two, three,
four, five, six, seven, eight, nine, ten, fewer than fifteen, or
zero, amino acid substitutions, deletions, and/or insertions from a
reference VH sequence of SEQ ID NO:165, and (ii) a VL sequence
having a total of one, two, three, four, five, six, seven, eight,
nine, ten, fewer than fifteen, or zero, amino acid substitutions,
deletions, and/or insertions from a reference VL sequence of SEQ ID
NO:171; and wherein the protein binds ALK7. In further embodiments,
the ALK7-binding protein has at least one characteristic selected
from the group consisting of: (a) decreases the formation of a
complex containing ALK7, a type II receptor (e.g., ActRIIA or
ActRIIB), and one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) on the
surface of cells expressing ALK7 and the ActRII receptor in the
presence of the one or more TGF-beta superfamily ligands; (b)
competes with one or more type II receptors for binding to ALK7;
(c) competes with one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) for binding
to ALK7; (d) decreases the phosphorylation of ALK7 in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA or ActRIIB)
in the presence of one or more TGF-beta super family ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (e)
decreases the phosphorylation of Smads (e.g., Smad2 and/or Smad3)
in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
and/or ActRIIB) in the presence of one or more TGF-beta ligands
(e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f)
binds to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM
(e.g., as determined by BIACORE.RTM. analysis), and (g) decreases
the formation of a complex containing ALK7, a co-receptor (e.g.,
cripto and/or cryptic), and one or more TGF-beta superfamily
ligands (e.g., Nodal). In some embodiments, the ALK7-binding
protein is an ALK7 antagonist (e.g., a neutralizing anti-ALK7
antibody). In further embodiments, the ALK-7 binding protein
increases lipolysis by 5% to 100%, 10% to 80%, or 10% to 60%. In
some embodiments, the ALK7-binding protein increase lipolysis in
adipocyte cells by 5% to 100%, 10% to 80%, or 10% to 60%. In some
embodiments, the ALK7-binding protein increase lipolysis in a
lipolysis assay using adipocyte cells (e.g., white adipocytes) by
5% to 100%, 10% to 80%, or 10% to 60%. In further embodiments the
lipolysis assay is performed in the presence of one or more ALK7
ligands selected from the group consisting of: GDF1, GDF3, GDF8,
activin B, activin A/B, and Nodal. In some embodiments, the
ALK7-binding protein has 2, 3, or 4 of the above characteristics.
In some embodiments, the ALK7-binding protein has at least 2, at
least 3, or at least 4, of the above characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:4; and the VL
sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:13; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:22; and the VL
sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:31; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:40; and the VL
sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:49; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:58 and the VL
sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:67; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:91; and the VL
sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:98; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:105; and the
VL sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:110; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TOF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO: 117; and the
VL sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:124; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:128 and the VL
sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:135; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB. Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair wherein the VH sequence has a total of one, two,
three, four, five, six, seven, eight, nine, ten, fewer than
fifteen, or zero, amino acid substitutions, deletions, and/or
insertions from a reference VH sequence of SEQ ID NO:140 and the VL
sequence has a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of SEQ ID NO:148; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (c) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal): (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 600%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VH
sequence having a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VH
sequence selected from the group consisting of (a) SEQ ID NO:4, (b)
SEQ ID NO:22, (c) SEQ ID NO:40, and (d) SEQ ID NO:58; and wherein
the protein binds ALK7. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VH
sequence having a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VH
sequence selected from the group consisting of (a) SEQ ID NO:91,
(b) SEQ ID NO:10S, (c) SEQ ID NO:117, (d) SEQ ID NO:128, and (e)
SEQ ID NO:140; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VL
sequence having a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of (a) SEQ ID NO:13; (b) SEQ ID NO:31; (c) SEQ ID NO:49;
and (d) SEQ ID NO:67; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein comprises a VL
sequence having a total of one, two, three, four, five, six, seven,
eight, nine, ten, fewer than fifteen, or zero, amino acid
substitutions, deletions, and/or insertions from a reference VL
sequence of (a) SEQ ID NO:98; (b) SEQ ID NO:110; (c) SEQ ID NO:124;
(d) SEQ ID NO:135, and (e) SEQ ID NO:148; and wherein the protein
binds ALK7. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments an ALK7-binding protein comprises a VH or a VL
which has at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to a reference VH or VL disclosed herein. In further
embodiments, the ALK7-binding protein comprises a VH or a VL which
has at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to a reference VH or VL disclosed in Table 1A. In further
embodiments, the ALK7-binding protein comprises a VH or a VL which
has at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to a reference VH or VL disclosed in Table 1B. In further
embodiments, the ALK7-binding protein comprises a VH or a VL which
has at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to a reference VH or VL disclosed in Table 3. In some
embodiments an ALK7-binding protein comprises a VH and VL which has
at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
a reference VH and VL disclosed herein. In further embodiments, the
ALK7-binding protein comprises a VH and VL which has at least 90%,
95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a reference
VH and VL disclosed in Table 1A. In further embodiments, the
ALK7-binding protein comprises a VH and VL which has at least 90%,
95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a reference
VH and VL disclosed in Table 1B. In further embodiments, the
ALK7-binding protein comprises a VH and VL which has at least 90%,
95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a reference
VH and VL disclosed in Table 3. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VH having (a) at least 90%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to SEQ ID NO:4; (b) at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:22; (c) at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:40; and (d) a VH having at least 90%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:58; and
wherein the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VH having (a) at least 90%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to SEQ ID NO:91; (b) at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:105; (c) at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:117; (d) a VH having at least 90%, 95%, 96%,
97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:128; and (e)
a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:140; and wherein the protein binds ALK7. In
further embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VL having: (a) at least 90%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to SEQ ID NO:13; (b) at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:31; (c) at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:49; and (d) at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO:67; and wherein the
protein binds ALK7. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VL having: (a) at least 90%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to SEQ ID NO:98; (b) at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO: 110; (c) at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to SEQ ID NO:124; (d) at least 90%, 95%, 96%,
97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:135; and (e)
at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
SEQ ID NO:148; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VH and a VL pair selected from the group
consisting of: (a)(i) a VH having at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO:4, and (ii) a VL having
at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
SEQ ID NO:13; (b)(i) a VH having at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO:22, and (ii) a VL
having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:31; (c)(i) a VH having at least 90%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:40, and
(ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to SEQ ID NO:49; and (d)(i) a VH having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:58, and (ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%,
or 100% sequence identity to SEQ ID NO:67; and wherein the protein
binds ALK7. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VH and a VL pair selected from the group
consisting of: (a)(i) a VH having at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO: 152, and (ii) a VL
having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:98; (b)(i) a VH having at least 90%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 159,
and (ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to SEQ ID NO:110; and (c)(i) a VH having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:165, and (ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%,
or 100% sequence identity to SEQ ID NO:171; and wherein the protein
binds ALK7. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal. GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VH and a VL pair selected from the group
consisting of: (a)(i) a VH having at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO:91, and (ii) a VL
having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:98; (b)(i) a VH having at least 90%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:105, and
(ii) a VL having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to SEQ ID NO:110; (c)(i) a VH having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO: 117, and (ii) a VL having at least 90%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to SEQ ID NO:124; (d)(i) a VH having
at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
SEQ ID NO: 128, and (ii) a VL having at least 90%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to SEQ ID NO: 135; and (e)(i) a
VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:140, and (ii) a VL having at least 90%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:148; and
wherein the protein binds ALK7. In further embodiments, the
ALK7-binding protein has at least one characteristic selected from
the group consisting of: (a) decreases the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competes with one or more
type II receptors for binding to ALK7; (c) competes with one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID NO:4, and a VL having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:13. In one embodiment, the ALK7-binding protein specifically
binds ALK7 and comprises a VH of SEQ ID NO:4 and a VL of SEQ ID
NO:13. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID SEQ ID NO:22, and a VL having at
least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
SEQ ID NO:31. In one embodiment, the ALK7-binding protein
specifically binds ALK7 and comprises a VH of SEQ ID SEQ ID NO:22
and a VL of SEQ ID NO:31. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal): (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID NO:40, and a VL having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:49. In one embodiment, the ALK7-binding protein specifically
binds ALK7 and comprises a VH of SEQ ID NO:40 and a VL of SEQ ID
NO:49. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 100% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID NO:58, and a VL having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:67. In one embodiment, the ALK7-binding protein specifically
binds ALK7 and comprises a VII of SEQ ID NO:58 and a VL of SEQ ID
NO:67. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7: (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID NO:91, and a VL having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:98. In one embodiment, the ALK7-binding protein specifically
binds ALK7 and comprises a VH of SEQ ID NO:91 and a VL of SEQ ID
NO:98. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID SEQ ID NO: 105, and a VL having at
least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
SEQ ID NO:110. In one embodiment, the ALK7-binding protein
specifically binds ALK7 and comprises a VH of SEQ ID SEQ ID NO:105
and a VL of SEQ ID NO:110. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID NO:117, and a VL having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:124. In one embodiment, the ALK7-binding protein specifically
binds ALK7 and comprises a VH of SEQ ID NO: 117 and a VL of SEQ ID
NO:124. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type IT receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%,
99.degree. %, or 100% sequence identity to SEQ ID NO: 128, and a VL
having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to SEQ ID NO:135. In one embodiment, the ALK7-binding
protein specifically binds ALK7 and comprises a VH of SEQ TD NO:128
and a VL of SEQ ID NO:135. In further embodiments, the ALK7-binding
protein has at least one characteristic selected from the group
consisting of: (a) decreases the formation of a complex containing
ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and one or
more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells expressing
ALK7 and the ActRII receptor in the presence of the one or more
TGF-beta superfamily ligands; (b) competes with one or more type II
receptors for binding to ALK7; (c) competes with one or more
TGF-beta superfamily ligands (e.g., activin B, activin AB, Nodal,
GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreases the
phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreases the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binds to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreases the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the ALK7-binding protein specifically binds ALK7
and comprises a VH having at least 90%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to SEQ ID NO:140, and a VL having at least
90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID
NO:148. In one embodiment, the ALK7-binding protein specifically
binds ALK7 and comprises a VH of SEQ ID NO:140 and a VL of SEQ ID
NO:148. In further embodiments, the ALK7-binding protein has at
least one characteristic selected from the group consisting of: (a)
decreases the formation of a complex containing ALK7, a type II
receptor (e.g., ActRIIA or ActRIIB), and one or more TGF-beta
superfamily ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3
and/or GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%4. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair selected from the group consisting of: (a) a VH
sequence of SEQ ID NO:4 and a VL sequence of SEQ ID NO:13; (b) a VH
sequence of SEQ ID NO:22, and a VL sequence of SEQ ID NO:31; (c) a
VH sequence of SEQ ID NO:40, and a VL sequence of SEQ ID NO:49; and
(d) a VH sequence of SEQ ID NO:58 and a VL sequence of SEQ ID
NO:67; and wherein the protein binds ALK7. In further embodiments,
the ALK7-binding protein has at least one characteristic selected
from the group consisting of: (a) decreases the formation of a
complex containing ALK7, a type II receptor (e.g., ActRIIA or
ActRIIB), and one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) on the
surface of cells expressing ALK7 and the ActRII receptor in the
presence of the one or more TGF-beta superfamily ligands; (b)
competes with one or more type II receptors for binding to ALK7;
(c) competes with one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) for binding
to ALK7; (d) decreases the phosphorylation of ALK7 in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA or ActRIIB)
in the presence of one or more TGF-beta super family ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (e)
decreases the phosphorylation of Smads (e.g., Smad2 and/or Smad3)
in cells expressing ALK7 and ActRIIA/B in the presence of GDF1,
GDF3, GDF8, activin B, activin A/B, and/or Nodal; (f) binds to ALK7
with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM (e.g., as
determined by BIACORE.RTM. analysis), and (g) decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In some embodiments, the ALK7-binding protein has 2, 3,
or 4 of the above characteristics. In some embodiments, the
ALK7-binding protein has at least 2, at least 3, or at least 4, of
the above characteristics.
In a further embodiment, the ALK7-binding protein comprises a VH
and a VL pair selected from the group consisting of: (a) a VH
sequence of SEQ ID NO:91 and a VL sequence of SEQ ID NO:98; (b) a
VH sequence of SEQ ID NO:105, and a VL sequence of SEQ ID NO: 110;
(c) a VH sequence of SEQ ID NO:117, and a VL sequence of SEQ ID
NO:124; (d) a VH sequence of SEQ ID NO:128 and a VL sequence of SEQ
ID NO:135; and (e) a VH sequence of SEQ ID NO:140 and a VL sequence
of SEQ ID NO:148; and wherein the protein binds ALK7. In further
embodiments, the ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and ActRIIA/B in the
presence of GDF1, GDF3, GDF8, activin B, activin A/B, and/or Nodal;
(f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM
(e.g., as determined by BIACORE.RTM. analysis), and (g) decreases
the formation of a complex containing ALK7, a co-receptor (e.g.,
cripto and/or cryptic), and one or more TGF-beta superfamily
ligands (e.g., Nodal). In some embodiments, the ALK7-binding
protein is an ALK7 antagonist (e.g., a neutralizing anti-ALK7
antibody). In further embodiments, the ALK-7 binding protein
increases lipolysis by 5% to 100%, 10% to 80%, or 10% to 60%. In
some embodiments, the ALK7-binding protein increase lipolysis in
adipocyte cells by 5% to 100%, 10% to 80%, or 10% to 60%. In some
embodiments, the ALK7-binding protein increase lipolysis in a
lipolysis assay using adipocyte cells (e.g., white adipocytes) by
5% to 100%, 10% to 80%, or 10% to 60%. In further embodiments the
lipolysis assay is performed in the presence of one or more ALK7
ligands selected from the group consisting of: GDF1, GDF3. GDF8,
activin B, activin A/B, and Nodal. In some embodiments, the
ALK7-binding protein has 2, 3, or 4 of the above characteristics.
In some embodiments, the ALK7-binding protein has at least 2, at
least 3, or at least 4, of the above characteristics.
In additional embodiments an ALK7-binding protein cross-blocks or
competes for binding to ALK7 with an antibody comprising a VH and a
VL sequence pair disclosed herein. In additional embodiments an
ALK7-binding protein cross-blocks or competes for binding to ALK7
with an antibody comprising a VH and a VL sequence pair disclosed
in Table 1A. In some embodiments, the ALK7-binding protein
specifically binds ALK7 and comprises a VH of SEQ ID NO:4, 22, 40,
or 58. In additional embodiments, the ALK7-binding protein
specifically binds ALK7 and comprises a VL of SEQ ID NO:13, 31, 49,
or 67. In further embodiments, the ALK7-binding protein
specifically binds ALK7 and comprises a VH of SEQ ID NO: 4, 22, 40,
or 58; and a VL of SEQ ID NO: 13, 31, 49, or 67. In certain
embodiments, an ALK7-binding protein binds to the same epitope as
an ALK7-binding protein disclosed herein. In additional
embodiments, an ALK7-binding protein binds to the same epitope as
an ALK7-binding protein disclosed in Table 1A. The ability of an
ALK7-binding protein to compete for binding with and/or bind the
same epitope of ALK7 as a reference ALK7-binding protein can
readily be determined using techniques disclosed herein or
otherwise known in the art.
In additional embodiments an ALK7-binding protein cross-blocks or
competes for binding to ALK7 with an antibody comprising a VH and a
VL sequence pair disclosed in Table 1B. In some embodiments, the
ALK7-binding protein specifically binds ALK7 and comprises a VH of
SEQ ID NO: 152, 159, or 166. In additional embodiments, the
ALK7-binding protein specifically binds ALK7 and comprises a VL of
SEQ ID NO:98, 110, or 171. In further embodiments, the ALK7-binding
protein specifically binds ALK7 and comprises a VH of SEQ ID NO:
152, 159, or 166; and a VL of SEQ ID NO: 98, 110, or 171. In
certain embodiments, an ALK7-binding protein binds to the same
epitope as an ALK7-binding protein disclosed herein. In additional
embodiments, an ALK7-binding protein binds to the same epitope as
an ALK7-binding protein disclosed in Table 1A. The ability of an
ALK7-binding protein to compete for binding with and/or bind the
same epitope of ALK7 as a reference ALK7-binding protein can
readily be determined using techniques disclosed herein or
otherwise known in the art.
In additional embodiments an ALK7-binding protein cross-blocks or
competes for binding to ALK7 with an antibody comprising a VH and a
VL sequence pair disclosed in Table 1B or Table 3. In some
embodiments, the ALK7-binding protein specifically binds ALK7 and
comprises a VH of SEQ ID NO: 91, 105, 117, 128, or 140. In
additional embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VL of SEQ ID NO: 98, 110, 124, 135, or 148. In
further embodiments, the ALK7-binding protein specifically binds
ALK7 and comprises a VH of SEQ ID NO: 91, 105, 117, 128, or 140;
and a VL of SEQ ID NO: 98, 110, 124, 135, or 148. In certain
embodiments, an ALK7-binding protein binds to the same epitope as
an ALK7-binding protein disclosed herein. In additional
embodiments, an ALK7-binding protein binds to the same epitope as
an ALK7-binding protein disclosed in Table 1A. In additional
embodiments, an ALK7-binding protein binds to the same epitope as
an ALK7-binding protein disclosed in Table 1B or Table 3. The
ability of an ALK7-binding protein to compete for binding with
and/or bind the same epitope of ALK7 as a reference ALK7-binding
protein can readily be determined using techniques disclosed herein
or otherwise known in the art.
In some embodiments, the ALK7-binding protein comprises a VH
sequence of SEQ ID NO:40 and a VL sequence of SEQ ID NO:49. In some
embodiments, an ALK7-binding protein cross-blocks or competes for
binding to ALK7 with an antibody comprising a VH sequence of SEQ ID
NO:40 and a VL sequence of SEQ ID NO:49. In further embodiments,
the ALK7-binding protein binds the same epitope of ALK7 as an
antibody comprising a VH sequence of SEQ ID NO:40 and a VL sequence
of SEQ ID NO:49.
In some embodiments, the ALK7-binding protein comprises a VH
sequence of SEQ ID NO:58 and a VL sequence of SEQ ID NO:67. In some
embodiments, an ALK7-binding protein cross-blocks or competes for
binding to ALK7 with an antibody comprising a VH sequence of SEQ ID
NO:58 and a VL sequence of SEQ ID NO:67. In further embodiments,
the ALK7-binding protein binds the same epitope of ALK7 as an
antibody comprising a VH sequence of SEQ ID NO:58 and a VL sequence
of SEQ ID NO:67.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody J01. In some embodiments, the ALK7-binding
protein comprises a VH sequence of SEQ ID NO: 152 and a VL sequence
of SEQ ID NO:98. In some embodiments, an ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH sequence of SEQ ID NO:152 and a VL sequence of SEQ
ID NO:98. In further embodiments, the ALK7-binding protein binds
the same epitope of ALK7 as an antibody comprising a VH sequence of
SEQ ID NO: 152 and a VL sequence of SEQ ID NO:98.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody J02. In some embodiments, the ALK7-binding
protein comprises a VH sequence of SEQ ID NO:91 and a VL sequence
of SEQ ID NO:98. In some embodiments, an ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH sequence of SEQ ID NO:91 and a VL sequence of SEQ
ID NO:98. In further embodiments, the ALK7-binding protein binds
the same epitope of ALK7 as an antibody comprising a VH sequence of
SEQ ID NO:91 and a VL sequence of SEQ ID NO:98.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody K01. In some embodiments, the the
ALK7-binding protein comprises a VH sequence of SEQ ID NO:159 and a
VL sequence of SEQ ID NO:110. In some embodiments, an ALK7-binding
protein cross-blocks or competes for binding to ALK7 with an
antibody comprising a VH sequence of SEQ ID NO: 159 and a VL
sequence of SEQ ID NO: 110. In further embodiments, the
ALK7-binding protein binds the same epitope of ALK7 as an antibody
comprising a VH sequence of SEQ ID NO: 159 and a VL sequence of SEQ
ID NO:110.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody K02. In some embodiments, the ALK7-binding
protein comprises a VH sequence of SEQ ID NO:105 and a VL sequence
of SEQ ID NO:110. In some embodiments, an ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH sequence of SEQ ID NO:105 and a VL sequence of SEQ
ID NO: 110. In further embodiments, the ALK7-binding protein binds
the same epitope of ALK7 as an antibody comprising a VH sequence of
SEQ ID NO:105 and a VL sequence of SEQ ID NO:110.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody 004. In some embodiments, the ALK7-binding
protein comprises a VH sequence of SEQ ID NO:4 and a VL sequence of
SEQ ID NO:13. In some embodiments, an ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH sequence of SEQ ID NO:4 and a VL sequence of SEQ ID
NO: 13. In further embodiments, the ALK7-binding protein binds the
same epitope of ALK7 as an antibody comprising a VII sequence of
SEQ ID NO:4 and a VL sequence of SEQ ID NO:13.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody G05. In some embodiments, the ALK7-binding
protein comprises a VH sequence of SEQ ID NO:117 and a VL sequence
of SEQ ID NO:124. In some embodiments, an ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH sequence of SEQ ID NO: 117 and a VL sequence of SEQ
ID NO:124. In further embodiments, the ALK7-binding protein binds
the same epitope of ALK7 as an antibody comprising a VH sequence of
SEQ ID NO: 117 and a VL sequence of SEQ ID NO:124.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody C02. In some embodiments, the ALK7-binding
protein comprises a VH sequence of SEQ ID NO:22 and a VL sequence
of SEQ ID NO:31. In some embodiments, an ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH sequence of SEQ ID NO:22 and a VL sequence of SEQ
ID NO:31. In further embodiments, the ALK7-binding protein binds
the same epitope of ALK7 as an antibody comprising a VH sequence of
SEQ ID NO:22 and a VL sequence of SEQ ID NO:31.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody C03. In some embodiments, the ALK7-binding
protein comprises a VH sequence of SEQ ID NO:128 and a VL sequence
of SEQ ID NO:135. In some embodiments, an ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH sequence of SEQ ID NO:128 and a VL sequence of SEQ
ID NO:135. In further embodiments, the ALK7-binding protein binds
the same epitope of ALK7 as an antibody comprising a VH sequence of
SEQ ID NO: 128 and a VL sequence of SEQ ID NO:135.
In some embodiments, the ALK7-binding protein comprises a VII and a
VL sequence of antibody L01. In some embodiments, the the
ALK7-binding protein comprises a VH sequence of SEQ ID NO:165 and a
VL sequence of SEQ ID NO:171. In some embodiments, an ALK7-binding
protein cross-blocks or competes for binding to ALK7 with an
antibody comprising a VH sequence of SEQ ID NO:165 and a VL
sequence of SEQ ID NO:171. In further embodiments, the ALK7-binding
protein binds the same epitope of ALK7 as an antibody comprising a
VH sequence of SEQ ID NO: 165 and a VL sequence of SEQ ID NO:
171.
In some embodiments, the ALK7-binding protein comprises a VH and a
VL sequence of antibody L02. In some embodiments, the ALK7-binding
protein comprises a VH sequence of SEQ ID NO:140 and a VL sequence
of SEQ ID NO:148. In some embodiments, an ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
comprising a VH sequence of SEQ ID NO:140 and a VL sequence of SEQ
ID NO:148. In further embodiments, the ALK7-binding protein binds
the same epitope of ALK7 as an antibody comprising a VH sequence of
SEQ ID NO: 140 and a VL sequence of SEQ ID NO:148.
In some embodiments, the ALK7-binding protein is an antibody that
specifically binds ALK7. In some embodiments, the anti-ALK7
antibody is a murine antibody, a humanized antibody, a chimeric
antibody, a monoclonal antibody, a polyclonal antibody, a
recombinant antibody, a multispecific antibody, or any combination
thereof. In some embodiments the anti-ALK7 antibody is an Fv
fragment, an Fab fragment, an F(ab')2 fragment, an Fab' fragment, a
dsFv fragment, an scFv fragment, or an sc(Fv)2 fragment.
In some embodiments, the ALK7-binding protein specifically binds
ALK7 and blocks an activity of an ALK7-ligand (e.g., GDF1, GDF3,
GDF8, activin B, activin A/B, or Nodal). In some embodiments, the
ALK7-binding protein specifically binds ALK7 and blocks an activity
of a co-receptor (e.g., cripto). In some embodiments the
ALK7-binding protein specifically binds ALK7 and decreases the fat
formation associated with the activity of an ALK7 ligand (e.g.,
GDF1, GDF3, GDF8, activin B, activin A/B, or Nodal). In some
embodiments the ALK7-binding protein specifically binds ALK7 and
treats or ameliorates one or more disease or conditions associated
with excess weight, obesity or a metabolic disorder. In some
embodiments, the disease or condition is type II diabetes. In some
embodiments, the disease or condition is hypertension. In some
embodiments, the metabolic disorder is dyslipidemia, insulin
resistance, hyperinsulinemia or hyperglycemia.
In particular embodiments, the ALK7-binding protein (e.g., an
anti-ALK7 antibody) decreases ALK7-mediated Smad signaling. In
another embodiment, an ALK7-binding protein antagonizes
ALK7-mediated inhibition of lipolysis in white and/or brown adipose
cells by 5% to 100%, 10% to 95%, 10 to 90%, 10 to 85%, 10 to 80%,
10 to 75%, 10 to 70%, 10 to 75%, 10 to 70%, 10 to 60%, 10 to 55%,
10 to 500, or 10 to 45%, as determined in a lipolysis assay. In
another embodiment, an ALK7-binding protein reduces or decreases
ALK7-mediated inhibition of lipolysis in white and/or brown adipose
cells by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
or 95%, or by about 100%, as determined in a lipolysis assay. In
some embodiments the lipolysis assay is performed in the presence
of one or more ALK7 ligands. In further embodiments, the lipolysis
assay is performed in the presence of one or more ALK7 ligands
selected from the group consisting of GDF1, GDF3, GDF8, activin B,
activin A/B, and Nodal). In some embodiments the ALK7-binding
protein binds ALK7 and inhibits or decreases one or more conditions
associated with overweight, obesity, insulin resistance, diabetes,
atherosclerosis, hypertension, inflammation, and/or NAFLD (e.g.,
fatty liver and/or NASH).
In particular embodiments, the ALK7-binding protein (e.g., an
anti-ALK7 antibody) decreases ALK7-mediated Smad signaling. In
another embodiment, the ALK7-binding protein inhibits ALK7-mediated
inhibition of lipolysis in white adipose cells by 5% to 100%, 10%
to 95%, 10 to 90%, 10 to 85%, 10 to 80%, 10 to 75%, 10 to 70%, 10
to 75%, 10 to 70%, 10 to 60%, 10 to 55%, 10 to 50%, or 10 to 45%,
as determined using standard techniques and conditions in a
lipolysis inhibition assay performed in the presence of activin B
(50 ng/ml) (e.g., as described in the examples herein). In another
embodiment, an ALK7-binding protein reduces or decreases
ALK7-mediated inhibition of lipolysis in white adipose cells by at
least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%, or
by about 100%, as determined, using standard techniques and
conditions in a lipolysis inhibition assay performed in the
presence of activin B (50 ng/ml) (e.g., as described in the
examples herein). In some embodiments the ALK7-binding protein
binds ALK7 and inhibits or decreases one or more conditions
associated with overweight, obesity, insulin resistance, diabetes,
atherosclerosis, hypertension, inflammation, and/or NAFLD (e.g.,
fatty liver and/or NASH).
In certain embodiments, the blocking of ALK7 activity by an
ALK7-binding protein (e.g., an anti-ALK7 antibody) described
herein, inhibits or decreases one or more conditions associated
with excess body weight, insulin resistance, obesity or diabetes,
such as hypertension, cancer, and neuropathy, retinopathy, and
cardiovascular, pulmonary and kidney disease. In further
embodiments the blocking of ALK7 inhibits or decreases one or more
conditions associated with metabolic disease. In particular
embodiments, the ALK7-binding protein (e.g., an anti-ALK7 antibody)
inhibits or decreases the binding to ALK7 by activin B, GDF8, or
Nodal. In another embodiment the ALK7-binding protein inhibits or
decreases the inhibition of lipolysis by a Smad-dependent
pathway.
As noted above, in some embodiments, an anti-ALK7 antibody (e.g., a
full-length ALK7-antibody and an ALK7-binding antibody fragment,
and a variant and derivative thereof) containing a VH and/or VL
amino acid sequence that binds ALK7 can have at least 85%, 90%,
95%, 96%, 97%, 98% 99%, or 100% sequence identity to a sequence set
forth herein. In some embodiments, the VH and/or VL amino acid
sequence(s) that binds ALK7 comprise 8, 7, 6, 5, 4, 3, 2, 1 amino
acid additions, substitutions (e.g., conservative substitutions) or
deletions relative to a sequence set forth herein. In additional
embodiments, the VH and/or VL amino acid sequence that binds ALK7
comprise 1, 2, 3, 4, 5 or more amino acid additions, substitutions
(e.g., conservative substitutions) or deletions relative to a
sequence set forth herein. An anti-ALK7 antibody containing VH and
VL regions having a certain percent similarity to a VH region or VL
region, or having one or more substitutions, deletions and/or
insertions (e.g., conservative substitutions) can be obtained by
mutagenesis (e.g., site-directed or PCR-mediated mutagenesis) of
nucleic acid molecules encoding VH and/or VL regions described
herein, followed by testing of the encoded altered antibody for
binding to ALK7 and optionally testing for retained function using
the functional assays described herein or an assay known in the art
that can routinely be modified to test the retained function.
The affinity or avidity of an ALK7-binding protein such as, an
anti-ALK7 antibody (e.g., a full-length ALK7-antibody and an
ALK7-binding antibody fragment, and a variant and derivative
thereof) for hALK7, or murALK7, can be determined experimentally
using any suitable method known in the art, e.g., flow cytometry,
enzyme-linked immunosorbent assay (ELISA), or radioimmunoassay
(RIA), or kinetics (e.g., BIACORE.RTM. or KINEXA.RTM. analysis).
Direct binding assays and competitive binding assay formats can be
readily employed. (See, for example, Berzofsky et al.,
"Antibody-Antigen Interactions," In Fundamental Immunology, Paul,
W. E., Ed., Raven Press: New York, N.Y. (1984); Kuby, Immunology,
W.H. Freeman and Company: New York, N.Y. (1992); and methods
described herein.) The measured affinity of a particular
antibody-antigen interaction can vary if measured under different
conditions (e.g., salt concentration, pH, temperature). Thus,
measurements of affinity and other ALK7-binding parameters (e.g.,
K.sub.D or Kd, K.sub.on, K.sub.off) are made with standardized
solutions of ALK7-binding proteins and ALK7 and the measurements
are performed using standardized conditions and methods, as
described herein or otherwise known in the art.
The disclosure further provides an ALK7-binding protein such as, an
anti-ALK7 antibody as described herein, where the ALK7-binding
protein is conjugated to a heterologous agent. In certain
embodiments the heterologous agent is an antimicrobial agent, a
therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a
lipid, a biological response modifier, a pharmaceutical agent, a
lymphokine, a heterologous antibody or antibody fragment, a
detectable label, or a polyethylene glycol (PEG). Heteroconjugate
ALK7-binding proteins are discussed in more detail elsewhere
herein.
In certain embodiments, the ALK7-binding protein is not an
anti-ALK7 antibody. A variety of methods for identifying and
producing non-antibody polypeptides that bind with high affinity to
a protein target are known in the art. See, e.g., Skerra, Curr.
Opin. Biotech. 18:295-304 (2007); Hosse et al., Protein Science
15:14-27 (2006); Gill et al., Curr. Opin. Biolechnol. 17:653-658
(2006); Nygren, FEBS J. 275:2668-2676 (2008); and Skerra, FEBS J.
275:2677-2683 (2008), each of which is incorporated by reference
herein in its entirety. In some embodiments, phage display
technology can been used to identify/produce an ALK7-binding
protein. In some embodiments, the ALK7-binding protein comprises a
protein scaffold based on a type selected from the group consisting
of VASP polypeptides, avian pancreatic polypeptide (aPP),
tetranectin (based on CTLD3), affilin (based on
.gamma.B-crystallin/ubiquitin), a knottin, an SH3 domain, a PDZ
domain, tendamistat, transferrin, an ankyrin consensus repeat
domain (e.g., DARPins), a lipocalin protein fold (e.g., anticalins
and Duocalins), a Protein Epitope Mimetic (PEM), a maxybody/avimer,
a domain antibody a fibronectin domain (e.g., 10 Fn3, see, e.g.,
U.S. Appl. Publ. Nos. 2003/0170753 and 20090155275, each of which
is herein incorporated by reference in its entirety), a domain of
protein A (e.g., Affibodies), and thioredoxin.
In some embodiments the disclosure provides an ALK7-binding protein
(e.g., an anti-ALK7 antibody such as, a full-length anti-ALK7
antibody and an ALK7-binding antibody fragment) that cross-blocks
or competes for binding ALK7 with an anti-ALK7 antibody provided
herein. In some embodiments the disclosure provides an ALK7-binding
protein that binds to the same epitope of ALK7 as an ALK7-binding
protein provided herein. The ability of a test ALK7-binding protein
to inhibit the binding of, for example, a reference binding protein
such as an antibody comprising a VH sequence of SEQ ID NO:4 and a
VL sequence of SEQ ID NO: 13, a VH sequence of SEQ ID NO:22 and a
VL sequence of SEQ ID NO:31, a VH sequence of SEQ ID NO:40 and a VL
sequence of SEQ ID NO:49, or a VH sequence of SEQ ID NO:58 and a VL
sequence of SEQ ID NO:67, to ALK7 demonstrates that the test
ALK7-binding protein can compete with the reference antibody for
binding to ALK7. Such an ALK7-binding protein can, according to
non-limiting theory, bind to the same or a related (e.g., a
structurally similar or spatially proximal) epitope on ALK7 as the
ALK7-reference antibody with which it competes. In one embodiment,
the ALK7-binding protein binds to the same epitope on ALK7 as an
antibody comprising a VH sequence of SEQ ID NO:4 and a VL sequence
of SEQ ID NO: 13, a VH sequence of SEQ ID NO:22 and a VL sequence
of SEQ ID NO:31, a VH sequence of SEQ ID NO:40 and a VL sequence of
SEQ ID NO:49, or a VH sequence of SEQ ID NO:58 and a VL sequence of
SEQ ID NO:67, respectively.
Likewise, the ability of a test ALK7-binding protein to inhibit the
binding of, for example, a reference binding protein such as an
antibody comprising a VH sequence of SEQ ID NO:91 and a VL sequence
of SEQ ID NO:98, a VH sequence of SEQ ID NO:105 and a VL sequence
of SEQ ID NO:110, a VH sequence of SEQ ID NO:117 and a VL sequence
of SEQ ID NO:124, a VH sequence of SEQ ID NO:128 and a VL sequence
of SEQ ID NO:135, or a VH sequence of SEQ ID NO:140 and a VL
sequence of SEQ ID NO: 148, to ALK7 demonstrates that the test
ALK7-binding protein can compete with the reference antibody for
binding to ALK7. Such an ALK7-binding protein can, according to
non-limiting theory, bind to the same or a related (e.g., a
structurally similar or spatially proximal) epitope on ALK7 as the
ALK7-reference antibody with which it competes. In one embodiment,
the ALK7-binding protein binds to the same epitope on ALK7 as an
antibody comprising a VH sequence of SEQ ID NO:91 and a VL sequence
of SEQ ID NO:98, a VH sequence of SEQ ID NO:105 and a VL sequence
of SEQ ID NO:110, a VH sequence of SEQ ID NO:117 and a VL sequence
of SEQ ID NO:124, a VH sequence of SEQ ID NO:128 and a VL sequence
of SEQ ID NO: 135, or a VH sequence of SEQ ID NO:140 and a VL
sequence of SEQ ID NO:148, respectively.
In general, type I TGF-beta receptor family members such as, ALK7,
are known to be phosphorylated by type II receptors (e.g., ActRIIA
and ActRIIB) and to signal through the phosphorylation of Smads
(e.g., Smad2 and/or Smad3). In some embodiments, an ALK7-binding
protein (e.g., an anti-ALK7 antibody) can decrease phosphorylation
of ALK7 by one or more type II receptors (e.g., ActRIIA and/or
ActRIIB) in an ALK7 and type II receptor-expressing cell (e.g.,
adipocyte). In some embodiments, an ALK7-binding protein (e.g., an
anti-ALK7 antibody) can decrease ALK7-mediated phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in an ALK7 and type II
receptor-expressing cell (e.g., adipocyte). In some embodiments the
ALK7 receptor expressing cell is murine. In some embodiments the
ALK7 receptor expressing cell is human. In some embodiments the
ALK7 receptor expressing cell is an adipocyte.
In some embodiments, an ALK7-binding protein has at least one
characteristic selected from: (a) decreasing the formation of a
complex containing ALK7, a type II receptor (e.g., ActRIIA or
ActRIIB), and one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) on the
surface of cells expressing ALK7 and the ActRII receptor in the
presence of the one or more TGF-beta superfamily ligands; (b)
competing with one or more type II receptors for binding to ALK7;
(c) competing with one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) for binding
to ALK7; (d) decreasing the phosphorylation of ALK7 in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA or ActRIIB)
in the presence of one or more TGF-beta super family ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (e)
decreasing the phosphorylation of Smads (e.g., Smad2 and/or Smad3)
in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
and/or ActRIIB) in the presence of one or more TGF-beta ligands
(e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f)
binding to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM
(e.g., as determined by BIACORE.RTM. analysis), and (g) decreasing
the formation of a complex containing ALK7, a co-receptor (e.g.,
cripto and/or cryptic), and one or more TGF-beta superfamily
ligands (e.g., Nodal). In some embodiments, the ALK7-binding
protein has 2, 3, or 4 of the above characteristics. In some
embodiments, the ALK7-binding protein has at least 2, at least 3,
or at least 4, of the above characteristics. In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In further
embodiments, the ALK7-binding protein cross-blocks or competes for
binding to ALK7 with an antibody having an ALK7-binding VH and VL
pair disclosed herein. In further embodiments, the ALK7-binding
protein is an anti-ALK7 antibody or an ALK7-binding antibody
fragment.
In some embodiments, an ALK7-binding protein decreases the
formation of a complex containing ALK7, a type II receptor (e.g.,
ActRIIA or ActRIIB), and one or more TGF-beta superfamily ligands
(e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) on the
surface of cells expressing ALK7 and the ActRII receptor in the
presence of the one or more of the TGF-beta superfamily ligands. In
some embodiments, the ALK7-binding protein is an ALK7 antagonist
(e.g., a neutralizing anti-ALK7 antibody). In further embodiments,
the ALK-7 binding protein increases lipolysis by 5% to 100%, 10% to
80%, or 10% to 60%. In some embodiments, the ALK7-binding protein
increase lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In further
embodiments, the ALK7-binding protein cross-blocks or competes for
binding to ALK7 with an antibody having an ALK7-binding VH and VL
pair disclosed herein. In further embodiments, the ALK7-binding
protein is an anti-ALK7 antibody or an ALK7-binding antibody
fragment.
In some embodiments, an ALK7-binding competes with one or more type
II receptors for binding to ALK7. In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In further
embodiments, the ALK7-binding protein cross-blocks or competes for
binding to ALK7 with an antibody having an ALK7-binding VH and VL
pair disclosed herein. In further embodiments, the ALK7-binding
protein is an anti-ALK7 antibody or an ALK7-binding antibody
fragment.
In some embodiments, an ALK7-binding protein (e.g., an anti-ALK7
antibody) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal). In some embodiments, the ALK7-binding protein
decreases the phosphorylation of Smads as measured using a
cell-based assay. In some embodiments, an ALK7-binding protein
decreases ALK7-mediated phosphorylation with an IC.sub.50 lower
than 500 pM, lower than 350 pM, lower than 250 pM, lower than 150
pM, lower than 100 pM, lower than 75 pM, lower than 60 pM, lower
than 50 pM, lower than 40 pM, lower than 30 pM, lower than 20 pM,
lower than 15 pM, lower than 10 pM, or lower than 5 pM, as measured
using a cell-based assay. In some embodiments, the ALK7-binding
protein is an ALK7 antagonist (e.g., a neutralizing anti-ALK7
antibody). In further embodiments, the ALK-7 binding protein
increases lipolysis by 5% to 100%, 10% to 80%, or 10% to 60%. In
some embodiments, the ALK7-binding protein increase lipolysis in
adipocyte cells by 5% to 100%, 10% to 80%, or 10% to 60%. In some
embodiments, the ALK7-binding protein increase lipolysis in a
lipolysis assay using adipocyte cells (e.g., white adipocytes) by
5% to 100%, 10% to 80%, or 10% to 60%. In further embodiments the
lipolysis assay is performed in the presence of one or more ALK7
ligands selected from the group consisting of: GDF1, GDF3, GDF8,
activin B, activin A/B, and Nodal. In further embodiments, the
ALK7-binding protein cross-blocks or competes for binding to ALK7
with an antibody having an ALK7-binding VH and VL pair disclosed
herein. In further embodiments, the ALK7-binding protein is an
anti-ALK7 antibody or an ALK7-binding antibody fragment.
In some embodiments, an ALK7-binding protein binds to ALK7 with a
K.sub.D of .ltoreq.1 nM and .gtoreq.1l pM (e.g., as determined by
BIACORE.RTM. analysis). In some embodiments, the ALK7-binding
protein is an ALK7 antagonist (e.g., a neutralizing anti-ALK7
antibody). In further embodiments, the ALK-7 binding protein
increases lipolysis by 5% to 100%, 10% to 80%, or 10% to 60%. In
some embodiments, the ALK7-binding protein increase lipolysis in
adipocyte cells by 5% to 100%, 10% to 80%, or 10% to 60%. In some
embodiments, the ALK7-binding protein increase lipolysis in a
lipolysis assay using adipocyte cells (e.g., white adipocytes) by
5% to 100%, 10% to 80%, or 10% to 60%. In further embodiments the
lipolysis assay is performed in the presence of one or more ALK7
ligands selected from the group consisting of: GDF1, GDF3, GDF8,
activin B, activin A/B, and Nodal. In further embodiments, the
ALK7-binding protein cross-blocks or competes for binding to ALK7
with an antibody having an ALK7-binding VH and VL pair disclosed
herein. In further embodiments, the ALK7-binding protein is an
anti-ALK7 antibody or an ALK7-binding antibody fragment.
In some embodiments, an ALK7-binding protein decreases the
formation of a complex containing ALK7, a co-receptor (e.g., cripto
and/or cryptic), and one or more TGF-beta superfamily ligands
(e.g., Nodal). In some embodiments, the ALK7-binding protein is an
ALK7 antagonist (e.g., a neutralizing anti-ALK7 antibody). In
further embodiments, the ALK-7 binding protein increases lipolysis
by 5% to 100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in adipocyte cells by 5% to
100%, 10% to 80%, or 10% to 60%. In some embodiments, the
ALK7-binding protein increase lipolysis in a lipolysis assay using
adipocyte cells (e.g., white adipocytes) by 5% to 100%, 10% to 80%,
or 10% to 60%. In further embodiments the lipolysis assay is
performed in the presence of one or more ALK7 ligands selected from
the group consisting of: GDF1, GDF3, GDF8, activin B, activin A/B,
and Nodal. In further embodiments, the ALK7-binding protein
cross-blocks or competes for binding to ALK7 with an antibody
having an ALK7-binding VH and VL pair disclosed herein. In further
embodiments, the ALK7-binding protein is an anti-ALK7 antibody or
an ALK7-binding antibody fragment.
Preparation of ALK7-Binding Proteins
In some embodiments, the ALK7-binding protein binds the
extracellular domain of ALK7. In further embodiments, the
ALK7-binding protein is an anti-ALK7 antibody such as, a
full-length anti-ALK7 antibody or an ALK7-binding antibody
fragment, and variants, and derivatives thereof.
ALK7-binding proteins can be readily prepared using known
techniques. Monoclonal anti-ALK7 antibodies can be prepared using
techniques known in the art, including hybridoma methods, such as
those described by Kohler and Milstein, Nature 256:495-497 (1975).
Using the hybridoma method, a mouse, hamster, or other appropriate
host animal, is immunized as described above to elicit the
production by lymphocytes of antibodies that will specifically bind
to an immunizing antigen. Lymphocytes can also be immunized in
vitro. Following immunization, the lymphocytes are isolated and
fused with a suitable myeloma cell line to form hybridoma cells
that can then be selected away from unfused lymphocytes and myeloma
cells. Hybridomas that produce monoclonal antibodies directed
specifically against ALK7 such as hALK7, as determined by
immunoprecipitation, immunoblotting, or by an in vitro binding
assay (e.g., radioimmunoassay (RIA); enzyme-linked immunosorbent
assay (ELISA)) can then be propagated either in in vitro culture
using standard methods (see, e.g., Goding, Monoclonal Antibodies:
Principles and Practice, Academic Press, 1986) or in vivo as
ascites tumors in an animal. The monoclonal antibodies can then be
purified from the culture medium or ascites fluid as described for
polyclonal antibodies above.
The provided monoclonal antibodies can also be made using
recombinant DNA methods as described in U.S. Pat. No. 4,816,567,
wherein the polynucleotides encoding a monoclonal antibody are
isolated from mature B-cells or a hybridoma cell, such as by RT-PCR
using oligonucleotide primers that specifically amplify the genes
encoding the heavy and light chains of the antibody, and their
sequence is determined using known procedures. The isolated
polynucleotides encoding the heavy and light chains are then cloned
into suitable expression vectors, which when transfected into host
cells such as E. coli cells, simian COS cells, Chinese hamster
ovary (CHO) cells, Per.C6 cells, or myeloma cells (e.g., NS0 cells)
that do not otherwise produce immunoglobulin protein, monoclonal
antibodies are generated by the host cells. Recombinant anti-ALK7
monoclonal antibodies can also readily be isolated from phage
display libraries expressing CDRs of the desired species using
known techniques (see, e.g., McCafferty et al., Nature 348:552-554
(1990); Clackson et al., Nature 352:624-628 (1991); and Marks et
al., J. Mol. Biol. 222:581-597 (1991)).
The anti-ALK7 antibodies can optionally be humanized, resurfaced,
and engineered to display high affinity for the ALK7 antigen and
other favorable biological properties. For example, a humanized (or
human) anti-ALK7 antibody, can readily be designed and prepared
using commonly available three-dimensional immunoglobulin modeling
and known procedures for selecting framework (FW) residues,
consensus sequences, and germline sequences to provide a desired
antibody characteristic, such as increased affinity for ALK7.
Affinity maturation strategies and chain shuffling strategies are
known in the art and can be employed to generate high affinity
anti-ALK7 antibodies as well as derivatives and variants of the
ALK7-binding proteins disclosed herein. See, e.g., Marks et al.,
Bio/Technology 10:779-783 (1992), which is herein incorporated by
reference in its entirety. An additional strategy for generating
high affinity anti-ALK7 antibodies as well as derivatives and
variants of the ALK7-binding proteins disclosed herein is to
generate novel VH or VL regions carrying CDR-derived sequences of
the disclosure using random mutagenesis of one or more selected VH
and/or VL genes to generate mutations within the entire variable
domain. Such a technique that uses error-prone PCR is described by
Gram et al. (PNAS USA 89:3576-3580 (1992)). In some embodiments,
one or two amino acid substitutions are made within a set of VH
CDRs and/or VL CDRs. A further strategy used direct mutagenesis to
CDR regions of VH or VL genes encoding anti-ALK7 antibodies
disclosed herein. Examples of such techniques are disclosed by
Barbas et al. (PNAS USA 91:3809-3813 (1994)) and Schier et al. (J.
Mol. Biol. 263:551-567 (1996)).
Humanization, resurfacing or engineering of anti-ALK7 antibodies of
the disclosure can be performed using any known method including,
but not limited to, those described in Jones et al., Nature 321:522
(1986); Riechmann et al., Nature 332:323 (1988); Verhoeyen et al.,
Science 239:1534 (1988)), Sims et al., J. Immunol. 151: 2296
(1993); Chothia et al., J. Mol. Biol. 196:901 (1987), Carter et
al., PNAS USA 89:4285 (1992); Presta et al., J. Immunol. 151:2623
(1993), U.S. Pat. Nos. 5,639,641, 5,723,323; 5,976,862; 5,824,514;
5,817,483; 5,814,476; 5,763,192; 5,723,323; 5,766,886; 5,714,352;
6,204,023; 6,180,370; 5,693,762; 5,530,101; 5,585,089; 5,225,539;
4,816,567, 7,557,189; 7,538,195; and 7,342,110; Intl. Appl. Nos.
PCT/US98/16280; PCT/US96/18978; PCT/US91/09630; PCT/US91/05939;
PCT/US94/01234; PCT/GB89/01334; PCT/GB91/01134; PCT/GB92/01755;
Intl. Appl. Publ. Nos. WO90/14443; WO90/14424; WO90/14430; and EP
Pat. Publ. No. EP 229246; each of which is herein incorporated by
reference in is entirely. Likewise, known assays are available for
readily selecting anti-ALK7-antibodies displaying desirable
features (e.g., assays for determining binding affinity to ALK7;
cross-blocking assays such as the BIACORE.RTM.-based human
ALK7-binding protein competition binding assays described
herein).
Methods for engineering, humanizing or resurfacing non-human or
human antibodies can also be used and are known in the art. A
humanized, resurfaced or similarly engineered antibody can have one
or more amino acid residues from a source that is non-human, e.g.,
but not limited to, mouse, rat, rabbit, non-human primate or other
mammal. These non-human amino acid residues are replaced by
residues that are often referred to as "import" residues, which are
typically taken from an "import" variable, constant or other domain
of a known human sequence. Such imported sequences can be used to
reduce immunogenicity or reduce, enhance or modify binding,
affinity, on-rate, off-rate, avidity, specificity, half-life, or
any other suitable characteristic, as known in the art. Preferably,
part or all of the non-human or human CDR sequences are maintained
while the non-human sequences of the variable and constant regions
can be replaced with human or other amino acids.
Nucleic acid(s) encoding an ALK7-binding protein, such as a
full-length anti-ALK7 antibody can further be modified in a number
of different manners using recombinant DNA technology to generate
alternative antibodies. In some embodiments, nucleic acid(s)
encoding the constant domains of the light and heavy chains of, for
example, a mouse monoclonal antibody can be substituted (a) for
those coding regions of, for example, a human antibody to generate
a chimeric antibody or (b) for non-immunoglobulin encoding nucleic
acid(s) to generate a fusion antibody. In some embodiments, the
constant regions are truncated or removed to generate the desired
antibody fragment of a monoclonal antibody. Site-directed or
high-density mutagenesis of the variable region coding sequence can
be used to optimize specificity, affinity, etc. of a monoclonal
antibody.
Anti-ALK7 human antibodies can be directly prepared using any of
the numerous techniques known in the art. (See, e.g., Cole et al.,
Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77
(1985); Boemer et al., J. Immunol. 147(1):86-95 (1991); and U.S.
Pat. No. 5,750,373). Similarly, human anti-ALK7 antibodies can
readily be obtained from immortalized human B lymphocyte immunized
in vitro or isolated from an immunized individual that produces an
antibody directed against ALK7.
Human anti-ALK7 antibodies can also be selected from a phage
library that expresses human antibodies, as described, for example,
in Vaughan et al., Nat. Biotech. 14:309-314 (1996), Sheets et al.,
PNAS 95:6157-6162 (1998), Hoogenboom and Winter, J. Mol. Biol.
227:381 (1991), and Marks et al., J. Mol. Biol. 222:581 (1991).
Techniques for the generating and screening antibody phage
libraries are also described in U.S. Pat. Nos. 5,969,108;
6,172,197; 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915;
6,593,081; 6,300,064; 6,653,068; 6,706,484; and 7,264,963; and
Rothe et al., J. Mol. Biol. 376(4):1182-1200 (2008)(each of which
is herein incorporated by reference in its entirety).
Human anti-ALK7 antibodies can also be made in transgenic mice
containing human immunoglobulin loci that are capable upon
immunization of producing human antibodies in the absence of
endogenous immunoglobulin production. This approach is described
for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825;
5,625,126; 5,633,425; and 5,661,016.
Human anti-ALK7 antibodies can also be selected and/or isolated
from yeast-based antibody presentation libraries, as disclosed in,
for example, WO012/009568; WO09/036379; WO10/105256; WO03/074679
and U.S. Appl. Publ. No. US2002/0177170, the contents of each of
which is herein incorporated by reference in its entirety. Such
libraries are designed in silico to be reflective of the diversity
afforded by the human preimmune repertoire.
Alternatively, anti-ALK7 antibodies may be selected from a
yeast-displayed antibody library see, for example: Blaise et al.,
Gene 342(2):211-218 (2004); Boder et al., Nat Biotechnol.
15(6):553-557 (1997); Kuroda et al., Biotechnol. Lett. 33(1):1-9
(2011). Review; Lauer et al., J. Pharm. Sci. 101(1):102-15 (2012);
Orcutt K. D. and Wittrup K. D. Antibody Engineering, yeast display
and selection (2010), 207-233; Rakestraw et al., Protein Eng. Des.
Sel. 24(6):525-30 (2011); and U.S. Pat. Nos. 6,423,538; 6,696,251;
and 6,699,658.
Various techniques are known for the production of antigen-binding
antibody fragments. Traditionally, these fragments are derived via
proteolytic digestion of intact antibodies (see, e.g., Morimoto et
al., J. Biochem. Biophys. Meth. 24:107-117 (1993); and Brennan et
al., Science 229:81 (1985)). In certain embodiments an ALK7-binding
antibody fragments produced recombinantly. Fab, Fv, and scFv
antibody fragments can all be expressed in and secreted from E.
coli or other host cells, thus allowing the production of large
amounts of these fragments. Such an ALK7-binding antibody fragments
can additionally be isolated from the antibody phage libraries
discussed above. In some embodiments, the ALK7-binding antibody
fragment is a linear antibody as described in U.S. Pat. No.
5,641,870. Other techniques for the production of antigen-binding
antibody fragments are known in the art.
Known techniques can be readily adapted for the production of
single-chain antibodies that bind ALK7 (see, e.g., U.S. Pat. No.
4,946,778). In addition, known methods can routinely be adapted for
the construction of Fab expression libraries (see, e.g., Huse et
al., Science 246:1275-1281 (1989)) to allow rapid and effective
identification of monoclonal Fab fragments with the desired
specificity for ALK7. ALK7-binding antibody fragments can be
produced by techniques known in the art including, but not limited
to: (a) a F(ab')2 fragment produced by pepsin digestion of an
antibody; (b) a Fab fragment generated by reducing the disulfide
bridges of an F(ab')2 fragment, (c) a Fab fragment generated by the
treatment of the anti-ALK7 antibody with papain and a reducing
agent, and (d) Fv fragments.
In certain embodiments, an ALK7-binding protein (e.g., an anti-ALK7
antibody) can be modified in order to increase its serum half-life.
This can be achieved, for example, by incorporation of a salvage
receptor binding epitope into the ALK7-binding protein by mutation
of an appropriate region in the ALK7-binding protein or by
incorporating the salvage receptor epitope into a peptide tag that
is then fused to the ALK7-binding protein at either end or in the
middle (e.g., by DNA or peptide synthesis). Other methods to
increase the serum half-life of an ALK7-binding protein, e.g.,
conjugation to a heterologous molecule such as PEG are known in the
art.
Heteroconjugate ALK7-binding proteins (e.g., anti-ALK7 antibodies,
such as a full-length anti-ALK7 antibodies and ALK7-binding
antibody fragments, and variants and derivatives thereof) are also
within the scope of the disclosure. Heteroconjugate ALK7-binding
proteins are composed of two covalently joined proteins. It is
contemplated that the heteroconjugate ALK7-binding proteins can be
prepared in vitro using known methods in synthetic protein
chemistry, including those involving crosslinking agents. For
example, immunotoxins can be constructed using a disulfide exchange
reaction or by forming a thioether bond. Examples of suitable
reagents for this purpose include iminothiolate and
methyl-4-mercaptobutyrimidate.
ALK7-binding proteins can comprise any type of variable region that
provides for the association of the antibody with ALK7. Such
variable region can comprise or be derived from any mammal that can
be induced to mount a humoral response and generate immunoglobulins
against the ALK7 antigen. The variable region of an anti-ALK7
antibody can be, for example, of human, murine, non-human primate
(e.g., cynomolgus monkeys, macaques, etc.) or lupine origin. In
some embodiments both the variable and constant regions of the
modified anti-ALK7 antibodies are human. In other embodiments the
variable regions of compatible antibodies (usually derived from a
non-human source) can be engineered or specifically tailored to
improve the binding properties or reduce the immunogenicity of the
molecule. In this respect, variable regions useful according to the
disclosure can be humanized or otherwise altered through the
inclusion of imported amino acid sequences using affinity
maturation, mutagenesis procedures, chain shuffling strategies
and/or other methods described herein or otherwise know in the
art.
In certain embodiments, the variable domains in both the heavy and
light chains of an anti-ALK7 antibody are altered by at least
partial replacement of one or more CDRs and/or by partial framework
region replacement and sequence changing. Although the CDRs can be
derived from an antibody of the same class or even subclass as the
antibody from which the framework regions are derived, it is
envisaged that the CDRs will be derived from an antibody of
different class and in certain embodiments from an antibody from a
different species. It is not necessary to replace all of the CDRs
with the complete CDRs from the donor variable region to transfer
the antigen-binding capacity of one variable domain to another.
Rather, it is only necessary to transfer those residues that are
necessary to maintain the activity of the antigen-binding site. It
is well within the competence of those of ordinary skill in the
art, to routinely obtain a functional antibody with reduced
immunogenicity. See, e.g., U.S. Pat. Nos. 5,585,089, 5,693,761 and
5,693,762.
Alterations to the variable region notwithstanding, those of
ordinary skill in the art will appreciate that the modified
anti-ALK7 antibody of the disclosure will comprise antibodies in
which at least a fraction of one or more of the constant region
domains has been deleted or otherwise altered so as to provide
desired biochemical characteristics such as decreased ADCC or
increased serum half-life when compared with an antibody of
approximately the same immunogenicity comprising a native or
unaltered constant region. In some embodiments, the constant region
of the modified anti-ALK7 antibodies comprise a human constant
region. Modifications to the constant region can include additions,
deletions or substitutions of one or more amino acids in one or
more domains. The modified anti-ALK7 antibodies disclosed herein
can comprise alterations or modifications to one or more of the
three heavy chain constant domains (CH1, CH2 or CH3) and/or to the
light chain constant domain (CL). In some embodiments, the modified
anti-ALK7 antibodies comprise constant regions wherein one or more
domains are partially or entirely deleted are contemplated. In some
embodiments, the modified anti-ALK7 antibodies comprise domain
deleted constructs or variants wherein the entire CH2 domain has
been removed (.DELTA.CH2 constructs). In some embodiments, the
omitted constant region domain can be replaced by a short amino
acid spacer (e.g., 10 residues) that provides some of the molecular
flexibility typically imparted by the absent constant region.
It is generally understood that the constant region mediates
several effector functions. For example, binding of the Cl
component of complement to antibodies activates the complement
system. Activation of complement is important in the opsonization
and lysis of cell pathogens. The activation of complement also
stimulates the inflammatory response and can also be involved in
autoimmune hypersensitivity. Further, antibodies bind to cells via
the Fc region, with a Fc receptor site on the antibody Fc region
binding to a Fc receptor (FcR) on a cell. There are a number of Fc
receptors that are specific for different classes of antibody,
including IgG (gamma receptors), IgE (eta receptors), IgA (alpha
receptors) and IgM (mu receptors). Binding of antibody to Fc
receptors on cell surfaces triggers a number of important and
diverse biological responses including engulfment and destruction
of antibody-coated particles, clearance of immune complexes, lysis
of antibody-coated target cells by killer cells (called
antibody-dependent cell-mediated cytotoxicity, or ADCC), release of
inflammatory mediators, placental transfer and control of
immunoglobulin production.
In certain embodiments, an anti-ALK7 antibody has an altered
effector function that, in turn, affects the biological profile of
the administered anti-ALK7 antibody. For example, the deletion or
inactivation (through point mutations or other means) of a constant
region domain can reduce Fc receptor binding of the circulating
modified antibody. In other cases the constant region
modifications, can moderate complement binding and thus reduce the
serum half-life and nonspecific association of a conjugated
cytotoxin. Yet other modifications of the constant region can be
used to eliminate disulfide linkages or oligosaccharide moieties
that allow for enhanced localization due to increased antigen
specificity or antibody flexibility. Similarly, modifications to
the constant region in accordance with this disclosure can easily
be made using biochemical or molecular engineering techniques known
to those of ordinary skill in the art.
In some embodiments, an ALK7-binding protein provided herein is an
ALK7 antibody that does not have one or more effector functions.
For instance, in some embodiments, the anti-ALK7 antibody has no
antibody-dependent cellular cytoxicity (ADCC) activity and/or no
complement-dependent cytoxicity (CDC) activity. In certain
embodiments, the anti-ALK7 antibody does not bind to an Fc receptor
and/or complement factors. In certain embodiments, the anti-ALK7
antibody has no effector function. Examples of Fc sequence
engineering modifications that reduce or eliminate ADCC and/or CDC
activity and Fc receptor and/or complement factor binding are
described herein or otherwise know in the art, as are assays and
procedures for testing the same.
In some embodiments, an anti-ALK7 antibody is engineered to fuse
the CH3 domain directly to the hinge region of the respective
modified antibody. In other constructs a peptide spacer is inserted
between the hinge region and the modified CH2 and/or CH3 domains.
For example, compatible constructs can be expressed in which the
CH2 domain has been deleted and the remaining CH3 domain (modified
or unmodified) is joined to the hinge region with a 5-20 amino acid
spacer. Such a spacer can be added, for instance, to ensure that
the regulatory elements of the constant domain remain free and
accessible or that the hinge region remains flexible. Amino acid
spacers can, in some cases, prove to be immunogenic and elicit an
unwanted immune response against the construct. Accordingly, in
certain embodiments, any spacer added to the construct can be
relatively non-immunogenic, or even omitted altogether, so as to
maintain the desired biochemical qualities of the modified
anti-ALK7 antibody.
In additional embodiments anti-ALK7 antibodies are modified by the
partial deletion or substitution of a few or even a single amino
acid in a constant region. For example, the mutation of a single
amino acid in selected areas of the CH2 domain can be enough to
substantially reduce Fc binding and thereby. Similarly one or more
constant region domains that control the effector function (e.g.,
complement Cl Q binding) can be fully or partially deleted. Such
partial deletions of the constant regions can improve selected
characteristics of the anti-ALK7 antibody (e.g., serum half-life)
while leaving other desirable functions associated with the
corresponding constant region domain intact. In some embodiments
the constant region of the anti-ALK7 antibody is modified through
the mutation or substitution of one or more amino acids that
enhances the profile of the resulting construct. In this respect it
is possible to disrupt the activity provided by a conserved binding
site (e.g., Fc binding) while substantially maintaining the
configuration and immunogenic profile of the modified anti-ALK7
antibody. The disclosure also provides an anti-ALK7 antibody that
contains the addition of one or more amino acids to the constant
region to enhance desirable characteristics such, as decreasing or
increasing effector function or providing attachments sites for one
or more cytotoxin, labeling or carbohydrate moieties. In such
embodiments it can be desirable to insert or replicate specific
sequences derived from selected constant region domains.
The disclosure also provides an ALK7-binding protein that is a
variant to an ALK7-binding protein provided herein (e.g., murine,
chimeric, humanized and human ALK7-binding proteins). In particular
embodiments, the variant ALK7-binding protein has at least one
characteristic selected from the group consisting of: (a) decreases
the formation of a complex containing ALK7, a type II receptor
(e.g., ActRIIA or ActRIIB), and one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) on the surface of cells expressing ALK7 and the ActRII
receptor in the presence of the one or more TGF-beta superfamily
ligands; (b) competes with one or more type II receptors for
binding to ALK7; (c) competes with one or more TGF-beta superfamily
ligands (e.g., activin B, activin AB, Nodal, GDF1, GDF3 and/or
GDF8) for binding to ALK7; (d) decreases the phosphorylation of
ALK7 in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
or ActRIIB) in the presence of one or more TGF-beta super family
ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or
Nodal); (e) decreases the phosphorylation of Smads (e.g., Smad2
and/or Smad3) in cells expressing ALK7 and a type II receptor
(e.g., ActRIIA and/or ActRIIB) in the presence of one or more
TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B, activin AB,
and/or Nodal); (f) binds to ALK7 with a K.sub.D of .ltoreq.1 nM and
.gtoreq.1 pM (e.g., as determined by BIACORE.RTM. analysis), and
(g) decreases the formation of a complex containing ALK7, a
co-receptor (e.g., cripto and/or cryptic), and one or more TGF-beta
superfamily ligands (e.g., Nodal). In some embodiments, the
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the ALK-7 binding
protein increases lipolysis by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
The provided ALK7-binding proteins, such as anti-ALK7 antibodies,
can be derivatized to contain additional chemical moieties known in
the art for improving for example, the solubility, biological
half-life, bioavailability, and to otherwise improve the stability,
formulation and/or therapeutic properties of the ALK7-binding
protein. A non-exhaustive overview for such moieties can be found
for example, in Remington's Pharmaceutical Sciences, 20th ed., Mack
Publishing Co., Easton, Pa. (2000).
Nucleic Acids Encoding ALK7-Binding Proteins and their
Expression
Nucleic acid molecules and combinations of nucleic acid molecules
that encode an ALK7-binding protein are also provided. In some
embodiments, the nucleic acids molecules encode an anti-ALK7
antibody, such as a full-length anti-ALK7 antibody and an
ALK7-binding antibody fragment. In further embodiments, the
disclosure provides nucleic acid molecules that encode a variant or
derivative of a full-length anti-ALK7 antibody or an ALK7-binding
antibody fragment provided herein.
The nucleic acid molecules disclosed herein can be in the form of
RNA or in the form of DNA. DNA includes cDNA, genomic DNA, and
synthetic DNA; and can be double-stranded or single-stranded, and
if single stranded can be the coding strand/or non-coding
(anti-sense) strand. In certain embodiments, the nucleic acid
molecule is isolated. In additional embodiments, a nucleic acid
molecule is substantially pure. In some embodiments the nucleic
acid is cDNA or is derived from cDNA. In some embodiments the
nucleic acid is be recombinantly produced.
In some embodiments, the nucleic acid molecule comprises an
ALK7-binding protein coding sequence operably linked to a control
sequence that controls the expression of the coding sequence in a
host cell or in vitro. In particular embodiments, the coding
sequence is a cDNA. The disclosure also relates to vectors
containing nucleic acid molecules comprises an ALK7-binding protein
coding sequence operably linked to a control sequence that controls
the expression of the coding sequence in a host cell or in
vitro.
In some embodiments, the nucleic acid molecule comprises a coding
sequence for a mature ALK7-binding protein that is fused in the
same reading frame to a heterologous polynucleotide sequence. In
some embodiments, the heterologous polynucleotide sequence encodes
a leader peptide sequence that facilitates the secretion of the
expressed protein from the host cell transformed with the
ALK7-binding protein encoding nucleic acid molecule(s). A protein
containing a leader sequence is referred to as a preprotein and can
have the leader sequence cleaved by the host cell to form the
mature form of the ALK7-binding protein. Such leader peptide
sequences and their use facilitating the secretion of recombinant
proteins in host cells is generally known in the art. In additional
embodiments, the heterologous polynucleotide sequence encodes
additional 5' amino acid residues that can function for example, to
facilitate purification, add or improve protein stability and/or
therapeutic or diagnostic properties of the recombinantly expressed
ALK7-binding protein.
In some embodiments the disclosure provides isolated nucleic acids
such as an ALK7-binding protein encoding cDNA fragments, sufficient
for use as a hybridization probe, PCR primer or sequencing
primer.
In some embodiments, the nucleic acid molecules encode an
ALK7-binding protein that has at least one characteristic selected
from the group consisting of: (a) decreases the formation of a
complex containing ALK7, a type II receptor (e.g., ActRIIA or
ActRIIB), and one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) on the
surface of cells expressing ALK7 and the ActRII receptor in the
presence of the one or more TGF-beta superfamily ligands; (b)
competes with one or more type II receptors for binding to ALK7;
(c) competes with one or more TGF-beta superfamily ligands (e.g.,
activin B, activin AB, Nodal, GDF1, GDF3 and/or GDF8) for binding
to ALK7; (d) decreases the phosphorylation of ALK7 in cells
expressing ALK7 and a type II receptor (e.g., ActRIIA or ActRIIB)
in the presence of one or more TGF-beta super family ligands (e.g.,
GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (e)
decreases the phosphorylation of Smads (e.g., Smad2 and/or Smad3)
in cells expressing ALK7 and a type II receptor (e.g., ActRIIA
and/or ActRIIB) in the presence of one or more TGF-beta ligands
(e.g., GDF1, GDF3, GDF8, activin B, activin AB, and/or Nodal); (f)
binds to ALK7 with a K.sub.D of .ltoreq.1 nM and .gtoreq.1 pM
(e.g., as determined by BIACORE.RTM. analysis), and (g) decreases
the formation of a complex containing ALK7, a co-receptor (e.g.,
cripto and/or cryptic), and one or more TGF-beta superfamily
ligands (e.g., Nodal). In some embodiments, the encoded
ALK7-binding protein is an ALK7 antagonist (e.g., a neutralizing
anti-ALK7 antibody). In further embodiments, the encoded ALK-7
binding protein increases lipolysis in adipose cells expressing
ALK7. In some embodiments, the encoded ALK7-binding protein has 2,
3, or 4 of the above characteristics. In some embodiments, the
encoded ALK7-binding protein has at least 2, at least 3, or at
least 4, of the above characteristics. In some embodiments, the
encoded ALK7-binding protein cross-blocks or competes for binding
to ALK7 with an antibody having an ALK7-binding VH and VL pair
disclosed herein. In additional embodiments, the encoded
ALK7-binding protein binds to the same epitope of ALK7 as an
antibody disclosed herein. In some embodiments, the encoded
ALK7-binding protein cross-blocks or competes for binding to ALK7
with an ALK7 binding antibody having a VH and VL pair disclosed
herein. In additional embodiments, the encoded ALK7-binding protein
binds to the same epitope of ALK7 as an antibody disclosed herein.
In further embodiments, the nucleic acid molecules encode an
ALK7-binding protein that specifically binds ALK7 and comprises a
VH and a VL.
In some embodiments, the disclosure provides vectors and sets of
vectors containing nucleic acids and sets of nucleic acids encoding
the ALK7-binding proteins provided herein. Host cells transformed
with these nucleic acids, sets of nucleic acids, vectors, and sets
of vectors are also provided, as are methods of making an using the
ALK7-binding proteins.
In some embodiments, the disclosure provides a host cell comprising
a nucleic acid molecule or combination of nucleic acid molecules or
a vector as provided above, where the host cell can, in some
instances express an ALK7-binding protein (e.g., an anti-ALK7
antibody such as, a full-length ALK7-antibody and an ALK7-binding
antibody fragment), that specifically binds to ALK7. In further
embodiments, the disclosure provides a host cell transformed with a
nucleic acid molecule or combination of nucleic acid molecules or a
vector as provided above, where the host cell can, in some
instances express an ALK7-binding protein that specifically binds
to ALK7. Such host cells can be utilized in a method of making an
ALK7-binding protein as provided herein, where the method includes
(a) culturing the host cell and (b) isolating the ALK7-binding
proteins expressed from the host cell.
The disclosure also provides a method for making an ALK7-binding
protein comprising culturing a host cell (e.g., a hybridoma or
transformed mammalian host cell) capable of expressing the
ALK7-binding protein under suitable conditions and optionally
provides a method for isolating the ALK7-binding protein secreted
from the host cell. And the disclosure additionally provides the
ALK7-binding protein isolated using the disclosed methods.
In certain embodiments the polynucleotides comprise the coding
sequence(s) for the mature ALK7-binding protein(s) (e.g., an
ALK7-antibody, such as a full-length antibody and an ALK7-binding
antibody fragment) fused in the same reading frame to a marker
sequence that allows, for example, for purification of the encoded
polypeptide. For example, the marker sequence can be a
hexa-histidine tag supplied by a pQE-9 vector to provide for
purification of the mature polypeptide fused to the marker in the
case of a bacterial host, or the marker sequence can be a
hemagglutinin (HA) tag derived from the influenza hemagglutinin
protein when a mammalian host (e.g., COS-7 cells) is used.
Nucleic acid variants encoding an ALK7-binding protein such as, an
anti-ALK7 antibody and an ALK7-binding antibody fragment, are also
provided. Nucleic acid variants can contain alterations in the
coding regions, non-coding regions, or both. In some embodiments
the nucleic acid variants contain alterations that produce silent
substitutions, additions, or deletions, but do not alter the
properties or activities of the encoded polypeptide. In some
embodiments, the nucleic acid variants are produced by silent
substitutions due to the degeneracy of the genetic code. Nucleic
acid variants can be produced for a variety of reasons, e.g., to
optimize codon expression for a particular host (change codons in
the human mRNA to those preferred by a bacterial host such as E.
coli). Vectors and cells comprising the nucleic acids described
herein are also provided.
In some embodiments a nucleic acid sequence encoding an
ALK7-binding protein (e.g., an anti-ALK7 antibody such as a
full-length antibody and an ALK7-binding antibody fragment) is
constructed by chemical synthesis using an oligonucleotide
synthesizer. Such oligonucleotides can be designed based on the
amino acid sequence of the desired polypeptide and codon
optimization based on the host cell preferences. Standard methods
can routinely be applied to synthesize an isolate polynucleotide
sequences encoding ALK7-binding proteins.
Once assembled (by synthesis, site-directed mutagenesis or another
method), the nucleic acid sequences encoding ALK7-binding proteins
can routinely be operably linked to a control sequence appropriate
for expression of the ALK7-binding protein in a desired host. In
some embodiments, the nucleic acid sequence(s) encoding an
ALK7-binding protein is inserted into one or more expression
vectors and operably linked to a control sequence(s) appropriate
for expression of the protein in a desired host. In order to obtain
high expression levels of a transfected coding sequence in a host,
the coding sequence can be operably linked to or associated with
transcriptional and translational expression control sequences that
are functional in the chosen expression host.
In certain embodiments, recombinant expression vectors are used to
amplify and express DNA encoding an ALK7-binding protein, such as,
an anti-ALK7 antibody or an ALK7-binding antibody fragment.
Recombinant expression vectors are replicable DNA constructs which
have synthetic or cDNA-derived DNA fragments encoding a polypeptide
chain of an ALK7-binding protein operably linked to suitable
transcriptional or translational regulatory elements derived from
mammalian, microbial, viral or insect genes. A transcriptional unit
generally comprises an assembly of (1) a genetic element or
elements having a regulatory role in gene expression, for example,
transcriptional promoters or enhancers, (2) a structural or coding
sequence which is transcribed into mRNA and translated into
protein, and (3) appropriate transcription and translation
initiation and termination sequences, as described in detail below.
Such regulatory elements can include an operator sequence to
control transcription. The ability to replicate in a host, usually
conferred by an origin of replication, and a selection gene to
facilitate recognition of transformants can additionally be
incorporated. DNA regions are operably linked when they are
functionally related to each other. For example, DNA for a signal
peptide (secretory leader) is operably linked to DNA for a
polypeptide if it is expressed as a precursor which participates in
the secretion of the polypeptide; a promoter is operably linked to
a coding sequence if it controls the transcription of the sequence;
or a ribosome binding site is operably linked to a coding sequence
if it is positioned so as to permit translation. Structural
elements intended for use in yeast expression systems include a
leader sequence enabling extracellular secretion of translated
protein by a host cell. Alternatively, where a recombinant protein
is expressed without a leader or transport sequence, the protein
can include an N-terminal methionine residue. This residue can
optionally be subsequently cleaved from the expressed recombinant
protein to provide a final protein. In certain embodiments, the
disclosure provides a composition, e.g., a pharmaceutical
composition, comprising a nucleic acid or vector of as described
above or elsewhere herein, optionally further comprising one or
more carriers, diluents, excipients, or other additives.
Also provided is a host cell transformed with the nucleic acid
molecule or cDNA molecules and/or the vectors disclosed herein. The
disclosure also provides host cells transformed with the disclosed
nucleic acid molecule or molecules operably linked to a control
sequence and optionally inserted into a vector. In some
embodiments, the host cell is a mammalian host cell. In further
embodiments, the mammalian host cell is a NS0 murine myeloma cell,
a PER.C6.RTM. human cell, or a Chinese hamster ovary (CHO) cell. In
other embodiments, the host cell is a hybridoma.
In additional embodiments, the disclosure provides a method of
making an ALK7-binding protein (e.g., an anti-ALK7 antibody such
as, a full-length ALK7-antibody and an ALK7-binding antibody
fragment, and variants and derivatives thereof) provided herein
comprising culturing a transformed host cell or a hybridoma
disclosed herein under suitable conditions for producing the
ALK7-binding protein. The disclosure optionally provides isolating
the ALK7-binding protein secreted from the host cell. The
disclosure also optionally provides the ALK7-binding protein
produced using this method and pharmaceutical compositions
comprising the ALK7-binding protein and a pharmaceutically
acceptable carrier.
The choice of expression control sequence and expression vector
will depend upon the choice of host. A wide variety of expression
host/vector combinations can be employed. Useful expression vectors
for eukaryotic hosts, include, for example, vectors comprising
expression control sequences from SV40, bovine papilloma virus,
adenovirus and cytomegalovirus. Useful expression vectors for
bacterial hosts include known bacterial plasmids, such as plasmids
from E. coli, including pCR1, pBR322, pMB9 and their derivatives,
and also wider host range plasmids, such as M13 and filamentous
single-stranded DNA phages.
Suitable host cells for expression of an ALK7-binding protein,
include prokaryotes, yeast, insect or higher eukaryotic cells under
the control of appropriate promoters. Prokaryotes include gram
negative or gram positive organisms, for example E. coli or
bacilli. Higher eukaryotic cells include established cell lines of
mammalian origin as described below. Cell-free translation systems
could also be employed. Additional information regarding methods of
protein production, including antibody production, can be found,
e.g., in U.S. Appl. Publ. No. 2008/0187954, U.S. Pat. Nos.
6,413,746 and 6,660,501, and Intl. Appl. Publ. No. WO04/009823,
each of which is herein incorporated by reference in its
entirety.
Various mammalian or insect cell culture systems can also be
advantageously employed to express recombinant ALK7-binding
proteins (e.g., an anti-ALK7 antibody such as, a full-length
ALK7-antibody and an ALK7-binding antibody fragment, and variants
and derivatives thereof). Expression of recombinant ALK7-binding
proteins in mammalian cells can be performed because such proteins
are generally correctly folded, appropriately modified and
completely functional. Examples of suitable mammalian host cell
lines include HEK-293 and HEK-293T, the COS-7 lines of monkey
kidney cells, described by Gluzman (Cell 23:175 (1981)), and other
cell lines including, for example, L cells, C127, 3T3. Chinese
hamster ovary (CHO), HeLa and BHK cell lines. Mammalian expression
vectors can comprise nontranscribed elements such as an origin of
replication, a suitable promoter and enhancer linked to the gene to
be expressed, and other 5' or 3' flanking nontranscribed sequences,
and 5' or 3' nontranslated sequences, such as necessary ribosome
binding sites, a polyadenylation site, splice donor and acceptor
sites, and transcriptional termination sequences. Baculovirus
systems for production of heterologous proteinsin sect cells are
reviewed by Luckow and Summers, BioTechnology 6:47 (1988).
ALK7-binding proteins produced by a transformed host cell or
hybridoma can be purified according to any suitable method. Such
standard methods include chromatography (e.g., ion exchange,
affinity and sizing column chromatography), centrifugation,
differential solubility, or by any other standard technique for
protein purification. Affinity tags such as hexahistidine, maltose
binding domain, influenza coat sequence and
glutathione-S-transferase can be attached to the protein to allow
easy purification by passage over an appropriate affinity column.
ALK7-binding proteins can also be physically characterized using
such techniques as proteolysis, nuclear magnetic resonance and
x-ray crystallography.
For example, supernatants from systems that secrete recombinant
ALK7-binding proteins into culture media can be first concentrated
using a commercially available protein concentration filter, for
example, an Amicon or Millipore Pellicon ultrafiltration unit.
Following the concentration step, the concentrate can be applied to
a suitable purification matrix. Alternatively, an anion exchange
resin can be employed, for example, a matrix or substrate having
pendant diethylaminoethyl (DEAE) groups. The matrices can be
acrylamide, agarose, dextran, cellulose or other types commonly
employed in protein purification. Alternatively, a cation exchange
step can be employed. Suitable cation exchangers include various
insoluble matrices comprising sulfopropyl or carboxymethyl groups.
Finally, one or more reversed-phase high performance liquid
chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media,
e.g., silica gel having pendant methyl or other aliphatic groups,
can be employed to further purify an ALK7-binding protein. Some or
all of the foregoing purification steps, in various combinations,
can also routinely be employed to provide a homogeneous recombinant
ALK7-binding proteins.
A recombinant ALK7-binding protein (e.g., an anti-ALK7 antibody
such as, a full-length ALK7-antibody and an ALK7-binding antibody
fragment and variants and derivatives thereof) produced in
bacterial culture can be isolated, for example, by initial
extraction from cell pellets, followed by one or more
concentration, salting-out, aqueous ion exchange or size exclusion
chromatography steps. High performance liquid chromatography (HPLC)
can be employed for final purification steps. Microbial cells
employed in expression of a recombinant protein can be disrupted by
any convenient method, including freeze-thaw cycling, sonication,
mechanical disruption, or use of cell lysing agents.
Methods known in the art for purifying target binding proteins such
as full-length antibodies and antigen-binding antibody fragments
also include, for example, those described in U.S. Appl. Publ. Nos.
2008/0312425, 2008/0177048, and 2009/0187005, each of which is
incorporated herein by reference herein in its entirety.
In certain embodiments, the ALK7-binding protein is not an
antibody. A variety of methods are known for identifying and
producing non-antibody polypeptides that bind with high affinity to
a protein target. See, e.g., Skerra, Curr. Opin. Biotechnol.
18:295-304 (2007), Hosse et al., Protein Science 15:14-27 (2006),
Gill et al., Curr. Opin. Biotechnol. 17:653-658 (2006), Nygren,
FEBS J. 275:2668-2676 (2008), and Skerra, FEBS J. 275:2677-2683
(2008), each of which is herein incorporated by reference in its
entirety. In certain embodiments, phage display technology is used
to identify/produce the ALK7-binding protein. In certain
embodiments, the polypeptide comprises a protein scaffold of a type
selected from the group consisting of protein A, a lipocalin, a
fibronectin domain (e.g., Fibronectin type III (Fn3)), an ankyrin
consensus repeat domain, and thioredoxin.
Methods of Use and Pharmaceutical Compositions
The provided ALK7-binding proteins (including antibodies,
immunoconjugates, and polypeptides) are useful in a variety of
applications including, but not limited to, diagnostic methods and
methods of treating and/or ameliorating various diseases and
conditions with an ALK7-binding protein (e.g., an anti-ALK7
antibody). Methods are provided for the use of an ALK7-binding
protein (e.g., an anti-ALK7 antibody such as, a full-length
antibody that specifically binds ALK7 and an ALK7-binding antibody
fragment, and variants and derivatives thereof) to treat subjects
having a disease or condition associated with ALK7 signaling,
altered ALK7 expression, and/or can be ameliorated by reduced ALK7
signaling. In additional embodiments, the disclosure provides a
pharmaceutical composition containing an ALK7-binding protein
provided herein and a pharmaceutically acceptable carrier. In some
embodiments, the disclosure provides a pharmaceutical composition
containing an ALK7-binding protein provided herein and a
pharmaceutically acceptable carrier, for use as a medicament. The
disclosure also provides the use of the pharmaceutical compositions
disclosed herein for treating and/or ameliorating a disease or
condition associated with ALK7 signaling, altered ALK7 expression,
and/or that can be ameliorated by reduced ALK7 signaling. In some
embodiments, the disease or condition treated using the
pharmaceutical composition provided herein is obesity (e.g.,
abdominal obesity); overweight; insulin resistance; metabolic
syndrome and other metabolic diseases or conditions; a lipid
disorder such as, low HDL, levels, high LDL levels, hyperlipidemia,
hypertriglyceridemia or dyslipidemia; lipoprotein aberrations;
decreased triglycerides; inflammation (e.g., liver inflammation
and/or inflammation of adipose tissue), fatty liver disease;
non-alcoholic fatty liver disease; hyperglycemia; impaired glucose
tolerance (IGT); hyperinsulinemia; high cholesterol (e.g., high LDL
levels and hypercholesterolemia); cardiovascular disease such as,
heart disease including coronary heart disease, congestive heart
failure, stroke, peripheral vascular disease, atherosclerosis;
arteriosclerosis, and hypertension; Syndrome X; vascular
restenosis; neuropathy; retinopathy; neurodegenerative disease;
endothelial dysfunction, respiratory dysfunction, renal disease
(e.g., nephropathy); pancreatitis; polycystic ovarian syndrome;
elevated uric acid levels; haemochromatosis (iron overload);
acanthosis nigricans (dark patches on the skin); or cancer such as,
myeloma (e.g., multiple myeloma, plasmacytoma, localized myeloma,
and extramedullary myeloma), ovarian, breast, endometrial, and
colon cancer); or a another disorders/conditions associated with
one or more of the above diseases or conditions. In some
embodiments, the disease or condition treated using the
pharmaceutical composition provided herein is associated with
overweight (e.g., BMI of .gtoreq.25 kg/m.sup.2), or with too much
body fat.
In some embodiments, a pharmaceutical composition contains an
ALK7-binding protein (e.g., an anti-ALK antagonist antibody) and a
pharmaceutically acceptable carrier, and the ALK7 binding protein
further comprises a labeling group or an effector group. A "label"
refers to one or more elements, isotopes, or chemical compounds
attached to enable the detection in a screen. Labels generally fall
into three classes: (a) isotopic labels, which may be radioactive
or heavy isotopes, (b) small molecule labels, which may include
fluorescent and colorimetric dyes, or molecules such as biotin that
enable other labeling methods, and (c) immune labels, which may be
an epitope incorporated as a fusion partner that is recognized by
an antibody, "Labeling group" refers to any detectable label. In
some embodiments, the labeling group is coupled to the ALK7-binding
protein via a spacer (e.g., a peptide spacer) to reduce potential
steric hindrance. Labels may be incorporated into the compound at
any position and may be incorporated in vitro or in vivo during
protein expression. Various methods for labeling proteins are known
in the art and may be used in performing the provided methods. In
additional embodiments, the labeling group is selected from the
group consisting of: isotopic labels, magnetic labels, redox active
moieties, optical dyes, biotinylated groups and polypeptide
epitopes recognized by a secondary reporter. In some embodiments,
the labeling group is a fluorescent protein such as a Green
Fluorescent Protein or derivative thereof (e.g., enhanced GFP, blue
fluorescent protein or derivative thereof (e.g., EBFP (Enhanced
Blue Fluorescent Protein), EBFP2, Azurite, mKalamal, cyan
fluorescent protein or derivative thereof (e.g., ECFP (Enhanced
Cyan Fluorescent Protein), Cerulean, CyPet), yellow fluorescent
protein or derivative thereof (e.g., YFP, Citrine, Venus, YPet). In
some embodiments, the polypeptide epitope is a member selected from
a biotin signaling peptide, histidine peptide (his), hemagglutinin
(HA), Flag, gold binding peptide. In additional embodiments the
effector group is selected from the group consisting of a
radioisotope, radionucleotide, a toxin, a therapeutic and a
chemotherapeutic agent.
The ALK7-binding proteins of the present disclosure have
applications in in vitro and in vivo diagnostic and therapeutic
utilities. For example, the ALK7-binding proteins can be
administered to cells in culture, e.g., in vitro or in vivo, or in
a subject, to treat, prevent or diagnose a variety of diseases or
conditions. In some embodiments, the ALK7-binding proteins are
human antibodies, murine antibodies, or humanized antibodies.
Also provided are methods of blocking ALK7 activity. In some
embodiments, the method comprises contacting ALK7 with an
antagonist ALK7-binding protein. In further embodiments, the
antagonist ALK7-binding protein is an anti-ALK7 antibody. In some
instances the method is performed in vivo. In other instances, the
method is performed in vitro. In some embodiments the blocked ALK7
activity is selected from (a) decreasing the formation of a complex
containing ALK7, a type II receptor (e.g., ActRIIA or ActRIIB), and
one or more TGF-beta superfamily ligands (e.g., activin B, activin
AB, Nodal, GDF1, GDF3 and/or GDF8) on the surface of cells
expressing ALK7 and the ActRII receptor in the presence of the one
or more TGF-beta superfamily ligands; (b) competing with one or
more type II receptors for binding to ALK7; (c) competing with one
or more TGF-beta superfamily ligands (e.g., activin B, activin AB,
Nodal, GDF1, GDF3 and/or GDF8) for binding to ALK7; (d) decreasing
the phosphorylation of ALK7 in cells expressing ALK7 and a type II
receptor (e.g., ActRIIA or ActRIIB) in the presence of one or more
TGF-beta super family ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (e) decreasing the phosphorylation of
Smads (e.g., Smad2 and/or Smad3) in cells expressing ALK7 and a
type II receptor (e.g., ActRIIA and/or ActRIIB) in the presence of
one or more TGF-beta ligands (e.g., GDF1, GDF3, GDF8, activin B,
activin AB, and/or Nodal); (f) binding to ALK7 with a K.sub.D of
.ltoreq.1 nM and .gtoreq.1 pM (e.g., as determined by BIACORE.RTM.
analysis), and (g) decreasing the formation of a complex containing
ALK7, a co-receptor (e.g., cripto and/or cryptic), and one or more
TGF-beta superfamily ligands (e.g., Nodal). In some embodiments,
the ALK7-binding protein is an ALK7 antagonist (e.g., a
neutralizing anti-ALK7 antibody). In further embodiments, the ALK-7
binding protein increases lipolysis by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in adipocyte cells by 5% to 100%, 10% to 80%, or 10% to
60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay using adipocyte cells (e.g., white
adipocytes) by 5% to 100%, 10% to 80%, or 10% to 60%. In further
embodiments the lipolysis assay is performed in the presence of one
or more ALK7 ligands selected from the group consisting of: GDF1,
GDF3, GDF8, activin B, activin A/B, and Nodal. In some embodiments,
the ALK7-binding protein has 2, 3, or 4 of the above
characteristics. In some embodiments, the ALK7-binding protein has
at least 2, at least 3, or at least 4, of the above
characteristics.
In one embodiment, the disclosure provides for the treatment,
prevention and/or amelioration of a disease or condition that
comprises administering an ALK7-binding protein (e.g., an anti-ALK
antagonist antibody) to a subject that has a disease or condition,
or is at risk of developing a disease or condition, associated with
ALK7 signaling, altered ALK7 expression, and/or can be ameliorated
by reduced ALK7 signaling. In another embodiment the treatment
includes the administration of an ALK7-binding protein to an
isolated tissue or cells from a subject, where the subject has a
disease or condition, or is at risk of developing a disease or
condition, associated with ALK7 expression or ALK7 signaling.
The disclosure provides pharmaceutical compositions comprising an
ALK7-binding protein and a pharmaceutically acceptable carrier.
Also provided are methods for treating and/or ameliorating
conditions associated with an ALK7-mediated activity in a subject,
comprising administering to a subject in need thereof an effective
amount of a pharmaceutical composition comprising an ALK7-binding
protein provided herein. In some embodiments, the ALK7-binding
protein is administered alone. In other embodiments, the
ALK7-binding protein is administered as a combination therapy. Also
provided are methods of reducing ALK7 activity in a subject
comprising administering an effective amount of an ALK7-binding
protein to a subject in need thereof.
As provided herein, an effective amount of an ALK7-binding protein
(e.g., an antagonist anti-ALK7 antibody that specifically binds
ALK7 or an antagonist ALK7-binding antibody fragment) can be
administered for reducing body weight (e.g., promoting weight
loss), reducing body weight gain (e.g., preventing weight gain),
and/or treating obesity. In some embodiments, the ALK7-binding
protein is an antibody disclosed herein. In some embodiments, the
ALK7-binding protein is an ALK7 antagonist antibody. In some
embodiments, the administered anti-ALK7-antibody cross-blocks or
competes for binding ALK7 with an antibody having a VH and a VL
pair disclosed in Table 1A. In some embodiments, the administered
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1A. In some
embodiments, the administered anti-ALK7-antibody cross-blocks or
competes for binding ALK7 with an antibody having a VH and a VL
pair disclosed in Table 1B or Table 3. In some embodiments, the
administered anti-ALK7-antibody binds to the same epitope of ALK7
as an antibody having a VH and a VL pair disclosed in Table 1B or
Table 3. In certain instances, the subject has type 2 diabetes
mellitus.
In one embodiment, the disclosure provides a method of reducing
body weight comprising administering to a subject desiring to
reduce body weight, or in need thereof, an effective amount of an
ALK7-binding protein (e.g., an antagonist antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In some embodiments, the ALK7-binding protein is an
antibody disclosed herein. In some embodiments, the ALK7-binding
protein is an ALK7 antagonist antibody. In some embodiments, the
administered antagonist anti-ALK7-antibody cross-blocks or competes
for binding ALK7 with an antibody having a VH and a VL pair
disclosed in Table 1A. In some embodiments, the administered
antagonist anti-ALK7-antibody binds to the same epitope of ALK7 as
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the administered antagonist anti-ALK7-antibody
cross-blocks or competes for binding ALK7 with an antibody having a
VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments, the administered antagonist anti-ALK7-antibody binds
to the same epitope of ALK7 as an antibody having a VH and a VL
pair disclosed in Table 1B or Table 3. In some embodiments, the
subject is overweight (e.g., pre-obese). In some embodiments, the
subject has a body mass index (BMI) of 25 kg/m.sup.2 or greater. In
further embodiments, the subject has a BMI of 25 kg/m.sup.2 to 29.9
kg/m.sup.2, 30 kg/m.sup.2 to 39.9 mkg/m.sup.2, 25 kg/m.sup.2 to
39.9 kg/m.sup.2, or 25 kg/m.sup.2 to 50 kg/m.sup.2. In some
embodiments, the subject is obese. In some embodiments, the subject
has a BMI of 30 kg/m.sup.2 or greater (e.g., 30 to 39.9 kg/m.sup.2
or 30 kg/m.sup.2 to 50 kg/m.sup.2). In some embodiments, the
subject is morbidly obese. In some embodiments, the subject has a
BMI of 40 kg/m.sup.2 or greater. In further embodiments, the
subject has a BMI of 40 kg/m.sup.2 to 45 kg/m.sup.2, or 40
kg/m.sup.2 to 50 kg/m.sup.2. In some embodiments, the subject has
central obesity (e.g., excess adiposity in the abdominal region,
including belly fat and/or visceral fat). In some embodiments, the
subject has a waist/hip circumference ratio (WHR) of 0.85 or
greater. In some embodiments, the subject has peripheral obesity
(e.g., excess adiposity on the hips). In some embodiments, the
subject has type 2 diabetes mellitus. The ALK7-binding protein is
administered alone or as a combination therapy. In some
embodiments, the administration is an adjunct to diet and/or
exercise.
In one embodiment, the disclosure provides a method of reducing
weight gain comprising administering to a subject desiring to
reduce weight gain, or in need thereof, an effective amount of an
ALK7-binding protein (e.g., an antagonist antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In some embodiments, the ALK7-binding protein is an
antibody disclosed herein. In some embodiments, the ALK7-binding
protein is an ALK7 antagonist antibody. In some embodiments, the
administered antagonist anti-ALK7-antibody cross-blocks or competes
for binding ALK7 with an antibody having a VH and a VL pair
disclosed in Table 1A. In some embodiments, the administered
antagonist anti-ALK7-antibody binds to the same epitope of ALK7 as
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the administered antagonist anti-ALK7-antibody
cross-blocks or competes for binding ALK7 with an antibody having a
VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments, the administered antagonist anti-ALK7-antibody binds
to the same epitope of ALK7 as an antibody having a VH and a VL
pair disclosed in Table 1B or Table 3. In some embodiments, the
subject is overweight (e.g., pre-obese). In some embodiments, the
subject has a BMI of 25 kg/m.sup.2 or greater. In further
embodiments, the subject has a BMI of 25 kg/m.sup.2 to 29.9
kg/m.sup.2, 30 kg/m.sup.2 to 39.9 mkg/m.sup.2, 25 kg/m.sup.2 to
39.9 kg/m.sup.2, or 25 kg/m.sup.2 to 50 kg/m.sup.2. In some
embodiments, the subject is obese. In some embodiments, the subject
has a BMI of 30 kg/m.sup.2 or greater (e.g., 30 to 39.9 kg/m.sup.2
or 30 kg/m.sup.2 to 50 kg/m.sup.2). In some embodiments, the
subject is morbidly obese. In some embodiments, the subject has a
BMI of 40 kg/m.sup.2 or greater. In further embodiments, the
subject has a BMI of 40 kg/m.sup.2 to 45 kg/m.sup.2, or 40
kg/m.sup.2 to 50 kg/m.sup.2. In some embodiments, the subject has
type 2 diabetes mellitus.
Also provided is a method of treating or preventing a disease or
condition associated with excess body weight, comprising
administering to a subject in need of treatment or prevention, an
effective amount of an ALK7-binding protein (e.g., an antagonist
antibody that specifically binds ALK7 or an antagonist ALK7-binding
antibody fragment). In some embodiments, the administered
ALK7-binding protein (e.g., an antagonist antibody) binds to the
same epitope of ALK7 as an antibody having a VH and a VL pair
disclosed in Table 1A. In some embodiments, the administered
ALK7-binding protein binds to the same epitope of ALK7 as an
antibody having a VH and a VL pair disclosed in Table 1B or Table
3. In one embodiment, the treated or prevented disease or condition
is obesity. In one embodiment, the treated or prevented disease or
condition is insulin resistance. In one embodiment, the treated or
prevented disease or condition is a member selected from the group
consisting of: dyslipidemia, hyperlipidemia (total cholesterol
level>240 mg/dL), hypercholesterolemia (e.g., total cholesterol
level of >200 mg/dL, >220 mg/dL, >240 mg/dL, >250
mg/dL, or >275 mg/dL), low HDL serum level (e.g., <40 mg/dL,
<45 mg/dL, or <50 mg/dL), high LDL serum level (e.g.,
.gtoreq.100 mg/dL, .gtoreq.130 mg/dL, .gtoreq.160 mg/dL, or
.gtoreq.190 mg/dL), and hypertriglyceridemia (e.g., a fasting TG
level of .gtoreq.150 mg/dL, .gtoreq.175 mg/dL, .gtoreq.200 mg/dL,
.gtoreq.300 mg/dL, .gtoreq.400 mg/dL, or .gtoreq.499 mg/dL). In
certain instances, the administration is an adjunct to diet and/or
exercise.
In another embodiment the disclosure provides a method of reducing
body weight in a subject who is overweight. The method includes
administering to an overweight subject an effective amount of an
ALK7-binding protein (e.g., an antagonist antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) cross-blocks or competes for
binding ALK7 with an antibody having a VH and a VL pair disclosed
in Table 1A. In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) cross-blocks or competes for
binding ALK7 with an antibody having a VH and a VL pair disclosed
in Table 1A. In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) binds to the same epitope of
ALK7 as an antibody having a VH and a VL pair disclosed in Table
1A. In some embodiments, the administered ALK7-binding protein
(e.g., an antagonist antibody) cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1B or Table 3. In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) cross-blocks or competes for
binding ALK7 with an antibody having a VH and a VL pair disclosed
in Table 1B or Table 3. In some embodiments, the administered
ALK7-binding protein (e.g., an antagonist antibody) binds to the
same epitope of ALK7 as an antibody having a VH and a VL pair
disclosed in Table 1B or Table 3. In some embodiments, the subject
has a body mass index (BMI) of 25 kg/m.sup.2 or greater. In further
embodiments, the subject has a BMI of 25 kg/m.sup.2 to 29.9
kg/m.sup.2, 30 kg/m.sup.2 to 39.9 mkg/m.sup.2, 25 kg/m.sup.2 to
39.9 kg/m.sup.2, or 25 kg/m.sup.2 to 50 kg/m.sup.2, or 27 to 40
kg/m.sup.2. In some embodiments, the subject is obese. In some
embodiments, the subject has a BMI of 30 kg/m.sup.2 or greater
(e.g., 30 to 39.9 kg/m.sup.2 or 30 kg/m.sup.2 to 50 kg/m.sup.2).
The ALK7-binding protein is administered alone or as a combination
therapy. In some embodiments, the administration is an adjunct to
diet and/or exercise.
In one embodiment the disclosure provides a method of reducing body
weight in an obese subject. The method includes administering to
the subject an effective amount of an ALK7-binding protein (e.g.,
an antagonist antibody that specifically binds ALK7 or an
antagonist ALK7-binding antibody fragment). In some embodiments,
the administered ALK7-binding protein (e.g., an antagonist
antibody) cross-blocks or competes for binding ALK7 with an
antibody having a VH and a VL pair disclosed in Table 1A. In some
embodiments, the administered ALK7-binding protein (e.g., an
antagonist antibody) binds to the same epitope of ALK7 as an
antibody having a VH and a VL pair disclosed in Table 1A. In some
embodiments, the administered ALK7-binding protein (e.g., an
antagonist antibody) cross-blocks or competes for binding ALK7 with
an antibody having a VH and a VL pair disclosed in Table 1B or
Table 3. In some embodiments, the administered ALK7-binding protein
(e.g., an antagonist antibody) binds to the same epitope of ALK7 as
an antibody having a VH and a VL pair disclosed in Table 1B or
Table 3. In some embodiments, the subject has a BMI of 30
kg/m.sup.2 or greater (e.g., 30 to 39.9 kg/m.sup.2 or 30 kg/m.sup.2
to 50 kg/m.sup.2. In some embodiments, the subject has a BMI of 40
kg/m.sup.2 or greater. In some embodiments, the subject has central
obesity (e.g., excess adiposity in the abdominal region, including
belly fat and/or visceral fat). In some embodiments, the subject
has a waist/hip circumference ratio (WHR) of 0.85 or greater. In
some embodiments, the subject has peripheral obesity (e.g., excess
adiposity on the hips). The ALK7-binding protein is administered
alone or as a combination therapy. In some embodiments, the
administration is an adjunct to diet and/or exercise.
In another embodiment, the disclosure provides a method of treating
and/or ameliorating obesity or a disease or condition associated
with obesity, comprising administering to an obese subject, an
effective amount of an ALK7-binding protein (e.g., an antagonist
antibody that specifically binds ALK7 or an antagonist ALK7-binding
antibody fragment). In some embodiments, the antagonist
ALK7-binding protein is an antibody disclosed herein. In some
embodiments, the ALK7-binding protein is an antibody disclosed
herein. In some embodiments, the ALK7-binding protein is an ALK7
antagonist antibody. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1A. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1A. In some
embodiments, the administered antagonist anti-ALK7-antibody
cross-blocks or competes for binding ALK7 with an antibody having a
VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments, the administered antagonist anti-ALK7-antibody binds
to the same epitope of ALK7 as an antibody having a VH and a VL
pair disclosed in Table 1B or Table 3. In some embodiments, the
subject has a BMI of 30 kg/m.sup.2 or greater. In further
embodiments, the subject has a BMI of 30 to 39.9 kg/m.sup.2 or 30
kg/m.sup.2 to 50 kg/m.sup.2. In some embodiments, the subject is
morbidly obese. In some embodiments, the subject has a body BMI of
40 kg/m.sup.2 or greater. In further embodiments, the subject has a
BMI of 40 kg/m.sup.2 to 45 kg/m.sup.2, or 40 kg/m.sup.2 to 50
kg/m.sup.2 In some embodiments, the subject has type 2 diabetes
mellitus. In some embodiments, the subject has a BMI of 30
kg/m.sup.2 or greater (e.g., 30 to 39.9 kg/m.sup.2). In some
embodiments, the subject has a BMI of at least 40 kg/m.sup.2. In
some embodiments, the subject has central obesity (e.g., excess
adiposity in the abdominal region, including belly fat and/or
visceral fat). In some embodiments, the subject has a waist/hip
circumference ratio (WHR) of 0.85 or greater. In some embodiments,
the subject has peripheral obesity (e.g., excess adiposity on the
hips). The ALK7-binding protein is administered alone or as a
combination therapy. In some embodiments, the administration is an
adjunct to diet and/or exercise.
Also provided is a method of treating or preventing a disease or
condition associated with obesity, comprising administering to a
subject in need of treatment or prevention, an effective amount of
an ALK7-binding protein (e.g., an antagonist antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) cross-blocks or competes for
binding ALK7 with an antibody having a VH and a VL pair disclosed
in Table 1A. In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) binds to the same epitope of
ALK7 as an antibody having a VH and a VL pair disclosed in Table
1A. In some embodiments, the administered ALK7-binding protein
(e.g., an antagonist antibody) cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1B or Table 3. In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) binds to the same epitope of
ALK7 as an antibody having a VH and a VL pair disclosed in Table 1B
or Table 3. In one embodiment, the treated or prevented disease or
condition is a member selected from the group consisting of:
dyslipidemia, hyperlipidemia (total cholesterol level>240
mg/dL), hypercholesterolemia (e.g., total cholesterol level of
>200 mg/dL, >220 mg/dL, >240 mg/dL, >250 mg/dL, or
>275 mg/dL), low HDL serum level (e.g., <40 mg/dL, <45
mg/dL, or <50 mg/dL), high LDL serum level (e.g., .gtoreq.100
mg/dL, .gtoreq.130 mg/dL, .gtoreq.160 mg/dL, or .gtoreq.190 mg/dL),
and hypertriglyceridemia (e.g., a fasting TG level of .gtoreq.150
mg/dL, .gtoreq.175 mg/dL, .gtoreq.200 mg/dL, .gtoreq.300 mg/dL,
.gtoreq.400 mg/dL, or .gtoreq.499 mg/dL). In one embodiment, the
treated or prevented disease or condition is cardiovascular
disease. In an additional embodiment, the treated or prevented
disease or condition is hypertension (high blood pressure),
myocardial infarction, stroke, peripheral artery disease,
vasoregulatoin dysfunction, arteriosclerosis congestive heart
failure, atherosclerosis, coronary heart disease, or microvascular
disease. In one embodiment, the treated or prevented disease or
condition is inflammation. In another embodiment, the treated or
prevented disease or condition is a member selected from the group:
retinopathy, bowel disease, ulcerative colitis, and asthma,
inflammation (e.g., inflammation of the liver and/or inflammation
of adipose tissue). In one embodiment, the treated or prevented
disease or condition is liver disease. In one embodiment, the
treated or prevented liver disease or condition is NAFLD. In one
embodiment, the liver disease is fatty liver. In one embodiment,
the liver disease is NASH. In another embodiment, the treated or
prevented disease or condition is a member selected from the group:
steatohepatitis, steatosis, fibrosis, and/or cirrhosis. In one
embodiment, the treated or prevented disease or condition is a
member selected from the group consisting of: cataract, macular
degeneration, obstructive sleep apnea, phlebitis, gout,
osteoarthritis, gallbladder disease, renal disease, pulmonary
disease (e.g., asthma, hypoventilation syndrome, or respiratory
dysfunction), and/or cancer (e.g., ovarian, breast, endometrial,
liver, kidney, and/or colon cancer, and/or cancer metastasis (e.g.,
lymphatic metastasis, bloodstream metastasis, and/or tumor growth
and invasion). In one embodiment, the treated or prevented disease
or condition is infection. In one embodiment, the treated or
prevented disease or condition is a slow healing or nonhealing
wound. In certain instances, the administration is an adjunct to
diet and/or exercise.
In one embodiment, the disclosure provides a method of reducing
liver fat comprising administering an effective amount of an
ALK7-binding protein (e.g., an antagonist antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment) to a subject in need thereof. In some embodiments, the
ALK7-binding protein is an antibody disclosed herein. In some
embodiments, the ALK7-binding protein is an ALK7 antagonist
antibody. In some embodiments, the administered antagonist
anti-ALK7-antibody cross-blocks or competes for binding ALK7 with
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the administered antagonist anti-ALK7-antibody
binds to the same epitope of ALK7 as an antibody having a VH and a
VL pair disclosed in Table 1A. In some embodiments, the
administered antagonist anti-ALK7-antibody cross-blocks or competes
for binding ALK7 with an antibody having a VH and a VL pair
disclosed in Table 1B or Table 3. In some embodiments, the
administered antagonist anti-ALK7-antibody binds to the same
epitope of ALK7 as an antibody having a VH and a VL pair disclosed
in Table 1B or Table 3. In some embodiments, the subject is
overweight (e.g., pre-obese). In some embodiments, the subject has
a body mass index (BMI) of 25 kg/m.sup.2 or greater. In further
embodiments, the subject has a BMI of 25 kg/m.sup.2 to 29.9
kg/m.sup.2, 30 kg/m.sup.2 to 39.9 mkg/m.sup.2, 25 kg/m.sup.2 to
39.9 kg/m.sup.2, or 25 kg/m.sup.2 to 50 kg/m.sup.2. In some
embodiments, the subject is obese. In some embodiments, the subject
has a BMI of 30 kg/m.sup.2 or greater (e.g., 30 to 39.9 kg/m.sup.2
or 30 kg/m.sup.2 to 50 kg/m.sup.2). In some embodiments, the
subject is morbidly obese. In some embodiments, the subject has a
BMI of 40 kg/m.sup.2 or greater. In further embodiments, the
subject has a BMI of 40 kg/m.sup.2 to 45 kg/m.sup.2, or 40
kg/m.sup.2 to 50 kg/m.sup.2. In some embodiments, the subject has
central obesity (e.g., excess adiposity in the abdominal region,
including belly fat and/or visceral fat). In some embodiments, the
subject has a waist/hip circumference ratio (WHR) of 0.85 or
greater. In some embodiments, the subject has peripheral obesity
(e.g., excess adiposity on the hips). In some embodiments, the
subject has type 2 diabetes mellitus. The ALK7-binding protein is
administered alone or as a combination therapy. In some
embodiments, the administration is an adjunct to diet and/or
exercise.
In another embodiment, the disclosure provides a method of
treating, ameliorating, and/or preventing type 2 diabetes mellitus
or a disease or condition associated with diabetes comprising
administering to a subject having type 2 diabetes mellitus, or at
risk of developing type 2 diabetes, an effective amount of an
ALK7-binding protein (e.g., an antagonist antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In some embodiments, the ALK7-binding protein is an
antibody disclosed herein. In some embodiments, the ALK7-binding
protein is an ALK7 antagonist antibody. In some embodiments, the
administered antagonist anti-ALK7-antibody cross-blocks or competes
for binding ALK7 with an antibody having a VH and a VL pair
disclosed in Table 1A. In some embodiments, the administered
antagonist anti-ALK7-antibody binds to the same epitope of ALK7 as
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the administered antagonist anti-ALK7-antibody
cross-blocks or competes for binding ALK7 with an antibody having a
VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments, the administered antagonist anti-ALK7-antibody binds
to the same epitope of ALK7 as an antibody having a VH and a VL
pair disclosed in Table 1B or Table 3. In some embodiments, the
subject has a body mass index BMI of 30 kg/m.sup.2 or greater
(e.g., 30 to 39.9 kg/m.sup.2). In some embodiments, the subject has
a BMI of at least 40 kg/m.sup.2. In some embodiments, the subject
has central obesity (e.g., excess adiposity in the abdominal
region, including belly fat and/or visceral fat). In some
embodiments, the subject has a WHR of 0.85 or greater. In some
embodiments, the subject has peripheral obesity (e.g., excess
adiposity on the hips). The ALK7-binding protein is administered
alone or as a combination therapy. In some embodiments, the
administration is an adjunct to diet and/or exercise.
Also provided is a method of treating, ameliorating or preventing a
disease or condition associated with diabetes, comprising
administering to a subject having diabetes, an effective amount of
an ALK7-binding protein (e.g., an antagonist antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) cross-blocks or competes for
binding ALK7 with an antibody having a VH and a VL pair disclosed
in Table 1A. In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) binds to the same epitope of
ALK7 as an antibody having a VH and a VL pair disclosed in Table
1A. In some embodiments, the administered ALK7-binding protein
(e.g., an antagonist antibody) cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1B or Table 3. In some embodiments, the administered ALK7-binding
protein (e.g., an antagonist antibody) binds to the same epitope of
ALK7 as an antibody having a VH and a VL pair disclosed in Table 1B
or Table 3. In one embodiment, the treated or prevented disease or
condition is a member selected from the group consisting of:
dyslipidemia, hyperlipidemia (total cholesterol level>240
mg/dL), hypercholesterolemia (e.g., total cholesterol level of
>200 mg/dL, >220 mg/dL, >240 mg/dL, >250 mg/dL, or
>275 mg/dL), low HDL serum level (e.g., <40 mg/dL, <45
mg/dL, or <50 mg/dL), high LDL serum level (e.g., .gtoreq. 100
mg/dL, .gtoreq.130 mg/dL, .gtoreq.160 mg/dL, or .gtoreq.190 mg/dL),
and hypertriglyceridemia (e.g., a fasting TG level of .gtoreq.150
mg/dL, .gtoreq.175 mg/dL, .gtoreq.200 mg/dL, .gtoreq.300 mg/dL,
.gtoreq.400 mg/dL, or .gtoreq.499 mg/dL). In one embodiment, the
treated or prevented disease or condition is cardiovascular
disease. In an additional embodiment, the treated or prevented
disease or condition is hypertension (high blood pressure),
myocardial infarction, stroke, peripheral artery disease,
vasoregulatoin dysfunction, or arteriosclerosis. In one embodiment,
the treated or prevented disease or condition is inflammation
(e.g., systemic inflammation, inflammation of the liver, and
inflammation of adipose tissue). In another embodiment, the treated
or prevented disease or condition is a member selected from the
group: atherosclerosis, retinopathy, bowel disease, ulcerative
colitis, asthma, inflammation of the liver, and/or inflammation of
adipose tissue). In one embodiment, the treated or prevented
disease or condition is liver disease. In another embodiment, the
treated or prevented disease or condition is a member selected from
the group: fatty liver disease, Steatohepatitis, steatosis, and/or
cirrhosis. In one embodiment, the treated or prevented disease or
condition is a member selected from the group consisting of:
cataract, macular degeneration, obstructive sleep apnea, phlebitis,
gout, osteoarthritis, gallbladder disease, high cholesterol,
pulmonary disease (e.g., asthma, and/or hypoventilation syndrome),
neuropathy, retinopathy, vasculopathy microangiopathy, nephropathy,
renal failure, and/or cancer (e.g., ovarian, breast, endometrial,
liver, kidney, pancreatic, and/or colon cancer), and cancer
metastasis (e.g., lymphatic metastasis, bloodstream metastasis,
and/or tumor growth and invasion). In one embodiment, the treated
or prevented disease or condition is infection or a nonhealing
wound. In certain instances, the administration is an adjunct to
diet and/or exercise.
The disclosure also provides a method for improving the blood-lipid
profile in a subject, comprising administering to a subject in need
of such treatment an effective amount of an ALK7-binding protein
(e.g., an antagonist (neutralizing) antibody that specifically
binds ALK7 or an antagonist ALK7-binding antibody fragment). In
some embodiments, the antagonist ALK7-binding protein is an
antibody disclosed herein. In some embodiments, the ALK7-binding
protein is an antibody disclosed herein. In some embodiments, the
ALK7-binding protein is an ALK7 antagonist antibody. In some
embodiments, the administered antagonist anti-ALK7-antibody
cross-blocks or competes for binding ALK7 with an antibody having a
VH and a VL pair disclosed in Table 1A. In some embodiments, the
administered antagonist anti-ALK7-antibody binds to the same
epitope of ALK7 as an antibody having a VH and a VL pair disclosed
in Table 1A. In some embodiments, the ALK7-binding protein is an
ALK7 antagonist antibody. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1B or Table 3. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments, the disclosure provides a method for reducing levels
of LDL cholesterol or increasing levels of HDL-cholesterol. In one
embodiment, the subject has dyslipidemia. In another embodiment,
the subject has elevated serum lipids (e.g., cholesterol
(hypercholesterolemia) and/or triglycerides (e.g.,
hypertriglyceridemia). In one embodiment the subject has an
LDL-C.gtoreq.100 mg/dL, .gtoreq.130 mg/dL, or .gtoreq.160 mg/dL).
In one embodiment the subject has a TG.gtoreq.150 mg/dL,
.gtoreq.160 mg/dL, .gtoreq.170 mg/dL). In one embodiment, the
subject has elevated plasma insulin levels (hyperinsulinemia; e.g.,
fasting insulin level of >20 ug/ml can exceed 100). In some
embodiments, the subject has type II diabetes.
According to one embodiment, the disclosure provides a method of
treating or preventing a metabolic disease or disorder or a
condition associated with a metabolic disease or disorder,
comprising administering an ALK7-binding protein (e.g., an
antagonist antibody that specifically binds ALK7 or an antagonist
ALK7-binding antibody fragment) to a subject in need thereof. In
one embodiment, the treated metabolic disease, disorder, or
condition is hyperglycemia (e.g., >130 mg/dL in the fasting
state or following glucose administration during an oral glucose
tolerance test). In one embodiment, the treated metabolic disease,
disorder, or condition is a lipid metabolism disease, disorder, or
condition. In one embodiment, the treated metabolic disease,
disorder, or condition is dislipidemia. In a further embodiment,
the lipid metabolism disease, disorder, or condition is a member
selected from: low HDL levels, high LDL levels, high triglyceride
levels, hyperlipidemia, and a lipoprotein aberration. In one
embodiment, the subject to which the ALK-7 binding protein is
administered has a total cholesterol level of >200 mg/dL,
>220 mg/dL, >240 mg/dL, >250 mg/dL, or >275 mg/dL. In
one embodiment, the subject to which the ALK-7 binding protein is
administered has a HDL serum level of <40 mg/dL, <45 mg/dL,
or <50 mg/dL). In one embodiment, the subject to which the ALK-7
binding protein is administered has a LDL serum level.gtoreq.100
mg/dL, .gtoreq.130 mg/dL, .gtoreq.160 mg/dL, or .gtoreq.190 mg/dL.
In one embodiment, the subject to which the ALK-7 binding protein
is administered has, fasting TG level of .gtoreq.150 mg/dL,
.gtoreq.175 mg/dL, .gtoreq.200 mg/dL, .gtoreq.300 mg/dL,
.gtoreq.400 mg/dL, or .gtoreq.499 mg/dL. In one embodiment, the
treated metabolic disease, disorder, or condition is a glucose
metabolism disease, disorder, or condition. In a further
embodiment, the glucose metabolism disease, disorder, or condition
is a member selected from: glucose intolerance, insulin resistance,
impaired glucose tolerance (IGT), impaired fasting glucose (IFG).
In one embodiment, the treated metabolic disease, disorder, or
condition is a member selected from the group consisting of: high
uric acid levels, NAFLD, fatty liver, NASH, and polycystic ovarian
syndrome. In one embodiment, the treated subject has
hyperinsulinemia. In one embodiment, the treated subject is obese
(e.g., the subject has visceral or abdominal obesity). In another
embodiment, the treated subject has type II diabetes.
Metabolic syndrome is a condition involving a set of disorders that
enhances the risk of heart disease. The major components of
metabolic syndrome are excess weight, the cardiovascular parameters
(high blood pressure, dyslipidemia, high levels of triglycerides
and/or low levels of HDL in the blood), atherosclerosis, diabetes,
and/or insulin resistance. A subject having several of these
components, i.e. metabolic syndrome, is highly prone to heart
disease, though each component is a risk factor. The disclosure
also provides a method for treating or preventing 1, 2, 3, or more
of the above components of metabolic syndrome, comprising
administering to a subject in need of treatment an effective amount
of an ALK7-binding protein (e.g., an antagonist antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment).
Additionally provided is a method of treating, preventing or
ameliorating a cardiovascular disease or condition, comprising
administering an ALK7-binding protein (e.g., an antagonist antibody
that specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment) to a subject in need thereof. In one embodiment, the
treated, prevented, or ameliorated cardiovascular disease or
condition is atherosclerosis. In one embodiment, the treated,
prevented, or ameliorated cardiovascular disease or condition is
hypertension (e.g., blood pressure>130/80 mmHg or >140/90
mmHg, in a resting state). In one embodiment, the cardiovascular
disease or condition is peripheral vascular disease, a
microvascular or microvascular complication, stroke, and/or
retinopathy. In one embodiment, the cardiovascular disease is
atherosclerosis (coronary heart disease disease).
In one embodiment, the disclosure provides a method for treating
and/or ameliorating an inflammatory disease or condition that
comprises administering an ALK7-binding protein (e.g., an
antagonist antibody that specifically binds ALK7 or an antagonist
ALK7-binding antibody fragment) to a subject in need thereof. In
one embodiment, the inflammatory disease or condition is chronic
inflammation. In another embodiment, the inflammatory disease or
condition is inflammation of adipose tissue. In another embodiment,
the disease or condition is inflammation of the liver. In one
embodiment, the disease or condition is NAFLD. In a further
embodiment, the disease or condition is fatty liver. In a further
embodiment, the disease or condition is steatosis (e.g.,
nonalcoholic Steatohepatitis (NASH).
This disclosure also provides a method of improving glycemic
control, comprising administering to a subject in need of treatment
an effective amount of an ALK7-binding protein (e.g., an antagonist
antibody that specifically binds ALK7 or an antagonist ALK7-binding
antibody fragment). In one embodiment, the subject to which the
ALK7-binding protein is administered has a fasting blood sugar
level of >130, >135, >140, >145, or >150 mg/dL. In
one embodiment, the subject to which the ALK7-binding protein is
administered has a postprandial blood sugar level of >180,
>185, >190, >195, or >200 mg/dL 2 hours after eating.
In certain instances, the administration is an adjunct to diet
and/or exercise. The administration can also reduce body weight or
treat obesity. In certain instances, the subject has type 2
diabetes mellitus. In certain instances, the subject has a BMI of
27 to 40 kg/m2. In certain instances, the subject has a BMI of 30
to 39.9 kg/m2. In certain instances, the subject has a BMI of at
least 40. In certain instances, the subject is overweight. In
certain instances, the subject is obese. An improvement in glycemic
control can be assessed using techniques known in the art such as a
mixed-meal test.
The disclosure also provides compositions and methods for treating,
preventing or ameliorating hyperglycemia or a condition associated
with hyperglycemia in a subject comprising administering to a
subject in need of such treatment an effective amount of an
ALK7-binding protein (e.g., an antagonist anti-ALK7 antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In one embodiment, the subject to which the ALK7-binding
protein is administered has a fasting blood sugar level of >130,
>135, >140, >145, or >150 mg/dL. In one embodiment, the
subject to which the ALK7-binding protein is administered has a
postprandial blood sugar level of >180, >185, >190,
>195, or >200 mg/dL 2 hours after eating. In one embodiment,
the result of the treatment, prevention or amelioration is a member
selected from the group consisting of: a decrease in serum levels
of glucose, a decrease in serum levels of triglycerides, a decrease
in serum levels of insulin, and/or a decrease in serum levels of
non-esterified fatty acids, as compared to serum levels in the
subject prior to treatment. In one embodiment, the result of the
treatment, prevention or amelioration is an increase in body
temperature of about 0.4.degree. C. to 1.degree. C. as compared to
body temperature of the subject prior to treatment. In some
embodiments, the ALK7-binding protein is an antagonist anti-ALK7
protein. In some embodiments, the ALK7-binding protein is an
antagonist anti-ALK7 antibody or an ALK7-binding fragment thereof.
In some embodiments, the ALK7-binding protein is an antagonist
anti-ALK7 antibody or an ALK7-binding fragment thereof disclosed
herein. In some embodiments, the administered antagonist
anti-ALK7-antibody cross-blocks or competes for binding ALK7 with
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the administered antagonist anti-ALK7-antibody
binds to the same epitope of ALK7 as an antibody having a VH and a
VL pair disclosed in Table 1A. In some embodiments, the
administered antagonist anti-ALK7-antibody cross-blocks or competes
for binding ALK7 with an antibody having a VH and a VL pair
disclosed in Table 1B or Table 3. In some embodiments, the
administered antagonist anti-ALK7-antibody binds to the same
epitope of ALK7 as an antibody having a VH and a VL pair disclosed
in Table 1B or Table 3. In some embodiments, the administration
also reduces body weight of the subject.
In another embodiment, the disclosure provides a method of
decreasing plasma insulin levels in a subject, comprising
administering an effective amount of an ALK7-binding protein (e.g.,
an antagonist anti-ALK7 antibody that specifically binds ALK7 or an
antagonist ALK7-binding antibody fragment) to a subject in need of
such treatment. In one embodiment, the subject to which the
ALK7-binding protein is administered has a fasting blood sugar
level of >130, >135, >140, >145, or >150 mg/dL. In
one embodiment, the subject to which the ALK7-binding protein is
administered has a postprandial blood sugar level of >180,
>185, >190, >195, or >200 mg/dL 2 hours after eating.
In one embodiment, the subject is overweight. In one embodiment,
the subject is obese. In another embodiment, the subject has type 2
diabetes. In some embodiments, the ALK7-binding protein is an
antagonist anti-ALK7 protein. In some embodiments, the ALK7-binding
protein is an antagonist anti-ALK7 antibody or an ALK7-binding
fragment thereof. In some embodiments, the ALK7-binding protein is
an antagonist anti-ALK7 antibody or an ALK7-binding fragment
thereof disclosed herein. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1A. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1A. In some
embodiments, the administered antagonist anti-ALK7-antibody
cross-blocks or competes for binding ALK7 with an antibody having a
VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments, the administered antagonist anti-ALK7-antibody binds
to the same epitope of ALK7 as an antibody having a VH and a VL
pair disclosed in Table 1B or Table 3.
The disclosure also provides compositions and methods for treating,
preventing or ameliorating hyperglycemia or a condition associated
with hyperglycemia in a subject comprising administering to a
subject in need of such treatment an effective amount of an
ALK7-binding protein (e.g., an antagonist anti-ALK7 antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In one embodiment, the subject to which the ALK7-binding
protein is administered has a fasting blood sugar level of >130,
>135, >140, >145, or >150 mg/dL. In one embodiment, the
subject to which the ALK7-binding protein is administered has a
postprandial blood sugar level of >180, >185, >190,
>195, or >200 mg/dL 2 hours after eating. In one embodiment,
the result of the treatment, prevention or amelioration is a member
selected from the group consisting of: a decrease in serum levels
of glucose, a decrease in serum levels of triglycerides, a decrease
in serum levels of insulin, and/or a decrease in serum levels of
non-esterified fatty acids, as compared to serum levels in the
subject prior to treatment. In one embodiment, the result of the
treatment, prevention or amelioration is an increase in body
temperature of about 0.4.degree. C. to 1.degree. C. as compared to
body temperature of the subject prior to treatment. In some
embodiments, the ALK7-binding protein is an antagonist anti-ALK7
protein. In some embodiments, the ALK7-binding protein is an
antagonist anti-ALK7 antibody or an ALK7-binding fragment thereof.
In some embodiments, the ALK7-binding protein is an antagonist
anti-ALK7 antibody or an ALK7-binding fragment thereof disclosed
herein. In some embodiments, the administered antagonist
anti-ALK7-antibody cross-blocks or competes for binding ALK7 with
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the administered antagonist anti-ALK7-antibody
binds to the same epitope of ALK7 as an antibody having a VH and a
VL pair disclosed in Table 1A. In some embodiments, the
administered antagonist anti-ALK7-antibody cross-blocks or competes
for binding ALK7 with an antibody having a VH and a VL pair
disclosed in Table 1B or Table 3. In some embodiments, the
administered antagonist anti-ALK7-antibody binds to the same
epitope of ALK7 as an antibody having a VH and a VL pair disclosed
in Table 1B or Table 3 In some embodiments, the administration also
reduces body weight of the subject.
In another embodiment, the disclosure provides a method of
decreasing plasma insulin levels in a subject, comprising
administering an effective amount of an ALK7-binding protein (e.g.,
an antagonist anti-ALK7 antibody that specifically binds ALK7 or an
antagonist ALK7-binding antibody fragment) to a subject in need of
such treatment. In one embodiment, the subject to which the
ALK7-binding protein is administered has a fasting blood sugar
level of >130, >135, >140, >145, or >150 mg/dL. In
one embodiment, the subject to which the ALK7-binding protein is
administered has a postprandial blood sugar level of >180,
>185, >190, >195, or >200 mg/dL 2 hours after eating.
In one embodiment, the subject is overweight. In one embodiment,
the subject is obese. In another embodiment, the subject has type 2
diabetes. In some embodiments, the ALK7-binding protein is an
antagonist anti-ALK7 protein. In some embodiments, the ALK7-binding
protein is an antagonist anti-ALK7 antibody or an ALK7-binding
fragment thereof. In some embodiments, the ALK7-binding protein is
an antagonist anti-ALK7 antibody or an ALK7-binding fragment
thereof disclosed herein. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1A. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1A. In some
embodiments, the administered antagonist anti-ALK7-antibody
cross-blocks or competes for binding ALK7 with an antibody having a
VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments, the administered antagonist anti-ALK7-antibody binds
to the same epitope of ALK7 as an antibody having a VH and a VL
pair disclosed in Table 1B or Table 3.
In another embodiment, the disclosure provides a method of
treating, preventing, or ameliorating liver disease in a subject,
comprising administering an effective amount of an ALK7-binding
protein (e.g., an antagonist anti-ALK7 antibody that specifically
binds ALK7 or an antagonist ALK7-binding antibody fragment) to a
subject having a liver disease. In one embodiment, the subject has
inflammation of the liver. In one embodiment, the subject has
NAFLD. In on embodiment the subject has fatty liver. In another
embodiment, the subject has NASH. In one embodiment, the treated,
prevented or ameliorated liver disease is fibrosis, scarring,
cirrhosis, or liver failure. In another embodiment, the treated,
prevented or ameliorated liver disease is liver cancer. In one
embodiment, the subject is overweight. In another embodiment, the
subject is obese. In another embodiment, the subject has type 2
diabetes. In some embodiments, the ALK7-binding protein is an
antagonist anti-ALK7 protein. In some embodiments, the ALK7-binding
protein is an antagonist anti-ALK7 antibody or an ALK7-binding
fragment thereof. In some embodiments, the ALK7-binding protein is
an antagonist anti-ALK7 antibody or an ALK7-binding fragment
thereof disclosed herein. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1A. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1A. In some
embodiments, the administered antagonist anti-ALK7-antibody
cross-blocks or competes for binding ALK7 with an antibody having a
VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments, the administered antagonist anti-ALK7-antibody binds
to the same epitope of ALK7 as an antibody having a VH and a VL
pair disclosed in Table 1B or Table 3.
In additional embodiments, the disclosure provides methods of
treating and/or ameliorating cancer or a condition associated with
cancer, that comprises administering an ALK7-binding protein (e.g.,
an anti-ALK7 antibody or ALK7-binding fragment thereof) to a
subject in need thereof. In some embodiments the ALK7-binding
protein is an anti-ALK7 antibody or an ALK7-binding fragment
thereof. In some embodiments, the subject has a cancer selected
from the group consisting of a myeloma (e.g., multiple myeloma,
plasmacytoma, localized myeloma, or extramedullary myeloma), or an
ovarian, breast, colon, endometrial, liver, kidney, pancreatic,
gastric, uterine or colon cancer. In some embodiments, ALK7-binding
protein is administered to treat or prevent lymphatic metastasis,
bloodstream metastasis, tumor growth, or tumor invasion.
In one embodiment, the disclosure provides a method of treating
cancer that comprises contacting a cancer cell, tumor
associated-stromal cell, or endothelial cell expressing ALK7 with
an ALK7-binding protein (e.g., an antagonist anti-ALK7 antibody
that specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment). In additional embodiments the cancer cell is a myeloma
(e.g., multiple myeloma, plasmacytoma, localized myeloma, or
extramedullary myeloma), ovarian, breast, colon, endometrial,
liver, kidney, pancreatic, gastric, uterine and/or colon cancer
cell. In some embodiments the contacted cell is from a cancer line.
In some embodiments the cancer cell is contacted in vivo.
In one embodiment, the disclosure provides a method of for
increasing lipolysis comprising contacting a white adipocyte or
adipose tissue with an antagonist ALK7-binding protein (e.g., an
antagonist anti-ALK7 antibody that specifically binds ALK7 or an
antagonist ALK7-binding antibody fragment). In some embodiments,
the ALK-7 binding protein increases lipolysis by 5% to 100%, 10% to
80%, or 10% to 60%. In some embodiments, the ALK7-binding protein
increase lipolysis in adipose cells by 5% to 100%, 10% to 80%, or
10% to 60%. In some embodiments, the ALK7-binding protein increase
lipolysis in a lipolysis assay by 5% to 100%, 10% to 80%, or 10% to
60%. In further embodiments the lipolysis assay is performed in the
presence of one or more ALK7 ligands selected from the group
consisting of: GDF1, GDF3, GDF8, activin B, activin A/B, and Nodal.
In some embodiments, the antagonist ALK7 binding protein is an
antibody. In some embodiments, the antagonist anti-ALK7-antibody
comprises an antibody provided herein. In some embodiments the
antagonist antibody cross-blocks or competes for binding ALK7 with
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the antagonist anti-ALK7-antibody binds to the
same epitope of ALK7 as an antibody having a VH and a VL pair
disclosed in Table 1A. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1B or Table 3. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments the white adipose cell or adipose tissue is contacted
in vitro. In some embodiments the differentiated white adipose cell
or adipose tissue is contacted in vivo. In one embodiment, the
method is carried out in vivo, for example, in a mammalian subject
(e.g., an animal model). In a further embodiment, the subject is a
human. In some embodiments, the method leads to increased glycerol
production. In further embodiments, the method leads to increased
glycerol and/or free fatty acid in an adipocyte culture. In some
embodiments, the method leads to decreased triglyceride (TG)
content in the adipose cell or tissue. In some embodiments, the
method leads to a decreased plasma TG level in a subject.
In another embodiment, the disclosure provides a method of
increasing adrenergic receptor-.beta. (ADRB) signaling in an
adipose cell or tissue. The method comprises contacting a
differentiated white adipocyte or adipose tissue with an antagonist
ALK7-binding protein (e.g., an antagonist anti-ALK7 antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment) in an amount sufficient to increase ADRB signaling. In
some embodiments, the antagonist ALK7 binding protein is an
antibody. In some embodiments, the antagonist anti-ALK7-antibody
comprises an antibody provided herein. In some embodiments the
antagonist antibody cross-blocks or competes for binding ALK7 with
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the antagonist anti-ALK7-antibody binds to the
same epitope of ALK7 as an antibody having a VH and a VL pair
disclosed in Table 1A. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1B or Table 3. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments the differentiated white adipocyte or adipose tissue is
contacted in vitro. In some embodiments the differentiated white
adipocyte or adipose tissue is contacted in vivo. In one
embodiment, the method is carried out in vivo, for example, in a
mammalian subject (e.g., an animal model). In a further embodiment,
the subject is a human. In some embodiments, the method leads to
increased glycerol production. In further embodiments, the method
leads to increased glycerol and/or free fatty acid in an adipocyte
culture. In some embodiments, the method leads to decreased TG
content in the adipose cell or tissue. In some embodiments, the
method leads to a decreased plasma TG level in a subject. In some
embodiments, the method leads to an increased ADRB signaling in an
adipocyte or adipose tissue during nutrient overload.
In another embodiment, the disclosure provides a method of
decreasing peroxisome proliferator-activated receptor-gamma (PPAR
gamma) signaling in an adipose cell or adipose tissue (e.g.,
differentiated white adipocytes). The method includes contacting a
differentiated white adipocyte or adipose tissue with an antagonist
ALK7-binding protein (e.g., an antagonist anti-ALK7 antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment) in an amount effective to decrease PPAR gamma activity.
In some embodiments, the antagonist ALK7 binding protein is an
antibody. In some embodiments, the antagonist anti-ALK7-antibody
comprises an antibody provided herein. In some embodiments the
antagonist antibody cross-blocks or competes for binding ALK7 with
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the antagonist anti-ALK7-antibody binds to the
same epitope of ALK7 as an antibody having a VH and a VL pair
disclosed in Table 1A. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1B or Table 3. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments the differentiated white adipocyte or adipose tissue is
contacted in vitro. In some embodiments the differentiated white
adipocyte or adipose tissue is contacted in vivo. In one
embodiment, the method is carried out in vivo, for example, in a
mammalian subject (e.g., an animal model). In a further embodiment,
the subject is a human. In some embodiments, the method leads to
increased glycerol production. In further embodiments, the method
leads to increased glycerol and/or free fatty acid in an adipocyte
culture. In some embodiments, the method leads to decreased TG
content in the adipose cell or tissue. In some embodiments, the
method leads to a decreased plasma TG level in a subject.
In another embodiment, the disclosure provides a method of
decreasing insulin resistance in an adipose cell or adipose tissue
(e.g., differentiated white adipocytes). The method includes
contacting an adipocyte or adipose tissue with an antagonist
ALK7-binding protein (e.g., an antagonist anti-ALK7 antibody that
specifically binds ALK7 or an antagonist ALK7-binding antibody
fragment) in an amount effective to reduce insulin resistance. In
some embodiments, the antagonist ALK7 binding protein is an
antibody. In some embodiments, the antagonist anti-ALK7-antibody
comprises an antibody provided herein. In some embodiments the
antagonist antibody cross-blocks or competes for binding ALK7 with
an antibody having a VH and a VL pair disclosed in Table 1A. In
some embodiments, the antagonist anti-ALK7-antibody binds to the
same epitope of ALK7 as an antibody having a VH and a VL pair
disclosed in Table 1A. In some embodiments, the administered
antagonist anti-ALK7-antibody cross-blocks or competes for binding
ALK7 with an antibody having a VH and a VL pair disclosed in Table
1B or Table 3. In some embodiments, the administered antagonist
anti-ALK7-antibody binds to the same epitope of ALK7 as an antibody
having a VH and a VL pair disclosed in Table 1B or Table 3. In some
embodiments the differentiated white adipocyte or adipose tissue is
contacted in vitro. In some embodiments the differentiated white
adipocyte or adipose tissue is contacted in vivo. In one
embodiment, the method is carried out in vivo, for example, in a
mammalian subject (e.g., an animal model). In a further embodiment,
the subject is a human.
In another embodiment, the disclosure provides a method of
increasing the metabolic rate of an adipose cell or tissue. The
method includes contacting an adipocyte or adipose tissue with an
antagonist ALK7-binding protein (e.g., an antagonist anti-ALK7
antibody that specifically binds ALK7 or an antagonist ALK7-binding
antibody fragment) in an amount effective to increase metabolism of
the adipocyte or tissue. In some embodiments, the antagonist ALK7
binding protein is an antibody. In some embodiments, the antagonist
anti-ALK7-antibody comprises an antibody provided herein. In some
embodiments the antagonist antibody cross-blocks or competes for
binding ALK7 with an antibody having a VH and a VL pair disclosed
in Table 1A. In some embodiments, the antagonist anti-ALK7-antibody
binds to the same epitope of ALK7 as an antibody having a VH and a
VL pair disclosed in Table 1A. In some embodiments, the
administered antagonist anti-ALK7-antibody cross-blocks or competes
for binding ALK7 with an antibody having a VH and a VL pair
disclosed in Table 1B or Table 3. In some embodiments, the
administered antagonist anti-ALK7-antibody binds to the same
epitope of ALK7 as an antibody having a VH and a VL pair disclosed
in Table 1B or Table 3. In some embodiments the differentiated
white adipocyte or adipose tissue is contacted in vitro. In some
embodiments the differentiated white adipocyte or adipose tissue is
contacted in vivo. In one embodiment, the method is carried out in
vivo, for example, in a mammalian subject (e.g., an animal model).
In a further embodiment, the subject is a human.
The disclosure provides methods that comprise administering a
therapeutically effective amount of a ALK7-binding protein (e.g.,
an antagonist anti-ALK7 antibody that specifically binds ALK7 or an
antagonist ALK7-binding antibody fragment), alone or in combination
with one or more additional therapies (e.g., one or more additional
therapeutic agents) to a subject having, or at risk for developing,
an ALK7-mediated disease and/or condition such as, obesity (e.g.,
abdominal or visceral obesity); overweight; insulin resistance;
metabolic syndrome and other metabolic diseases or conditions; a
lipid disorder such as, low HDL levels, high LDL levels,
hyperlipidemia, hypertriglyceridemia or dyslipidemia; lipoprotein
aberrations; decreased triglycerides; inflammation (e.g., liver
inflammation and/or inflammation of adipose tissue), fatty liver
disease; non-alcoholic fatty liver disease; hyperglycemia; impaired
glucose tolerance (IGT); hyperinsulinemia; high cholesterol (e.g.,
high LDL levels and/or hypercholesterolemia); cardiovascular
disease such as, heart disease including coronary heart disease,
congestive heart failure, stroke, peripheral vascular disease,
atherosclerosis; arteriosclerosis, and/or hypertension; Syndrome X;
vascular restenosis; neuropathy; retinopathy; neurodegenerative
disease; endothelial dysfunction, respiratory dysfunction, renal
disease (e.g., nephropathy); pancreatitis; polycystic ovarian
syndrome; elevated uric acid levels; haemochromatosis (iron
overload); acanthosis nigricans (dark patches on the skin); and/or
cancer (e.g., myeloma (e.g., multiple myeloma, plasmacytoma,
localized myeloma, or extramedullary myeloma), ovarian, breast,
colon, endometrial, liver, kidney, pancreatic, gastric, uterine or
colon cancer r); and/or other disorders/conditions associated with
one or more of the above diseases or conditions, and/or with
overweight (e.g., BMI of .gtoreq.25 kg/m.sup.2), or with too much
body fat.
Also provided is the use of an ALK7-binding protein provided herein
for diagnostic monitoring of protein levels (e.g., ALK7 levels) in
blood or tissue as part of a clinical testing procedure, e.g., to
determine the efficacy of a given treatment regimen. For example,
detection can be facilitated by coupling an ALK7-binding protein to
a detectable substance. Examples of detectable substances include
various enzymes, prosthetic groups, fluorescent materials,
luminescent materials, bioluminescent materials, and/or radioactive
materials. Examples of suitable enzymes include horseradish
peroxidase, alkaline phosphatase, .beta.-galactosidase, or
acetylcholinesterase; examples of suitable prosthetic group
complexes include streptavidin/biotin and avidin/biotin; examples
of suitable fluorescent materials include umbelliferone,
fluorescein, fluorescein isothiocyanate, rhodamine,
dichlorotriazinylamine fluorescein, dansyl chloride or
phycoerythrin; an example of a luminescent material includes
luminol; examples of bioluminescent materials include luciferase,
luciferin, and aequorin; and examples of suitable radioactive
material include .sup.125I, .sup.131I, .sup.35S, or .sup.3H.
Pharmaceutical Compositions and Administration Methods
Methods of preparing and administering an ALK7-binding protein to a
subject in need thereof are known to or are readily determined by
those of ordinary skill in the art. The route of administration of
the ALK7-binding proteins can be, for example, oral, parenteral, by
inhalation or topical. The term parenteral includes, e.g.,
intravenous, intraarterial, intraperitoneal, intramuscular,
intraocular, subcutaneous, rectal, or vaginal administration. While
all these forms of administration are clearly contemplated as being
within the scope of the disclosure, another example of a form for
administration would be a solution for injection, in particular for
intravenous or intraarterial injection or drip. Usually, a suitable
pharmaceutical composition can comprise a buffer (e.g., acetate,
phosphate or citrate buffer), a surfactant (e.g., polysorbate),
optionally a stabilizer agent (e.g., human albumin), etc. In other
methods compatible with the teachings herein, ALK7-binding proteins
as provided herein can be delivered directly to the organ and/or
site of a fibrosis or tumor, thereby increasing the exposure of the
diseased tissue to therapeutic agent. In one embodiment, the
administration is directly to the airway, e.g., by inhalation or
intranasal administration.
As discussed herein, ALK7-binding proteins can be administered in a
pharmaceutically effective amount for the in vivo treatment of
ALK7-mediated diseases and conditions such as, obesity, diabetes,
metabolic disease, dyslipidemia; cardiovascular disease, type 2
diabetes, inflammation, or a cardiovascular, pulmonary, fatty liver
disease, neurologic, and hepatic, or renal disease, and and/cancer.
In this regard, it will be appreciated that the disclosed
ALK7-binding proteins can be formulated so as to facilitate
administration and promote stability of the active agent.
Pharmaceutical compositions in accordance with the disclosure can
comprise a pharmaceutically acceptable, non-toxic, sterile carrier
such as physiological saline, non-toxic buffers, preservatives and
the like. For the purposes of the instant application, a
pharmaceutically effective amount of a ALK7-binding protein,
conjugated or unconjugated, means an amount sufficient to achieve
effective binding to ALK7 and to achieve a benefit, e.g., to
ameliorate symptoms of a disease or condition or to detect a
substance or a cell. Suitable formulations for use in therapeutic
methods disclosed herein are described in Remington's
Pharmaceutical Sciences (Mack Publishing Co.) 16th ed. (1980).
Certain pharmaceutical compositions provided herein can be orally
administered in an acceptable dosage form including, e.g.,
capsules, tablets, aqueous suspensions or solutions. Certain
pharmaceutical compositions also can be administered by nasal
aerosol or inhalation. Such compositions can be prepared as
solutions in saline, employing benzyl alcohol or other suitable
preservatives, absorption promoters to enhance bioavailability,
and/or other conventional solubilizing or dispersing agents.
The amount of an ALK7-binding protein (e.g., an antibody that
specifically binds ALK7) that can be combined with carrier
materials to produce a single dosage form will vary depending upon
the subject treated and the particular mode of administration. The
composition can be administered as a single dose, multiple doses or
over an established period of time in an infusion. Dosage regimens
also can be adjusted to provide the optimum desired response (e.g.,
a therapeutic or prophylactic response).
ALK7-binding proteins provided herein can be administered to a
human or other subject in accordance with the aforementioned
methods of treatment in an amount sufficient to produce a
therapeutic effect. The ALK7-binding proteins provided herein can
be administered to such human or other animal in a conventional
dosage form prepared by combining the ALK7-binding proteins with a
conventional pharmaceutically acceptable carrier or diluent
according to known techniques. The form and character of the
pharmaceutically acceptable carrier or diluent can be dictated by
the amount of active ingredient with which it is to be combined,
the route of administration and other well-known variables. A
cocktail comprising one or more different ALK7-binding proteins can
also be used.
Therapeutically effective doses of ALK7-binding compositions for
treatment of an ALK7-mediated disease or condition such as,
obesity, diabetes, metabolic disease, dyslipidemia; cardiovascular
disease, type 2 diabetes, inflammation, or a cardiovascular,
pulmonary, fatty liver disease, neurologic, and hepatic, or renal
disease and/or cancer, vary depending upon many different factors,
including means of administration, target site, physiological state
of the subject, whether the subject is human or an animal, other
medications administered, and whether treatment is prophylactic or
therapeutic. Usually, the subject is a human, but non-human mammals
including transgenic mammals can also be treated. Treatment dosages
can be titrated using routine methods known to those of ordinary
skill in the art to optimize safety and efficacy.
To ameliorate the symptoms of a particular disease or condition by
administration of an ALK7-binding protein refers to any lessening,
whether permanent or temporary, lasting or transient that can be
attributed to or associated with administration of the
ALK7-binding.
The disclosure also provides for the use of an ALK7-binding
protein, such as, an anti-ALK7 antibody in the manufacture of a
medicament for example, for treating, preventing or ameliorating
obesity, diabetes, metabolic disease, dyslipidemia; cardiovascular
disease, type 2 diabetes, inflammation, or a cardiovascular,
pulmonary, fatty liver disease, neurologic, and hepatic, or renal
disease and/or cancer.
Combination Therapies
In some embodiments, an ALK7-binding protein (e.g., an anti-ALK7
antibody such as, a full-length ALK7-antibody and an ALK7-binding
antibody fragment, or a variant or derivative thereof) is
administered in combination with one or more other therapies. Such
therapies include additional therapeutic agents as well as other
medical interventions. Exemplary therapeutic agents that can be
administered in combination with the ALK7-binding proteins provided
herein include, but are not limited to, anti-SDI-fibrotics,
corticosteroids, anti-inflammatories, angiotensin converting enzyme
inhibitors, angiotensin receptor blockers, diuretics,
antidiabetics, immune suppressants, chemotherapeutic agents,
anti-metabolites, and/or immunomodulators. In various embodiments,
an ALK7-binding protein is administered to a subject before,
during, and/or after a surgical excision/removal procedure.
In some embodiments, an ALK7-binding protein (e.g., an anti-ALK7
antibody such as, a full-length ALK7-antibody and an ALK7-binding
antibody fragment, or a variant or derivative thereof) is
administered in combination with one or more (a) biguanides (e.g.,
buformin, metformin, phenformin), (b) insulin, (c) somatostatin,
(d) alpha-glucosidase inhibitors (e.g., voglibose, miglitol,
acarbose), (e) DPP-IV inhibitors, such as sitagliptin,
vildagliptin, alogliptin, saxagliptin (e.g., as disclosed in U.S.
Pat. No. 6,699,871B1) (f) LXR modulators, (g) insulin secretagogues
(e.g., acetohexamide, carbutamide, chlorpropamide, glibornuride,
gliclazide, glimerpiride, glipizide, gliquidine, glisoxepid,
glyburide, glyhexamide, glypinamide, phenbutamide, tolazamide,
tolbutamide, tolcyclamide, nateglinide and/or repaglinide), (k) CB1
inhibitors, such as, rimonabant, taranabant, and compounds
disclosed in Intl. Appl. Publ. Nos. WO03/077847A2 and WO05/000809
A1, or (i). sibutramine, topiramate, orlistat, Qnexa, mevastatin,
simvastatin, ezetimibe, atorvastatin, naltrexone, bupriopion,
phentermine, hydrochlorothiazide, or losartan.
Diagnostics
The disclosure also provides a diagnostic method useful during
diagnosis of ALK7-mediated diseases and conditions (such as,
obesity (e.g., abdominal or visceral obesity); overweight; insulin
resistance; metabolic syndrome and/or other metabolic diseases or
conditions; a lipid disorder such as, low HDL levels, high LDL
levels, hyperlipidemia, hypertriglyceridemia or dyslipidemia;
lipoprotein aberrations; decreased triglycerides; inflammation
(e.g., liver inflammation and/or inflammation of adipose tissue),
fatty liver disease; non-alcoholic fatty liver disease;
hyperglycemia; impaired glucose tolerance (IGT); hyperinsulinemia;
high cholesterol (e.g., high LDL levels and/or
hypercholesterolemia); cardiovascular disease such as, heart
disease including coronary heart disease, congestive heart failure,
stroke, peripheral vascular disease, atherosclerosis;
arteriosclerosis, and/or hypertension; Syndrome X; vascular
restenosis; neuropathy; retinopathy; neurodegenerative disease;
endothelial dysfunction, respiratory dysfunction, renal disease
(e.g., nephropathy); pancreatitis; polycystic ovarian syndrome;
elevated uric acid levels; haemochromatosis (iron overload);
acanthosis nigricans (dark patches on the skin); and/or cancer
(e.g., a myeloma (e.g., multiple myeloma, plasmacytoma, localized
myeloma, or extramedullary myeloma), or an ovarian, breast, colon,
endometrial, liver, kidney, pancreatic, gastric, uterine or colon
cancer); and/or other disorders/conditions associated with one or
more of the above diseases or conditions, or with too much body
fat.), which involves measuring the expression level of ALK7
protein tissue or body fluid from an individual and comparing the
measured expression level with a standard ALK7 expression level in
normal tissue or body fluid, whereby an increase in ALK7 expression
level compared to the standard is indicative of a disorder
treatable by an ALK7-binding protein provided herein, such as a
full-length anti-ALK7 antibody and ALK7-binding antibody fragment
as provided herein.
The ALK7-binding proteins provided herein such as, anti-ALK7
antibodies (e.g., full-length ALK7-antibodies and ALK7-binding
antibody fragment, and variants and derivatives thereof) can be
used to assay ALK7 levels in a biological sample using classical
immunohistological methods known to those of skill in the art (see,
e.g., Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen
et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based
methods useful for detecting ALK7 protein expression include
immunoassays, such as the enzyme linked immunosorbent assay
(ELISA), immunoprecipitation, or Western blotting.
By "assaying the expression level of ALK7 protein" is intended
qualitatively or quantitatively measuring or estimating the level
of ALK7 protein in a first biological sample either directly (e.g.,
by determining or estimating absolute protein level) or relatively
(e.g., by comparing to the disease associated polypeptide level in
a second biological sample). The ALK7 protein expression level in
the first biological sample can be measured or estimated and
compared to a standard ALK7 protein level, the standard being taken
from a second biological sample obtained from an individual not
having the disorder or being determined by averaging levels from a
population of individuals not having the disorder. As will be
appreciated in the art, once the "standard" ALK7 protein level is
known, it can be used repeatedly as a standard for comparison.
By "biological sample" is intended any biological sample obtained
from an individual, cell line, tissue culture, or other source of
cells potentially expressing ALK7. Methods for obtaining tissue
biopsies and body fluids from mammals are known in the art.
Kits Comprising ALK7-Binding Proteins
This disclosure further provides kits that include an ALK7-binding
protein (e.g., an antibody that specifically binds ALK7 such as, a
full-length ALK7-antibody and an ALK7-binding antibody fragment,
and variants and derivatives thereof) in suitable packaging, and
written material and that can be used to perform the methods
described herein. The written material can include any of the
following information: instructions for use, discussion of clinical
studies, listing of side effects, scientific literature references,
package insert materials, clinical trial results, and/or summaries
of these and the like. The written material can indicate or
establish the activities and/or advantages of the composition,
and/or describe dosing, administration, side effects, drug
interactions, or other information useful to the health care
provider. Such information can be based on the results of various
studies, for example, studies using experimental animals involving
in vivo models and/or studies based on human clinical trials. The
kit can further contain another therapy (e.g., another agent)
and/or written material such as that described above that serves to
provide information regarding the other therapy (e.g., the other
agent).
In certain embodiments, a kit comprises at least one purified
ALK7-binding protein in one or more containers. In some
embodiments, the kits contain all of the components necessary
and/or sufficient to perform a detection assay, including all
controls, directions for performing assays, and/or any necessary
software for analysis and presentation of results.
Immunoassays
ALK7-binding proteins (e.g., antibodies that specifically bind ALK7
and ACTRIIA/B-binding fragments of antibodies that specifically
bind ALK7, and variants, or derivatives thereof) can be assayed for
immunospecific binding by any method known in the art. The
immunoassays that can be used include, but are not limited to,
competitive and non-competitive assay systems using techniques such
as Western blots, radioimmunoassays (REA), ELISA (enzyme linked
immunosorbent assay), "sandwich" immunoassays, immunoprecipitation
assays, precipitin reactions, gel diffusion precipitin reactions,
immunodiffusion assays, agglutination assays, complement-fixation
assays, immunoradiometric assays, fluorescent immunoassays, or
protein A immunoassays. Such assays are routine and known in the
art (see, e.g., Ausubel et al., eds, (1994) Current Protocols in
Molecular Biology (John Wiley & Sons, Inc., NY) Vol. 1, which
is herein incorporated by reference in its entirety).
ALK7-binding proteins (e.g., antibodies that specifically binds
ALK7 and an ActRII receptor (e.g., ActRIIA or ActRIIB)-binding
fragments of antibodies that specifically bind ALK7, and variants,
or derivatives thereof) provided herein can be employed
histologically, as in immunofluorescence, immunoelectron microscopy
or non-immunological assays, for in situ detection of ALK7 or
conserved variants or peptide fragments thereof. In situ detection
can be accomplished according to methods known in the art. Those of
ordinary skill in the art will be able to determine operative and
optimal assay conditions for each determination by employing
routine experimentation. Methods suitable for determination of
binding characteristics of an ALK7-binding protein are described
herein or otherwise known in the art. Equipment and software
designed for such kinetic analyses are commercially available
(e.g., BIACORE.RTM., BIAevaluation.RTM. software, GE Healthcare;
KINEXA.RTM. Software, Sapidyne Instruments).
Unless otherwise indicated, the practice of the disclosure employs
conventional techniques of cell biology, cell culture, molecular
biology, transgenic biology, microbiology, recombinant DNA, and
immunology, which are within the skill of the art.
The following examples are offered by way of illustration and not
by way of limitation.
EXAMPLES
The foregoing description of the specific embodiments will so fully
reveal the general nature of the disclosure that others can, by
applying knowledge within the skill of the art, readily modify
and/or adapt for various applications such specific embodiments,
without undue experimentation, without departing from the general
concept of the present disclosure. Therefore, such adaptations and
modifications are intended to be within the meaning and range of
equivalents of the disclosed embodiments, based on the teaching and
guidance presented herein. It is to be understood that the
phraseology or terminology herein is for the purpose of description
and not of limitation, such that the terminology or phraseology of
the present specification is to be interpreted by the skilled
artisan in light of the teachings and guidance.
The breadth and scope of the present disclosure should not be
limited by any of the above-described exemplary embodiments, but
should be defined only in accordance with the following claims and
their equivalents.
All publications, patents, patent applications, and/or other
documents cited in this application are incorporated by reference
in their entirety for all purposes to the same extent as if each
individual publication, patent, patent application, and/or other
document were individually indicated to be incorporated by
reference for all purposes.
Example 1. Selection, Characterization and Production of
ALK7-Binding Antibodies
A multi-round selection procedure was used to select for human IgG
antibodies that bind ALK7 with high affinity which is detailed
below.
Materials and Methods
Human ALK7-Fc comprising protein was biotinylated using the EZ-Link
Sulfo-NHS-Biotinylation Kit from Pierce. Goat anti-human
F(ab').sub.2 kappa-FITC (LC-FITC), Extravidin-PE (EA-PE) and
streptavidin-633 (SA-633) were obtained from Southern Biotech,
Sigma and Molecular Probes, respectively. Streptavidin MicroBeads
and MACS LC separation columns were purchased from Miltenyi
Biotec.
Experiments were performed using a Biacore T100/T200 biosensor
(Biacore/GE Healthcare) at 25.degree. C. and 37.degree. C.
ALK7antibodies were captured on custom made FAB chip. A
concentration series of ALK7-Fc comprising protein was injected
over the flow cells at a flow rate of 50 .mu.l/ml. To obtain
kinetic rate constants the corrected data were fit to a 1:1
interaction model using BiaEvaluation software (GE Healthcare). The
equilibrium binding constant KD was determined by the ratio of
binding rate constants kd/ka.
Eight naive human synthetic yeast libraries each of .about.10.sup.9
diversity were propagated as described previously (see, e.g.,
WO09/036379; WO10/105256; WO12/009568). For the first two rounds of
selection, a magnetic bead sorting technique utilizing the Miltenyi
MACs system was performed, as described (see, e.g., Siegel et al.,
J. Immunol. Meth. 286(1-2):141-153 (2004)). Briefly, yeast cells
(.about.10.sup.10 cells/library) were incubated with 3 ml of 10 nM
biotinylated ALK7-Fc comprising protein for 15 minute at room
temperature in FACS wash buffer (phosphate-buffered saline
(PBS)/0.1% bovine serum albumin (BSA)). After washing once with 50
ml ice-cold wash buffer, the cell pellet was resuspended in 40 mL
wash buffer, and Streptavidin MicroBeads (500 .mu.l) were added to
the yeast and incubated for 15 minutes at 4.degree. C. Next, the
yeast were pelleted, resuspended in 5 mL wash buffer, and loaded
onto a Miltenyi LS column. After the 5 mL was loaded, the column
was washed 3 times with 3 ml FACS wash buffer. The column was then
removed from the magnetic field, and the yeast were eluted with 5
mL of growth media and then grown overnight. The following rounds
of sorting were performed using flow cytometry. Approximately
1.times.10.sup.8 yeast were pelleted, washed three times with wash
buffer, and incubated with decreasing concentrations of
biotinylated ALK7-Fc comprising protein (100 to 1 nM) under
equilibrium conditions at room temperature. Yeast were then washed
twice and stained with LC-FITC (diluted 1:100) and either SA-633
(diluted 1:500) or EA-PE (diluted 1:50) secondary reagents for 15
minutes at 4.degree. C. After washing twice with ice-cold wash
buffer, the cell pellets were resuspended in 0.4 mL wash buffer and
transferred to strainer-capped sort tubes. Sorting was performed
using a FACS ARIA sorter (BD Biosciences) and sort gates were
assigned to select for specific binders relative to a background
control. Subsequent rounds of selection were employed in order to
reduce the number non-specific reagent binders utilizing soluble
membrane proteins from CHO cells (See, e.g., WO14/179363 and Xu et
al., Protein Eng. Des. Sel. 26(10):663-670 (2013)), and to identify
binders with improved affinity to ALK7 using the ALK7-Fc comprising
protein. After the final round of sorting, yeast were plated and
individual colonies were picked for characterization and for
nomination of clones for affinity maturation.
Antibody Production and Purification
In order to produce sufficient amounts of selected antibodies for
further characterization, the yeast clones were grown to saturation
and then induced for 48 h at 30.degree. C. with shaking. After
induction, yeast cells were pelleted and the supernatants were
harvested for purification. IgGs were purified using a Protein A
column and eluted with acetic acid, pH 2.0. Fab fragments were
generated by papain digestion and purified over KappaSelect (GE
Healthcare LifeSciences).
ForteBio K.sub.D Measurements
ForteBio affinity measurements of selected antibodies were
performed generally as previously described (see, e.g., Estep et
al., Mabs, 5(2):270-278 (2013)). Briefly, ForteBio affinity
measurements were performed by loading IgGs on-line onto AHQ
sensors. Sensors were equilibrated off-line in assay buffer for 30
minutes and then monitored on-line for 60 seconds for baseline
establishment. Sensors with loaded IgGs were exposed to 100 nM
antigen for 5 minutes, afterwards they were transferred to assay
buffer for 5 minutes for off-rate measurement. Kinetics were
analyzed using the 1:1 binding model.
Octet Red384 Epitope Binning/Ligand Blocking
Epitope binning/ligand blocking of selected antibodies was
performed using a standard sandwich format cross-blocking assay.
Control anti-target IgG was loaded onto AHQ sensors and unoccupied
Fc-binding sites on the sensor were blocked with an irrelevant
human IgG1 antibody. The sensors were then exposed to 100 nM target
antigen followed by a second anti-target antibody or ligand. Data
was processed using ForteBio's Data Analysis Software 7.0.
Additional binding by the second antibody or ligand after antigen
association indicates an unoccupied epitope (non-competitor), while
no binding indicates epitope blocking (competitor or ligand
blocking).
Size Exclusion Chromatography
A TSKgel SuperSW mAb HTP column (22855) was used for fast SEC
analysis of yeast-produced mAbs at 0.4 mL/minute with a cycle time
of 6 min/run. 200 mM Sodium Phosphate and 250 mM Sodium Chloride
was used as the mobile phase.
Dynamic Scanning Fluorimetry
10 uL of 20.times. Sypro Orange was added to 20 uL of 0.2-1 mg/mL
mAb or Fab solution. An RT-PCR instrument (BioRad CFX96 RT PCR) was
used to ramp the sample plate temperature from 40.degree. to
95.degree. C. at 0.5.degree. C. increment, with a 2 minute
equilibration at each temperature. The negative of the first
derivative for the raw data was used to extract Tm.
Example 2. Characterization of ALK7-Binding Antibodies
Exemplary ALK7-binding proteins generated according to the previous
example were further characterized by sequence, SPR, and cell-based
lipolysis inhibition assay analyses.
Sequences of exemplary ALK7-binding antibodies generated according
to the methods described in Example 1 are presented in Table 1A
(exemplary CDR sequences are underscored).
TABLE-US-00002 TABLE 1A Exemplary ALK7-binding proteins G04 VH FR1
QVQLVQSGAEVKKPGSSVKVSCKASGGTFS (SEQ ID NO: 6) VH CDR1 SYAIS (SEQ ID
NO: 1) VH FR2 WVRQAPGQGLEWMG (SEQ ID NO: 7) VH CDR2
GIIPIFGTASYAQKFQG (SEQ ID NO: 2) VH FR3
RVTITADESTSTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 8) VH CDR3
TPYYDSSGYLDV (SEQ ID NO: 3) VH FR4 WGQGTMVTVSS (SEQ ID NO: 9) VH
ABRs ABR1: GTFSSYAIS (SEQ ID NO: 73) ABR2: GIIPIFGTASYAQKFQG (SEQ
ID NO: 74) ABR3: ARTPYYDSSGYLDV (SEQ ID NO: 75) VH DNA
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT
CCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCCCC
TGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAGCTACGCA
CAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGG
AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAACTCCTTACTA
CGACAGCAGCGGATACCTAGACGTATGGGGTCAGGGTACAATGGTCACCGTCTCCTCA (SEQ ID
NO: 5) VH Protein
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTASYA
QKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARTPYYDSSGYLDVWGQGTMVTVSS (SEQ
ID NO: 4) VL FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 15) VL CDR1
QASQDISNYLN (SEQ ID NO: 10) VL FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 16)
VL CDR2 DASNLAT (SEQ ID NO: 11) VL FR3
GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC (SEQ ID NO: 17) VL CDR3 QQSLDLPPT
(SEQ ID NO: 12) VL FR4 FGGGTKVEIK (SEQ ID NO: 18) VL DNA
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCA
TCACTTGCCAGGCGAGTCAGGACATTAGCAACTATTTAAATTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTACGATGCATCCAATTTGGCAACAGGGGTCCCATCAAGG
TTCAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAG
ATATTGCAACATATTACTGTCAGCAGTCCCTCGACCTCCCTCCTACTTTTGGCGGAGGGAC
CAAGGTTGAGATCAAA (SEQ ID NO: 14) VL Protein
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLATGVPSR
FSGSGSGTDFTFTISSLQPEDIATYYCQQSLDLPPTFGGGTKVEIK (SEQ ID NO: 13) C02
VH FR1 QLQLQESGPGLVKPSETLSLTCTVSGGSIS (SEQ ID NO: 24) VH CDR1
SSSYYWG (SEQ ID NO: 19) VH FR2 WIRQPPGKGLEWIG (SEQ ID NO: 25) VH
CDR2 NIYYSGSTYYNPSLKS (SEQ ID NO: 20) VH FR3
RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR (SEQ ID NO: 26) VH CDR3
DGRYQSATADYYYGMDV (SEQ ID NO: 21) VH FR4 WGQGTTVTVSS (SEQ ID NO:
27) VH ABRS ABR1: GSISSSSYYWG (SEQ ID NO: 76) ABR2:
NIYYSGSTYYNPSLKS (SEQ ID NO: 77) ABR3: ARDGRYQSATADYYYGMDV (SEQ ID
NO: 78) VH DNA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGACACCCTGTCCCTCA
CCTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTAGTTACTACTGGGGCTGGATCCGCCA
GCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAACATCTATTATAGTGGGAGCACCTACTAC
AACCCGTCCCTCAAGAGTCGAGTCACCATATCCGTAGACACGTCCAAGAACCAGTTCTCCC
TGAAGCTGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGACGGCAG
ATACCAAAGCGCCACAGCCGATTACTATTACGGTATGGATGTCTGGGGCCAGGGAAGAACT
GTCACCGTCTCCTCA (SEQ ID NO: 23) VH Protein
QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGNIYYSGSTYY
NPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDGRYQSATADYYYGMDVWGQGTT VTVSS
(SEQ ID NO: 22) VL FR1 EIVLTQSPGTLSLSPGERATLSC (SEQ ID NO: 33) VL
CDR1 RASQSVSSSYLA (SEQ ID NO: 28) VL FR2 WYQQKPGQAPRLLIY (SEQ ID
NO: 34) VL CDR2 GASSRAT (SEQ ID NO: 29) VL FR3
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC (SEQ ID NO: 35) VL CDR3 QQVFSYPFT
(SEQ ID NO: 30) VL FR4 FGGGTKVEIK (SEQ ID NO: 36) VL DNA
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC
AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG
AAGATTTTGCAGTGTATTACTGTCAGCAGGTCTTCAGTTACCCTTTCACTTTTGGCGGAGG
GACCAAGGTTGAGATCAAA (SEQ ID NO: 32) VL Protein
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPD
RFSGSGSGTDFTLTISRLEPEDFAVYYCQQVFSYPFTFGGGTKVEIK (SEQ ID NO: 31) D04
VH FR1 EVQLLESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 42) VH CDR1 SYAMS
(SEQ ID NO: 37) VH FR2 WVRQAPGKGLEWVS (SEQ ID NO: 43) VH CDR2
AISGSGGSTYYADSVKG (SEQ ID NO: 38) VH FR3
RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 44) VH CDR3 RYRGVSFDI
(SEQ ID NO: 39) VH FR4 WGRGTMVTVSS (SEQ ID NO: 45) VH ABRs ABR1:
FTFSSYAMS (SEQ ID NO: 79) ABR2: AISGSGGSTYYADSVKG (SEQ ID NO: 80)
ABR3: ARRYRGVSFDI (SEQ ID NO: 81) VH DNA
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT
CCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCC
AGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCA
GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGC
AAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGGAGATACAGAGG
AGTGTCATTCGACATATGGGGTCGGGGTACAATGGTCACCGTCTCCTCA (SEQ ID NO: 41)
VH Protein
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYA
DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRYRGVSFDIWGRGTMVTVSS (SEQ ID
NO: 40) VL FR1 EIVLTQSPGTLSLSPGERATLSC (SEQ ID NO: 51) VL CDR1
RASQSVSSSYLA (SEQ ID NO: 46) VL FR2 WYQQKPGQAPRLLIY (SEQ ID NO: 52)
VL CDR2 GASSRAT (SEQ ID NO: 47) VL FR3
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC (SEQ ID NO: 53) VL CDR3 QQDSIDIT
(SEQ ID NO: 48) VL FR4 FGGGTKVEIK (SEQ ID NO: 54) VL DNA
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC
AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG
AAGATTTTGCAGTGTATTACTGTCAGCAGGACTCCATCGACATCACTTTTGGCGGAGGGAC
CAAGGTTGAGATCAAA (SEQ ID NO: 50) VL Protein
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPD
RFSGSGSGTDFTLTISRLEPEDFAVYYCQQDSIDITPGGGTKVEIK (SEQ ID NO: 49) H03
VH FR1 EVQLLESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 60) VH CDR1 SYAMS
(SEQ ID NO: 55) VH FR2 WVRQAPGKGLEWVS (SEQ ID NO: 61) VH CDR2
AISGSGGSTYYADSVKG (SEQ ID NO: 56) VH FR3
RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 62) VH CDR3 PYQARAFDI
(SEQ ID NO: 57) VH FR4 WGQGTMVTVSS (SEQ ID NO: 63) VH ABRs ABR1:
FTFSSYAMS (SEQ ID NO: 82) ABR2: AISGSGGSTYYADSVKG (SEQ ID NO: 83)
ABR3: ARPYQARAFDI (SEQ ID NO: 84) VH DNA
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT
CCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCC
AGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCA
GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGC
AAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGACCTTACCAAGC
CAGAGCCTTTGATATTTGGGGTCAGGGTACAATGGTCACCGTCTCCTCA (SEQ ID NO: 59)
VH Protein
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYA
DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPYQARAFDIWGQGTMVTVSS (SEQ ID
NO: 58) VL FR1 EIVLTQSPGTLSLSPGERATLSC (SEQ ID NO: 51) VL CDR1
RASQSVSSSFLA (SEQ ID NO: 64) VL FR2 WYQQKPGQAPRLLIY (SEQ ID NO: 52)
VL CDR2 GASSRAT (SEQ ID NO: 65) VL FR3
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC (SEQ ID NO: 53) VL CDR3 QQYVVAPIT
(SEQ ID NO: 66) VL FR4 FGGGTKVEIK (SEQ ID NO: 54) VL DNA
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTTCTTAGCCTGGTACCAGCAGAAACC
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC
AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG
AAGATTTTGCAGTGTATTACTGTCAGCAGTACGTCGTCGCCCCTATCACTTTTGGCGGAGG
GACCAAGGTTGAGATCAAA (SEQ ID NO: 68) VL Protein
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPD
RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVVAPITFGGGTKVEIK (SEQ ID NO: 67)
TABLE-US-00003 TABLE 1B Additional exemplary ALK7-binding proteins
J01 VH FR1 EVQLLESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 42) VH CDR1
SYAMS (SEQ ID NO: 37) VH FR2 WVRQAPGKGLEWVS (SEQ ID NO: 43) VH CDR2
AISGSGGSTYYADSVKG (SEQ ID NO: 56) VH FR3
RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK (SEQ ID NO: 93) VH CDR3 PSYQPIY
(SEQ ID NO: 90) VH FR4 WGQGTLVTVSS (SEQ ID NO: 94) VH ABRs ABR1:
FRFSSYAMS (SEQ ID NO: 153) ABR2: AISGSGGSTYYADSVKG (SEQ ID NO: 154)
ABR3: AKPSYQPIY (SEQ ID NO: 155) VH DNA
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT
CCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCC
AGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCA
GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGC
AAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAAGCCTTCTTACCA
ACCAATATACTGGGGACAGGGTACATTGGTCACCGTCTCCTCA (SEQ ID NO: 151) VH
Protein
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYA
DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPSYQPIYWGQGTLVTVSS (SEQ ID NO:
152) VL FR1 DIQMTQSPSSVSASVGDRVTITC (SEQ ID NO: 100) VL CDR1
RASQGISSWLA (SEQ ID NO: 95) VL2 FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 16)
VL CDR2 AASSLQS (SEQ ID NO: 96) VL FR3
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 101) VL CDR3 QQAASYPLT
(SEQ ID NO: 97) VL FR4 FGGGTKVEI (SEQ ID NO: 18) VL DNA
GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCA
TCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGG
CTTAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAG
ATTTTGCAACTTATTACTGTCAGCAGGCAGCCAGTTACCCTCTCACTTTTGGCGGAGGGAC
CAAGGTTGAGATCAAA (SEQ ID NO: 99) VL Protein
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSR
FSGSGSGTDFTLTISSLQPEDFATYYCQQAASYPLTFGGGTKVEIK (SEQ ID NO: 98) KO1
VH FR1 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS (SEQ ID NO: 6) VH CDR1 NYAIS
(SEQ ID NO: 156) VH FR2 WVRQAPGQGLEWMG (SEQ ID NO: 7) VH CDR2
GIIPIFGTANYAQKFQG (SEQ ID NO: 157) VH FR3
RVTITADESTSTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 8) VH CDR3 DPREYIHVFDI
(SEQ ID NO: 104) VH FR4 WGQGTMVTVSS (SEQ ID NO: 9) VH ABRs ABR1:
GTFSNYAIS (SEQ ID NO: 160) ABR2: GIIPIFGTANYAQKFQG (SEQ ID NO: 161)
ABR3: ARDPREYIHVFDI (SEQ ID NO: 162) VH DNA
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT
CCTGCAAGGCTTCTGGAGGCACCTTCAGCAACTATGCTATCAGCTGGGTGCGACAGGCCCC
TGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTACGCA
CAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGG
AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGATCCAAGAGA
ATATATCCACGTATTCGACATATGGGGTCAGGGTACAATGGTCACCGTCTCCTCA (SEQ ID NO:
158) VH Protein
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGGIIPIFGTANYA
QKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPREYIHVFDIWGQGTMVTVSS (SEQ ID
NO: 159) VL FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 15) VL CDR1
RASQSISSYLN (SEQ ID NO: 107) VL FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 16)
VL CDR2 GASSLQS (SEQ ID NO: 108) VL FR3
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 112) VL CDR3 QQAYSFPWT
(SEQ ID NO: 109) VL FR4 FGGGIKVEIK (SEQ ID NO: 113) VL DNA
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCA
TCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTATGGTGCAGCCAGTTTGCAAAGTGGGGTCCCATCAAGG
TTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAG
ATTTTGCAACTTACTACTGTCAGCAAGCATACAGTTTCCCTTGGACTTTTGGCGGAGGGAT
CAAGGTTGAGATCAAA (SEQ ID NO: 111) VL Protein
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASSLQSGVPSR
FSGSGSGTDFTLTISSLQPEDFATYYCQQAYSFPWTFGGGIKVEIK (SEQ ID NO: 110) L01
VH FR1 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS (SEQ ID NO: 6) VH CDR1 SYAIS
(SEQ ID NO: 1) VH FR2 WVRQAPGQGLEWMG (SEQ ID NO: 7) VH CDR2
SIIPIFGTANYAQKFQG (SEQ ID NO: 163) VH FR3
RVTITADESTSTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 8) VH CDR3
DPVGARYEVFDY (SEQ ID NO: 164) VH FR4 WGQGTLVTVSS (SEQ ID NO: 94) VH
ABRs ABR1: GTFSSYAIS (SEQ ID NO: 172) ABR2: SIIPIFGTANYAQKFQG (SEQ
ID NO: 173) ABR3: ARDPVGARYEVFDY (SEQ ID NO: 174) VH DNA
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT
CCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCCCC
TGGACAAGGGCTTGAGTGGATGGGAAGCATCATCCCTATCTTTGGTACAGCAAACTACGCA
CAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGG
AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGACCCTGTCGG
AGCAAGATACGAGGTTTTCGATTACTGGGGACAGGGTACATTGGTCACCGTCTCCTCA (SEQ ID
NO: 165) VH Protein
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGSIIPIFGTANYA
QKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPVGARYEVFDYWGQGTLVTVSS (SEQ
ID NO: 166) VL FR1 EIVMTQSPATLSVSPGERATLSC (SEQ ID NO: 150) VL CDR1
RASQSVSSNLA (SEQ ID NO: 167) VL FR2 WYQQKPGQAPRLLIY (SEQ ID NO: 34)
VL CDR2 SASTRAT (SEQ ID NO: 168) VL FR3
GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC (SEQ ID NO: 151) VL CDR3 QQANTFPLT
(SEQ ID NO: 169) VL FR4 FGGGTKVEIK (SEQ ID NO: 54) VL DNA
GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG
CCAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGG
TTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAG
ATTTTGCAGTTTATTACTGTCAGCAGGCCAATACCTTCCCTCTCACTTTTGGCGGAGGGAC
CAAGGTTGAGATCAAA (SEQ ID NO: 170) VL Protein
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYSASTRATGIPAR
FSGSGSGTEFTLTISSLQSEDFAVYYCQQANTFPLTFGGGTKVEIK (SEQ ID NO: 171)
SPR (BIACORE.TM.-based analysis) and a cell-based lipolysis
inhibition assay was used to more fully characterize and exemplary
set of the ALK7-binding proteins described in Table 1A, Table 1B,
or Table 3.
Surface Plasmon Resonance Analysis--
Experiments were performed using a Biacore T100/T200 biosensor
(Biacore/GE Healthcare) at 25 and 37.degree. C. ALK7 antibodies
were captured on custom made FAB chip. A concentration series of
ALK7-Fc comprising protein was injected over the flow cells at a
flow rate of 50 .mu.l/ml. To obtain kinetic rate constants the
corrected data were fit to a 1:1 interaction model using
BiaEvaluation software (GE Healthcare). The equilibrium binding
constant KD was determined by the ratio of binding rate constants
kd/ka.
Lipolysis Inhibition Assay
Lipolysis is the hydrolysis of triglycerides within the cell into
glycerol and free fatty acids. The glycerol and free fatty acids
are then released into the bloodstream or culture media. While
lipolysis occurs in essentially all cells, it is most abundant in
white and brown adipocytes. 3T3-L1 cells (supplied by ATCC;
ATCC.RTM. CL-173.TM.) were grown in Dulbecco's Modified Eagle
Medium (ATCC; ATCC.RTM. 30-2002.TM.) containing 10% Bovine Serum
(Life Technologies; 16170-060) until reaching confluency. To induce
differentiation, at 2 days post-confluency medium was replaced by
fresh Dulbecco's Modified Eagle Medium (ATCC; ATCC.RTM.
30-2002.TM.) containing 10% fetal Bovine serum (Life Technologies;
Ser. No. 10/082,147), dexamethasone (Sigma, D8893), IBMX (Sigma,
17018) and insulin (Sigma, 10516) for 2 weeks. Accumulation of
lipid droplets on the cells, as determined by microscopy, was used
to confirm a complete differentiation into mature adipocyte cells.
Adipocytes were treated overnight with vehicle (PBS), activin B (50
ng/ml) or co-treated with activin B (50 ng/ml) and ALK7antibodies
(5 .mu.g/ml). Cells were washed two times with PBS and incubated
with lipolysis assay buffer (supplied by Abcam; ab185433).
Lipolysis assay buffer was collected after 3 hours and glycerol
levels were measured according to manufacturer's instruction
(Abcam; ab185433).
Results of the SPR are presented in Table 2A and 2B and cell-based
lipolysis inhibition assay for exemplary ALK-7 binding proteins are
presented in Table 2A.
Results of the SPR and cell-based lipolysis inhibition assay for
exemplary ALK-7 binding proteins are presented in Table 3.
TABLE-US-00004 TABLE 2A Binding characterization and activity of
exemplary ALK7-binding proteins Increase in lipolysis Binding to
human ALK7-Fc comprising protein Binding to rat Alk7-Fc comprising
protein activity k.sub.on (M.sup.-1s.sup.-1) k.sub.off (s.sup.-1)
K.sub.D (nM) k.sub.on (M.sup.-1s.sup.-1) koff (s.sup.-1) K.sub.D
(nM) (%) C02 2.31 .times. 10.sup.4 1.42 .times. 10.sup.-3 61.2 N/A
55.8% D04 7.40 .times. 10.sup.4 3.78 .times. 10.sup.-3 51.1 6.13
.times. 10.sup.3 1.38 .times. 10.sup.-3 225 109.2% G04 8.96 .times.
10.sup.4 2.22 .times. 10.sup.-2 247 N/A 45.8% H03 1.79 .times.
10.sup.5 4.32 .times. 10.sup.-3 24.1 1.07 .times. 10.sup.4 1.54
.times. 10.sup.-3 144 91.8%
TABLE-US-00005 TABLE 2B Binding characterization of exemplary
ALK7-binding proteins Binding to human ALK7-Fc comprising protein
Binding to rat Alk7-Fc comprising protein k.sub.on
(M.sup.-1s.sup.-1) k.sub.off (s.sup.-1) K.sub.D (nM) k.sub.on
(M.sup.-1s.sup.-1) koff (s.sup.-1) K.sub.D (nM) J01 N/A 1.62
.times. 10.sup.4 4.78 .times. 10.sup.-2 29.5 K01 4.56 .times.
10.sup.4 9.16 .times. 10.sup.-3 200.8 1.71 .times. 10.sup.4 1.39
.times. 10.sup.-4 8.14 L01 2.43 .times. 10.sup.4 3.67 .times.
10.sup.4 15.1 1.18 .times. 10.sup.4 2.71 .times. 10.sup.-4 22.9
ALK7 signaling is thought to suppress lipolysis and to consequently
lead to fat accumulation in adipocytes and adipose tissue. The
ability of antibodies H03, D04, C02, and 004 to interfere with
ALK7-mediated inhibition of lipolysis was assessed in a cell-based
lipolysis inhibition assay. The antibodies H03, D04, C02, and 004
increased lipolysis activity by 91.8%, 109.2%, 55.8%, and 45.8%,
respectively. Accordingly, these data indicate that ALK7 antibodies
can be used to antagonize ALK7-mediated suppression of lipolysis
and thereby increase fatty acid breakdown in adipocytes. Together,
these data indicate that ALK7 antibodies may be used to treat a
variety of disorder or conditions associated with low lipolysis
activity and/or excessive fatty acid accumulation in cells,
particularly adipocytes (adipose cells), including for example,
obesity, diabetes, insulin resistance; metabolic syndrome fatty
liver disease and other metabolic diseases or conditions.
The extracellular domain of human ALK7 (SEQ ID NO: 85) and rat ALK7
(SEQ ID NO: 86) share 97% sequence identity. The binding of
antibodies 1-103, 004. C02 and D04 to human ALK7 and rat ALK7 was
determined using SPR. The antibodies H03, D04, K01, and L01 bind to
both human ALK7 and rat ALK7. F03 and C02 only bound human ALK7.
J01 only bound rat ALK7.
Example 3. Binding Optimization of ALK7 Antibodies
Binding optimization of naive clones was carried out utilizing
three maturation strategies: light chain diversification;
diversification of CDRH and/CDR1-12; and performing sequential VH
and VL mutagenesis.
Light chain diversification: Heavy chain plasmids were extracted
naive outputs (described above) and transformed into a light chain
library with a diversity of 1.times.10.sup.6. Selections were
performed as described above with one round of MACS sorting and two
rounds of FACS sorting using 10 nM or 1 nM biotinylated ALK7-Fc
antigen (for respective rounds.
CDRH1 and CDRH2 selection: The CDRH3s from clones selected from the
light chain diversification procedure of was recombined into a
premade library with CDRH1 and CDRH2 variants of a diversity of
1.times.10.sup.8 and selections were performed using ALK7, as
described above. Affinity pressures were applied by incubating the
biotinylated antigen-antibody yeast complex with unbiotinylated
antigen for different amounts of time to select for the highest
affinity antibodies.
VHmut/VKmut selection: Clones obtained from the CDRH1 and CDRH2
selection procedure were subject to additional rounds of affinity
maturation via error prone PCR-based mutagenesis of the heavy chain
and/or light chain. Selections were performed using ALK7 as antigen
generally as described in Example 2 above, but with the addition of
employing FACS sorting for all selection rounds. Antigen
concentration was reduced and cold antigen competition times were
increased to pressure further for optimal affinity.
The sequence of exemplary optimized ALK7 antibodies is provided in
Table 3.
TABLE-US-00006 TABLE 3 Exemplary affinity matured ALK7-binding
proteins J02 VH FR1 EVQLLESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 42)
VH CDR1 VYAMS (SEQ ID NO: 88) VH FR2 WVRQAPGKGLEWVS (SEQ ID NO: 43)
VH CDR2 AISGSGDSTVYADSVKG (SEQ ID NO: 89) VH FR3
RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK (SEQ ID NO: 93) VH CDR3 PSYQPIY
(SEQ ID NO: 90) VH FR4 WGQGTLVTVSS (SEQ ID NO: 94) VH ABRs ABR1:
FTFSVYAMS (SEQ ID NO: 175) ABR2: AISGSGDSTVYADSVKG (SEQ ID NO: 176)
ABR3: AKPSYQPIY (SEQ ID NO: 177) VH DNA
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT
CCTGTGCAGCCTCTGGATTCACCTTTTCGGTGTATGCCATGAGCTGGGTCCGCCAGGCTCC
AGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGAAGTGGTGATAGCACAGTGTACGCA
GACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGC
AAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAAGCCTTCTTACCA
ACCAATATACTGGGGACAGGGTACATTGGTCACCGTCTCCTCA (SEQ ID NO: 92) VH
Protein
EVQLLESGGGLVQPGGSLRLSCAASGFTFSVYAMSWVRQAPGKGLEWVSAISGSGDSTVYA
DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPSYQPIYWGQGTLVTVSS (SEQ ID NO:
91) VL FR1 DIQMTQSPSSVSASVGDRVTITC (SEQ ID NO: 100) VL CDR1
RASQGISSWLA (SEQ ID NO: 95) VL FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 16)
VL CDR2 AASSLQS (SEQ ID NO: 96) VL FR3
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 101) VL CDR3 QQAASYPLT
(SEQ ID NO: 97) VL FR4 FGGGTKVEIK (SEQ ID NO: 18) VL DNA
GACATCCAGATGACCCAAAGCCCTAGTTCCGTCTCTGCAAGCGTGGGAGATAGGGTCACAA
TCACATGTAGAGCTTCTCAGGGGATCTCTAGCTGGCTGGCTTGGTATCAGCAGAAGCCCGG
TAAGGCCCCAAAGCTCTTGATATACGCCGCCTCTTCTCTTCAATCTGGGGTGCCATCCCGC
TTCTCAGGGAGCGGTAGCGGGACCGATTTCACCCTCACTATCAGCAGCCTGCAGCCTGAAG
ACTTTGCTACCTACTACTGCCAGCAAGCCGCTTCTTATCCTCTGACTTTCGGTGGGGGTAC
TAAAGTGGAGATTAAA (SEQ ID NO: 99) VL Protein
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSQSGVP
SRFSGSGSGTDFTLTISSLQPEDFATYYCQQAASYPLTFGGGTKVEIK (SEQ ID NO: 98)
KO2 VH FR1 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS (SEQ ID NO: 6) VH CDR1
SSAIG (SEQ ID NO: 102) VH FR2 WVRQAPGQGLEWMG (SEQ ID NO: 7) VH CDR2
GIWPIFGTALYAQKFQG (SEQ ID NO: 103) VH FR3
RVTITADESTSTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 8) VH CDR3 DPREYIHVFDI
(SEQ ID NO: 104) VH FR4 WGQGTMVTVSS (SEQ ID NO: 9) VH ABRs ABR1:
GTFSSSAIG (SEQ ID NO: 178) ABR2: GIWPIFGTALYAQKFQG (SEQ ID NO: 179)
ABR3: ARDPREYIHVFDI (SEQ ID NO: 180) VH DNA
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT
CCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCAGTGCTATCGGGTGGGTGCGAGAGGCCCC
TGGACAAGGGCTTGAGTGGATGGGAGGGATCTGGCCTATCTTTGGTACAGCACTTTACGCA
CAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGG
AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGATCCAAGAGA
ATATATCCACGTATTCGACATATGGGGTCAGGGTACAATGGTCACCGTCTCCTCA (SEQ ID NO:
106) VH Protein
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSSAIGWVRQAPGQGLEWMGGIWPIFGTALYA
QKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDPREYIHVFDIWGQGTMVTVSS (SEQ ID
NO: 105) VL FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 15) VL CDR1
RASQSISSYLN (SEQ ID NO: 107) VL FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 16)
VL CDR2 GASSLQS (SEQ ID NO: 108) VL FR3
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 112) VL CDR3 QQAYSFPWT
(SEQ ID NO: 109) VL FR4 FGGGIKVEIK (SEQ ID NO: 113) VL DNA
GATATTCAGATGACACAGTCACCTAGCAGTCTGAGCGCATCAGTGGGTGATCGAGTGACAA
TCACTTGTAGAGCTTCCCAGTCTATTAGCTCATACCTGAACTGGTATCAGCAAAAGCCTGG
GAAGGCTCCTAAGCTGTTGATCTATGGAGCATCTAGCCTGCAGTCCGGCGTGCCATCCCGC
TTCAGCGGGAGCGGCTCCGGGACCGATTTTACCCTGACAATCTCTAGCCTGCAGCCTGAAG
ATTTTGCAACCTACTACTGCCAGCAGGCATACAGCTTCCCCTGGACATTCGGAGGTGGCAT
AAAAGTTGAAATCAAA (SEQ ID NO: 111) VL Protein
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASSLQSGVPSR
FSGSGSGTDFTLTISSLQPEDFATYYCQQAYSFPWTFGGGIKVEIK (SEQ ID NO: 110) G05
VH FR1 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS (SEQ ID NO: 6) VH CDR1 GQAIS
(SEQ ID NO: 114) VH FR2 WVRQAPGQGLEWMG (SEQ ID NO: 7) VH CDR2
GIIPSFGTARYAQKFQG (SEQ ID NO: 115) VH FR3
RVTITADESTSTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 119) VH CDR3
TPYYDSSGYLDV (SEQ ID NO: 116) VH FR4 WGQGTMVTVS (SEQ ID NO: 120) VH
ABRs ABR1: GTFSGQAIS (SEQ ID NO: 181) ABR2: GIIPSFGTARYAQKFQG (SEQ
ID NO: 182) ABR3: ARTPYYDSSGYLDV (SEQ ID NO: 183) VH DNA
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT
CCTGCAAGGCTTCTGGAGGCACCTTCAGCGGTCAGGCTATCAGCTGGGTGCGAGAGGCCCC
TGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTTCGTTTGGTACAGCACGGTACGCA
CAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGCCTACATGG
AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAACTCCTTACTA
CGACAGCAGCGGATACCTAGACGTATGGGGTCAGGGTACAATGGTCACCGTCTCCTCA (SEQ ID
NO: 118) VH Protein
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSGQAISWVRQAPGQGLEWMGGIIPSFGTARYA
QKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARTPYYDSSGYLDVWGQGTMVTVS (SEQ ID
NO: 117) VL FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 15) VL CDR1
QASHDIDNYLN (SEQ ID NO: 121) VL FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 16)
VL CDR2 YASNLKT (SEQ ID NO: 122) VL FR3
GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC (SEQ ID NO: 17) VL CDR3 QQSRASPPT
(SEQ ID NO: 123) VL FR4 FGGGTKVEIK (SEQ ID NO: 18) VL DNA
GACATCCAGATGACACAGTCCCCTAGCAGCTTGTCAGCCTCAGTGGGCGATAGAGTGACCA
TCACCTGTCAAGCCAGCCATGATATAGACAACTATCTCAATTGGTACCAGCAGAAACCAGG
CAAGGCACCAAAGCTCCTGATCTATTACGCCTCAAACCTTAAGACCGGCGTCCCAAGCCGG
TTTTCAGGCAGCGGCAGCGGGACAGATTTCACCTTCACAATTTCATCACTGCAACCTGAGG
ATATAGCCACTTACTATTGTCAGCAGAGCAGAGCCAGCCCCCCTACCTTCGGCGGCGGTAC
CAAAGTTGAAATCAAG (SEQ ID NO: 125) VL Protein
DIQMTQSPSSLSASVGDRVTITCQASHDIDNYLNWYQQKPGKAPKLLIYYASNLKTGVPSR
FSGSGSGTDFTFTISSLQPEDIATYYCQQSRASPPTFGGGTKVEIK (SEQ ID NO: 124) CO3
VH FR1 QLQLQESGPGLVKPSETLSLTCTVS (SEQ ID NO: 130) VH CDR1 GGSISSSAY
(SEQ ID NO: 125) VH FR2 YWAWIRQPPGKGLEWIG (SEQ ID NO: 131) VH CDR2
SIYLSGSTTYNPSLKS (SEQ ID NO: 126) VH FR3
RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR (SEQ ID NO: 26) VH CDR3
DGRYQSRSPDYYYGMDV (SEQ ID NO: 127) VH FR4 WGQGTTVTVSS (SEQ ID NO:
27) VH ABRs ABR1: GSISSSAYYWA (SEQ ID NO: 184) ABR2:
SIYLSGSTTYNPSLKS (SEQ ID NO: 185) ABR3: ARDGRYQSRSPDYYYGMDV (SEQ ID
NO: 186) VH DNA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCA
CCTGCACTGTCTCTGGTGGCTCCATCAGCAGTAGTGCTTACTACTGGGCGTGGATCCGCCA
GCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATTTGAGTGGGAGCACCACTTAC
AACCCGTCCCTCAAGAGTCGAGTCACCATATCCGTAGACACGTCCAAGAACCAGTTCTCCC
TGAAGCTGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGACGGCAG
ATACCAAAGCAGGTCGCCGGATTACTATTACGGTATGGATGTCTGGGGCCAGGGAACAACG
GTCACCGTCTCCTCA (SEQ ID NO: 129) VH Protein
QLQLQESGPGLVKPSETLSLTCTVSGGSISSSAYYWAWIRQPPGKGLEWIGSIYLSGSTTY
NPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDGRYQSRSPDYYYGMDVWGQGTT VTVSS
(SEQ ID NO: 128) VL FR1 EIVLTQSPGTLSLSPGERATLSC (SEQ ID NO: 33) VL
CDR1 KASQSVSSSYLA (SEQ ID NO: 132) VL FR2 WYQQKPGQAPRLLIY (SEQ ID
NO: 34) VL CDR2 GAFSRAN (SEQ ID NO: 133) VL FR3
GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC (SEQ ID NO: 35) VL CDR3 QQLVSYPFT
(SEQ ID NO: 134) VL FR4 FGGGTKVEIK (SEQ ID NO: 18) VL DNA
GAGATAGTCTTGACCCAGTCACCAGGCACCCTTAGCTTGTCTCCCGGGGAACGCGCCACAC
TCAGCTGTAAAGCCTCTCAGTCAGTTTCTAGTTCCTACCTCGCTTGGTATCAACAAAAGCC
CGGACAAGCACCAAGGCTGTTGATCTACGGAGCTTTCAGTCGCGCAAATGGCATTCCCGAC
CGATTCTCTGGCAGTGGTAGTGGCACCGACTTCACTCTCACAATTTCTAGGTTGGAACCTG
AGGACTTTGCTGTGTACTACTGTCAACAACTGGTTTCTTATCCCTTTACATTCGGTGGCGG
CACAAAAGTCGAGATTAAA (SEQ ID NO: 136) VL Protein
EIVLTQSPGTLSLSPGERATLSCKASQSVSSSYLAWYQQKPGQAPRLLIYGAFSRANGIPD
RFSGSGSGTDFTLTISRLEPEDFAVYYCQQLVSYPFTFGGGTKVEIK (SEQ ID NO: 135)
L02 VH FR1 QVQLVQSGAEVKKPGASVKVSCKASGYTFA (SEQ ID NO: 142) VH CDR1
GYNMH (SEQ ID NO: 137) VH FR2 WVRQAPGQGLEWVGII (SEQ ID NO: 143) VH
CDR2 NPNSGW (SEQ ID NO: 138) VH FR3
TNYAQKFQGRVTMTRDTSVSAAYMELSRLRSDDTAVYYCAR (SEQ ID NO: 152) VH CDR3
DPVGARYEVFDY (SEQ ID NO: 139) VH FR4 WGQGTLVTVSS (SEQ ID NO: 144)
VH ABRs ABR1: YTFAGYNMH (SEQ ID NO: 187) ABR2: IINPNSGWTNYAQKFQG
(SEQ ID NO: 188) ABR3: ARDPVGARYEVFDY (SEQ ID NO: 189) VH DNA
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCT
CCTGCAAGGCTTCTGGATACACCTTCGCTGGCTACAATATGCACTGGGTGCGACAGGCCCC
TGGACAAGGGCTTGAGTGGGTGGGAATTATCAACCCTAACAGTGGTTGGACAAACTATGCA
CAGAAGTTCCAGGGCAGGGTCACGATGACCAGGGACACGTCCGTCAGCGCAGCCTACATGG
AGCTGAGCAGGCTGAGATCTGACGACACGGCGGTGTACTACTGCGCCAGAGACCCTGTCGG
AGCAAGATACGAGGTTTTCGATTACTGGGGACAGGGTACATTGGTCACCGTCTCCTCA (SEQ ID
NO: 141) VH Protein
QVQLVQSGAEVKKPGASVKVSCKASGYTFAGYNMHWVRQAPGQGLEWVGIINPNSGWTNYA
QKFQGRVTMTRDTSVSAAYMELSRLRSDDTAVYYCARDPVGARYEVFDYWGQGTLVTVSS (SEQ
ID NO: 140) VL FR1 EIVMTQSPATLSVSPGERATLSC (SEQ ID NO: 150) VL CDR1
RASQSVSSALA (SEQ ID NO: 145) VL FR2 WYQQKPGQAPRLLIY (SEQ ID NO: 34)
VL CDR2 SAFTRAS (SEQ ID NO: 146) VL FR3
GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC (SEQ ID NO: 151) VL CDR3 QQAWAFPLT
(SEQ ID NO: 147) VL FR4 FGGGTKVEIK (SEQ ID NO: 18) VL DNA
GAAATCGTGATGACCCAATCACCTGCCACTCTGTCTGTTAGCCCTGGGGAACGGGCCACCC
TCAGTTGTAGGGCCAGTCAGAGTGTTAGTTCAGCTTTGGCTTGGTATCAGCAGAAGCCCGG
ACAGGCCCCAAGGCTGCTGATCTACTCTGCTTTCACCCGCGCAAGCGGCATCCCCGCACGC
TTTAGCGGCTCCGGAAGCGGCACCGAGTTTACTCTTACTATTTCTTCTTTGCAGAGTGAGG
ATTTTGCCGTGTACTACTGCCAGCAGGCCTGGGCATTTCCACTCACTTTCGGGGGCGGGAC
CAAGGTCGAAATCAAG (SEQ ID NO: 149) VL Protein
EIVMTQSPATLSVSPGERATLSCRASQSVSSALAWYQQKPGQAPRLLIYSAFTRASGIPAR
FSGSGSGTEFTLTISSLQSEDFAVYYCQQAWAFPLTFGGGTKVEIK (SEQ ID NO: 148)
SPR (BIACORE.TM.-based analysis) was used to more fully
characterize the affinity matured ALK7 antibodies described in
Table 3.
Surface Plasmon Resonance Analysis--
Experiments were performed using a Biacore T100/T200 biosensor
(Biacore/GE Healthcare) at 25 and 37.degree. C. ALK7 antibodies
were captured on custom made FAB chip. A concentration series of
ALK7-Fc comprising protein was injected over the flow cells at a
flow rate of 50 .mu.l/ml. To obtain kinetic rate constants the
corrected data were fit to a 1:1 interaction model using
BiaEvaluation software (GE Healthcare). The equilibrium binding
constant KD was determined by the ratio of binding rate constants
kd/ka.
Results of the SPR performed as described above are presented in
Table 4.
TABLE-US-00007 TABLE 4 Binding characterization of exemplary
affinity matured ALK7 antibodies Binding to ALK7-Fc comprising
protein (25.degree. C.) k.sub.on (M.sup.-1s.sup.-1) k.sub.off
(s.sup.-1) K.sub.D (nM) Parental Antibody J02 2.36 .times. 10.sup.4
1.26 .times. 10.sup.-4 5.33 J01 K02 2.35 .times. 10.sup.4 2.91
.times. 10.sup.-4 12.42 K01 G05 2.99 .times. 10.sup.4 2.59 .times.
10.sup.-5 0.87 G04 C03 3.83 .times. 10.sup.4 1.27 .times. 10.sup.-5
0.33 C02 L02 2.74 .times. 10.sup.4 1.21 .times. 10.sup.-5 0.44
L01
Example 4. The Effects of ALK7 Abs on Adiposity and Lean Body Mass
in Obese Mice
Applicants investigated the effect of several human monoclonal ALK7
antibodies (ALK7 mAbs) on fat and lean tissue mass in a murine
model of diet-induced obesity.
Male mice (n=8 per group) were assessed at baseline for fat and
lean muscle amounts using NMR. Mice were then divided into
different treatments groups: 1) mice fed a standard chow diet (SD)
and treated subcutaneously twice per week with TBS vehicle; 2) mice
fed a high fat diet (HFD) and treated subcutaneously twice per week
with TBS vehicle; 3) HDF mice treated subcutaneously twice per week
with 10 mg/kg of the ALK7 mAb J02; 4) HDF mice treated
subcutaneously twice per week with 10 mg/kg of the ALK7 mAb K02; 5)
HDF mice treated subcutaneously twice per week with 10 mg/kg of the
ALK7 mAb G05; 6) HDF mice treated subcutaneously twice per week
with 10 mg/kg of the ALK7 mAb C03; and 7) HDF mice treated
subcutaneously twice per week with 10 mg/kg of the ALK7 mAb L02.
After three weeks, mice were again subjected to whole-body NMR scan
to assess for fat and lean tissue mass amounts, and these
measurements were compared to the baseline amounts of fat and lean
muscle.
TBS treated HFD mice displayed significantly higher amounts of
adipose tissue compared to TBS treated SD mice (FIG. 1). On
average, treatment with each ALK7 mAb resulted in significant less
adipose tissue accumulation in HFD mice (approximately -30% less)
compared to the TBS treated HFD mice (FIG. 1). In contrast, while
all mice displayed increases in muscle mass from baseline, there
was no significant difference among the treatment groups (FIG.
2).
Together, these data demonstrate that ALK7 mAbs can be used to
reduce adipose levels in vivo. Therefore, the data indicate that
ALK7 antibodies may be useful in treating various disorders and
complications associated with undesirably high fat levels,
particularly in obese patients. Moreover, the show that fat
reduction may be achieved without concurrently increasing lean body
mass, indicating that ALK7 Abs may be particularly useful in
treating patients where it is desirable to reduce body fat content
without also increasing muscle mass.
SEQUENCE LISTINGS
1
18915PRThomo sapiens 1Ser Tyr Ala Ile Ser1 5217PRThomo sapiens 2Gly
Ile Ile Pro Ile Phe Gly Thr Ala Ser Tyr Ala Gln Lys Phe Gln1 5 10
15Gly312PRThomo sapiens 3Thr Pro Tyr Tyr Asp Ser Ser Gly Tyr Leu
Asp Val1 5 104121PRThomo sapiens 4Gln Val Gln Leu Val Gln Ser Gly
Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ser Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro
Ile Phe Gly Thr Ala Ser Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val
Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Arg Thr Pro Tyr Tyr Asp Ser Ser Gly Tyr Leu Asp Val Trp Gly 100 105
110Gln Gly Thr Met Val Thr Val Ser Ser 115 1205363DNAhomo sapiens
5caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc
60tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc
120cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac
agcaagctac 180gcacagaagt tccagggcag agtcacgatt accgcggacg
aatccacgag cacagcctac 240atggagctga gcagcctgag atctgaggac
acggcggtgt actactgcgc cagaactcct 300tactacgaca gcagcggata
cctagacgta tggggtcagg gtacaatggt caccgtctcc 360tca 363630PRThomo
sapiens 6Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe
Ser 20 25 30714PRThomo sapiens 7Trp Val Arg Gln Ala Pro Gly Gln Gly
Leu Glu Trp Met Gly1 5 10832PRThomo sapiens 8Arg Val Thr Ile Thr
Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu1 5 10 15Leu Ser Ser Leu
Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25 30911PRThomo
sapiens 9Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser1 5
101011PRThomo sapiens 10Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu
Asn1 5 10117PRThomo sapiens 11Asp Ala Ser Asn Leu Ala Thr1
5129PRThomo sapiens 12Gln Gln Ser Leu Asp Leu Pro Pro Thr1
513107PRThomo sapiens 13Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Gln Ala Ser
Gln Asp Ile Ser Asn Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Leu Ala Thr
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe
Thr Phe Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Ile Ala Thr
Tyr Tyr Cys Gln Gln Ser Leu Asp Leu Pro Pro 85 90 95Thr Phe Gly Gly
Gly Thr Lys Val Glu Ile Lys 100 10514321DNAhomo sapiens
14gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc aggcgagtca ggacattagc aactatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctacgat gcatccaatt tggcaacagg
ggtcccatca 180aggttcagtg gaagtggatc tgggacagat tttactttca
ccatcagcag cctgcagcct 240gaagatattg caacatatta ctgtcagcag
tccctcgacc tccctcctac ttttggcgga 300gggaccaagg ttgagatcaa a
3211523PRThomo sapiens 15Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
201615PRThomo sapiens 16Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile Tyr1 5 10 151732PRThomo sapiens 17Gly Val Pro Ser Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr1 5 10 15Phe Thr Ile Ser
Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys 20 25 301810PRThomo
sapiens 18Phe Gly Gly Gly Thr Lys Val Glu Ile Lys1 5 10197PRThomo
sapiens 19Ser Ser Ser Tyr Tyr Trp Gly1 52016PRThomo sapiens 20Asn
Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser1 5 10
152117PRThomo sapiens 21Asp Gly Arg Tyr Gln Ser Ala Thr Ala Asp Tyr
Tyr Tyr Gly Met Asp1 5 10 15Val22127PRThomo sapiens 22Gln Leu Gln
Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu
Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser 20 25 30Ser
Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40
45Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln
Phe65 70 75 80Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr 85 90 95Cys Ala Arg Asp Gly Arg Tyr Gln Ser Ala Thr Ala
Asp Tyr Tyr Tyr 100 105 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr
Val Thr Val Ser Ser 115 120 12523381DNAhomo sapiens 23cagctgcagc
tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60acctgcactg
tctctggtgg ctccatcagc agtagtagtt actactgggg ctggatccgc
120cagcccccag ggaaggggct ggagtggatt gggaacatct attatagtgg
gagcacctac 180tacaacccgt ccctcaagag tcgagtcacc atatccgtag
acacgtccaa gaaccagttc 240tccctgaagc tgagttctgt gaccgccgca
gacacggcgg tgtactactg cgccagagac 300ggcagatacc aaagcgccac
agccgattac tattacggta tggatgtctg gggccaggga 360acaactgtca
ccgtctcctc a 3812430PRThomo sapiens 24Gln Leu Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys
Thr Val Ser Gly Gly Ser Ile Ser 20 25 302514PRThomo sapiens 25Trp
Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly1 5
102632PRThomo sapiens 26Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn
Gln Phe Ser Leu Lys1 5 10 15Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys Ala Arg 20 25 302711PRThomo sapiens 27Trp Gly Gln
Gly Thr Thr Val Thr Val Ser Ser1 5 102812PRThomo sapiens 28Arg Ala
Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala1 5 10297PRThomo sapiens
29Gly Ala Ser Ser Arg Ala Thr1 5309PRThomo sapiens 30Gln Gln Val
Phe Ser Tyr Pro Phe Thr1 531108PRThomo sapiens 31Glu Ile Val Leu
Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile
Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55
60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65
70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Phe Ser Tyr
Pro 85 90 95Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
10532324DNAhomo sapiens 32gaaattgtgt tgacgcagtc tccaggcacc
ctgtctttgt ctccagggga aagagccacc 60ctctcctgca gggccagtca gagtgttagc
agcagctact tagcctggta ccagcagaaa 120cctggccagg ctcccaggct
cctcatctat ggtgcatcca gcagggccac tggcatccca 180gacaggttca
gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
240cctgaagatt ttgcagtgta ttactgtcag caggtcttca gttacccttt
cacttttggc 300ggagggacca aggttgagat caaa 3243323PRThomo sapiens
33Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1
5 10 15Glu Arg Ala Thr Leu Ser Cys 203415PRThomo sapiens 34Trp Tyr
Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr1 5 10
153532PRThomo sapiens 35Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr1 5 10 15Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp
Phe Ala Val Tyr Tyr Cys 20 25 303610PRThomo sapiens 36Phe Gly Gly
Gly Thr Lys Val Glu Ile Lys1 5 10375PRThomo sapiens 37Ser Tyr Ala
Met Ser1 53817PRThomo sapiens 38Ala Ile Ser Gly Ser Gly Gly Ser Thr
Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly399PRThomo sapiens 39Arg Tyr
Arg Gly Val Ser Phe Asp Ile1 540118PRThomo sapiens 40Glu Val Gln
Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Ala
Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Arg Tyr Arg Gly Val Ser Phe Asp Ile Trp
Gly Arg Gly Thr 100 105 110Met Val Thr Val Ser Ser 11541354DNAhomo
sapiens 41gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc
cctgagactc 60tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt
ccgccaggct 120ccagggaagg ggctggagtg ggtctcagct attagtggta
gtggtggtag cacatactac 180gcagactccg tgaagggccg gttcaccatc
tccagagaca attccaagaa cacgctgtat 240ctgcaaatga acagcctgag
agccgaggac acggcggtgt actactgcgc caggagatac 300agaggagtgt
cattcgacat atggggtcgg ggtacaatgg tcaccgtctc ctca 3544230PRThomo
sapiens 42Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Ser 20 25 304314PRThomo sapiens 43Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val Ser1 5 104432PRThomo sapiens 44Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln1 5 10 15Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25
304511PRThomo sapiens 45Trp Gly Arg Gly Thr Met Val Thr Val Ser
Ser1 5 104612PRThomo sapiens 46Arg Ala Ser Gln Ser Val Ser Ser Ser
Tyr Leu Ala1 5 10477PRThomo sapiens 47Gly Ala Ser Ser Arg Ala Thr1
5488PRThomo sapiens 48Gln Gln Asp Ser Ile Asp Ile Thr1
549107PRThomo sapiens 49Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu
Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg Ala
Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala
Val Tyr Tyr Cys Gln Gln Asp Ser Ile Asp Ile 85 90 95Thr Phe Gly Gly
Gly Thr Lys Val Glu Ile Lys 100 10550321DNAhomo sapiens
50gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc
60ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa
120cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac
tggcatccca 180gacaggttca gtggcagtgg gtctgggaca gacttcactc
tcaccatcag cagactggag 240cctgaagatt ttgcagtgta ttactgtcag
caggactcca tcgacatcac ttttggcgga 300gggaccaagg ttgagatcaa a
3215123PRThomo sapiens 51Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys
205215PRThomo sapiens 52Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg
Leu Leu Ile Tyr1 5 10 155332PRThomo sapiens 53Gly Ile Pro Asp Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr1 5 10 15Leu Thr Ile Ser
Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys 20 25 305410PRThomo
sapiens 54Phe Gly Gly Gly Thr Lys Val Glu Ile Lys1 5 10555PRThomo
sapiens 55Ser Tyr Ala Met Ser1 55617PRThomo sapiens 56Ala Ile Ser
Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10
15Gly579PRThomo sapiens 57Pro Tyr Gln Ala Arg Ala Phe Asp Ile1
558118PRThomo sapiens 58Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Ser Gly Ser Gly Gly
Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Pro Tyr
Gln Ala Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110Met Val
Thr Val Ser Ser 11559354DNAhomo sapiens 59gaggtgcagc tgttggagtc
tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
cacctttagc agctatgcca tgagctgggt ccgccaggct 120ccagggaagg
ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac
180gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa
cacgctgtat 240ctgcaaatga acagcctgag agccgaggac acggcggtgt
actactgcgc cagaccttac 300caagccagag cctttgatat ttggggtcag
ggtacaatgg tcaccgtctc ctca 3546030PRThomo sapiens 60Glu Val Gln Leu
Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser 20 25 306114PRThomo
sapiens 61Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser1
5 106232PRThomo sapiens 62Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr Leu Gln1 5 10 15Met Asn Ser Leu Arg Ala Glu Asp Thr
Ala Val Tyr Tyr Cys Ala Arg 20 25 306311PRThomo sapiens 63Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser1 5 106412PRThomo sapiens 64Arg
Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala1 5 10657PRThomo sapiens
65Gly Ala Ser Ser Arg Ala Thr1 5669PRThomo sapiens 66Gln Gln Tyr
Val Val Ala Pro Ile Thr1 567108PRThomo sapiens 67Glu Ile Val Leu
Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Phe Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile
Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55
60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65
70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Val Ala
Pro 85 90 95Ile Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
10568324DNAhomo sapiens 68gaaattgtgt tgacgcagtc tccaggcacc
ctgtctttgt ctccagggga aagagccacc 60ctctcctgca gggccagtca gagtgttagc
agcagcttct tagcctggta ccagcagaaa 120cctggccagg ctcccaggct
cctcatctat ggtgcatcca gcagggccac tggcatccca 180gacaggttca
gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
240cctgaagatt ttgcagtgta ttactgtcag cagtacgtcg tcgcccctat
cacttttggc 300ggagggacca aggttgagat caaa 3246923PRThomo sapiens
69Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1
5 10 15Glu Arg Ala Thr Leu Ser Cys 207015PRThomo sapiens 70Trp Tyr
Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr1 5 10
157132PRThomo sapiens 71Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser
Gly Thr Asp Phe Thr1 5 10 15Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp
Phe Ala Val Tyr Tyr Cys 20 25 307210PRThomo sapiens 72Phe Gly Gly
Gly Thr Lys Val Glu Ile Lys1 5 10739PRThomo sapiens 73Gly Thr Phe
Ser Ser Tyr Ala Ile Ser1 57417PRThomo sapiens 74Gly Ile Ile Pro Ile
Phe Gly Thr Ala Ser Tyr Ala Gln Lys Phe Gln1 5 10 15Gly7514PRThomo
sapiens 75Ala Arg Thr Pro Tyr Tyr Asp Ser Ser Gly Tyr Leu Asp Val1
5 107611PRThomo sapiens 76Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp
Gly1 5 107716PRThomo sapiens 77Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr
Tyr Asn Pro Ser Leu Lys Ser1 5 10 157819PRThomo sapiens 78Ala Arg
Asp Gly Arg Tyr Gln Ser Ala Thr Ala Asp Tyr Tyr Tyr Gly1 5 10 15Met
Asp Val799PRThomo sapiens 79Phe Thr Phe Ser Ser Tyr Ala Met Ser1
58017PRThomo sapiens 80Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr
Ala Asp Ser Val Lys1 5 10 15Gly8111PRThomo sapiens 81Ala Arg Arg
Tyr Arg Gly Val Ser Phe Asp Ile1 5 10829PRThomo sapiens 82Phe Thr
Phe Ser Ser Tyr Ala Met Ser1 58317PRThomo sapiens 83Ala Ile Ser Gly
Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10
15Gly8411PRThomo sapiens 84Ala Arg Pro Tyr Gln Ala Arg Ala Phe Asp
Ile1 5 1085493PRThomo sapiens 85Met Thr Arg Ala Leu Cys Ser Ala Leu
Arg Gln Ala Leu Leu Leu Leu1 5 10 15Ala Ala Ala Ala Glu Leu Ser Pro
Gly Leu Lys Cys Val Cys Leu Leu 20 25 30Cys Asp Ser Ser Asn Phe Thr
Cys Gln Thr Glu Gly Ala Cys Trp Ala 35 40 45Ser Val Met Leu Thr Asn
Gly Lys Glu Gln Val Ile Lys Ser Cys Val 50 55 60Ser Leu Pro Glu Leu
Asn Ala Gln Val Phe Cys His Ser Ser Asn Asn65 70 75 80Val Thr Lys
Thr Glu Cys Cys Phe Thr Asp Phe Cys Asn Asn Ile Thr 85 90 95Leu His
Leu Pro Thr Ala Ser Pro Asn Ala Pro Lys Leu Gly Pro Met 100 105
110Glu Leu Ala Ile Ile Ile Thr Val Pro Val Cys Leu Leu Ser Ile Ala
115 120 125Ala Met Leu Thr Val Trp Ala Cys Gln Gly Arg Gln Cys Ser
Tyr Arg 130 135 140Lys Lys Lys Arg Pro Asn Val Glu Glu Pro Leu Ser
Glu Cys Asn Leu145 150 155 160Val Asn Ala Gly Lys Thr Leu Lys Asp
Leu Ile Tyr Asp Val Thr Ala 165 170 175Ser Gly Ser Gly Ser Gly Leu
Pro Leu Leu Val Gln Arg Thr Ile Ala 180 185 190Arg Thr Ile Val Leu
Gln Glu Ile Val Gly Lys Gly Arg Phe Gly Glu 195 200 205Val Trp His
Gly Arg Trp Cys Gly Glu Asp Val Ala Val Lys Ile Phe 210 215 220Ser
Ser Arg Asp Glu Arg Ser Trp Phe Arg Glu Ala Glu Ile Tyr Gln225 230
235 240Thr Val Met Leu Arg His Glu Asn Ile Leu Gly Phe Ile Ala Ala
Asp 245 250 255Asn Lys Asp Asn Gly Thr Trp Thr Gln Leu Trp Leu Val
Ser Glu Tyr 260 265 270His Glu Gln Gly Ser Leu Tyr Asp Tyr Leu Asn
Arg Asn Ile Val Thr 275 280 285Val Ala Gly Met Ile Lys Leu Ala Leu
Ser Ile Ala Ser Gly Leu Ala 290 295 300His Leu His Met Glu Ile Val
Gly Thr Gln Gly Lys Pro Ala Ile Ala305 310 315 320His Arg Asp Ile
Lys Ser Lys Asn Ile Leu Val Lys Lys Cys Glu Thr 325 330 335Cys Ala
Ile Ala Asp Leu Gly Leu Ala Val Lys His Asp Ser Ile Leu 340 345
350Asn Thr Ile Asp Ile Pro Gln Asn Pro Lys Val Gly Thr Lys Arg Tyr
355 360 365Met Ala Pro Glu Met Leu Asp Asp Thr Met Asn Val Asn Ile
Phe Glu 370 375 380Ser Phe Lys Arg Ala Asp Ile Tyr Ser Val Gly Leu
Val Tyr Trp Glu385 390 395 400Ile Ala Arg Arg Cys Ser Val Gly Gly
Ile Val Glu Glu Tyr Gln Leu 405 410 415Pro Tyr Tyr Asp Met Val Pro
Ser Asp Pro Ser Ile Glu Glu Met Arg 420 425 430Lys Val Val Cys Asp
Gln Lys Phe Arg Pro Ser Ile Pro Asn Gln Trp 435 440 445Gln Ser Cys
Glu Ala Leu Arg Val Met Gly Arg Ile Met Arg Glu Cys 450 455 460Trp
Tyr Ala Asn Gly Ala Ala Arg Leu Thr Ala Leu Arg Ile Lys Lys465 470
475 480Thr Ile Ser Gln Leu Cys Val Lys Glu Asp Cys Lys Ala 485
4908688PRThomo sapiens 86Leu Lys Cys Val Cys Leu Leu Cys Asp Ser
Ser Asn Phe Thr Cys Gln1 5 10 15Thr Glu Gly Ala Cys Trp Ala Ser Val
Met Leu Thr Asn Gly Lys Glu 20 25 30Gln Val Ile Lys Ser Cys Val Ser
Leu Pro Glu Leu Asn Ala Gln Val 35 40 45Phe Cys His Ser Ser Asn Asn
Val Thr Lys Thr Glu Cys Cys Phe Thr 50 55 60Asp Phe Cys Asn Asn Ile
Thr Leu His Leu Pro Thr Ala Ser Pro Asn65 70 75 80Ala Pro Lys Leu
Gly Pro Met Glu 858788PRTrat 87Leu Lys Cys Val Cys Leu Leu Cys Asp
Ser Ser Asn Phe Thr Cys Gln1 5 10 15Thr Glu Gly Ala Cys Trp Ala Ser
Val Met Leu Thr Asn Gly Lys Glu 20 25 30Gln Val Ser Lys Ser Cys Val
Ser Leu Pro Glu Leu Asn Ala Gln Val 35 40 45Phe Cys His Ser Ser Asn
Asn Val Thr Lys Thr Glu Cys Cys Phe Thr 50 55 60Asp Phe Cys Asn Asn
Ile Thr Gln His Leu Pro Thr Ala Ser Pro Asp65 70 75 80Ala Pro Arg
Leu Gly Pro Thr Glu 85885PRTArtificial SequenceVH CDR1 88Val Tyr
Ala Met Ser1 58917PRTArtificial SequenceVH CDR2 89Ala Ile Ser Gly
Ser Gly Asp Ser Thr Val Tyr Ala Asp Ser Val Lys1 5 10
15Gly907PRTArtificial SequenceVH CDR3 90Pro Ser Tyr Gln Pro Ile
Tyr1 591116PRTArtificial SequenceVH Protein 91Glu Val Gln Leu Leu
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Tyr 20 25 30Ala Met Ser
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala
Ile Ser Gly Ser Gly Asp Ser Thr Val Tyr Ala Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75
80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Lys Pro Ser Tyr Gln Pro Ile Tyr Trp Gly Gln Gly Thr Leu
Val 100 105 110Thr Val Ser Ser 11592348DNAArtificial SequenceVH DNA
92gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
60tcctgtgcag cctctggatt caccttttcg gtgtatgcca tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcagct attagtggaa gtggtgatag
cacagtgtac 180gcagactccg tgaagggccg gttcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggcggtgt actactgcgc caagccttct 300taccaaccaa tatactgggg
acagggtaca ttggtcaccg tctcctca 3489332PRTArtificial SequenceVH FR3
93Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln1
5 10 15Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
Lys 20 25 309411PRTArtificial SequenceVH FR4 94Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser1 5 109511PRTArtificial SequenceVL CDR1
95Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala1 5 10967PRTArtificial
SequenceVL CDR2 96Ala Ala Ser Ser Leu Gln Ser1 5979PRTArtificial
SequenceVL CDR3 97Gln Gln Ala Ala Ser Tyr Pro Leu Thr1
598107PRTArtificial SequenceVL Protein 98Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Val Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile
Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30Leu Ala Trp Tyr
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Ala
Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ala Ser Tyr Pro Leu
85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
10599321DNAArtificial SequenceVL DNA 99gacatccaga tgacccaaag
ccctagttcc gtctctgcaa gcgtgggaga tagggtcaca 60atcacatgta gagcttctca
ggggatctct agctggctgg cttggtatca gcagaagccc 120ggtaaggccc
caaagctctt gatatacgcc gcctcttctc ttcaatctgg ggtgccatcc
180cgcttctcag ggagcggtag cgggaccgat ttcaccctca ctatcagcag
cctgcagcct 240gaagactttg ctacctacta ctgccagcaa gccgcttctt
atcctctgac tttcggtggg 300ggtactaaag tggagattaa a
32110023PRTArtificial SequenceVL FR1 100Asp Ile Gln Met Thr Gln Ser
Pro Ser Ser Val Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr
Cys 2010132PRTArtificial SequenceVL FR3 101Gly Val Pro Ser Arg Phe
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr1 5 10 15Leu Thr Ile Ser Ser
Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 20 25
301025PRTArtificial SequenceVH CDR1 102Ser Ser Ala Ile Gly1
510317PRTArtificial SequenceVH CDR2 103Gly Ile Trp Pro Ile Phe Gly
Thr Ala Leu Tyr Ala Gln Lys Phe Gln1 5 10 15Gly10411PRTArtificial
SequenceVH CDR3 104Asp Pro Arg Glu Tyr Ile His Val Phe Asp Ile1 5
10105120PRTArtificial SequenceVH Protein 105Gln Val Gln Leu Val Gln
Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Ser 20 25 30Ala Ile Gly Trp
Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ile
Trp Pro Ile Phe Gly Thr Ala Leu Tyr Ala Gln Lys Phe 50 55 60Gln Gly
Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Asp Pro Arg Glu Tyr Ile His Val Phe Asp Ile Trp Gly
Gln 100 105 110Gly Thr Met Val Thr Val Ser Ser 115
120106360DNAArtificial SequenceVH DNA 106caggtgcagc tggtgcagtc
tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60tcctgcaagg cttctggagg
caccttcagc agcagtgcta tcgggtgggt gcgacaggcc 120cctggacaag
ggcttgagtg gatgggaggg atctggccta tctttggtac agcactttac
180gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag
cacagcctac 240atggagctga gcagcctgag atctgaggac acggcggtgt
actactgcgc cagagatcca 300agagaatata tccacgtatt cgacatatgg
ggtcagggta caatggtcac cgtctcctca 36010711PRTArtificial SequenceVL
CDR1 107Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn1 5
101087PRTArtificial SequenceVL CDR2 108Gly Ala Ser Ser Leu Gln Ser1
51099PRTArtificial SequenceVL CDR3 109Gln Gln Ala Tyr Ser Phe Pro
Trp Thr1 5110107PRTArtificial SequenceVL Protein 110Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30Leu Asn
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr
Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Ser Phe Pro
Trp 85 90 95Thr Phe Gly Gly Gly Ile Lys Val Glu Ile Lys 100
105111321DNAArtificial SequenceVL DNA 111gatattcaga tgacacagtc
acctagcagt ctgagcgcat cagtgggtga tcgagtgaca 60atcacttgta gagcttccca
gtctattagc tcatacctga actggtatca gcaaaagcct 120gggaaggctc
ctaagctgtt gatctatgga gcatctagcc tgcagtccgg cgtgccatcc
180cgcttcagcg ggagcggctc cgggaccgat tttaccctga caatctctag
cctgcagcct 240gaagattttg caacctacta ctgccagcag gcatacagct
tcccctggac attcggaggt 300ggcataaaag ttgaaatcaa a
32111232PRTArtificial SequenceVL FR3 112Gly Val Pro Ser Arg Phe Ser
Gly Ser Gly Ser Gly Thr Asp Phe Thr1 5 10 15Leu Thr Ile Ser Ser Leu
Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 20 25 3011310PRTArtificial
SequenceVL FR4 113Phe Gly Gly Gly Ile Lys Val Glu Ile Lys1 5
101145PRTArtificial SequenceVH CDR1 114Gly Gln Ala Ile Ser1
511517PRTArtificial SequenceVH CDR2 115Gly Ile Ile Pro Ser Phe Gly
Thr Ala Arg Tyr Ala Gln Lys Phe Gln1 5 10 15Gly11612PRTArtificial
SequenceVH CDR3 116Thr Pro Tyr Tyr Asp Ser Ser Gly Tyr Leu Asp Val1
5 10117120PRTArtificial SequenceVH Protein 117Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Gly Gln 20 25 30Ala Ile Ser
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly
Ile Ile Pro Ser Phe Gly Thr Ala Arg Tyr Ala Gln Lys Phe 50 55 60Gln
Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Thr Pro Tyr Tyr Asp Ser Ser Gly Tyr Leu Asp Val Trp
Gly 100 105 110Gln Gly Thr Met Val Thr Val Ser 115
120118363DNAArtificial SequenceVH DNA 118caggtgcagc tggtgcagtc
tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60tcctgcaagg cttctggagg
caccttcagc ggtcaggcta tcagctgggt gcgacaggcc 120cctggacaag
ggcttgagtg gatgggaggg atcatccctt cgtttggtac agcacggtac
180gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag
cacagcctac 240atggagctga gcagcctgag atctgaggac acggcggtgt
actactgcgc cagaactcct 300tactacgaca gcagcggata cctagacgta
tggggtcagg gtacaatggt caccgtctcc 360tca 36311932PRTArtificial
SequenceVH FR3 119Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr
Ala Tyr Met Glu1 5 10 15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
Tyr Tyr Cys Ala Arg 20 25 3012010PRTArtificial SequenceVH FR4
120Trp Gly Gln Gly Thr Met Val Thr Val Ser1 5 1012111PRTArtificial
SequenceVL CDR1 121Gln Ala Ser His Asp Ile Asp Asn Tyr Leu Asn1 5
101227PRTArtificial SequenceVL CDR2 122Tyr Ala Ser Asn Leu Lys Thr1
51239PRTArtificial SequenceVL CDR3 123Gln Gln Ser Arg Ala Ser Pro
Pro Thr1 5124107PRTArtificial SequenceVL Protein 124Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val
Thr Ile Thr Cys Gln Ala Ser His Asp Ile Asp Asn Tyr 20 25 30Leu Asn
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr
Tyr Ala Ser Asn Leu Lys Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro65
70 75 80Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Ser Arg Ala Ser Pro
Pro 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
1051259PRTArtificial SequenceVH CDR1 125Gly Gly Ser Ile Ser Ser Ser
Ala Tyr1 512616PRTArtificial SequenceVH CDR2 126Ser Ile Tyr Leu Ser
Gly Ser Thr Thr Tyr Asn Pro Ser Leu Lys Ser1 5 10
1512717PRTArtificial SequenceVH CDR3 127Asp Gly Arg Tyr Gln Ser Arg
Ser Pro Asp Tyr Tyr Tyr Gly Met Asp1 5 10 15Val128127PRTArtificial
SequenceVH Protein 128Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu
Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
Gly Ser Ile Ser Ser Ser 20 25 30Ala Tyr Tyr Trp Ala Trp Ile Arg Gln
Pro Pro Gly Lys Gly Leu Glu 35 40 45Trp Ile Gly Ser Ile Tyr Leu Ser
Gly Ser Thr Thr Tyr Asn Pro Ser 50 55 60Leu Lys Ser Arg Val Thr Ile
Ser Val Asp Thr Ser Lys Asn Gln Phe65 70 75 80Ser Leu Lys Leu Ser
Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg Asp
Gly Arg Tyr Gln Ser Arg Ser Pro Asp Tyr Tyr Tyr 100 105 110Gly Met
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
125129381DNAArtificial SequenceVH DNA 129cagctgcagc tgcaggagtc
gggcccagga ctggtgaagc cttcggagac cctgtccctc 60acctgcactg tctctggtgg
ctccatcagc agtagtgctt actactgggc gtggatccgc 120cagcccccag
ggaaggggct ggagtggatt gggagtatct atttgagtgg gagcaccact
180tacaacccgt ccctcaagag tcgagtcacc atatccgtag acacgtccaa
gaaccagttc 240tccctgaagc tgagttctgt gaccgccgca gacacggcgg
tgtactactg cgccagagac 300ggcagatacc aaagcaggtc gccggattac
tattacggta tggatgtctg gggccaggga 360acaacggtca ccgtctcctc a
38113025PRTArtificial SequenceVH FR1 130Gln Leu Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys
Thr Val Ser 20 2513117PRTArtificial SequenceVH FR2 131Tyr Trp Ala
Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile1 5 10
15Gly13212PRTArtificial SequenceVL CDR1 132Lys Ala Ser Gln Ser Val
Ser Ser Ser Tyr Leu Ala1 5 101337PRTArtificial SequenceVL CDR2
133Gly Ala Phe Ser Arg Ala Asn1 51349PRTArtificial SequenceVL CDR3
134Gln Gln Leu Val Ser Tyr Pro Phe Thr1 5135108PRTArtificial
SequenceVL Protein 135Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu
Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Lys Ala Ser
Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Phe Ser Arg Ala
Asn Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala
Val Tyr Tyr Cys Gln Gln Leu Val Ser Tyr Pro 85 90 95Phe Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 105136324DNAArtificial
SequenceVL DNA 136gagatagtct tgacccagtc accaggcacc cttagcttgt
ctcccgggga acgcgccaca 60ctcagctgta aagcctctca gtcagtttct agttcctacc
tcgcttggta tcaacaaaag 120cccggacaag caccaaggct gttgatctac
ggagctttca gtcgcgcaaa tggcattccc 180gaccgattct ctggcagtgg
tagtggcacc gacttcactc tcacaatttc taggttggaa 240cctgaggact
ttgctgtgta ctactgtcaa caactggttt cttatccctt tacattcggt
300ggcggcacaa aagtcgagat taaa 3241375PRTArtificial SequenceVH CDR1
137Gly Tyr Asn Met His1 51386PRTArtificial SequenceVH CDR2 138Asn
Pro Asn Ser Gly Trp1 513912PRTArtificial SequenceVH CDR3 139Asp Pro
Val Gly Ala Arg Tyr Glu Val Phe Asp Tyr1 5 10140121PRTArtificial
SequenceVH Protein 140Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Tyr Thr Phe Ala Gly Tyr 20 25 30Asn Met His Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Val 35 40 45Gly Ile Ile Asn Pro Asn Ser Gly
Trp Thr Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Met Thr
Arg Asp Thr Ser Val Ser Ala Ala Tyr65 70 75 80Met Glu Leu Ser Arg
Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Pro
Val Gly Ala Arg Tyr Glu Val Phe Asp Tyr Trp Gly 100 105 110Gln Gly
Thr Leu Val Thr Val Ser Ser 115 120141363DNAArtificial SequenceVH
DNA 141caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc
agtgaaggtc 60tcctgcaagg cttctggata caccttcgct ggctacaata tgcactgggt
gcgacaggcc 120cctggacaag ggcttgagtg ggtgggaatt atcaacccta
acagtggttg gacaaactat 180gcacagaagt tccagggcag ggtcacgatg
accagggaca cgtccgtcag cgcagcctac 240atggagctga gcaggctgag
atctgacgac acggcggtgt actactgcgc cagagaccct 300gtcggagcaa
gatacgaggt tttcgattac tggggacagg gtacattggt caccgtctcc 360tca
36314230PRTArtificial SequenceVH FR1 142Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Ala 20 25 3014316PRTArtificial
SequenceVH FR2 143Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Val Gly Ile Ile1 5 10 1514411PRTArtificial SequenceVH FR4 144Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser1 5 1014511PRTArtificial
SequenceVL CDR1 145Arg Ala Ser Gln Ser Val Ser Ser Ala Leu Ala1 5
101467PRTArtificial SequenceVL CDR2 146Ser Ala Phe Thr Arg Ala Ser1
51479PRTArtificial SequenceVL CDR3 147Gln Gln Ala Trp Ala Phe Pro
Leu Thr1 5148107PRTArtificial SequenceVL Protein 148Glu Ile Val Met
Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ala 20 25 30Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr
Ser Ala Phe Thr Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly 50 55
60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65
70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Trp Ala Phe Pro
Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105149321DNAArtificial SequenceVL DNA 149gaaatcgtga tgacccaatc
acctgccact ctgtctgtta gccctgggga acgggccacc 60ctcagttgta gggccagtca
gagtgttagt tcagctttgg cttggtatca gcagaagccc 120ggacaggccc
caaggctgct gatctactct gctttcaccc gcgcaagcgg catccccgca
180cgctttagcg gctccggaag cggcaccgag tttactctta ctatttcttc
tttgcagagt 240gaggattttg ccgtgtacta ctgccagcag gcctgggcat
ttccactcac tttcgggggc 300gggaccaagg tcgaaatcaa g
321150321DNAArtificial SequenceVL DNA 150gacatccaga tgacacagtc
ccctagcagc ttgtcagcct cagtgggcga tagagtgacc 60atcacctgtc aagccagcca
tgatatagac aactatctca attggtacca gcagaaacca 120ggcaaggcac
caaagctcct gatctattac gcctcaaacc ttaagaccgg cgtcccaagc
180cggttttcag gcagcggcag cgggacagat ttcaccttca caatttcatc
actgcaacct 240gaggatatag ccacttacta ttgtcagcag agcagagcca
gcccccctac cttcggcggc 300ggtaccaaag ttgaaatcaa g
321151348DNAArtificial SequenceVH DNA 151gaggtgcagc tgttggagtc
tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
cacctttagc agctatgcca tgagctgggt ccgccaggct 120ccagggaagg
ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac
180gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa
cacgctgtat 240ctgcaaatga acagcctgag agccgaggac acggcggtgt
actactgcgc caagccttct 300taccaaccaa tatactgggg acagggtaca
ttggtcaccg tctcctca 348152116PRTArtificial SequenceVH Protein
152Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Pro Ser Tyr Gln Pro Ile Tyr
Trp Gly Gln Gly Thr Leu Val 100 105 110Thr Val Ser Ser
1151539PRTArtificial SequenceVH ABR1 153Phe Thr Phe Ser Ser Tyr Ala
Met Ser1 515417PRTArtificial SequenceVH ABR2 154Ala Ile Ser Gly Ser
Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10
15Gly1559PRTArtificial SequenceVH ABR3 155Ala Lys Pro Ser Tyr Gln
Pro Ile Tyr1 51565PRTArtificial SequenceVH CDR1 156Asn Tyr Ala Ile
Ser1 515717PRTArtificial SequenceVH CDR2 157Gly Ile Ile Pro Ile Phe
Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln1 5 10
15Gly158360DNAArtificial SequenceVH DNA 158caggtgcagc tggtgcagtc
tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60tcctgcaagg cttctggagg
caccttcagc aactatgcta tcagctgggt gcgacaggcc 120cctggacaag
ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac
180gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag
cacagcctac 240atggagctga gcagcctgag atctgaggac acggcggtgt
actactgcgc cagagatcca 300agagaatata tccacgtatt cgacatatgg
ggtcagggta caatggtcac cgtctcctca 360159120PRTArtificial SequenceVH
Protein 159Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe
Ser Asn Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly
Leu Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn
Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu
Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Pro Arg Glu Tyr
Ile His Val Phe Asp Ile Trp Gly Gln 100 105 110Gly Thr Met Val Thr
Val Ser Ser 115 1201609PRTArtificial SequenceVH ABR1 160Gly Thr Phe
Ser Asn Tyr Ala Ile Ser1 516117PRTArtificial SequenceVH ABR2 161Gly
Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln1 5 10
15Gly16213PRTArtificial SequenceVH ABR3 162Ala Arg Asp Pro Arg Glu
Tyr Ile His Val Phe Asp Ile1 5 1016317PRTArtificial SequenceVH CDR2
163Ser Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln1
5 10 15Gly16412PRTArtificial SequenceVH CDR3 164Asp Pro Val Gly Ala
Arg Tyr Glu Val Phe Asp Tyr1 5 10165363DNAArtificial SequenceVH DNA
165caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc
ggtgaaggtc 60tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt
gcgacaggcc 120cctggacaag ggcttgagtg gatgggaagc atcatcccta
tctttggtac agcaaactac 180gcacagaagt tccagggcag agtcacgatt
accgcggacg aatccacgag cacagcctac 240atggagctga gcagcctgag
atctgaggac acggcggtgt actactgcgc cagagaccct 300gtcggagcaa
gatacgaggt tttcgattac tggggacagg gtacattggt caccgtctcc 360tca
363166121PRTArtificial SequenceVH Protein 166Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ser
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Ser
Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln
Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Asp Pro Val Gly Ala Arg Tyr Glu Val Phe Asp Tyr Trp
Gly 100 105 110Gln Gly Thr Leu Val Thr Val Ser Ser 115
12016711PRTArtificial SequenceVL CDR1 167Arg Ala Ser Gln Ser Val
Ser Ser Asn Leu Ala1 5 101687PRTArtificial SequenceVL CDR2 168Ser
Ala Ser Thr Arg Ala Thr1 51699PRTArtificial SequenceVL CDR3 169Gln
Gln Ala Asn Thr Phe Pro Leu Thr1 5170321DNAArtificial SequenceVL
DNA 170gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga
aagagccacc 60ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca
gcagaaacct 120ggccaggctc ccaggctcct catctatagc gcatccacca
gggccactgg tatcccagcc 180aggttcagtg gcagtgggtc tgggacagag
ttcactctca ccatcagcag cctgcagtct 240gaagattttg cagtttatta
ctgtcagcag gccaatacct tccctctcac ttttggcgga 300gggaccaagg
ttgagatcaa a 321171107PRTArtificial SequenceVL Protein 171Glu Ile
Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu
Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25
30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45Tyr Ser Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser
Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu
Gln Ser65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Asn
Thr Phe Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 1051729PRTArtificial SequenceVH ABR1 172Gly Thr Phe Ser Ser Tyr
Ala Ile Ser1 517317PRTArtificial SequenceVH ABR2 173Ser Ile Ile Pro
Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln1 5 10
15Gly17414PRTArtificial SequenceVH ABR3 174Ala Arg Asp Pro Val Gly
Ala Arg Tyr Glu Val Phe Asp Tyr1 5 101759PRTArtificial SequenceVH
ABR1 175Phe Thr Phe Ser Val Tyr Ala Met Ser1 517617PRTArtificial
SequenceVH ABR2 176Ala Ile Ser Gly Ser Gly Asp Ser Thr Val Tyr Ala
Asp Ser Val Lys1 5 10 15Gly1779PRTArtificial SequenceVH ABR3 177Ala
Lys Pro Ser Tyr Gln Pro Ile Tyr1 51789PRTArtificial SequenceVH ABR1
178Gly Thr Phe Ser Ser Ser Ala Ile Gly1 517917PRTArtificial
SequenceVH ABR2 179Gly Ile Trp Pro Ile Phe Gly Thr Ala Leu Tyr Ala
Gln Lys Phe Gln1 5 10 15Gly18013PRTArtificial SequenceVH ABR3
180Ala Arg Asp Pro Arg Glu Tyr Ile His Val Phe Asp Ile1 5
101819PRTArtificial SequenceVH ABR1 181Gly Thr Phe Ser Gly Gln Ala
Ile Ser1 518217PRTArtificial SequenceVH ABR2 182Gly Ile Ile Pro Ser
Phe Gly Thr Ala Arg Tyr Ala Gln Lys Phe Gln1 5 10
15Gly18314PRTArtificial SequenceVH ABR3 183Ala Arg Thr Pro Tyr Tyr
Asp Ser Ser Gly Tyr Leu Asp Val1 5 1018411PRTArtificial SequenceVH
ABR1 184Gly Ser Ile Ser Ser Ser Ala Tyr Tyr Trp Ala1 5
1018516PRTArtificial SequenceVH ABR2 185Ser Ile Tyr Leu Ser Gly Ser
Thr Thr Tyr Asn Pro Ser Leu Lys Ser1 5 10 1518619PRTArtificial
SequenceVH ABR3 186Ala Arg Asp Gly Arg Tyr Gln Ser Ala Thr Ala Asp
Tyr Tyr Tyr Gly1 5 10 15Met Asp Val1879PRTArtificial SequenceVH
ABR1 187Tyr Thr Phe Ala Gly Tyr Asn Met His1 518817PRTArtificial
SequenceVH ABR2 188Ile Ile Asn Pro Asn Ser Gly Trp Thr Asn Tyr Ala
Gln Lys Phe Gln1 5 10 15Gly18914PRTArtificial SequenceVH ABR3
189Ala Arg Asp Pro Val Gly Ala Arg Tyr Glu Val Phe Asp Tyr1 5
10
* * * * *
References